

Preexposure Chemoprophylaxis for HIV Prevention in M

New England Journal of Medicine

363, 2587-2599

DOI: [10.1056/nejmoa1011205](https://doi.org/10.1056/nejmoa1011205)

Citation Report

#	ARTICLE	IF	CITATIONS
3	Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. , 2009, , CD007189.		61
4	Oral Preexposure Prophylaxis for HIV “ Another Arrow in the Quiver?. New England Journal of Medicine, 2010, 363, 2663-2665.	13.9	21
5	Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2011, 23, 1136-1145.	0.6	132
6	Self-Perceived Risk of HIV Infection and Attitudes About Preexposure Prophylaxis Among Sexually Transmitted Disease Clinic Attendees in South Carolina. AIDS Patient Care and STDs, 2011, 25, 365-370.	1.1	49
7	Re: Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Journal of Urology, 2011, 185, 1729-1729.	0.2	6
8	The introduction of new antiretroviral-based HIV prevention methods into health systems: key issues. Reproductive Health Matters, 2011, 19, 208-212.	1.3	4
9	Acute HIV-1 Infection. New England Journal of Medicine, 2011, 364, 1943-1954.	13.9	543
10	Preexposure Chemoprophylaxis for HIV Prevention. New England Journal of Medicine, 2011, 364, 1372-1375.	13.9	10
11	Post-exposure prophylaxis for HIV infection. Expert Review of Anti-Infective Therapy, 2011, 9, 431-442.	2.0	15
12	Topical Tenofovir, a Microbicide Effective against HIV, Inhibits Herpes Simplex Virus-2 Replication. Cell Host and Microbe, 2011, 10, 379-389.	5.1	113
13	Human immunodeficiency virus/acquired immunodeficiency syndrome and infertility: emerging problems in the era of highly active antiretrovirals. Fertility and Sterility, 2011, 96, 546-553.	0.5	74
17	The potential impact of an HIV vaccine with limited protection on HIV incidence in Thailand: A modeling study. Vaccine, 2011, 29, 6079-6085.	1.7	18
18	The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand. Vaccine, 2011, 29, 6092-6099.	1.7	14
19	Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia. Vaccine, 2011, 29, 6125-6129.	1.7	11
20	Socioecological influences on community involvement in HIV vaccine research. Vaccine, 2011, 29, 6136-6143.	1.7	25
21	Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: A review. Vaccine, 2011, 29, 6191-6218.	1.7	91
22	Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine, 2011, 29, 8309-8316.	1.7	70
24	Circumcised HIV-infected men and HPV transmission. Lancet Infectious Diseases, The, 2011, 11, 581-582.	4.6	9

#	ARTICLE	IF	CITATIONS
25	Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost?. <i>Clinical Infectious Diseases</i> , 2011, 53, 1265-1270.	2.9	94
26	Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?. <i>Patient Preference and Adherence</i> , 2011, 5, 645.	0.8	7
27	Can further placebo-controlled trials of antiretroviral drugs to prevent sexual transmission of HIV be justified?. <i>Lancet, The</i> , 2011, 378, 285-287.	6.3	7
28	HIV prevention transformed: the new prevention research agenda. <i>Lancet, The</i> , 2011, 378, 269-278.	6.3	238
29	Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. <i>Lancet, The</i> , 2011, 378, 279-281.	6.3	220
30	Antiretrovirals for HIV prevention: translating promise into praxis. <i>Lancet, The</i> , 2011, 378, 206-208.	6.3	12
31	Antiretroviral prophylaxis: a defining moment in HIV control. <i>Lancet, The</i> , 2011, 378, e23-e25.	6.3	84
32	Critical appraisal and update on tenofovir in management of human immunodeficiency virus infection. <i>Virus Adaptation and Treatment</i> , 2011, , 55.	1.5	3
33	Advances in the Prevention of Heterosexual Transmission of HIV/AIDS Among Women in the United States. <i>Gastroenterology Insights</i> , 2011, 3, e6.	0.7	11
34	HIV Epidemiology and Prevention. , 2011, , .		0
35	Advances in the prevention of heterosexual transmission of HIV/AIDS among women in the United States. <i>Gastroenterology Insights</i> , 2011, 3, .	0.7	11
36	Delayed Maturation of Antibody Avidity but Not Seroconversion in Rhesus Macaques Infected With Simian HIV During Oral Pre-Exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 355-362.	0.9	26
37	Antiretroviral therapy and the prevention of sexually transmitted HIV infection. <i>BMJ: British Medical Journal</i> , 2011, 343, d7796-d7796.	2.4	3
38	Nephrotoxicity of HAART. <i>AIDS Research and Treatment</i> , 2011, 2011, 1-11.	0.3	65
39	Factors Influencing the Emergence and Spread of HIV Drug Resistance Arising from Rollout of Antiretroviral Pre-Exposure Prophylaxis (PrEP). <i>PLoS ONE</i> , 2011, 6, e18165.	1.1	57
40	HIV Incidence among Men Who Have Sex with Men in China: A Meta-Analysis of Published Studies. <i>PLoS ONE</i> , 2011, 6, e23431.	1.1	74
41	Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco. <i>PLoS ONE</i> , 2011, 6, e23688.	1.1	144
42	HIV Incidence, Risk Factors, and Motivation for Biomedical Intervention among Gay, Bisexual Men, and Transgender Persons in Northern Thailand. <i>PLoS ONE</i> , 2011, 6, e24295.	1.1	69

#	ARTICLE	IF	CITATIONS
43	Characteristics of HIV-1 Serodiscordant Couples Enrolled in a Clinical Trial of Antiretroviral Pre-Exposure Prophylaxis for HIV-1 Prevention. PLoS ONE, 2011, 6, e25828.	1.1	75
44	A US Policy Perspective on Oral Preexposure Prophylaxis for HIV. American Journal of Public Health, 2011, 101, 982-985.	1.5	34
45	Association of osteonecrosis and peripheral neuropathy in HIV-1-infected patients. Aids, 2011, 25, 2305-2306.	1.0	1
46	The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis. Aids, 2011, 25, 2308-2310.	1.0	23
47	Game Changers: Why Did the Scale-Up of HIV Treatment Work Despite Weak Health Systems?. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S61-S63.	0.9	40
48	Australian Gay Men Who Have Taken Nonoccupational Postexposure Prophylaxis for HIV Are in Need of Effective HIV Prevention Methods. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 424-428.	0.9	39
49	What do mathematical models tell us about the emergence and spread of drug-resistant HIV?. Current Opinion in HIV and AIDS, 2011, 6, 131-140.	1.5	16
50	Proof of principle: antiretroviral drugs can prevent sexual transmission of HIV-1. Future Virology, 2011, 6, 549-551.	0.9	0
51	Anti-HIV microbicide development: targeting the virus is the key. Future Virology, 2011, 6, 553-556.	0.9	1
52	MSM: resurgent epidemics. Current Opinion in HIV and AIDS, 2011, 6, 326-332.	1.5	24
53	Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission. Aids, 2011, 25, 2295-2299.	1.0	35
54	Sex Worker Studies: The Science, Semantics, and Politics of Targeting Our HIV Prevention Response. Sexually Transmitted Diseases, 2011, 38, 395-397.	0.8	0
55	Is expanded HIV treatment preventing new infections? Impact of antiretroviral therapy on sexual risk behaviors in the developing world. Aids, 2011, 25, 1939-1949.	1.0	47
56	Condom-Use Decision Making in the Context of Hypothetical Pre-Exposure Prophylaxis Efficacy Among Substance-Using Men Who Have Sex With Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 319-327.	0.9	22
57	The 14th Bangkok International Symposium on HIV Medicine. Future Virology, 2011, 6, 409-412.	0.9	0
58	Abuse by Priests, Homosexuality, Humanae vitae, and a Crisis of Masculinity in the Church. Linacre quarterly, The, 2011, 78, 274-293.	0.1	1
59	Preexposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child. Aids, 2011, 25, 2005-2008.	1.0	168
60	Investigators Involvement in the Care of HIV-Infected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, e118-e119.	0.9	3

#	ARTICLE	IF	CITATIONS
61	Incorporation of the HIV-1 Microbicide Cyanovirin-N in a Food Product. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, 379-384.	0.9	12
62	Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. , 2011, , CD009153.		25
63	Life Expectancy in Africa: Back to the Future?. <i>Annals of Internal Medicine</i> , 2011, 155, 265.	2.0	5
64	Thirty Years of HIV and AIDS: Future Challenges and Opportunities. <i>Annals of Internal Medicine</i> , 2011, 154, 766.	2.0	140
65	Antiretroviral-based microbicides and oral pre-exposure prophylaxis for HIV prevention. <i>Future Virology</i> , 2011, 6, 997-1014.	0.9	4
66	Targeting strategies and behavior change to combat the HIV epidemic in southern Africa. <i>Future Virology</i> , 2011, 6, 793-800.	0.9	5
67	Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings. <i>HIV/AIDS - Research and Palliative Care</i> , 2011, 3, 35.	0.4	32
68	Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance. <i>Scientific Reports</i> , 2011, 1, 185.	1.6	48
69	Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. , 2011, , CD009153.		46
70	Internet-based behavioral interventions for preventing HIV infection in men who have sex with men (MSM). <i>The Cochrane Library</i> , 0, , .	1.5	2
71	Update on microbicide research and development-seeking new HIV prevention tools for women. <i>European Journal of Medical Research</i> , 2011, 16, 1.	0.9	17
72	Modeling Interventions to Assess HIV Epidemic Impact in Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, 121-124.	0.9	14
73	HIV prevention in southern Africa: why we must reassess our strategies?. <i>Tropical Medicine and International Health</i> , 2011, 16, 1120-1130.	1.0	7
74	HIV testing and antiretroviral treatment strategies for prevention of HIV infection: impact on antiretroviral drug resistance. <i>Journal of Internal Medicine</i> , 2011, 270, 532-549.	2.7	14
75	The ART of preventing HIV. <i>Nature Medicine</i> , 2011, 17, 46-47.	15.2	1
76	Trial success spurs planning for rollout of HIV prevention pills. <i>Nature Medicine</i> , 2011, 17, 392-392.	15.2	1
77	Drugs that prevent HIV infection. <i>Nature</i> , 2011, 469, 306-307.	13.7	16
78	A big disease with a little name. <i>Nature</i> , 2011, 474, 5-5.	13.7	33

#	ARTICLE	IF	CITATIONS
79	Children of the AIDS pandemic. <i>Nature</i> , 2011, 474, 27-29.	13.7	23
80	Stigma impedes AIDS prevention. <i>Nature</i> , 2011, 474, 29-31.	13.7	25
81	Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. <i>Journal of Controlled Release</i> , 2011, 156, 161-169.	4.8	53
82	Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques. <i>Virology</i> , 2011, 412, 435-440.	1.1	18
83	Reverse transcriptase mutation K65N confers a decreased replication capacity to HIV-1 in comparison to K65R due to a decreased RT processivity. <i>Virology</i> , 2011, 414, 34-41.	1.1	8
84	Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa. <i>Journal of the International AIDS Society</i> , 2011, 14, 49-49.	1.2	64
85	Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 204, 488.e1-488.e8.	0.7	120
86	The clinical potential of the acyclic (and cyclic) nucleoside phosphonates. The magic of the phosphonate bond. <i>Biochemical Pharmacology</i> , 2011, 82, 99-109.	2.0	116
87	Dilemma of concepts and strategies for the prevention of spread of HIV in relation to human behavior, law and human rights. <i>Journal of Zhejiang University: Science B</i> , 2011, 12, 591-610.	1.3	1
88	Spot the hotspot. <i>Nature</i> , 2011, 469, 307-308.	13.7	33
89	Towards a More Coordinated Federal Response to Improving HIV Prevention and Sexual Health among Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2011, 15, 107-111.	1.4	10
90	Sexual HIV Transmission and Antiretroviral Therapy: A Prospective Cohort Study of Behavioral Risk Factors Among Men and Women Living with HIV/AIDS. <i>Annals of Behavioral Medicine</i> , 2011, 42, 111-119.	1.7	27
91	Pharmacokinetics of UC781-loaded intravaginal ring segments in rabbits: a comparison of polymer matrices. <i>Drug Delivery and Translational Research</i> , 2011, 1, 238-246.	3.0	16
92	Topical Prophylaxis for HIV Prevention in Women: Becoming a Reality. <i>Current HIV/AIDS Reports</i> , 2011, 8, 104-113.	1.1	6
93	Preexposure Prophylaxis for HIV Prevention. <i>Current HIV/AIDS Reports</i> , 2011, 8, 94-103.	1.1	45
94	Promising Prevention Approaches: Tenofovir Gel and Prophylactic Use of Antiretroviral Medications. <i>Current HIV/AIDS Reports</i> , 2011, 8, 241-248.	1.1	23
95	HIV Risk and Associations of HIV Infection among men who have sex with men in Peri-Urban Cape Town, South Africa. <i>BMC Public Health</i> , 2011, 11, 766.	1.2	110
96	The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment. <i>Retrovirology</i> , 2011, 8, 65.	0.9	101

#	ARTICLE	IF	CITATIONS
97	The first decade of antiretroviral therapy in Africa. <i>Globalization and Health</i> , 2011, 7, 33.	2.4	72
98	A cross-sectional assessment of population demographics, HIV risks and human rights contexts among men who have sex with men in Lesotho. <i>Journal of the International AIDS Society</i> , 2011, 14, 36-36.	1.2	89
99	Facing up to programmatic challenges created by the HIV/AIDS epidemic in sub-Saharan Africa. <i>Journal of the International AIDS Society</i> , 2011, 14, S1.	1.2	8
100	Treatment as prevention: preparing the way. <i>Journal of the International AIDS Society</i> , 2011, 14, S6.	1.2	30
101	The HIV/AIDS epidemic in sub-Saharan Africa: thinking ahead on programmatic tasks and related operational research. <i>Journal of the International AIDS Society</i> , 2011, 14, S7.	1.2	10
102	Epistemic fault lines in biomedical and social approaches to HIV prevention. <i>Journal of the International AIDS Society</i> , 2011, 14, S2.	1.2	70
103	Framing the social in biomedical HIV prevention trials: a 20-year retrospective. <i>Journal of the International AIDS Society</i> , 2011, 14, S3.	1.2	21
104	HIV sexual transmission and microbicides. <i>Reviews in Medical Virology</i> , 2011, 21, 110-133.	3.9	47
105	Circulation HIV-1 subtypes B, C, and CRF31_BC in a drug-naïve population from Southernmost Brazil: Analysis of primary resistance mutations. <i>Journal of Medical Virology</i> , 2011, 83, 1682-1688.	2.5	28
106	HIV/AIDS: 30 Years of progress and future challenges. <i>European Journal of Immunology</i> , 2011, 41, 3401-3411.	1.6	30
107	Sexually Transmitted Diseases Treatment Guidelines, 2010. <i>Annals of Emergency Medicine</i> , 2011, 58, 67-68.	0.3	925
108	Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 56, 390-401.	1.4	97
109	Combinatorial prevention of HIV transmission in women: the case for a vaginal microbicide. <i>Future Microbiology</i> , 2011, 6, 731-737.	1.0	7
110	HIV Prevention in Women: Next Steps. <i>Science</i> , 2011, 331, 284-284.	6.0	15
111	HIV vaccine development: a new beginning. <i>Expert Review of Vaccines</i> , 2011, 10, 925-927.	2.0	1
112	Universal Testing and Treatment as an HIV Prevention Strategy: Research Questions and Methods. <i>Current HIV Research</i> , 2011, 9, 429-445.	0.2	62
113	Modelling the Impact of Antiretroviral Therapy on the Epidemic of HIV. <i>Current HIV Research</i> , 2011, 9, 367-382.	0.2	51
114	Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission. <i>Science Translational Medicine</i> , 2011, 3, 112re4.	5.8	310

#	ARTICLE	IF	CITATIONS
115	Antiretroviral Treatment as Prevention. <i>New England Journal of Medicine</i> , 2011, 365, 561-562.	13.9	37
117	Harnessing the Prevention Benefits of Antiretroviral Therapy to Address HIV and Tuberculosis. <i>Current HIV Research</i> , 2011, 9, 355-366.	0.2	6
118	HIV in Young Men Who Have Sex with Men: A Review of Epidemiology, Risk and Protective Factors, and Interventions. <i>Journal of Sex Research</i> , 2011, 48, 218-253.	1.6	309
119	Topical Nucleoside Reverse Transcriptase Inhibitor MC 1220 Partially Prevents Vaginal RT-SHIV Infection of Macaques. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 933-943.	0.5	22
120	Oral Preexposure Anti-HIV Prophylaxis for High-Risk U.S. Populations: Current Considerations in Light of New Findings. <i>AIDS Patient Care and STDs</i> , 2011, 25, 63-71.	1.1	66
121	Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components. <i>Clinical Infectious Diseases</i> , 2011, 53, 469-479.	2.9	137
122	Turning the Tide Against HIV. <i>Science</i> , 2011, 333, 42-43.	6.0	84
123	Development of Dual-Acting Pyrimidinediones as Novel and Highly Potent Topical Anti-HIV Microbicides. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5243-5254.	1.4	20
124	Concentrations of Tenofovir and Emtricitabine in Saliva: Implications for Preexposure Prophylaxis of Oral HIV Acquisition. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4905-4907.	1.4	20
125	The rapidly changing paradigm of HIV prevention: time to strengthen social and behavioural approaches. <i>Health Education Research</i> , 2011, 26, 381-392.	1.0	33
126	Awareness of, usage of and willingness to use HIV pre-exposure prophylaxis among men in downtown Toronto, Canada. <i>International Journal of STD and AIDS</i> , 2011, 22, 738-741.	0.5	47
127	“Test and Treat” Is It Enough?. <i>Clinical Infectious Diseases</i> , 2011, 52, 801-802.	2.9	18
128	Clinical round-up. <i>Sexually Transmitted Infections</i> , 2011, 87, 177-177.	0.8	0
129	Commentary: Thirty Years of AIDS in America: A Story of Infinite Hope. <i>AIDS Education and Prevention</i> , 2011, 23, 479-494.	0.6	16
130	Acyclic nucleoside phosphonates: An unfinished story. <i>Collection of Czechoslovak Chemical Communications</i> , 2011, 76, 829-842.	1.0	13
131	'Less education' is associated with use and sharing of antiretroviral medications for prophylaxis of HIV infection by US men who have sex with men. <i>Sexually Transmitted Infections</i> , 2011, 87, 510-510.	0.8	7
132	Awareness of post-exposure HIV prophylaxis in high-risk men who have sex with men in New York City. <i>Sexually Transmitted Infections</i> , 2011, 87, 344-348.	0.8	78
133	Protection against Rectal Transmission of an Emtricitabine-Resistant Simian/Human Immunodeficiency Virus SHIV162p3_{M184V} Mutant by Intermittent Prophylaxis with Truvada. <i>Journal of Virology</i> , 2011, 85, 7933-7936.	1.5	39

#	ARTICLE	IF	CITATIONS
134	Ethical Allocation of Preexposure HIV Prophylaxis. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 191.	3.8	20
135	Pharmacokinetics and Safety of Single-Dose Tenofovir Disoproxil Fumarate and Emtricitabine in HIV-1-Infected Pregnant Women and Their Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5914-5922.	1.4	53
136	The importance of the vaginal delivery route for antiretrovirals in HIV prevention. <i>Therapeutic Delivery</i> , 2011, 2, 1535-1550.	1.2	50
137	ARVs as HIV Prevention: A Tough Road to Wide Impact. <i>Science</i> , 2011, 334, 1645-1646.	6.0	30
138	Interventions to Prevent Sexually Transmitted Infections, Including HIV Infection. <i>Clinical Infectious Diseases</i> , 2011, 53, S64-S78.	2.9	40
139	Validation of a Dye Stain Assay for Vaginally Inserted Hydroxyethylcellulose-Filled Microbicide Applicators. <i>Sexually Transmitted Diseases</i> , 2011, 38, 1050-1055.	0.8	16
140	The Cost-Effectiveness of Pre-Exposure Prophylaxis in Men Who Have Sex With Men in the United States: An Epidemic Model. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, e51-e52.	0.9	54
141	The 30-Year War on AIDS: Have We Reached the Tipping Point?. <i>Sexually Transmitted Diseases</i> , 2011, 38, 1089-1093.	0.8	0
142	HIV Transmission: Time for Translational Studies to Bridge the Gap. <i>Science Translational Medicine</i> , 2011, 3, 77ps11.	5.8	9
143	Experience in international clinical research: the HIV Prevention Trials Network. <i>Clinical Investigation</i> , 2011, 1, 1609-1618.	0.0	14
144	Can Devices for Adult Male Circumcision Help Bridge the Implementation Gap for HIV Prevention Services?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, 506-508.	0.9	14
145	Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient. <i>Aids</i> , 2011, 25, 2306-2308.	1.0	5
146	Quantifying the Impact of Nevirapine-Based Prophylaxis Strategies To Prevent Mother-to-Child Transmission of HIV-1: a Combined Pharmacokinetic, Pharmacodynamic, and Viral Dynamic Analysis To Predict Clinical Outcomes. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5529-5540.	1.4	23
147	The impact of HIV research on health outcome and healthcare policy. <i>Annals of Oncology</i> , 2011, 22, vii50-vii53.	0.6	3
148	Natural Substrate Concentrations Can Modulate the Prophylactic Efficacy of Nucleotide HIV Reverse Transcriptase Inhibitors. <i>Journal of Virology</i> , 2011, 85, 6610-6617.	1.5	69
149	30 years after HIV identification: where to from here?. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 947-949.	2.0	0
150	One Percent Tenofovir Applied Topically to Humanized BLT Mice and Used According to the CAPRISA 004 Experimental Design Demonstrates Partial Protection from Vaginal HIV Infection, Validating the BLT Model for Evaluation of New Microbicide Candidates. <i>Journal of Virology</i> , 2011, 85, 7582-7593.	1.5	133
151	Indian married men's interest in microbicide use. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2011, 23, 1344-1349.	0.6	6

#	ARTICLE	IF	CITATIONS
152	On the Psychogenesis of Homosexuality. <i>Linacre quarterly, The</i> , 2011, 78, 330-354.	0.1	9
153	Transmission Network Parameters Estimated From HIV Sequences for a Nationwide Epidemic. <i>Journal of Infectious Diseases</i> , 2011, 204, 1463-1469.	1.9	184
154	Optimal Uses of Antiretrovirals for Prevention in HIV-1 Serodiscordant Heterosexual Couples in South Africa: A Modelling Study. <i>PLoS Medicine</i> , 2011, 8, e1001123.	3.9	130
155	Redesigning the AIDS response for long-term impact. <i>Bulletin of the World Health Organization</i> , 2011, 89, 846-852.	1.5	32
156	Health Care Providers: A Missing Link in Understanding Acceptability of The Female Condom. <i>AIDS Education and Prevention</i> , 2011, 23, 65-77.	0.6	28
157	Prospects for using pre-exposure prophylaxis to control the prevalence of HIV/AIDS in China. <i>Drug Discoveries and Therapeutics</i> , 2011, 5, 159-161.	0.6	1
159	Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men. <i>Science Translational Medicine</i> , 2012, 4, 151ra125.	5.8	807
160	Preparing for PrEP. <i>European Journal of Contraception and Reproductive Health Care</i> , 2012, 17, 482-486.	0.6	1
161	Cross-reactive broadly neutralizing antibodies: timing is everything. <i>Frontiers in Immunology</i> , 2012, 3, 215.	2.2	27
162	Controlling the HIV/AIDS epidemic: current status and global challenges. <i>Frontiers in Immunology</i> , 2012, 3, 250.	2.2	25
163	The Potential Impact of Pre-Exposure Prophylaxis for HIV Prevention among Men Who Have Sex with Men and Transwomen in Lima, Peru: A Mathematical Modelling Study. <i>PLoS Medicine</i> , 2012, 9, e1001323.	3.9	76
164	Reduced Inflammation and CD4 Loss in Acute SHIV Infection During Oral Pre-Exposure Prophylaxis. <i>Journal of Infectious Diseases</i> , 2012, 206, 770-779.	1.9	20
165	Clinical round-up. <i>Sexually Transmitted Infections</i> , 2012, 88, 475-476.	0.8	0
166	Preconception and Contraceptive Care for Women Living with HIV. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2012, 2012, 1-14.	0.4	25
167	Antiretroviral medication for preventing HIV infection in nonoccupational settings. <i>Cmaj</i> , 2012, 184, 1153-1157.	0.9	3
168	Challenges for HIV Pre-Exposure Prophylaxis among Men Who Have Sex with Men in the United States. <i>PLoS Medicine</i> , 2012, 9, e1001286.	3.9	56
169	Pregnancy and Infant Outcomes among HIV-Infected Women Taking Long-Term ART with and without Tenofovir in the DART Trial. <i>PLoS Medicine</i> , 2012, 9, e1001217.	3.9	116
170	Pharmacokinetics of Tenofovir following Intravaginal and Intrarectal Administration of Tenofovir Gel to Rhesus Macaques. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 103-109.	1.4	70

#	ARTICLE	IF	CITATIONS
171	Antiretroviral-Based HIV-1 Prevention: Antiretroviral Treatment and Pre-Exposure Prophylaxis. <i>Antiviral Therapy</i> , 2012, 17, 1483-1493.	0.6	34
172	HIV Treatment as Prevention: Models, Data, and Questionsâ€”Towards Evidence-Based Decision-Making. <i>PLoS Medicine</i> , 2012, 9, e1001259.	3.9	64
173	â€œThe study has taught me to be supportive of herâ€™: empowering women and involving men in microbicide research. <i>Culture, Health and Sexuality</i> , 2012, 14, 181-194.	1.0	36
174	The HIV Epidemic: High-Income Countries. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a007195-a007195.	2.9	33
175	Compared to Subcutaneous Tenofovir, Oral Tenofovir Disoproxyl Fumarate Administration Preferentially Concentrates the Drug into Gut-Associated Lymphoid Cells in Simian Immunodeficiency Virus-Infected Macaques. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4980-4984.	1.4	10
176	Perceptions of Sexual Risk Compensation Following Posttrial HIV Vaccine Uptake Among Young South Africans. <i>Qualitative Health Research</i> , 2012, 22, 668-678.	1.0	17
177	HIV-1 Drug Resistance Resulting from Antiretroviral Therapy Far Exceeds That From Pre-exposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2012, 55, 303-304.	2.9	27
178	Behavioral and Biomedical Combination Strategies for HIV Prevention. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a007435-a007435.	2.9	59
179	The Cost-effectiveness of Pre-Exposure Prophylaxis for HIV Infection in South African Women. <i>Clinical Infectious Diseases</i> , 2012, 54, 1504-1513.	2.9	85
180	Considerations regarding antiretroviral chemoprophylaxis and heterosexuals in generalized epidemic settings. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 557-562.	1.5	5
181	Testing for acute HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 125-130.	1.5	40
182	Animal models of antiretroviral prophylaxis for HIV prevention. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 505-513.	1.5	42
184	Women and HIV. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 58-65.	1.3	9
185	Costâ€“effectiveness of pre-exposure prophylaxis for HIV. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 587-592.	1.5	51
186	The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 563-568.	1.5	18
187	Engaging healthcare providers to implement HIV pre-exposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 593-599.	1.5	76
188	Treatment-for-prevention. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 131-139.	1.5	18
189	Considerations regarding antiretroviral chemoprophylaxis in MSM. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 549-556.	1.5	7

#	ARTICLE	IF	CITATIONS
190	Antiretrovirals and safer conception for HIV-serodiscordant couples. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 569-578.	1.5	122
191	Tenofovir-based pre-exposure prophylaxis for HIV prevention. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 51-57.	1.3	139
192	The clinical pharmacology of antiretrovirals for HIV prevention. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 498-504.	1.5	21
193	Antiretrovirals and HIV prevention. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 495-497.	1.5	1
194	Tuberculosis and HIV Control in Sub-Saharan African Prisons: "Thinking Outside the Prison Cell". <i>Journal of Infectious Diseases</i> , 2012, 205, S265-S273.	1.9	50
195	Clinical round-up. <i>Sexually Transmitted Infections</i> , 2012, 88, 394-394.	0.8	0
196	HIV Prevention by Oral Preexposure Prophylaxis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a007419-a007419.	2.9	29
197	Preexposure Prophylaxis for HIV Infection among African Women. <i>New England Journal of Medicine</i> , 2012, 367, 411-422.	13.9	1,377
198	Willingness to use HIV pre-exposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual men. <i>Sexually Transmitted Infections</i> , 2012, 88, 258-263.	0.8	111
199	The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK. <i>International Journal of STD and AIDS</i> , 2012, 23, 1-4.	0.5	34
200	Reply to Parikh and Mellors. <i>Clinical Infectious Diseases</i> , 2012, 55, 304-304.	2.9	6
201	Microbicides: Topical Prevention against HIV. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a007385-a007385.	2.9	99
202	Untested and undiagnosed: barriers to HIV testing among men who have sex with men, Beijing, China. <i>Sexually Transmitted Infections</i> , 2012, 88, 187-193.	0.8	62
203	Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. <i>New England Journal of Medicine</i> , 2012, 367, 423-434.	13.9	1,692
204	Future Prospects and Perspectives on Microbicides. <i>Current HIV Research</i> , 2012, 10, 113-115.	0.2	5
205	A decade of research involving men who have sex with men in sub-Saharan Africa: Current knowledge and future directions. <i>Sahara J</i> , 2012, 9, 137-147.	0.4	55
206	Antiretrovirals for HIV Exposure Prophylaxis. <i>Current Medicinal Chemistry</i> , 2012, 19, 5924-5939.	1.2	1
207	Ethical Issues in Microbicide Clinical Trials for HIV Prevention. <i>Current HIV Research</i> , 2012, 10, 105-112.	0.2	1

#	ARTICLE	IF	CITATIONS
208	Preexposure Prophylaxis with Albumin-Conjugated C34 Peptide HIV-1 Fusion Inhibitor in SCID-hu Thy/Liv Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2162-2165.	1.4	14
209	Antiretroviral treatment in low-resource settings: what has changed in the last 10 years and what needs to change in the coming years?. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 1287-1296.	2.0	5
210	Non-Specific Microbicide Product Development: Then and Now. <i>Current HIV Research</i> , 2012, 10, 9-18.	0.2	18
211	Formulation and Delivery of Microbicides. <i>Current HIV Research</i> , 2012, 10, 88-96.	0.2	24
212	Preexposure Prophylaxis for HIV Prevention. <i>New England Journal of Medicine</i> , 2012, 367, 462-465.	13.9	9
213	Preexposure Prophylaxis for HIV – Where Do We Go from Here?. <i>New England Journal of Medicine</i> , 2012, 367, 459-461.	13.9	55
214	Mechanisms and Modifications of Naturally Occurring Host Defense Peptides for Anti-HIV Microbicide Development. <i>Current HIV Research</i> , 2012, 10, 61-72.	0.2	22
215	New HIV prevention technologies and their relevance to MARPS in African epidemics. <i>Sahara J</i> , 2012, 9, 164-166.	0.4	7
216	Correlation of Prospective and Cross-Sectional Measures of HIV Type 1 Incidence in a Higher-Risk Cohort in Ho Chi Minh City, Vietnam. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 866-873.	0.5	11
217	RMP-02/MTN-006: A Phase 1 Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Tenofovir 1% Gel Compared with Oral Tenofovir Disoproxil Fumarate. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1412-1421.	0.5	129
218	The Nonnucleoside Reverse Transcription Inhibitor MIV-160 Delivered from an Intravaginal Ring, But Not from a Carrageenan Gel, Protects Against Simian/Human Immunodeficiency Virus-RT Infection. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1467-1475.	0.5	28
219	The Use of Nonhuman Primate Models of HIV Infection for the Evaluation of Antiviral Strategies. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 16-35.	0.5	47
220	<i>In Vitro</i> Restoration of Th17 Response During HIV Infection with an Antiretroviral Drug and Th17 Differentiation Cytokines. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 823-834.	0.5	12
221	Partially Hidden Markov Model for Time-Varying Principal Stratification in HIV Prevention Trials. <i>Journal of the American Statistical Association</i> , 2012, 107, 52-65.	1.8	8
222	Evolution of Massachusetts Physician Attitudes, Knowledge, and Experience Regarding the Use of Antiretrovirals for HIV Prevention. <i>AIDS Patient Care and STDs</i> , 2012, 26, 395-405.	1.1	84
223	“œ Think Having the Option Available is a No-Brainer” Will Gay and Bisexually Active Men at High Risk of Infection Use Over-the-Counter Rapid HIV Tests to Screen Sexual Partners?. <i>Journal of Sex Research</i> , 2012, 49, 388-389.	1.6	3
224	Will Gay and Bisexually Active Men at High Risk of Infection Use Over-the-Counter Rapid HIV Tests to Screen Sexual Partners?. <i>Journal of Sex Research</i> , 2012, 49, 379-387.	1.6	95
225	HIV epidemic in Asia: optimizing and expanding vaccine development. <i>Expert Review of Vaccines</i> , 2012, 11, 805-819.	2.0	10

#	ARTICLE	IF	CITATIONS
226	Associations of Consistent Condom Use Among Men Who Have Sex with Men in Abuja, Nigeria. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1756-1762.	0.5	26
227	Social Network and Risk-Taking Behavior Most Associated with Rapid HIV Testing, Circumcision, and Preexposure Prophylaxis Acceptability Among High-Risk Indian Men. <i>AIDS Patient Care and STDs</i> , 2012, 26, 631-640.	1.1	20
228	Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2012, 24, 468-477.	0.6	40
229	How Good Is "Good Enough"? The Case for Varying Standards of Evidence According to Need for New Interventions in HIV Prevention. <i>American Journal of Bioethics</i> , 2012, 12, 21-30.	0.5	18
230	Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 8694-8698.	3.3	44
231	Meta-Analysis of Single-Session Behavioral Interventions to Prevent Sexually Transmitted Infections: Implications for Bundling Prevention Packages. <i>American Journal of Public Health</i> , 2012, 102, e34-e44.	1.5	75
232	The impact of peer outreach on HIV knowledge and prevention behaviours of male sex workers in Mombasa, Kenya. <i>Sexually Transmitted Infections</i> , 2012, 88, 357-362.	0.8	49
233	Trends in the incidence of HIV in Scotland, 1988-2009. <i>Sexually Transmitted Infections</i> , 2012, 88, 194-199.	0.8	12
234	Sustained Release of the CCR5 Inhibitors CMPD167 and Maraviroc from Vaginal Rings in Rhesus Macaques. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2251-2258.	1.4	60
235	Safety and Pharmacokinetics of Intravaginal Rings Delivering Tenofovir in Pig-Tailed Macaques. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5952-5960.	1.4	43
236	Risks for HIV Infection Among Gay, Bisexual, and Other Men Who Have Sex with Men in Moscow and St. Petersburg, Russia. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 874-879.	0.5	14
237	A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 695-715.	1.9	22
238	Sexual Risk Behaviors and Acceptability of HIV Pre-Exposure Prophylaxis Among HIV-Negative Gay and Bisexual Men in Serodiscordant Relationships: A Mixed Methods Study. <i>AIDS Patient Care and STDs</i> , 2012, 26, 87-94.	1.1	161
239	The Future of HIV Prevention in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 347.	3.8	33
241	HIV Racial Disparities. <i>Archives of Internal Medicine</i> , 2012, 172, 1599.	4.3	5
242	Attitudes and Program Preferences of African-American Urban Young Adults About Pre-Exposure Prophylaxis (PrEP). <i>AIDS Education and Prevention</i> , 2012, 24, 408-421.	0.6	168
243	Reproductive Counseling by Clinic Healthcare Workers in Durban, South Africa: Perspectives from HIV-Infected Men and Women Reporting Serodiscordant Partners. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2012, 2012, 1-9.	0.4	42
244	Evaluating Safer Conception Options for HIV-Serodiscordant Couples (HIV-Infected) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 67 and Gynecology, 2012, 2012, 1-7.	0.4	48

#	ARTICLE	IF	CITATIONS
245	Low Bone Mass in Behaviorally HIV-Infected Young Men on Antiretroviral Therapy: Adolescent Trials Network Study 021B. <i>Clinical Infectious Diseases</i> , 2012, 55, 461-468.	2.9	52
246	Effect of HIV-1 Infection and Sex on the Cellular Pharmacology of the Antiretroviral Drugs Zidovudine and Lamivudine. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3011-3019.	1.4	12
248	Rectal microbicide development. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 526-533.	1.5	17
249	Oral antiretroviral chemoprophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 514-519.	1.5	23
250	Next-generation oral preexposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 600-606.	1.5	29
251	HIV Treatment As Prevention: How Scientific Discovery Occurred And Translated Rapidly Into Policy For The Global Response. <i>Health Affairs</i> , 2012, 31, 1439-1449.	2.5	40
252	The Program Science initiative: improving the planning, implementation and evaluation of HIV/STI prevention programs. <i>Sexually Transmitted Infections</i> , 2012, 88, 157-159.	0.8	37
254	Progress, Challenges, and New Opportunities for the Prevention of Mother-to-Child Transmission of HIV Under the US President's Emergency Plan for AIDS Relief. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, S78-S87.	0.9	59
255	Declining adherence is a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial. <i>Aids</i> , 2012, 26, 2261.	1.0	4
256	Characterization of Peripheral and Mucosal Immune Responses In Rhesus Macaques on Long-Term Tenofovir and Emtricitabine Combination Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 425-435.	0.9	10
257	Sexual Risk Behaviors, Circumcision Status, and Preexisting Immunity to Adenovirus Type 5 Among Men Who Have Sex With Men Participating in a Randomized HIV-1 Vaccine Efficacy Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 405-413.	0.9	31
258	PEPFAR's Evolving HIV Prevention Approaches for Key Populations—People Who Inject Drugs, Men Who Have Sex With Men, and Sex Workers. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, S145-S151.	0.9	26
259	HIV incidence and prevalence among cohorts of women with higher risk behaviour in Bloemfontein and Rustenburg, South Africa: a prospective study. <i>BMJ Open</i> , 2012, 2, e000626.	0.8	14
260	Views of policymakers, healthcare workers and NGOs on HIV pre-exposure prophylaxis (PrEP): a multinational qualitative study. <i>BMJ Open</i> , 2012, 2, e001234.	0.8	49
261	Design challenges facing clinical trials of the effectiveness of new HIV-prevention technologies. <i>Aids</i> , 2012, 26, 529-532.	1.0	9
262	Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. <i>Aids</i> , 2012, 26, F13-F19.	1.0	285
263	Prevention of sexual transmission of HIV. <i>Aids</i> , 2012, 26, 1223-1229.	1.0	17
264	Condom use: still a sexual health staple. <i>Sexual Health</i> , 2012, 9, 1.	0.4	16

#	ARTICLE	IF	CITATIONS
265	Beyond the Distinction Between Biomedical and Social Dimensions of HIV Prevention Through the Lens of a Social Public Health. <i>American Journal of Public Health</i> , 2012, 102, 789-799.	1.5	152
266	Obama, Marriage Equality, and the Health of Gay Men. <i>American Journal of Public Health</i> , 2012, 102, 1628-1629.	1.5	18
267	Editorial: [Hot Topic: Use of Microbicides to Prevent HIV Sexual Transmission (Guest Editor: Miguel E.) <i>Tj ETQq0 0 0 rgBT /Overlock 10 T</i>	0.2	16
268	The design and evaluation of HIV-1 vaccines. <i>Aids</i> , 2012, 26, 1293-1302.	1.0	41
269	Antiviral agents and HIV prevention. <i>Aids</i> , 2012, 26, 1585-1598.	1.0	89
270	Unprotected Sex, Underestimated Risk, Undiagnosed HIV and Sexually Transmitted Diseases Among Men Who Have Sex With Men Accessing Testing Services in a New England Bathhouse. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 194-198.	0.9	45
271	Preexposure Prophylaxis for HIV Infection. <i>Southern Medical Journal</i> , 2012, 105, 199-206.	0.3	84
272	The 15th Bangkok International Symposium on HIV Medicine. <i>Future Virology</i> , 2012, 7, 341-344.	0.9	0
273	Oral antiretroviral therapy for the prevention of HIV-1 infection: ready for prime time?. <i>Clinical Investigation</i> , 2012, 2, 1-4.	0.0	1
274	Evaluation of Microbicide Gel Adherence Monitoring Methods. <i>Sexually Transmitted Diseases</i> , 2012, 39, 335-340.	0.8	21
275	Reply to "Declining adherence as a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial". <i>Aids</i> , 2012, 26, 2262-2263.	1.0	0
276	The pros and cons of urinary lipoarabinomannan testing. <i>Aids</i> , 2012, 26, 2263-2264.	1.0	3
277	Is an HIV Vaccine Possible?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, S41-S43.	0.9	6
278	Does maternal use of tenofovir during pregnancy affect growth of HIV-exposed uninfected infants?. <i>Aids</i> , 2012, 26, 1167-1169.	1.0	5
279	Reply to Boyles. <i>Aids</i> , 2012, 26, 2264-2265.	1.0	0
280	Development of a Clinical Screening Index Predictive of Incident HIV Infection Among Men Who Have Sex With Men in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 421-427.	0.9	213
281	State of The Science of Adherence in Pre-Exposure Prophylaxis and Microbicide Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 490-498.	0.9	51
282	Treatment as prevention. <i>Aids</i> , 2012, 26, 519-520.	1.0	1

#	ARTICLE	IF	CITATIONS
283	Prevention of Sexually Transmitted HIV Infections Through the President's Emergency Plan for AIDS Relief. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 60, S70-S77.	0.9	2
284	Safety of Tenofovir Gel, a Vaginal Microbicide, in South African Women: Results of the Caprisa 004 Trial. <i>Antiviral Therapy</i> , 2013, 18, 301-310.	0.6	21
286	Voluntary counseling and testing (VCT) for changing HIV-related risk behavior in developing countries. <i>The Cochrane Library</i> , 2012, , CD001224.	1.5	128
287	The Future of HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 60, S22-S26.	0.9	16
288	The United States President's Emergency Plan for AIDS Relief. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 60, S51-S56.	0.9	40
289	Apparent declining efficacy in randomized trials. <i>Aids</i> , 2012, 26, 123-126.	1.0	35
290	High HIV incidence among MSM prescribed postexposure prophylaxis, 2000â€“2009. <i>Aids</i> , 2012, 26, 505-512.	1.0	34
291	Identifying At-Risk Populations in Kenya and South Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, 185-193.	0.9	103
292	Gene data to hit milestone. <i>Nature</i> , 2012, 487, 282-283.	13.7	31
293	Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. <i>Yearbook of Pediatrics</i> , 2012, 2012, 271-272.	0.2	21
294	Raltegravir, Tenofovir DF, and Emtricitabine for Postexposure Prophylaxis to Prevent the Sexual Transmission of HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, 354-359.	0.9	71
295	Pre-exposure prophylaxis: Where HIV prevention and responsibility intersect. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2012, 25, 61-62.	0.1	3
296	Canadian HIV Pregnancy Planning Guidelines. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2012, 34, 575-590.	0.3	37
297	What Primary Care Providers Need to Know About Preexposure Prophylaxis for HIV Prevention. <i>Annals of Internal Medicine</i> , 2012, 157, 490.	2.0	32
298	Why I Voted â€œNoâ€ to Truvada PrEP. <i>Annals of Internal Medicine</i> , 2012, 157, 519.	2.0	10
299	Truvada PrEP: Why I Voted â€œYesâ€ Annals of Internal Medicine, 2012, 157, 521.	2.0	5
300	Guidelines for Improving Entry Into and Retention in Care and Antiretroviral Adherence for Persons With HIV: Evidence-Based Recommendations From an International Association of Physicians in AIDS Care Panel. <i>Annals of Internal Medicine</i> , 2012, 156, 817.	2.0	519
301	Antiretroviral Medication and HIV Prevention: New Steps Forward and New Questions. <i>Annals of Internal Medicine</i> , 2012, 156, 312.	2.0	28

#	ARTICLE	IF	CITATIONS
302	HIV Infection and Older Americans: The Public Health Perspective. American Journal of Public Health, 2012, 102, 1516-1526.	1.5	175
303	Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet, The, 2012, 379, 2409-2411.	6.3	64
304	Antiretroviral prophylaxis for HIV prevention reaches a key milestone. Lancet, The, 2012, 379, 2047-2048.	6.3	8
305	From personal survival to public health: community leadership by men who have sex with men in the response to HIV. Lancet, The, 2012, 380, 400-410.	6.3	106
306	Successes and challenges of HIV prevention in men who have sex with men. Lancet, The, 2012, 380, 388-399.	6.3	349
307	A call to action for comprehensive HIV services for men who have sex with men. Lancet, The, 2012, 380, 424-438.	6.3	226
308	Predicting effect of pre-exposure prophylaxis on HIV epidemics. Lancet, The, 2012, 379, 2423.	6.3	2
309	Safety and efficacy of tenofovir/IQP-0528 combination gels "A dual compartment microbicide for HIV-1 prevention. Antiviral Research, 2012, 96, 221-225.	1.9	34
310	Periodontal disease in HIV/AIDS. Periodontology 2000, 2012, 60, 78-97.	6.3	61
311	Plasmacytoid Dendritic Cells in HIV Infection. Advances in Experimental Medicine and Biology, 2012, 762, 71-107.	0.8	58
312	Given Financial Constraints, It Would Be Unethical To Divert Antiretroviral Drugs From Treatment To Prevention. Health Affairs, 2012, 31, 1537-1544.	2.5	34
313	Modulation of HIV reservoirs by host HLA: bridging the gap between vaccine and cure. Current Opinion in Virology, 2012, 2, 599-605.	2.6	8
314	Antiviral therapy: old and current issues. International Journal of Antimicrobial Agents, 2012, 40, 95-102.	1.1	62
315	Synthesis and Cytotoxic Activity of Novel 5-Substituted-1-(β -L-Arabinofuranosyl) Pyrimidine Nucleosides. Nucleosides, Nucleotides and Nucleic Acids, 2012, 31, 482-500.	0.4	7
316	Ten Paths to the Discovery of Antivirally Active Nucleoside and Nucleotide Analogues. Nucleosides, Nucleotides and Nucleic Acids, 2012, 31, 339-352.	0.4	19
317	Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infectious Diseases, The, 2012, 12, 19-26.	4.6	375
318	HIV Incidence in Young Girls in KwaZulu-Natal, South Africa-Public Health Imperative for Their Inclusion in HIV Biomedical Intervention Trials. AIDS and Behavior, 2012, 16, 1870-1876.	1.4	54
319	High Acceptability of a Vaginal Ring Intended as a Microbicide Delivery Method for HIV Prevention in African Women. AIDS and Behavior, 2012, 16, 1775-1786.	1.4	84

#	ARTICLE	IF	CITATIONS
320	Can Money Prevent the Spread of HIV? A Review of Cash Payments for HIV Prevention. <i>AIDS and Behavior</i> , 2012, 16, 1729-1738.	1.4	164
321	Vaginal Ring Adherence in Sub-Saharan Africa: Expulsion, Removal, and Perfect Use. <i>AIDS and Behavior</i> , 2012, 16, 1787-1798.	1.4	74
322	Use of a Rapid HIV Home Test Prevents HIV Exposure in a High Risk Sample of Men Who Have Sex With Men. <i>AIDS and Behavior</i> , 2012, 16, 1753-1760.	1.4	124
323	Sustained Local Delivery of Structurally Diverse HIV-1 Microbicides Released from Sublimation Enthalpy Controlled Matrices. <i>Pharmaceutical Research</i> , 2012, 29, 3156-3168.	1.7	8
324	Pharmacists as providers of HIV pre-exposure prophylaxis. <i>International Journal of Clinical Pharmacy</i> , 2012, 34, 803-806.	1.0	29
325	Demographic and Behavioral Correlates of HIV Risk among Men and Transgender Women Recruited from Gay Entertainment Venues and Community-based Organizations in Thailand: Implications for HIV Prevention. <i>Prevention Science</i> , 2012, 13, 483-492.	1.5	38
326	As Good As It Gets? The Problem of HIV Persistence despite Antiretroviral Drugs. <i>Cell Host and Microbe</i> , 2012, 12, 132-138.	5.1	35
328	A typology of structural approaches to HIV prevention: A commentary on Roberts and Matthews. <i>Social Science and Medicine</i> , 2012, 75, 1562-1567.	1.8	17
330	Intimacy and Sexual Decision Making: Exploring the Perspective of HIV Positive Women Over 50. <i>AIDS Patient Care and STDs</i> , 2012, 26, 755-760.	1.1	32
331	HIV Treatment Adherence, Patient Health Literacy, and Health Care Provider's Patient Communication. <i>Journal of the International Association of Providers of AIDS Care</i> , 2012, 11, 128-133.	1.2	45
332	A social vaccine? Social and structural contexts of HIV vaccine acceptability among most-at-risk populations in Thailand. <i>Global Public Health</i> , 2012, 7, 1009-1024.	1.0	24
333	A control systems approach to HIV prevention with impulsive control input. , 2012, , .		2
334	Improved outlook on HIV-1 prevention and vaccine development. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 983-994.	1.4	5
335	Combination Nucleoside/Nucleotide Reverse Transcriptase Inhibitors for Treatment of HIV Infection. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 65-79.	0.9	18
336	HIV-Negative Seroconcordant Gay Male Couples' Attitudes, Intentions, and Perceived Behavioral Control for Planned Condom Use Within and Outside of Their Relationships. <i>International Journal of Sexual Health</i> , 2012, 24, 239-253.	1.2	9
337	Antiviral Breadth and Combination Potential of Peptide Triazole HIV-1 Entry Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1073-1080.	1.4	33
338	Transformations in the Medicalization of Sex: HIV Prevention between Discipline and Biopolitics. <i>Journal of Sex Research</i> , 2012, 49, 353-361.	1.6	37
339	Bring safe sex to China. <i>Nature</i> , 2012, 485, 576-577.	13.7	88

#	ARTICLE	IF	CITATIONS
340	HIV Risk Perception and Preexposure Prophylaxis Interest Among a Heterosexual Population Visiting a Sexually Transmitted Infection Clinic. <i>AIDS Patient Care and STDs</i> , 2012, 26, 222-233.	1.1	72
341	Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. <i>Trends in Microbiology</i> , 2012, 20, 268-274.	3.5	60
342	Virological and molecular characterization of a simian human immunodeficiency virus (SHIV) encoding the envelope and reverse transcriptase genes from HIV-1. <i>Virology</i> , 2012, 432, 173-183.	1.1	9
343	The Surprising Role of Amyloid Fibrils in HIV Infection. <i>Biology</i> , 2012, 1, 58-80.	1.3	56
344	Preexposure Prophylaxis for HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 865.	3.8	9
345	Ethical Challenges of Preexposure Prophylaxis for HIV. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 867.	3.8	23
347	Canadian HIV Pregnancy Planning Guidelines. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 119, 89-99.	1.0	20
350	The Beginning of the End of AIDS?. <i>New England Journal of Medicine</i> , 2012, 367, 685-687.	13.9	48
351	Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis. <i>Retrovirology</i> , 2012, 9, 40.	0.9	14
352	Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation. <i>Implementation Science</i> , 2012, 7, 116.	2.5	72
353	Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. <i>New England Journal of Medicine</i> , 2012, 367, 399-410.	13.9	2,665
354	NRTI Backbone in HIV Treatment. <i>Drugs</i> , 2012, 72, 2051-2062.	4.9	19
355	Human Immunodeficiency Virus Infection : from Biological Observations to Mechanistic Mathematical Modelling. <i>Mathematical Modelling of Natural Phenomena</i> , 2012, 7, 78-104.	0.9	43
356	A conceptual framework for understanding HIV risk behavior in the context of supporting fertility goals among HIV-serodiscordant couples. <i>Reproductive Health Matters</i> , 2012, 20, 50-60.	1.3	59
357	Human viral diseases: what is next for antiviral drug discovery?. <i>Current Opinion in Virology</i> , 2012, 2, 572-579.	2.6	30
358	Microbicides: still a long road to success. <i>Trends in Microbiology</i> , 2012, 20, 369-375.	3.5	27
359	Pediatric HIV Infection. <i>Advances in Pediatrics</i> , 2012, 59, 9-26.	0.5	7
361	Special issues regarding women with HIV infection. , 2012, , 521-536.		0

#	ARTICLE	IF	CITATIONS
362	HIV prevention. , 2012, , 113-121.		0
363	Overview of antiretroviral therapy. , 2012, , 133-153.		0
364	Targeting host cofactors to inhibit viral infection. <i>Frontiers in Biology</i> , 2012, 7, 445-458.	0.7	0
365	The Cost of Science. <i>Journal of Bioethical Inquiry</i> , 2012, 9, 295-310.	0.9	25
366	HIV and chemoprophylaxis, the importance of considering social structures alongside biomedical and behavioral intervention. <i>Social Science and Medicine</i> , 2012, 75, 1555-1561.	1.8	29
367	Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 489-500.	1.9	7
368	The World Must Build On Three Decades Of Scientific Advances To Enable A New Generation To Live Free Of HIV/AIDS. <i>Health Affairs</i> , 2012, 31, 1529-1536.	2.5	14
369	Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. <i>The Cochrane Library</i> , 2012, , CD007189.	1.5	73
370	Understanding Factors That Modulate HIV Infection at the Female Genital Tract Mucosae for the Rationale Design of Microbicides. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1485-1497.	0.5	7
371	Safety and Adherence to Intermittent Pre-Exposure Prophylaxis (PrEP) for HIV-1 in African Men Who Have Sex with Men and Female Sex Workers. <i>PLoS ONE</i> , 2012, 7, e33103.	1.1	131
372	High and Persistent HIV Seroincidence in Men Who Have Sex with Men across 47 U.S. Cities. <i>PLoS ONE</i> , 2012, 7, e34972.	1.1	52
373	Allocating HIV Prevention Funds in the United States: Recommendations from an Optimization Model. <i>PLoS ONE</i> , 2012, 7, e37545.	1.1	31
374	Biomarker-Based HIV Incidence in a Community Sample of Men Who Have Sex with Men in Paris, France. <i>PLoS ONE</i> , 2012, 7, e39872.	1.1	34
375	Transmitted Antiretroviral Drug Resistance in New York State, 2006-2008: Results from a New Surveillance System. <i>PLoS ONE</i> , 2012, 7, e40533.	1.1	21
376	A Qualitative Study of Provider Thoughts on Implementing Pre-Exposure Prophylaxis (PrEP) in Clinical Settings to Prevent HIV Infection. <i>PLoS ONE</i> , 2012, 7, e40603.	1.1	123
377	Searching for Lower Female Genital Tract Soluble and Cellular Biomarkers: Defining Levels and Predictors in a Cohort of Healthy Caucasian Women. <i>PLoS ONE</i> , 2012, 7, e43951.	1.1	69
378	A Complex Systems Approach to Evaluate HIV Prevention in Metropolitan Areas: Preliminary Implications for Combination Intervention Strategies. <i>PLoS ONE</i> , 2012, 7, e44833.	1.1	42
379	Attitudes and Acceptance of Oral and Parenteral HIV Preexposure Prophylaxis among Potential User Groups: A Multinational Study. <i>PLoS ONE</i> , 2012, 7, e28238.	1.1	205

#	ARTICLE	IF	CITATIONS
380	Expanding ART for Treatment and Prevention of HIV in South Africa: Estimated Cost and Cost-Effectiveness 2011-2050. PLoS ONE, 2012, 7, e30216.	1.1	125
381	Prevention of Vaginal SHIV Transmission in Macaques by a Coitally-Dependent Truvada Regimen. PLoS ONE, 2012, 7, e50632.	1.1	64
382	HIV pre-exposure prophylaxis. BMJ, The, 2012, 345, e5412-e5412.	3.0	7
383	Increased HIV testing in men who have sex with men. BMJ: British Medical Journal, 2012, 344, e501-e501.	2.4	4
384	Simian-Human Immunodeficiency Viruses and Their Impact on Non-Human Primate Models for AIDS. , 2012, , .		3
385	Sexual transmission of HIV. , 2012, , 11-73.		4
386	Wary approval for drug to prevent HIV. Nature, 2012, 487, 283-283.	13.7	2
387	Prevention of Human Immunodeficiency Virus Infection. , 2012, , 2182-2185.		0
388	What's Love Got to Do With It? Explaining Adherence to Oral Antiretroviral Pre-Exposure Prophylaxis for HIV-Serodiscordant Couples. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 463-468.	0.9	221
389	Operational Research to Improve HIV Prevention in the United States. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 530-536.	0.9	18
390	Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females. International Journal of Women's Health, 2012, 4, 341.	1.1	14
391	Beyond Virological Suppression: The Role of Adherence in the Late Haart Era. Antiviral Therapy, 2012, 17, 785-792.	0.6	33
392	Willingness to use pre-exposure prophylaxis for HIV prevention among female sex workers: a cross-sectional study in China. HIV/AIDS - Research and Palliative Care, 2012, 4, 149.	0.4	20
393	Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis. Journal of the International AIDS Society, 2012, 15, 17701.	1.2	13
394	The Cost-Effectiveness of Preexposure Prophylaxis for HIV Prevention in the United States in Men Who Have Sex With Men. Annals of Internal Medicine, 2012, 156, 541.	2.0	186
395	The use of preexposure treatments for HIV prophylaxis. HIV/AIDS - Research and Palliative Care, 2012, 4, 17.	0.4	3
396	An Intravaginal Ring for the Simultaneous Delivery of Multiple Drugs. Journal of Pharmaceutical Sciences, 2012, 101, 2833-2843.	1.6	77
397	<i>Tenofovir: Quo Vadis Anno 2012 (Where Is It Going in the Year 2012)</i>?. Medicinal Research Reviews, 2012, 32, 765-785.	5.0	21

#	ARTICLE	IF	CITATIONS
398	Two Unique Recombinant Forms Identified in Incident HIV Type 1 Infections in Thai Blood Donors. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1703-1711.	0.5	3
399	Current Status of Research on HIV Epidemic, Pathogenesis, Management and Prevention in India. <i>Proceedings of the National Academy of Sciences India Section B - Biological Sciences</i> , 2012, 82, 167-180.	0.4	3
400	Polymeric Nanoparticles Affect the Intracellular Delivery, Antiretroviral Activity and Cytotoxicity of the Microbicide Drug Candidate Dapivirine. <i>Pharmaceutical Research</i> , 2012, 29, 1468-1484.	1.7	74
401	HIV Prevention Interventions to Reduce Racial Disparities in the United States: A Systematic Review. <i>Journal of General Internal Medicine</i> , 2012, 27, 1047-1067.	1.3	37
402	HIV-1 Prevention for HIV-1 Serodiscordant Couples. <i>Current HIV/AIDS Reports</i> , 2012, 9, 160-170.	1.1	80
403	The Promise of Antiretrovirals for HIV Prevention. <i>Current Infectious Disease Reports</i> , 2012, 14, 185-193.	1.3	13
404	Willingness to Participate in Future HIV Prevention Studies Among Gay and Bisexual Men in Scotland, UK: A Challenge for Intervention Trials. <i>AIDS and Behavior</i> , 2012, 16, 1420-1429.	1.4	3
405	Using Conjoint Analysis to Measure the Acceptability of Rectal Microbicides Among Men Who Have Sex with Men in Four South American Cities. <i>AIDS and Behavior</i> , 2012, 16, 1436-1447.	1.4	32
406	HIV/AIDS-Related Stigmatizing and Discriminatory Attitudes and Recent HIV Testing Among Men Who Have Sex With Men in Beijing. <i>AIDS and Behavior</i> , 2012, 16, 499-507.	1.4	57
407	Supporting Study Product Use and Accuracy in Self-Report in the iPrEx Study: Next Step Counseling and Neutral Assessment. <i>AIDS and Behavior</i> , 2012, 16, 1243-1259.	1.4	71
408	A natural theaflavins preparation inhibits HIV-1 infection by targeting the entry step: Potential applications for preventing HIV-1 infection. <i>FA-toterapA-Åç</i> , 2012, 83, 348-355.	1.1	51
409	Safer conception options for HIV-serodiscordant couples. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 206, e21.	0.7	5
411	Pre-exposure chemoprophylaxis of HIV infection: Quo vadis?. <i>Biochemical Pharmacology</i> , 2012, 83, 567-573.	2.0	7
412	Derivation of non-infectious envelope proteins from virions isolated from plasma negative for HIV antibodies. <i>Biologicals</i> , 2012, 40, 15-20.	0.5	4
413	Overview of microbicides for the prevention of human immunodeficiency virus. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012, 26, 427-439.	1.4	34
414	Carbosilane dendrimer nanotechnology outlines of the broad HIV blocker profile. <i>Journal of Controlled Release</i> , 2012, 161, 949-958.	4.8	82
415	Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. <i>Virology</i> , 2012, 422, 22-36.	1.1	22
416	Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-infectious population of men who have sex with men. <i>HIV Medicine</i> , 2012, 13, 309-314.	1.0	11

#	ARTICLE	IF	CITATIONS
417	"Now we are in a different time; various bad diseases have come." understanding men's acceptability of male circumcision for HIV prevention in a moderate prevalence setting. BMC Public Health, 2012, 12, 67.	1.2	28
418	HIV/AIDS in Women and Racial/Ethnic Minorities in the U.S.. Current Infectious Disease Reports, 2012, 14, 53-60.	1.3	25
419	HIV in Africa: Challenges and Directions for the Next Decade. Current Infectious Disease Reports, 2012, 14, 91-101.	1.3	8
421	Fertility Desires Among HIV-Infected Men and Women in Los Angeles County: Client Needs and Provider Perspectives. Maternal and Child Health Journal, 2013, 17, 593-600.	0.7	33
422	Operations Research and Health Care Policy. Profiles in Operations Research, 2013, , .	0.3	10
423	The Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors in the Treatment of HIV Infections (AIDS). Advances in Pharmacology, 2013, 67, 317-358.	1.2	63
424	Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence. Expert Opinion on Pharmacotherapy, 2013, 14, 1777-1785.	0.9	14
425	A Sensitive Assay Using a Native Protein Substrate for Screening HIV-1 Maturation Inhibitors Targeting the Protease Cleavage Site between the Matrix and Capsid. Biochemistry, 2013, 52, 4929-4940.	1.2	8
426	Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists. BMC Infectious Diseases, 2013, 13, 217.	1.3	63
427	Reducing HIV and AIDS in Adolescents: Opportunities and Challenges. Current HIV/AIDS Reports, 2013, 10, 159-168.	1.1	46
428	Portfolios of Biomedical HIV Interventions in South Africa: A Cost-Effectiveness Analysis. Journal of General Internal Medicine, 2013, 28, 1294-1301.	1.3	35
429	Combination HIV Prevention: The Value and Interpretation of Mathematical Models. Current HIV/AIDS Reports, 2013, 10, 195-198.	1.1	7
430	HIV Testing: Current Practice and Future Directions. Current HIV/AIDS Reports, 2013, 10, 134-141.	1.1	34
431	Use of Antiretrovirals for HIV Prevention: What Do We Know and What Donâ€™t We Know?. Current HIV/AIDS Reports, 2013, 10, 142-151.	1.1	60
432	Antiretroviral Therapy for Prevention Is a Combination Strategy. Current HIV/AIDS Reports, 2013, 10, 152-158.	1.1	32
433	Combination Prevention: New Hope for Stopping the Epidemic. Current HIV/AIDS Reports, 2013, 10, 169-186.	1.1	68
434	State of Condom Use in HIV Prevention Science and Practice. Current HIV/AIDS Reports, 2013, 10, 59-64.	1.1	36
435	Methodological Lessons from Clinical Trials and the Future of Microbicide Research. Current HIV/AIDS Reports, 2013, 10, 89-102.	1.1	29

#	ARTICLE	IF	CITATIONS
436	A Peer-Educator Network HIV Prevention Intervention Among Injection Drug Users: Results of a Randomized Controlled Trial in St. Petersburg, Russia. <i>AIDS and Behavior</i> , 2013, 17, 2510-2520.	1.4	42
437	Emtricitabine/Tenofovir Disoproxil Fumarate: A Review of its Use in HIV-1 Pre-Exposure Prophylaxis. <i>Drugs</i> , 2013, 73, 279-291.	4.9	31
438	Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2083-2090.	6.3	1,197
439	HIV prevention for people who use substances: Evidence-based strategies. <i>Journal of Food and Drug Analysis</i> , 2013, 21, S91-S94.	0.9	2
440	Sexual behaviour among users of antiretroviral pre-exposure prophylaxis. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 996-997.	4.6	3
441	Rectal pre-exposure prophylaxis (PrEP). <i>Antiviral Research</i> , 2013, 100, S17-S24.	1.9	7
444	HIV treatment as prevention: The key to an AIDS-free generation. <i>Journal of Food and Drug Analysis</i> , 2013, 21, S95-S101.	0.9	40
445	Study designs for identifying risk compensation behavior among users of biomedical HIV prevention technologies: Balancing methodological rigor and research ethics. <i>Social Science and Medicine</i> , 2013, 94, 115-123.	1.8	41
446	Past, present and future: 30 years of HIV research. <i>Nature Reviews Microbiology</i> , 2013, 11, 877-883.	13.6	230
447	Development of the First AIDS Drugs: AZT and Other Dideoxynucleosides. , 2013, , 1-20.		0
448	Exploring Concentration Response in HIV Pre-Exposure Prophylaxis to Optimize Clinical Care and Trial Design. <i>Cell</i> , 2013, 155, 515-518.	13.5	60
449	Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. <i>New England Journal of Medicine</i> , 2013, 369, 2083-2092.	13.9	518
450	HIV prevention strategies. <i>Medicine</i> , 2013, 41, 466-469.	0.2	4
451	Summary Measures of Adherence Using Pill Counts in Two HIV Prevention Trials: The Need for Standardisation in Reporting. <i>AIDS and Behavior</i> , 2013, 17, 3108-3119.	1.4	9
452	Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention. <i>Retrovirology</i> , 2013, 10, 82.	0.9	6
453	Knowledge and Use of Pre-Exposure Prophylaxis Among an Online Sample of Young Men Who Have Sex with Men in New York City. <i>AIDS and Behavior</i> , 2013, 17, 2180-2184.	1.4	60
454	Adherence Support Approaches in Biomedical HIV Prevention Trials: Experiences, Insights and Future Directions from Four Multisite Prevention Trials. <i>AIDS and Behavior</i> , 2013, 17, 2143-2155.	1.4	123
455	Perceived Likelihood of Using HIV Pre-exposure Prophylaxis Medications Among Young Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2013, 17, 2173-2179.	1.4	75

#	ARTICLE	IF	CITATIONS
456	High Acceptability of HIV Pre-exposure Prophylaxis but Challenges in Adherence and Use: Qualitative Insights from a Phase I Trial of Intermittent and Daily PrEP in At-Risk Populations in Kenya. <i>AIDS and Behavior</i> , 2013, 17, 2162-2172.	1.4	222
457	HIV-Negative and HIV-Positive Gay Men's Attitudes to Medicines, HIV Treatments and Antiretroviral-based Prevention. <i>AIDS and Behavior</i> , 2013, 17, 2156-2161.	1.4	32
458	Moderate Levels of Depression Predict Sexual Transmission Risk in HIV-Infected MSM: A Longitudinal Analysis of Data From Six Sites Involved in a "Prevention for Positives" Study. <i>AIDS and Behavior</i> , 2013, 17, 1764-1769.	1.4	65
459	A Cross-Sectional Evaluation of Correlates of HIV Testing Practices Among Men Who Have Sex with Men (MSM) in Mongolia. <i>AIDS and Behavior</i> , 2013, 17, 1378-1385.	1.4	14
460	A Systematic Review to Identify Challenges of Demonstrating Efficacy of HIV Behavioral Interventions for Gay, Bisexual, and Other Men Who Have Sex with Men (MSM). <i>AIDS and Behavior</i> , 2013, 17, 1231-1244.	1.4	54
461	"It's Hard to Know What is a Risky or not a Risky Decision": Gay Men's Beliefs About Risk During Sex. <i>AIDS and Behavior</i> , 2013, 17, 1352-1361.	1.4	24
462	Prevalence and Predictors of Conscious Risk Behavior Among San Franciscan Men who have Sex with Men. <i>AIDS and Behavior</i> , 2013, 17, 1338-1343.	1.4	31
463	Sexual Risk Behavior and Risk Reduction Beliefs Among HIV-Positive Young Men Who have Sex with Men. <i>AIDS and Behavior</i> , 2013, 17, 1515-1523.	1.4	24
464	What constitutes the best sex life for gay and bisexual men? Implications for HIV prevention. <i>BMC Public Health</i> , 2013, 13, 1083.	1.2	22
465	Assessing the Cost Effectiveness of Pre-Exposure Prophylaxis for HIV Prevention in the US. <i>Pharmacoeconomics</i> , 2013, 31, 1091-1104.	1.7	10
466	Estimating the Number of Young Black Men who have Sex with Men (YBMSM) on the South Side of Chicago: Towards HIV Elimination within US Urban Communities. <i>Journal of Urban Health</i> , 2013, 90, 1205-1213.	1.8	16
467	World AIDS Day: together we will stop HIV transmission and conquer AIDS. <i>Retrovirology</i> , 2013, 10, 129.	0.9	1
468	The Holy Trinity. <i>Advances in Pharmacology</i> , 2013, 67, 293-316.	1.2	19
469	Participation in research involving novel sampling and study designs to identify acute HIV-1 infection among minority men who have sex with men. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013, 25, 828-834.	0.6	5
470	Host genomic influences on HIV/AIDS. <i>Genome Biology</i> , 2013, 14, 201.	13.9	20
471	Treatment is Prevention. <i>Cultural Studies</i> , 2013, 27, 901-932.	1.2	7
472	From modeling to morals: Imagining the future of HIV PREP in Lesotho. <i>Developing World Bioethics</i> , 2013, 13, 70-78.	0.6	7
473	Pharmacokinetics and Pharmacodynamics in HIV Prevention; Current Status and Future Directions: A Summary of the DAIDS and BMGF Sponsored Think Tank on Pharmacokinetics (PK)/Pharmacodynamics (PD) in HIV Prevention. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1418-1427.	0.5	24

#	ARTICLE	IF	CITATIONS
474	Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013, 25, 961-967.	0.6	91
475	Increasing Extracellular Protein Concentration Reduces Intracellular Antiretroviral Drug Concentration and Antiviral Effect. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1434-1442.	0.5	14
476	Integrating Behavioral HIV Interventions Into Biomedical Prevention Trials With Youth: Lessons From Chicago's Project PrEPare. <i>Journal of HIV/AIDS and Social Services</i> , 2013, 12, 333-348.	0.7	18
477	In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Nonvaccine Prevention Modalities. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1513-1523.	0.5	19
478	Microbicides for the prevention of sexually transmitted HIV infection. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 12-23.	2.0	11
479	Knowledge of and Opinions on HIV Preexposure Prophylaxis Among Front-Line Service Providers at Canadian AIDS Service Organizations. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1183-1189.	0.5	22
480	Stochastic Analysis of Pre- and Postexposure Prophylaxis against HIV Infection. <i>SIAM Journal on Applied Mathematics</i> , 2013, 73, 904-928.	0.8	45
481	Participant Experiences and Facilitators and Barriers to Pill Use Among Men Who Have Sex with Men in the iPrEx Pre-Exposure Prophylaxis Trial in San Francisco. <i>AIDS Patient Care and STDs</i> , 2013, 27, 560-566.	1.1	76
482	HIV Prevalence and Incidence Among Women at Higher Risk of Infection in Addis Ababa, Ethiopia. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 535-540.	0.5	3
483	Developing an adherence support intervention for patients on antiretroviral therapy in the context of the recent IDU-driven HIV/AIDS epidemic in Estonia. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013, 25, 863-873.	0.6	12
484	HIV and AIDS in Women. , 2013, , 505-522.		0
485	The Ethics of Barebacking: Implications of gay Men's Concepts of Right and Wrong in the Context of HIV. <i>International Journal of Sexual Health</i> , 2013, 25, 198-211.	1.2	7
486	Advances in catheter-ablation treatment of AF. <i>Nature Reviews Cardiology</i> , 2013, 10, 63-64.	6.1	7
487	Has testing been normalized? An analysis of changes in barriers to <sc>HIV</sc> testing among men who have sex with men between 2000 and 2010 in Scotland, <sc>UK</sc>. <i>HIV Medicine</i> , 2013, 14, 92-98.	1.0	64
488	â€œIt Looks Like You Just Want Them When Things Get Roughâ€™: Civil Society Perspectives on Negative Trial Results and Stakeholder Engagement in <sc>HIV</sc> Prevention Trials. <i>Developing World Bioethics</i> , 2013, 13, 138-148.	0.6	17
489	Reproductive Decision-Making and Periconception Practices Among HIV-Positive Men and Women Attending HIV Services in Durban, South Africa. <i>AIDS and Behavior</i> , 2013, 17, 461-470.	1.4	88
490	Characteristics of Female Sex Workers in Southern India Willing and Unwilling to Participate in a Placebo Gel Trial. <i>AIDS and Behavior</i> , 2013, 17, 585-597.	1.4	10
491	Correlation Between Pill Counts and Biologic Effects in an HIV-1 Prevention Clinical Trial: Implications for Measuring Adherence. <i>AIDS and Behavior</i> , 2013, 17, 632-639.	1.4	10

#	ARTICLE	IF	CITATIONS
492	Effect of Computer-Assisted Interviewing on Self-Reported Sexual Behavior Data in a Microbicide Clinical Trial. <i>AIDS and Behavior</i> , 2013, 17, 790-800.	1.4	55
493	Oral Adherence Monitoring Using a Breath Test to Supplement Highly Active Antiretroviral Therapy. <i>AIDS and Behavior</i> , 2013, 17, 298-306.	1.4	14
494	Adherence and Acceptability in MTN 001: A Randomized Cross-Over Trial of Daily Oral and Topical Tenofovir for HIV Prevention in Women. <i>AIDS and Behavior</i> , 2013, 17, 737-747.	1.4	65
495	Are HIV-Negative Men Who Have Sex with Men and Who Bareback Concerned About HIV Infection? Implications for HIV Risk Reduction Interventions. <i>Archives of Sexual Behavior</i> , 2013, 42, 279-289.	1.2	24
496	Differences Between HIV-Positive and HIV-Negative African American Men Who Have Sex with Men in Two Major U.S. Metropolitan Areas. <i>Archives of Sexual Behavior</i> , 2013, 42, 267-278.	1.2	5
497	Thinking about an AIDS end game. <i>Lancet, The</i> , 2013, 382, 1462-1464.	6.3	0
498	Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. <i>Lancet Infectious Diseases, The</i> , 2013, 13, 1021-1028.	4.6	95
499	Challenges in clinical trial design for HIV-1 cure research. <i>Lancet, The</i> , 2013, 382, 1464-1465.	6.3	37
500	HIV antiretroviral prophylaxis for injecting drug users – Authors' reply. <i>Lancet, The</i> , 2013, 382, 855.	6.3	1
501	Management of Human Immunodeficiency Virus in Primary Care. <i>Primary Care - Clinics in Office Practice</i> , 2013, 40, 589-617.	0.7	3
502	A Pill for HIV Prevention: Dã©jã Vu All Over Again?. <i>Clinical Infectious Diseases</i> , 2013, 56, 1604-1612.	2.9	51
503	The development and validation of an UHPLCâ€™MS/MS method for the rapid quantification of the antiretroviral agent dapivirine in human plasma. <i>Bioanalysis</i> , 2013, 5, 2771-2783.	0.6	24
504	Who would use PrEP? Factors associated with intention to use among MSM in London: a community survey. <i>Sexually Transmitted Infections</i> , 2013, 89, 207-211.	0.8	77
505	Pre-Exposure Prophylaxis: An Ethical Discussion. <i>Journal of the Association of Nurses in AIDS Care</i> , 2013, 24, 6-10.	0.4	5
506	A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 48, 406-415.	1.9	77
507	Prioritizing multipurpose prevention technology development and investments using a target product profile. <i>Antiviral Research</i> , 2013, 100, S32-S38.	1.9	25
508	Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?. <i>Vaccine</i> , 2013, 31, 2089-2096.	1.7	20
509	HIV: So Near and Yet So Far. <i>Current HIV/AIDS Reports</i> , 2013, 10, 1-2.	1.1	4

#	ARTICLE	IF	CITATIONS
510	Polymeric Nanoparticles Containing Combination Antiretroviral Drugs for HIV Type 1 Treatment. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 746-754.	0.5	69
511	The Acyclic Nucleoside Phosphonates (ANPs): Anton Å Holm's Legacy. <i>Medicinal Research Reviews</i> , 2013, 33, 1278-1303.	5.0	36
512	Mathematical Insights in Evaluating State Dependent Effectiveness of HIV Prevention Interventions. <i>Bulletin of Mathematical Biology</i> , 2013, 75, 649-675.	0.9	25
513	Development and validation of an assay for the simultaneous determination of zidovudine, abacavir, emtricitabine, lamivudine, tenofovir and ribavirin in human plasma using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 919-920, 43-51.	1.2	34
514	Systemic and Topical Drugs for the Prevention of HIV Infection: Antiretroviral Pre-exposure Prophylaxis. <i>Annual Review of Medicine</i> , 2013, 64, 219-232.	5.0	59
515	A holistic approach to addressing HIV infection disparities in gay, bisexual, and other men who have sex with men.. <i>American Psychologist</i> , 2013, 68, 261-273.	3.8	124
516	Gay men and other men who have sex with men in West Africa: evidence from the field. <i>Culture, Health and Sexuality</i> , 2013, 15, 7-21.	1.0	33
517	Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 214-222.	4.6	1,212
518	Human Immunodeficiency Virus Infection. , 2013, , 217-247.		0
519	Response to the AIDS Pandemic – A Global Health Model. <i>New England Journal of Medicine</i> , 2013, 368, 2210-2218.	13.9	141
520	Social Justice, Public Health Ethics, and the Use of HIV Pre-Exposure Prophylaxis. <i>American Journal of Preventive Medicine</i> , 2013, 44, S137-S140.	1.6	27
521	Disseminating HIV Pre-Exposure Prophylaxis Information in Underserved Communities. <i>American Journal of Preventive Medicine</i> , 2013, 44, S133-S136.	1.6	9
522	Providing HIV Pre-Exposure Prophylaxis. <i>American Journal of Preventive Medicine</i> , 2013, 44, S147-S150.	1.6	3
523	Brief Risk-Reduction Counseling in Clinical Settings for HIV Pre-Exposure Prophylaxis. <i>American Journal of Preventive Medicine</i> , 2013, 44, S112-S118.	1.6	4
524	Provider-Initiated HIV Risk Behavior Counseling in the Context of HIV Pre-Exposure Prophylaxis. <i>American Journal of Preventive Medicine</i> , 2013, 44, S108-S111.	1.6	3
525	Moving HIV Pre-Exposure Prophylaxis Into Clinical Settings. <i>American Journal of Preventive Medicine</i> , 2013, 44, S86-S90.	1.6	7
526	Preparing for HIV Pre-Exposure Prophylaxis. <i>American Journal of Preventive Medicine</i> , 2013, 44, S80-S85.	1.6	36
527	Designing for Diffusion of a Biomedical Intervention. <i>American Journal of Preventive Medicine</i> , 2013, 44, S70-S76.	1.6	33

#	ARTICLE	IF	CITATIONS
528	A Proposed Framework to Monitor Daily Oral Antiretroviral Pre-Exposure Prophylaxis in the U.S. American Journal of Preventive Medicine, 2013, 44, S141-S146.	1.6	8
529	State Adolescent Consent Laws and Implications for HIV Pre-Exposure Prophylaxis. American Journal of Preventive Medicine, 2013, 44, S119-S124.	1.6	49
530	Antiretroviral Prophylaxis for Sexual and Injection Drug Use Acquisition of HIV. American Journal of Preventive Medicine, 2013, 44, S63-S69.	1.6	24
531	Adherence to Antiretroviral Medications for HIV Pre-Exposure Prophylaxis. American Journal of Preventive Medicine, 2013, 44, S91-S98.	1.6	78
532	Pre-Exposure Prophylaxis for HIV. American Journal of Preventive Medicine, 2013, 44, S161-S162.	1.6	8
533	Pre-Exposure Prophylaxis for HIV. American Journal of Preventive Medicine, 2013, 44, S163-S166.	1.6	24
534	From Efficacy to Impact. American Journal of Preventive Medicine, 2013, 44, S167-S170.	1.6	6
535	Turning the Corner on the HIV Epidemic Among Adolescents: Prioritizing Directions for Future Prevention Research. Journal of HIV/AIDS and Social Services, 2013, 12, 258-265.	0.7	1
536	Oral Antiretroviral Drugs as Public Health Tools for HIV Prevention: Global Implications for Adherence, Drug Resistance, and the Success of HIV Treatment Programs. Journal of Infectious Diseases, 2013, 207, S101-S106.	1.9	21
537	Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe?. BMC Medicine, 2013, 11, 186.	2.3	17
538	Assessing Priorities for Combination HIV Prevention Research for Men Who have Sex with Men (MSM) in Africa. AIDS and Behavior, 2013, 17, 60-69.	1.4	47
539	Epidemiology of Human Immunodeficiency Virus-Associated Pulmonary Disease. Clinics in Chest Medicine, 2013, 34, 165-179.	0.8	16
540	Substance Use and HIV Risk Behavior among Men Who Have Sex with Men: The Role of Sexual Compulsivity. Journal of Urban Health, 2013, 90, 948-952.	1.8	29
541	Audit of HIV testing frequency and behavioural interventions for men who have sex with men: policy and practice in sexual health clinics in England. Sexually Transmitted Infections, 2013, 89, 404-408.	0.8	13
542	Assessing willingness to test for HIV among men who have sex with men using conjoint analysis, evidence for uptake of the FDA-approved at-home HIV test. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2013, 25, 1592-1598.	0.6	34
543	Human immunodeficiency virus vaccines. , 2013, , 1097-1121.		1
544	Animal models in virus research: their utility and limitations. Critical Reviews in Microbiology, 2013, 39, 325-361.	2.7	20
545	Tenofovir, Emtricitabine, and Tenofovir Diphosphate in Dried Blood Spots for Determining Recent and Cumulative Drug Exposure. AIDS Research and Human Retroviruses, 2013, 29, 384-390.	0.5	257

#	ARTICLE	IF	CITATIONS
546	Preventing HIV Among Young People. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, S155-S160.	0.9	85
547	Intentions to Use Preexposure Prophylaxis Among Current Phase 2B Preventive HIV-1 Vaccine Efficacy Trial Participants. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, 259-262.	0.9	17
549	<i>Innovation and Biomedicine.</i> , 2013, , .		21
550	The Informal Use of Antiretrovirals for Preexposure Prophylaxis of HIV Infection Among Gay Men in Australia. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 62, 334-338.	0.9	42
551	Integrated Strategies for Combination HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, S213-S220.	0.9	20
552	DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge. <i>Aids</i> , 2013, 27, 2841-2851.	1.0	21
553	The Acceptability and Feasibility of an HIV Preexposure Prophylaxis (PrEP) Trial With Young Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 62, 447-456.	0.9	159
554	Translation of Biomedical Prevention Strategies for HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, S12-S25.	0.9	33
555	Translational Research Insights From Completed HIV Vaccine Efficacy Trials. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, S150-S154.	0.9	6
556	NIH Support of Centers for AIDS Research and Department of Health Collaborative Public Health Research. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 64, S1-S6.	0.9	11
557	Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals. <i>Aids</i> , 2013, 27, 2155-2160.	1.0	124
558	Randomized Trial of Clinical Safety of Daily Oral Tenofovir Disoproxil Fumarate Among HIV-Uninfected Men Who Have Sex With Men in the United States. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 64, 79-86.	0.9	158
559	Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa. <i>Aids</i> , 2013, 27, 2943-2951.	1.0	61
560	HIV Postexposure Prophylaxis in an Urban Population of Female Sex Workers in Nairobi, Kenya. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 62, 220-225.	0.9	19
561	High HIV Prevalence Among Men Who Have Sex With Men in Nigeria. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, 221-227.	0.9	78
562	Feasibility of Identifying a Cohort of US Women at High Risk for HIV Infection for HIV Vaccine Efficacy Trials. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, 239-244.	0.9	15
563	Preparing for the Unexpected. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, S183-S186.	0.9	24
564	HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, S115-S116.	0.9	11

#	ARTICLE	IF	CITATIONS
565	Transmission of chimeric HIV by mating in conventional mice: prevention by pre-exposure antiretroviral therapy and reduced susceptibility during estrus. <i>DMM Disease Models and Mechanisms</i> , 2013, 6, 1292-8.	1.2	18
566	Rectal Microbicide Development. <i>Current Topics in Microbiology and Immunology</i> , 2013, 383, 117-136.	0.7	15
567	Sex work and HIV in Cambodia: trajectories of risk and disease in two cohorts of high-risk young women in Phnom Penh, Cambodia. <i>BMJ Open</i> , 2013, 3, e003095.	0.8	35
568	Microbicides for Prevention of HIV Infection: Clinical Efficacy Trials. <i>Current Topics in Microbiology and Immunology</i> , 2013, 383, 97-115.	0.7	10
569	Mixed results of pre-exposure prophylaxis for HIV prevention. <i>Nature Reviews Urology</i> , 2013, 10, 74-75.	1.9	1
570	From IEDs to AIDS? Detection of HIV in human corpses by rapid screening tests after suspected intentional transmission in terrorist attacks. <i>Journal of the Royal Army Medical Corps</i> , 2013, 159, 278-282.	0.8	6
571	A Strange New Disease in San Francisco. A Brief History of the City and Its Response to the HIV/AIDS Epidemic. <i>Annals of the American Thoracic Society</i> , 2013, 10, 143-147.	1.5	5
572	HIV pre-exposure prophylaxis trials: the road to success. <i>Clinical Investigation</i> , 2013, 3, 295-308.	0.0	16
573	Modelling the impact of HIV prevention and treatment for men who have sex with men on HIV epidemic trajectories in low- and middle-income countries. <i>International Journal of STD and AIDS</i> , 2013, 24, 18-30.	0.5	21
574	A social ecology of rectal microbicide acceptability among young men who have sex with men and transgender women in Thailand. <i>Journal of the International AIDS Society</i> , 2013, 16, 18476.	1.2	26
575	A systematic review of interventions to reduce HIV-related stigma and discrimination from 2002 to 2013: how far have we come?. <i>Journal of the International AIDS Society</i> , 2013, 16, 18734.	1.2	499
576	Global action to reduce HIV stigma and discrimination. <i>Journal of the International AIDS Society</i> , 2013, 16, 18881.	1.2	108
577	A pilot cohort study to assess the feasibility of HIV prevention science research among men who have sex with men in Dakar, Senegal. <i>Journal of the International AIDS Society</i> , 2013, 16, 18753.	1.2	32
578	Outcomes of a community-based HIV prevention pilot programme for township men who have sex with men in Cape Town, South Africa. <i>Journal of the International AIDS Society</i> , 2013, 16, 18754.	1.2	34
579	Oral Administration of the CCR5 Inhibitor, Maraviroc, Blocks HIV Ex Vivo Infection of Langerhans Cells within the Epithelium. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2803-2805.	0.3	7
580	HIV-1 Concentrations in Human Breast Milk Before and After Weaning. <i>Science Translational Medicine</i> , 2013, 5, 181ra51.	5.8	27
581	HIV-1 Prevention With ART and PrEP: Mathematical Modeling Insights Into Resistance, Effectiveness, and Public Health Impact. <i>Journal of Infectious Diseases</i> , 2013, 208, 189-191.	1.9	33
582	Foundations and Principles. <i>SpringerBriefs in Public Health</i> , 2013, , 1-29.	0.2	2

#	ARTICLE	IF	CITATIONS
583	Antiretroviral Therapy and Pre-exposure Prophylaxis: Combined Impact on HIV Transmission and Drug Resistance in South Africa. <i>Journal of Infectious Diseases</i> , 2013, 208, 224-234.	1.9	75
584	Developing Regulatory Strategy for Microbicides. <i>Current Topics in Microbiology and Immunology</i> , 2013, 383, 137-152.	0.7	3
585	Opportunities for HIV combination prevention to reduce racial and ethnic health disparities.. <i>American Psychologist</i> , 2013, 68, 237-246.	3.8	24
586	The Cost and Impact of Scaling Up Pre-exposure Prophylaxis for HIV Prevention: A Systematic Review of Cost-Effectiveness Modelling Studies. <i>PLoS Medicine</i> , 2013, 10, e1001401.	3.9	188
587	Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E. <i>Journal of Infectious Diseases</i> , 2013, 207, 1195-1205.	1.9	56
588	Reproductive assistance in HIV serodiscordant couples. <i>Human Reproduction Update</i> , 2013, 19, 136-150.	5.2	61
589	Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa. <i>PLoS Medicine</i> , 2013, 10, e1001511.	3.9	192
590	Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 13540-13545.	3.3	73
591	Identifying the Correlates of Membership in HIV-Serodiscordant Partnerships in New York City. <i>Sexually Transmitted Diseases</i> , 2013, 40, 784-791.	0.8	2
592	Editorial Commentary: Balancing Disease Eradication With the Emergence of Multidrug-Resistant HIV in Test-and-Treat Policies. <i>Clinical Infectious Diseases</i> , 2013, 56, 1797-1799.	2.9	3
593	The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 50-58.	1.5	54
594	Long-acting injectable antiretrovirals for HIV treatment and prevention. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 565-571.	1.5	216
595	Antibody and Antiretroviral Preexposure Prophylaxis Prevent Cervicovaginal HIV-1 Infection in a Transgenic Mouse Model. <i>Journal of Virology</i> , 2013, 87, 8535-8544.	1.5	24
596	New clinical trial designs for HIV vaccine evaluation. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 437-442.	1.5	6
597	Stay current with options for HIV prevention. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2013, 26, 14-20.	0.1	3
598	Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 19-26.	1.5	70
599	Association of Higher Plasma Vitamin D Binding Protein and Lower Free Calcitriol Levels with Tenofovir Disoproxil Fumarate Use and Plasma and Intracellular Tenofovir Pharmacokinetics: Cause of a Functional Vitamin D Deficiency?. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5619-5628.	1.4	53
600	Lack of Prophylactic Efficacy of Oral Maraviroc in Macaques despite High Drug Concentrations in Rectal Tissues. <i>Journal of Virology</i> , 2013, 87, 8952-8961.	1.5	52

#	ARTICLE	IF	CITATIONS
601	Estimating the Efficacy of Preexposure Prophylaxis for HIV Prevention Among Participants With a Threshold Level of Drug Concentration. <i>American Journal of Epidemiology</i> , 2013, 177, 256-263.	1.6	21
602	Ethics of medical care and clinical research: a qualitative study of principal investigators in biomedical HIV prevention research. <i>Journal of Medical Ethics</i> , 2013, 39, 231-235.	1.0	5
603	Evaluation of Combinations of 4â€™-Ethynyl-2-Fluoro-2-Deoxyadenosine with Clinically Used Antiretroviral Drugs. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4554-4558.	1.4	21
604	Topical Microbicides for Human Immunodeficiency Virus and Sexually Transmitted Disease Prevention. , 2013, , 213-227.		0
605	How effective is effective enough? Opinions of potential end-users of microbicides from a rural South African community. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013, 25, 573-578.	0.6	7
606	HIV Incidence Among Men With and Those Without Sexually Transmitted Rectal Infections: Estimates From Matching Against an HIV Case Registry. <i>Clinical Infectious Diseases</i> , 2013, 57, 1203-1209.	2.9	125
607	Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?. <i>Sexually Transmitted Infections</i> , 2013, 89, 628-634.	0.8	30
608	Aiming at a moving target: research ethics in the context of evolving standards of care and prevention. <i>Journal of Medical Ethics</i> , 2013, 39, 699-702.	1.0	2
609	Protein-Free Efavirenz Concentrations in Cerebrospinal Fluid and Blood Plasma Are Equivalent: Applying the Law of Mass Action To Predict Protein-Free Drug Concentration. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1409-1414.	1.4	45
610	Preventive misconception and adolescentsâ€™ knowledge about HIV vaccine trials. <i>Journal of Medical Ethics</i> , 2013, 39, 765-771.	1.0	24
611	Acceptability of Oral versus Rectal HIV Preexposure Prophylaxis among Men Who Have Sex with Men and Transgender Women in Peru. <i>Journal of the International Association of Providers of AIDS Care</i> , 2013, 12, 278-283.	0.6	38
612	Prophylactic Efficacy of Oral Emtricitabine and Tenofovir Disoproxil Fumarate Combination Therapy Against a Tenofovir-Resistant Simian/Human Immunodeficiency Virus Containing the K65R Mutation in Macaques. <i>Journal of Infectious Diseases</i> , 2013, 208, 463-467.	1.9	20
613	Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2013, 208, 1231-1239.	1.9	73
614	Undisclosed Antiretroviral Drug Use in a Multinational Clinical Trial (HIV Prevention Trials Network) Tj ETQq1 1 0.784314 rgBT /Overlook	1.9	68
615	Improving Engagement and Retention in Adult Care Settings for Lesbian, Gay, Bisexual, Transgender and Questioning (LGBTQ) Youth Living with HIV: Recommendations for Health Care Providers. <i>Journal of Gay and Lesbian Mental Health</i> , 2013, 17, 80-95.	0.8	7
616	From the Laboratory to Clinical Trials and Back Again: Lessons Learned from <sc>HIV</sc> Prevention Trials. <i>American Journal of Reproductive Immunology</i> , 2013, 69, 106-115.	1.2	4
617	HIV drug resistance: problems and perspectives. <i>Gastroenterology Insights</i> , 2013, 5, e5.	0.7	117
618	Controlling the HIV Epidemic with Antiretrovirals. <i>Journal of the International Association of Providers of AIDS Care</i> , 2013, 12, 208-216.	0.6	36

#	ARTICLE	IF	CITATIONS
619	Human Immunodeficiency Virus Reverse Transcriptase. , 2013, , .		0
620	Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2013, 208, 1102-1112.	1.9	35
621	Ethical Considerations in Determining Standard of Prevention Packages for <sc>HIV</sc> Prevention Trials: Examining <sc>P</sc><sc>r</sc><sc>EP</sc>. <i>Developing World Bioethics</i> , 2013, 13, 87-94.	0.6	28
622	Ethical Use of Antiretroviral Resources for <sc>HIV</sc> Prevention in Resource Poor Settings. <i>Developing World Bioethics</i> , 2013, 13, 79-86.	0.6	9
623	In search of the optimal delivery method for anti-HIV microbicides: are intravaginal rings the way forward?. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 5-8.	2.0	9
624	A reanalysis of a behavioral intervention to prevent incident HIV infections: Including indirect effects in modeling outcomes of Project EXPLORE. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013, 25, 805-811.	0.6	11
625	“He lacks his fatherhood”: safer conception technologies and the biological imperative for fatherhood among recently-diagnosed Xhosa-speaking men living with HIV in South Africa. <i>Culture, Health and Sexuality</i> , 2013, 15, 1101-1114.	1.0	34
626	Short Communication: Synergism Between a CD4-Mimic Peptide and Antibodies Elicited by a Constrained V3 Peptide. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 718-724.	0.5	0
627	Prophylactic Effect of Antiretroviral Therapy on Hepatitis B Virus Infection. <i>Clinical Infectious Diseases</i> , 2013, 56, 1812-1819.	2.9	61
628	Highly Active Antiretroviral Therapy is Associated with Decreased Incidence of Sexually Transmitted Diseases in a Taiwanese HIV-Positive Population. <i>AIDS Patient Care and STDs</i> , 2013, 27, 155-162.	1.1	6
629	The Female Condom in the Age of Antiretroviral-Based HIV Prevention. <i>Journal of Women's Health</i> , 2013, 22, 7-8.	1.5	4
630	Serodiscordance and Disclosure Among HIV-Positive Pregnant Women in the Southwestern United States. <i>AIDS Patient Care and STDs</i> , 2013, 27, 242-247.	1.1	15
631	Anti-retrovirals for treatment and prevention “time for new paradigms in our response to the <sc>HIV/AIDS</sc> epidemic?. <i>Developing World Bioethics</i> , 2013, 13, ii-iii.	0.6	6
632	Single Dose Pharmacokinetics of Oral Tenofovir in Plasma, Peripheral Blood Mononuclear Cells, Colonic Tissue, and Vaginal Tissue. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1443-1450.	0.5	134
633	Attitudes Toward HIV Pre-Exposure Prophylaxis Among Men Who Have Sex with Men in Western China. <i>AIDS Patient Care and STDs</i> , 2013, 27, 137-141.	1.1	60
634	HIV Risk in Group Sexual Encounters: An Event-Level Analysis from a National Online Survey of MSM in the U.S.. <i>Journal of Sexual Medicine</i> , 2013, 10, 2285-2294.	0.3	49
635	Expression of Membrane Drug Efflux Transporters in the Sigmoid Colon of HIV-Infected and Uninfected Men. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 934-945.	1.0	23
636	Ethics of <sc>ARV</sc> Based Prevention: Treatment-as-Prevention and <sc>PrEP</sc>. <i>Developing World Bioethics</i> , 2013, 13, 63-69.	0.6	22

#	ARTICLE	IF	CITATIONS
637	Prevalence of Drug-Resistant HIV Type 1 at the Time of Initiation of Antiretroviral Therapy in Portland, Oregon. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 337-342.	0.5	4
638	From Efficacy to Effectiveness: Facilitators and Barriers to PrEP Acceptability and Motivations for Adherence Among MSM and Transgender Women in New York City. <i>AIDS Patient Care and STDs</i> , 2013, 27, 248-254.	1.1	297
639	Pre-Exposure Prophylaxis (PrEP) for HIV Infection: Results of a Survey of HIV Healthcare Providers Evaluating Their Knowledge, Attitudes, and Prescribing Practices. <i>AIDS Patient Care and STDs</i> , 2013, 27, 553-559.	1.1	119
640	HIV and the LGBT Community: A Medical Update. <i>Journal of Gay and Lesbian Mental Health</i> , 2013, 17, 64-79.	0.8	4
641	Substance Use Disorders and HIV/AIDS Prevention and Treatment Intervention: Research and Practice Considerations. <i>Social Work in Public Health</i> , 2013, 28, 333-348.	0.7	24
642	Isoosmolar Enemas Demonstrate Preferential Gastrointestinal Distribution, Safety, and Acceptability Compared with Hyperosmolar and Hypoosmolar Enemas as a Potential Delivery Vehicle for Rectal Microbicides. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1487-1495.	0.5	39
643	Preexposure Prophylaxis for Adolescents and Young Adults at Risk for HIV Infection: Is an Ounce of Prevention Worth a Pound of Cure?. <i>Clinical Infectious Diseases</i> , 2013, 56, 1149-1155.	2.9	43
644	Knowledge of and Interest in Using Preexposure Prophylaxis for HIV Prevention among Men Who Have Sex with Men in Thailand. <i>Journal of the International Association of Providers of AIDS Care</i> , 2013, 12, 227-231.	0.6	33
645	Editorial Commentary: HIV Chemoprophylaxis for Adolescents: Educable Moment, Not Magic Bullet. <i>Clinical Infectious Diseases</i> , 2013, 56, 1156-1158.	2.9	2
646	Standard of Prevention in the Real World: A Qualitative Study of Principal Investigators in HIV Biomedical Prevention Trials. <i>American Journal of Bioethics Primary Research</i> , 2013, 4, 14-25.	1.5	2
647	Tenofovir-based HIV pre-exposure prophylaxis. <i>Future Virology</i> , 2013, 8, 1207-1218.	0.9	1
648	Fertility treatment options for HIV-infected individuals. <i>Future Virology</i> , 2013, 8, 1219-1231.	0.9	1
649	Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties. <i>Retrovirology</i> , 2013, 10, 113.	0.9	19
650	Global Action to reduce HIV stigma and discrimination. <i>Journal of the International AIDS Society</i> , 2013, 16, 18934.	1.2	16
652	Update in General Internal Medicine: Evidence Published in 2012. <i>Annals of Internal Medicine</i> , 2013, 158, 615.	2.0	0
653	Anti-CD4 Monoclonal Antibody Ibalizumab Exhibits Breadth and Potency Against HIV-1, With Natural Resistance Mediated by the Loss of a V5 Glycan in Envelope. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 1-9.	0.9	61
654	Tenofovir Diphosphate and Emtricitabine Triphosphate Concentrations in Blood Cells Compared With Isolated Peripheral Blood Mononuclear Cells. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 260-266.	0.9	37
655	Antiretroviral Pharmacology in Mucosal Tissues. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S240-S247.	0.9	51

#	ARTICLE	IF	CITATIONS
656	Phylogenetic inferences on HIV-1 transmission. <i>Aids</i> , 2013, 27, 1045-1057.	1.0	83
657	Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies. <i>Aids</i> , 2013, 27, 1119-1128.	1.0	2
658	Sexual Risk Behavior Among HIV-Uninfected Men Who Have Sex With Men Participating in a Tenofovir Preexposure Prophylaxis Randomized Trial in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 87-94.	0.9	118
659	Future of Phylogeny in HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S248-S254.	0.9	34
660	Antiretroviral Therapy for Prevention of HIV and Tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S200-S207.	0.9	10
661	Development of sulphated and naphthylsulphonated carbosilane dendrimers as topical microbicides to prevent HIV-1 sexual transmission. <i>Aids</i> , 2013, 27, 1219-1229.	1.0	49
662	Racial Differences and Correlates of Potential Adoption of Preexposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S95-S101.	0.9	75
663	Ethics and Pre-exposure Prophylaxis for HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S135-S139.	0.9	18
664	Preexposure Prophylaxis for HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S122-S129.	0.9	139
665	Not Just the Needle. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S174-S178.	0.9	72
666	The increase in global HIV epidemics in MSM. <i>Aids</i> , 2013, 27, 2665-2678.	1.0	295
667	Integrating Behavioral and Biomedical Research in HIV Interventions. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S6-S11.	0.9	16
668	Overcoming Biological, Behavioral, and Structural Vulnerabilities. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S161-S167.	0.9	59
669	Can Combination Prevention Strategies Reduce HIV Transmission in Generalized Epidemic Settings in Africa? The HPTN 071 (PopART) Study Plan in South Africa and Zambia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S221-S227.	0.9	39
670	Evidence of an explosive epidemic of HIV infection in a cohort of men who have sex with men in Thailand. <i>Aids</i> , 2013, 27, 825-832.	1.0	151
671	The new role of antiretrovirals in combination HIV prevention. <i>Aids</i> , 2013, 27, 447-458.	1.0	122
672	Safety and Tolerability of Tenofovir for Preexposure Prophylaxis Among Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 3-6.	0.9	1
673	Microbicides from a regulatory perspective. <i>Aids</i> , 2013, 27, 2261-2269.	1.0	4

#	ARTICLE	IF	CITATIONS
674	Tenofovir, Emtricitabine Intracellular and Plasma, and Efavirenz Plasma Concentration Decay Following Drug Intake Cessation. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 62, 275-281.	0.9	48
675	Perspectives on HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, S255-S259.	0.9	9
676	Beating the Placebo in HIV Prevention Efficacy Trials. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 62, 95-101.	0.9	7
677	Higher Baseline CD4 Cell Count Predicts Treatment Interruptions and Persistent Viremia in Patients Initiating ARVs in Rural Uganda. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 62, 317-321.	0.9	43
678	Intimate Partner Violence and Condom and Diaphragm Nonadherence Among Women in an HIV Prevention Trial in Southern Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 64, 400-408.	0.9	38
679	HIV Medical Providers' Perceptions of the Use of Antiretroviral Therapy as Nonoccupational Postexposure Prophylaxis in 2 Major Metropolitan Areas. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 64, S68-S79.	0.9	36
680	Linkage to HIV Care in San Francisco. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 64, S27-S32.	0.9	14
681	Improving the Efficiency of HIV Testing With Peer Recruitment, Financial Incentives, and the Involvement of Persons Living With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, e56-e63.	0.9	47
682	Study Design Considerations for Evaluating Efficacy of Systemic Preexposure Prophylaxis Interventions. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, S130-S134.	0.9	17
683	Preparing for HIV Vaccine Trials in Nigeria: Building the Capacity of the Community and National Coordinating, Regulatory and Ethical Bodies. <i>Journal of AIDS & Clinical Research</i> , 2013, 04, .	0.5	2
684	Predicting and controlling infectious disease epidemics using temporal networks. <i>F1000prime Reports</i> , 2013, 5, 6.	5.9	149
685	Pre-exposure prophylaxis for HIV prevention: Ready for prime time in South Africa?. <i>South African Medical Journal</i> , 2013, 103, 515.	0.2	13
687	From GRID to gridlock: the relationship between scientific biomedical breakthroughs and HIV/AIDS policy in the US Congress. <i>Journal of the International AIDS Society</i> , 2013, 16, 18446.	1.2	3
688	Neurological syndrome in an HIV-prevention trial participant randomized to daily tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) in Bondo, Kenya. <i>International Medical Case Reports Journal</i> , 2013, 6, 91.	0.3	5
690	Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS. <i>HIV/AIDS - Research and Palliative Care</i> , 2013, 5, 295.	0.4	10
691	Ending the pandemic: reducing new HIV infections to zero. <i>Journal of the International AIDS Society</i> , 2013, 16, 18933.	1.2	1
692	Beyond Measuring What Matters to Managing What Matters: Improving Public Health Quality and Accountability in the U.S. <i>HIV Epidemic Response. Public Health Reports</i> , 2013, 128, 360-363.	1.3	2
693	Risk Behaviors Among HIV-Positive Gay and Bisexual Men at Party-Oriented Vacations. <i>Journal of Studies on Alcohol and Drugs</i> , 2013, 74, 158-167.	0.6	17

#	ARTICLE	IF	CITATIONS
694	Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial. PLoS ONE, 2013, 8, e56400.	1.1	9
695	Prevalence of HIV-1 Drug Resistance among Women Screening for HIV Prevention Trials in KwaZulu-Natal, South Africa (MTN-009). PLoS ONE, 2013, 8, e59787.	1.1	27
696	Determinants of Prevalent HIV Infection and Late HIV Diagnosis among Young Women with Two or More Sexual Partners in Beira, Mozambique. PLoS ONE, 2013, 8, e63427.	1.1	17
697	Awareness and Willingness to Use HIV Pre-Exposure Prophylaxis amongst Gay and Bisexual Men in Scotland: Implications for Biomedical HIV Prevention. PLoS ONE, 2013, 8, e64038.	1.1	58
698	Awareness of and Willingness to Use Oral Pre-Exposure Prophylaxis for HIV Prevention among HIV-Serodiscordant Heterosexual Couples: A Cross-Sectional Survey in Xinjiang, China. PLoS ONE, 2013, 8, e67392.	1.1	13
699	Sex Role Segregation and Mixing among Men Who Have Sex with Men: Implications for Biomedical HIV Prevention Interventions. PLoS ONE, 2013, 8, e70043.	1.1	9
700	Willingness to Use the Internet to Seek Information on HIV Prevention and Care among Men Who Have Sex with Men in Ho Chi Minh City, Vietnam. PLoS ONE, 2013, 8, e71471.	1.1	23
701	Safety, Adherence and Acceptability of Intermittent Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis (PrEP) among HIV-Uninfected Ugandan Volunteers Living in HIV-Serodiscordant Relationships: A Randomized, Clinical Trial. PLoS ONE, 2013, 8, e74314.	1.1	69
702	Acceptability of Pre-Exposure Prophylaxis among Men Who Have Sex with Men and Transgender Women in Northern Thailand. PLoS ONE, 2013, 8, e76650.	1.1	63
703	Conceptualizing Community Mobilization for HIV Prevention: Implications for HIV Prevention Programming in the African Context. PLoS ONE, 2013, 8, e78208.	1.1	56
704	Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) in Preventing HIV-1 Infections in Rural Zambia: A Modeling Study. PLoS ONE, 2013, 8, e59549.	1.1	40
705	Are Thai MSM Willing to Take PrEP for HIV Prevention? An Analysis of Attitudes, Preferences and Acceptance. PLoS ONE, 2013, 8, e54288.	1.1	79
706	HIV prevalence and factors associated with HIV infection among men who have sex with men in Cameroon. Journal of the International AIDS Society, 2013, 16, 18752.	1.2	45
707	Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies. International Journal of Women's Health, 2013, 5, 695.	1.1	73
708	An HIV Vaccine for South-East Asia—Opportunities and Challenges. Vaccines, 2013, 1, 348-366.	2.1	5
709	Access to Basic HIV-Related Services and PrEP Acceptability among Men Who Have sex with Men Worldwide: Barriers, Facilitators, and Implications for Combination Prevention. Journal of Sexually Transmitted Diseases, 2013, 2013, 1-11.	1.0	109
710	Epidemiology of Sexually Transmitted Infections among Human Immunodeficiency Virus Positive United States Military Personnel. Journal of Sexually Transmitted Diseases, 2013, 2013, 1-8.	1.0	6
712	The epidemiology of HIV and prevention needs among men who have sex with men in Africa. Journal of the International AIDS Society, 2013, 16, 18972.	1.2	2

#	ARTICLE	IF	CITATIONS
713	Neuropsychiatric effects of tenofovir in comparison with other antiretroviral drugs. <i>Neurobehavioral HIV Medicine</i> , 0, , 1.	2.0	2
714	Reproductive Health Challenges of Living with HIV-Infection in Sub Saharan Africa. , 2013, , .		4
715	HIV Pharmacogenetics and Pharmacogenomics. , 2013, , 1211-1229.		0
716	Perceptions and Attitudes About Preexposure Prophylaxis Among Seronegative Partners and the Potential of Sexual Disinhibition. <i>Southern Medical Journal</i> , 2013, 106, 558-564.	0.3	28
717	'Getting to zero' in Asia and the Pacific through more strategic use of antiretrovirals for HIV prevention. <i>Sexual Health</i> , 2014, 11, 107.	0.4	4
718	Current perspectives in HIV post-exposure prophylaxis. <i>HIV/AIDS - Research and Palliative Care</i> , 2014, 6, 147.	0.4	40
719	How Can We Get Close to Zero? The Potential Contribution of Biomedical Prevention and the Investment Framework towards an Effective Response to HIV. <i>PLoS ONE</i> , 2014, 9, e111956.	1.1	67
720	High rates of sexually transmissible infections in HIV-positive patients in the Australian HIV Observational Database: a prospective cohort study. <i>Sexual Health</i> , 2014, 11, 291.	0.4	5
721	Effectiveness and Cost Effectiveness of Oral Pre-Exposure Prophylaxis in a Portfolio of Prevention Programs for Injection Drug Users in Mixed HIV Epidemics. <i>PLoS ONE</i> , 2014, 9, e86584.	1.1	47
722	Strong Relationship between Oral Dose and Tenofovir Hair Levels in a Randomized Trial: Hair as a Potential Adherence Measure for Pre-Exposure Prophylaxis (PrEP). <i>PLoS ONE</i> , 2014, 9, e83736.	1.1	125
723	HIV Pre-Exposure Prophylaxis Interest among Female Sex Workers in Guangxi, China. <i>PLoS ONE</i> , 2014, 9, e86200.	1.1	41
724	Concomitant Socioeconomic, Behavioral, and Biological Factors Associated with the Disproportionate HIV Infection Burden among Black Men Who Have Sex with Men in 6 U.S. Cities. <i>PLoS ONE</i> , 2014, 9, e87298.	1.1	122
725	Mathematical Modeling of HIV Prevention Measures Including Pre-Exposure Prophylaxis on HIV Incidence in South Korea. <i>PLoS ONE</i> , 2014, 9, e90080.	1.1	27
726	Efficacy of Peer-Led Interventions to Reduce Unprotected Anal Intercourse among Men Who Have Sex with Men: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e90788.	1.1	30
727	The HIV-Brazil Cohort Study: Design, Methods and Participant Characteristics. <i>PLoS ONE</i> , 2014, 9, e95673.	1.1	24
728	Improving Ethical and Participatory Practice for Marginalized Populations in Biomedical HIV Prevention Trials: Lessons from Thailand. <i>PLoS ONE</i> , 2014, 9, e100058.	1.1	11
729	Preparing for PrEP: Perceptions and Readiness of Canadian Physicians for the Implementation of HIV Pre-Exposure Prophylaxis. <i>PLoS ONE</i> , 2014, 9, e105283.	1.1	54
730	A Multi-Compartment Single and Multiple Dose Pharmacokinetic Comparison of Rectally Applied Tenofovir 1% Gel and Oral Tenofovir Disoproxil Fumarate. <i>PLoS ONE</i> , 2014, 9, e106196.	1.1	28

#	ARTICLE	IF	CITATIONS
731	Clinical Effectiveness and Cost-Effectiveness of HIV Pre-Exposure Prophylaxis in Men Who Have Sex with Men: Risk Calculators for Real-World Decision-Making. PLoS ONE, 2014, 9, e108742.	1.1	53
732	Access to Healthcare, HIV/STI Testing, and Preferred Pre-Exposure Prophylaxis Providers among Men Who Have Sex with Men and Men Who Engage in Street-Based Sex Work in the US. PLoS ONE, 2014, 9, e112425.	1.1	59
733	Challenges to the Vision and Mission of Lifelong Learning in Sub-Saharan Africa. International Journal of Educational Sciences, 2014, 7, 595-603.	0.0	1
734	High Risk for HIV following Syphilis Diagnosis among Men in Florida, 2000â€“2011. Public Health Reports, 2014, 129, 164-169.	1.3	45
735	Can treatment-based HIV prevention curb the epidemic among gay and other men who have sex with men? A narrative synthesis of increasing evidence for moderating and countervailing effects. Sexual Health, 2014, 11, 137.	0.4	7
736	HIV Treatment as Prevention: Contradictory Perspectives from Dynamic Mathematical Models. Scientific World Journal, The, 2014, 2014, 1-9.	0.8	2
737	Combination methods for HIV prevention in men who have sex with men (MSM). The Cochrane Library, 0, , .	1.5	2
738	Biomedical HIV prevention research and epidemic control in Thailand: two sides of the same coin. Sexual Health, 2014, 11, 180.	0.4	19
739	Acceptability of Condoms, Circumcision and PrEP among Young Black Men Who Have Sex with Men: A Descriptive Study Based on Effectiveness and Cost. Vaccines, 2014, 2, 129-137.	2.1	18
740	STD patients’ preferences for HIV prevention strategies. HIV/AIDS - Research and Palliative Care, 2014, 6, 171.	0.4	3
741	Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICEâ€“ qualitative study in Johannesburg, South Africa. Journal of the International AIDS Society, 2014, 17, 19146.	1.2	111
742	ARV-based HIV prevention for women â€“ where we are in 2014. Journal of the International AIDS Society, 2014, 17, 19154.	1.2	17
743	HIV preâ€“exposure prophylaxis for people who inject drugs: a review of current results and an agenda for future research. Journal of the International AIDS Society, 2014, 17, 18899.	1.2	31
746	Attitudes and Barriers towards Pre-Exposure Prophylaxis (Prep) among High-Risk HIV-Seronegative Men who have Sex with Men. Journal of AIDS & Clinical Research, 2014, 05, .	0.5	7
747	AIDS advocacy and intellectual property regulation in Brazil: information and influence. Journal of the International AIDS Society, 2014, 17, 19396.	1.2	2
748	Acceptability of PrEP among HIV negative Portuguese men who have sex with men that attended 2014 Lisbon pride fair. Journal of the International AIDS Society, 2014, 17, 19734.	1.2	14
749	HIV/AIDS Prevention. , 2014, , 100-111.e2.		3
750	Spending of HIV resources in Asia and Eastern Europe: systematic review reveals the need to shift funding allocations towards priority populations. Journal of the International AIDS Society, 2014, 17, 18822.	1.2	10

#	ARTICLE	IF	CITATIONS
751	Women and ARV-based prevention: opportunities and challenges. <i>Journal of the International AIDS Society</i> , 2014, 17, 19419.	1.2	1
752	Cost-Effectiveness of PrEP in HIV/AIDS Control in Zambia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 221-228.	0.9	25
753	HIV negative men who have sex with men should consider taking daily antiretroviral, says WHO. <i>BMJ</i> , The, 2014, 349, g4660-g4660.	3.0	0
755	Will Risk Compensation Accompany Pre-Exposure Prophylaxis for HIV?. <i>AMA Journal of Ethics</i> , 2014, 16, 909-915.	0.4	48
757	Successful Discontinuation of the Placebo Arm and Provision of an Effective HIV Prevention Product After a Positive Interim Efficacy Result. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 206-212.	0.9	26
758	Using geospatial modelling to optimize the rollout of antiretroviral-based pre-exposure HIV interventions in Sub-Saharan Africa. <i>Nature Communications</i> , 2014, 5, 5454.	5.8	30
759	Relationship between hunger, adherence to antiretroviral therapy and plasma HIV RNA suppression among HIV-positive illicit drug users in a Canadian setting. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 459-465.	0.6	19
760	Preexposure prophylaxis (PrEP) of HIV infection in France: A nationwide cross-sectional study (PREVIC) <i>Tj ETQq1 1 0,784314 rgBT /Over</i>	0.6	17
761	A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 314-323.	2.3	97
762	Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical prevention. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1974-1984.	1.4	10
763	Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial. <i>BMC Pharmacology & Toxicology</i> , 2014, 15, 77.	1.0	16
764	Combination HIV Prevention Interventions: The Potential of Integrated Behavioral and Biomedical Approaches. <i>Current HIV/AIDS Reports</i> , 2014, 11, 363-375.	1.1	30
765	Getting to zero the biomedical way in Africa: outcomes of deliberation at the 2013 Biomedical HIV Prevention Forum in Abuja, Nigeria. <i>BMC Proceedings</i> , 2014, 8, S1.	1.8	0
766	Live Simian Immunodeficiency Virus Vaccine Correlate of Protection: Immune Complexes Inhibit Fc Receptor Interactions That Reduce Target Cell Availability. <i>Journal of Immunology</i> , 2014, 193, 3126-3133.	0.4	35
767	Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 1521-1525.	0.6	14
768	An assessment of fishing communities around Lake Victoria, Uganda, as potential populations for future HIV vaccine efficacy studies: an observational cohort study. <i>BMC Public Health</i> , 2014, 14, 986.	1.2	25
769	Editorial Commentary: The Next Tsunami? HIV Spread in Asian Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2014, 58, 1760-1762.	2.9	3
770	Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 2307-2312.	3.3	579

#	ARTICLE	IF	CITATIONS
771	Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography-tandem mass spectrometry. <i>Bioanalysis</i> , 2014, 6, 1907-1921.	0.6	15
772	Antiretroviral Chemoprophylaxis: State of Evidence and the Research Agenda. <i>Clinical Infectious Diseases</i> , 2014, 59, S47-S51.	2.9	17
773	Oral Pre-Exposure Prophylaxis (PrEP) for Prevention of HIV in Serodiscordant Heterosexual Couples in the United States: Opportunities and Challenges. <i>AIDS Patient Care and STDs</i> , 2014, 28, 462-474.	1.1	66
774	Pharmacology Lessons From Chemoprophylaxis Studies. <i>Clinical Infectious Diseases</i> , 2014, 59, S52-S54.	2.9	4
775	Patient Attrition Between the Emergency Department and Clinic Among Individuals Presenting for HIV Nonoccupational Postexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2014, 58, 1618-1624.	2.9	49
776	Multipurpose prevention technologies for reproductive and sexual health. <i>Reproductive Health Matters</i> , 2014, 22, 213-217.	1.3	10
777	Pharmacokinetics and Preliminary Safety Study of Pod-Intravaginal Rings Delivering Antiretroviral Combinations for HIV Prophylaxis in a Macaque Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5125-5135.	1.4	33
778	Engagement with Peer Health Educators Is Associated with Willingness to Use Pre-Exposure Prophylaxis Among Male Sex Workers in Ho Chi Minh City, Vietnam. <i>AIDS Patient Care and STDs</i> , 2014, 28, 109-112.	1.1	34
779	Challenges in the Design of a T Cell Vaccine in the Context of HIV-1 Diversity. <i>Viruses</i> , 2014, 6, 3968-3990.	1.5	18
780	HIV-1 Drug Resistance in Preexposure Prophylaxis Trials. , 2014, , 1-18.		0
781	Antiretroviral Therapy for the Prevention of HIV Transmission: What Will It Take?. <i>Clinical Infectious Diseases</i> , 2014, 58, 1003-1011.	2.9	50
782	Social Psychology and the Fight Against AIDS. <i>Advances in Experimental Social Psychology</i> , 2014, , 105-193.	2.0	32
783	Neurology and the Global HIV Epidemic. <i>Seminars in Neurology</i> , 2014, 34, 070-077.	0.5	9
784	The Rise and Fall of HIV in High-Prevalence Countries: A Challenge for Mathematical Modeling. <i>PLoS Computational Biology</i> , 2014, 10, e1003459.	1.5	22
785	HIV Prevalence Trends, Risky Behaviours, and Governmental and Community Responses to the Epidemic among Men Who Have Sex with Men in China. <i>BioMed Research International</i> , 2014, 2014, 1-19.	0.9	61
786	Gene Therapy Targeting HIV Entry. <i>Viruses</i> , 2014, 6, 1395-1409.	1.5	12
787	Genotypic and Functional Impact of HIV-1 Adaptation to Its Host Population during the North American Epidemic. <i>PLoS Genetics</i> , 2014, 10, e1004295.	1.5	45
788	Early Experiences Implementing Pre-exposure Prophylaxis (PrEP) for HIV Prevention in San Francisco. <i>PLoS Medicine</i> , 2014, 11, e1001613.	3.9	213

#	ARTICLE	IF	CITATIONS
789	Vaginal Challenge with an SIV-Based Dual Reporter System Reveals That Infection Can Occur throughout the Upper and Lower Female Reproductive Tract. <i>PLoS Pathogens</i> , 2014, 10, e1004440.	2.1	84
790	Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy. <i>Frontiers in Immunology</i> , 2014, 5, 202.	2.2	14
791	NLM Workshop Marks 20 Years of Community Outreach and Capacity Building in HIV/AIDS. <i>Journal of Consumer Health on the Internet</i> , 2014, 18, 357-366.	0.2	1
792	Pre-Exposure Prophylaxis to Prevent HIV Infection: Why Do We Need It, What Are the Limitations, and Can We Successfully Provide It Today?. <i>LGBT Health</i> , 2014, 1, 250-252.	1.8	1
793	Considering Pre-Exposure Prophylaxis: Do the Pros Outweigh the Cons as an HIV Prevention Strategy?. <i>LGBT Health</i> , 2014, 1, 253-255.	1.8	2
794	Failure to Identify HIV-Infected Individuals in a Clinical Trial Using a Single HIV Rapid Test for Screening. <i>HIV Clinical Trials</i> , 2014, 15, 62-68.	2.0	17
795	Long-Chain Peer Referral to Recruit Black MSM and Black Transgender Women for an HIV Vaccine Efficacy Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, e94-e97.	0.9	13
796	Learning from the private sector: towards a keener understanding of the end-user for microbicide introduction planning. <i>Journal of the International AIDS Society</i> , 2014, 17, 19162.	1.2	16
797	Communicating about microbicides with women in mind: tailoring messages for specific audiences. <i>Journal of the International AIDS Society</i> , 2014, 17, 19151.	1.2	11
798	The importance of choice in the rollout of ARV-based prevention to user groups in Kenya and South Africa: a qualitative study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19157.	1.2	58
799	An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV-based vaginal rings. <i>Journal of the International AIDS Society</i> , 2014, 17, 19158.	1.2	21
800	WHO guidance grounded in a comprehensive approach to sexual and reproductive health and human rights: topical pre-exposure prophylaxis. <i>Journal of the International AIDS Society</i> , 2014, 17, 19279.	1.2	5
801	Pregnancy Incidence and Outcomes Among Women Receiving Preexposure Prophylaxis for HIV Prevention. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 362.	3.8	110
802	HIV Prevention and Treatment Fields Join Forces. <i>EBioMedicine</i> , 2014, 1, 4-5.	2.7	2
803	Untangling the cost-effectiveness knot: who is oral antiretroviral HIV pre-exposure prophylaxis really for?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 167-170.	0.7	5
805	Multimodality vaccination against clade C SHIV: Partial protection against mucosal challenges with a heterologous tier 2 virus. <i>Vaccine</i> , 2014, 32, 6527-6536.	1.7	9
806	Antiretrovirals for HIV prevention: when should they be recommended?. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 431-445.	2.0	1
807	Helping our patients take <sc>HIV</sc> pre-exposure prophylaxis (<sc>PrEP</sc>): a systematic review of adherence interventions. <i>HIV Medicine</i> , 2014, 15, 385-395.	1.0	52

#	ARTICLE	IF	CITATIONS
808	Strategies for Preventing Mucosal Cell-Associated HIV Transmission. <i>Journal of Infectious Diseases</i> , 2014, 210, S674-S680.	1.9	12
809	Site migration in seeking care services from multiple providers is associated with worse clinical outcomes among HIV-infected individuals in Washington, DC. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 1346-1351.	0.6	4
810	An Intravaginal Ring for the Sustained Delivery of Antibodies. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 3611-3620.	1.6	31
811	Preventing HIV infection: Pre-exposure and postexposure prophylaxis. <i>IUBMB Life</i> , 2014, 66, 453-461.	1.5	3
812	Prevalence and correlates of willingness to participate in a rectal microbicide trial among men who have sex with men in Bangkok. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 1359-1369.	0.6	5
813	Medication Adherence Among Men Who Have Sex with Men at Risk for HIV Infection in the United States: Implications for Pre-Exposure Prophylaxis Implementation. <i>AIDS Patient Care and STDs</i> , 2014, 28, 622-627.	1.1	34
814	When is good good enough for HIV-1 prophylaxis?. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1024-1025.	4.6	1
815	Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1325-1329.	1.3	10
816	Pharmacokinetic evaluation of tenofovir disoproxil fumarate released from an intravaginal ring in pigtailed macaques after 6 months of continuous use. <i>Journal of Medical Primatology</i> , 2014, 43, 364-369.	0.3	16
817	Provider Attitudes Toward Oral Preexposure Prophylaxis for HIV Prevention Among High-Risk Men Who Have Sex with Men in Lima, Peru. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 416-424.	0.5	22
818	Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1055-1064.	4.6	94
819	Raltegravir+emtricitabine+tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence. <i>HIV Medicine</i> , 2014, 15, 13-22.	1.0	45
820	Designing Preclinical Perceptibility Measures to Evaluate Topical Vaginal Gel Formulations: Relating User Sensory Perceptions and Experiences to Formulation Properties. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 78-91.	0.5	31
821	Exposure Ethics: Does Hiv Pre-Exposure Prophylaxis Raise Ethical Problems for the Health Care Provider and Policy Maker?. <i>Bioethics</i> , 2014, 28, 269-274.	0.7	20
822	Analysis of the HIV eradication phenomenon at the early stage of infection with an extracellular deterministic model. , 2014, 2014, 330-3.		1
823	Pre-exposure Prophylaxis for Human Immunodeficiency Virus. <i>Infectious Disease Clinics of North America</i> , 2014, 28, 563-583.	1.9	17
824	Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 150-160.	1.0	10
825	The Adolescent and Young Adult HIV Cascade of Care in the United States: Exaggerated Health Disparities. <i>AIDS Patient Care and STDs</i> , 2014, 28, 128-135.	1.1	348

#	ARTICLE	IF	CITATIONS
826	Stochastic variation in network epidemic models: implications for the design of community level HIV prevention trials. <i>Statistics in Medicine</i> , 2014, 33, 3894-3904.	0.8	9
827	Role of Fc-mediated antibody function in protective immunity against HIV-1. <i>Immunology</i> , 2014, 142, 46-57.	2.0	69
828	Short Communication: Cheminformatics Analysis to Identify Predictors of Antiviral Drug Penetration into the Female Genital Tract. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1058-1064.	0.5	14
829	Topical microbicides and HIV prevention in the female genital tract. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 603-615.	1.0	21
830	Modified Silicone Elastomer Vaginal Gels for Sustained Release of Antiretroviral HIV Microbicides. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1422-1432.	1.6	20
831	Syphilis Predicts HIV Incidence Among Men and Transgender Women Who Have Sex With Men in a Preexposure Prophylaxis Trial. <i>Clinical Infectious Diseases</i> , 2014, 59, 1020-1026.	2.9	132
832	A scoping review of risk behaviour interventions in young men. <i>BMC Public Health</i> , 2014, 14, 957.	1.2	27
833	Acceptability and willingness among men who have sex with men (MSM) to use a tablet-based HIV risk assessment in a clinical setting. <i>SpringerPlus</i> , 2014, 3, 708.	1.2	18
834	Engaging, Recruiting, and Retaining Black Men Who Have Sex With Men in Research Studies. <i>Journal of Public Health Management and Practice</i> , 2014, 20, E1-E9.	0.7	32
835	Willingness to Use HIV Pre-Exposure Prophylaxis Has Declined Among Australian Gay and Bisexual Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 222-226.	0.9	18
836	HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 340-348.	0.9	270
837	HIV epidemics among transgender women. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 168-173.	1.5	176
838	Factors associated with recency of HIV testing amongst men residing in Scotland who have sex with men. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 297-303.	0.6	35
839	Modelling in concentrated epidemics. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 134-149.	1.5	13
840	Patterns and Correlates of PrEP Drug Detection Among MSM and Transgender Women in the Global iPrEx Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 528-537.	0.9	63
841	Oral preexposure prophylaxis to prevent HIV infection. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2014, 27, 10-17.	0.1	2
842	Epidemiology of HIV in Latin America and the Caribbean. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 192-198.	1.5	100
843	High Medication Adherence During Periconception Periods Among HIV-1-Uninfected Women Participating in a Clinical Trial of Antiretroviral Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 91-97.	0.9	33

#	ARTICLE	IF	CITATIONS
844	HIV infection and its implication for nurse leaders. <i>Nursing Management</i> , 2014, 45, 24-31.	0.2	3
845	An Intervention to Support HIV Preexposure Prophylaxis Adherence in HIV-Serodiscordant Couples in Uganda. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 66, 522-529.	0.9	56
846	HIV sexual transmission risk among serodiscordant couples. <i>Aids</i> , 2014, 28, 1521-1529.	1.0	56
847	Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception. <i>Aids</i> , 2014, 28, 2771-2776.	1.0	38
848	HIV Prevention Counseling Intervention Delivered During Routine Clinical Care Reduces HIV Risk Behavior in HIV-Infected South Africans Receiving Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, 499-507.	0.9	32
849	Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men. <i>Aids</i> , 2014, 28, 1977-1982.	1.0	18
850	Perception of HIV Risk and Adherence to a Daily, Investigational Pill for HIV Prevention in FEM-PrEP. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, 555-563.	0.9	65
851	Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York. <i>Aids</i> , 2014, 28, 2683-2691.	1.0	56
852	Study Product Adherence Measurement in the iPrEx Placebo-Controlled Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 66, 530-537.	0.9	73
853	Strategies to manage the HIV epidemic in gay, bisexual, and other men who have sex with men. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 1-8.	1.3	26
854	FEM-PrEP. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 66, 324-331.	0.9	139
855	Preexposure prophylaxis. <i>Nurse Practitioner</i> , 2014, 39, 50-53.	0.2	3
856	Emerging antiretroviral drug resistance in sub-Saharan Africa. <i>Aids</i> , 2014, 28, 2643-2648.	1.0	5
857	Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2470-2476.	1.3	19
858	HIV Prevention in Clinical Care Settings. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 390.	3.8	109
859	A Cost-effectiveness Analysis of HIV Preexposure Prophylaxis for Men Who Have Sex With Men in Australia. <i>Clinical Infectious Diseases</i> , 2014, 58, 1027-1034.	2.9	54
860	Prevalence, correlates and trends in seroadaptive behaviours among men who have sex with men from serial cross-sectional surveillance in San Francisco, 2004-2011. <i>Sexually Transmitted Infections</i> , 2014, 90, 498-504.	0.8	57
861	An empirical test of the Theory of Planned Behaviour applied to contraceptive use in rural Uganda. <i>Journal of Health Psychology</i> , 2014, 19, 1564-1575.	1.3	21

#	ARTICLE	IF	CITATIONS
862	Human Immunodeficiency Viruses Types 1 and 2. , 2014, , 1001-1062.		0
863	Beyond the Ball: Implications for HIV Risk and Prevention Among the Constructed Families of African American Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2014, 18, 2156-2168.	1.4	27
864	Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants. <i>Vaccine Journal</i> , 2014, 21, 1589-1599.	3.2	10
865	Systemic Preexposure Prophylaxis for HIV. <i>Annals of Pharmacotherapy</i> , 2014, 48, 507-518.	0.9	2
866	Role of biomedical and behavioral interventions and their evidence in prevention of HIV infection: A literature review. <i>International Journal of Medicine and Public Health</i> , 2014, 4, 324.	0.3	3
867	Barriers to Legal and Human Rights in Australia in the Era of HIV Treatment as Prevention. <i>AIDS Education and Prevention</i> , 2014, 26, 202-213.	0.6	9
868	Herausforderungen in der Diagnostik und Prävention von Viruserkrankungen. <i>Laboratoriums Medizin</i> , 2014, 38, .	0.1	0
869	Pre-exposure prophylaxis for conception (PrEP-C) as a risk reduction strategy in HIV-positive men and HIV-negative women in the UK. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 332-336.	0.6	38
870	Using Virtual Spaces to Engage HIV-Positive Men Who Have Sex With Men Online. <i>Sexually Transmitted Diseases</i> , 2014, 41, 756-758.	0.8	5
871	Physiologic doses of depot-medroxyprogesterone acetate do not increase acute plasma simian HIV viremia or mucosal virus shedding in pigtail macaques. <i>Aids</i> , 2014, 28, 1431-1439.	1.0	31
872	Estimating per-act HIV transmission risk. <i>Aids</i> , 2014, 28, 1509-1519.	1.0	609
873	Antiretroviral Concentrations in Small Hair Samples as a Feasible Marker of Adherence in Rural Kenya. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 311-315.	0.9	80
874	The need for multipurpose prevention technologies in sub-Saharan Africa. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014, 121, 27-34.	1.1	35
875	Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014, 121, 53-61.	1.1	7
876	The future of multipurpose prevention technology product strategies: understanding the market in parallel with product development. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014, 121, 15-18.	1.1	13
877	Your blues ain't like mine: considering integrative antiracism in HIV prevention research with black men who have sex with men in Canada and the United States. <i>Nursing Inquiry</i> , 2014, 21, 270-282.	1.1	20
878	Abasic Phosphorothioate Oligomers Inhibit HIV-1 Reverse Transcription and Block Virus Transmission across Polarized Ectocervical Organ Cultures. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7056-7071.	1.4	1
879	Effect of community-based voluntary counselling and testing on HIV incidence and social and behavioural outcomes (NIMH Project Accept; HPTN 043): a cluster-randomised trial. <i>The Lancet Global Health</i> , 2014, 2, e267-e277.	2.9	141

#	ARTICLE	IF	CITATIONS
880	Impact of Tenofovir gel as a PrEP on HIV infection: A mathematical model. <i>Journal of Theoretical Biology</i> , 2014, 347, 151-159.	0.8	6
881	HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 468-475.	4.6	128
882	Transformation of HIV from pandemic to low-endemic levels: a public health approach to combination prevention. <i>Lancet</i> , The, 2014, 384, 272-279.	6.3	107
883	Adh�sion au traitement antir�troviral et �thique de la responsabilit�: devons-nous prescrire une th�rapie antir�trovirale aux personnes non adh�rentes? <i>�thique & Sant�</i> , 2014, 11, 4-12.	0.1	1
884	Knowledge of Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex with Men in Denver, Colorado. <i>AIDS and Behavior</i> , 2014, 18, 340-347.	1.4	31
885	Adherence to Post-Exposure Prophylaxis for Non-forcible Sexual Exposure to HIV: A Systematic Review and Meta-Analysis. <i>AIDS and Behavior</i> , 2014, 18, 217-225.	1.4	31
886	Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. <i>International Journal of Clinical Pharmacy</i> , 2014, 36, 70-85.	1.0	43
887	Racial/Ethnic Differences in Trust in Health Care: HIV Conspiracy Beliefs and Vaccine Research Participation. <i>Journal of General Internal Medicine</i> , 2014, 29, 140-146.	1.3	43
888	Resilience as a Research Framework and as a Cornerstone of Prevention Research for Gay and Bisexual Men: Theory and Evidence. <i>AIDS and Behavior</i> , 2014, 18, 1-9.	1.4	167
889	Sexual Partnerships and Considerations for HIV Antiretroviral Pre-Exposure Prophylaxis Utilization Among High-Risk Substance Using Men Who Have Sex with Men. <i>Archives of Sexual Behavior</i> , 2014, 43, 99-106.	1.2	71
890	The Prevalence of Undiagnosed HIV Serodiscordance Among Male Couples Presenting for HIV Testing. <i>Archives of Sexual Behavior</i> , 2014, 43, 173-180.	1.2	26
891	Incorporating Couples-Based Approaches into HIV Prevention for Gay and Bisexual Men: Opportunities and Challenges. <i>Archives of Sexual Behavior</i> , 2014, 43, 35-46.	1.2	36
892	Food Security in the Context of HIV: Towards Harmonized Definitions and Indicators. <i>AIDS and Behavior</i> , 2014, 18, 476-489.	1.4	25
893	�Set it and Forget it�: Women�s Perceptions and Opinions of Long-Acting Topical Vaginal Gels. <i>AIDS and Behavior</i> , 2014, 18, 862-870.	1.4	29
894	Virulence and Pathogenesis of HIV-1 Infection: An Evolutionary Perspective. <i>Science</i> , 2014, 343, 1243727.	6.0	215
895	Sensitive Tenofovir Resistance Screening of HIV-1 From the Genital and Blood Compartments of Women With Breakthrough Infections in the CAPRISA 004 Tenofovir Gel Trial. <i>Journal of Infectious Diseases</i> , 2014, 209, 1916-1920.	1.9	13
896	Understanding Structural Barriers to Accessing HIV Testing and Prevention Services Among Black Men Who Have Sex with Men (BMSM) in the United States. <i>AIDS and Behavior</i> , 2014, 18, 972-996.	1.4	227
897	Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children. <i>BMC Infectious Diseases</i> , 2014, 14, 28.	1.3	36

#	ARTICLE	IF	CITATIONS
898	Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices. <i>BMC Infectious Diseases</i> , 2014, 14, 14.	1.3	28
899	Effects of Partnership Change on Microbicide Gel Adherence in a Clinical Trial (HPTN 035). <i>AIDS and Behavior</i> , 2014, 18, 855-861.	1.4	9
900	Setting the Bar High or Setting Up to Fail? Interpretations and Implications of The EXPLORE Study (HPTN 015). <i>AIDS and Behavior</i> , 2014, 18, 625-633.	1.4	8
901	Utilization of HIV Prevention Services Across Racial/Ethnic Groups Among Men Who Have Sex with Men in San Francisco, California, 2008. <i>AIDS and Behavior</i> , 2014, 18, 316-323.	1.4	6
902	Altitudinal Changes in Malaria Incidence in Highlands of Ethiopia and Colombia. <i>Science</i> , 2014, 343, 1154-1158.	6.0	270
903	Methods for Measuring, Enhancing, and Accounting for Medication Adherence in Clinical Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 617-626.	2.3	107
904	A control systems analysis of HIV prevention model using impulsive input. <i>Biomedical Signal Processing and Control</i> , 2014, 13, 123-131.	3.5	20
905	Why primate models matter. <i>American Journal of Primatology</i> , 2014, 76, 801-827.	0.8	451
906	New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents. <i>Drugs</i> , 2014, 74, 7-13.	4.9	35
907	Are We Prepped for Preexposure Prophylaxis (PrEP)? Provider Opinions on the Real-World Use of PrEP in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2014, 58, 704-712.	2.9	158
908	Role of Oral Pre-exposure Prophylaxis (PrEP) in Current and Future HIV Prevention Strategies. <i>Current HIV/AIDS Reports</i> , 2014, 11, 393-403.	1.1	23
909	HIV pre-exposure prophylaxis. <i>Cmaj</i> , 2014, 186, E588-E588.	0.9	0
910	A Polyvalent Clade B Virus-Like Particle HIV Vaccine Combined with Partially Protective Oral Preexposure Prophylaxis Prevents Simianâ€”Human Immunodeficiency Virus Infection in Macaques and Primates for Virus-Amplified Immunity. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1072-1081.	0.5	6
911	Induction of Intestinal Immunity by Mucosal Vaccines As a Means of Controlling HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1027-1040.	0.5	16
912	â€œPayment by Resultsâ€”Financial Incentives and Motivational Interviewing, Adherence Interventions in Young Adults with Perinatally Acquired HIV-1 Infection: A Pilot Program. <i>AIDS Patient Care and STDs</i> , 2014, 28, 28-32.	1.1	47
913	An Overview of Antiretroviral Preâ€”Exposure Prophylaxis of <sc>HIV</sc> Infection. <i>American Journal of Reproductive Immunology</i> , 2014, 71, 624-630.	1.2	23
914	HIV Providersâ€™ Perceived Barriers and Facilitators to Implementing Pre-exposure Prophylaxis in Care Settings: A Qualitative Study. <i>AIDS and Behavior</i> , 2014, 18, 1712-1721.	1.4	259
915	Pre-Exposure Prophylaxis Accessibility Research and Evaluation (PrEPARE Study). <i>AIDS and Behavior</i> , 2014, 18, 1722-1725.	1.4	73

#	ARTICLE	IF	CITATIONS
916	Effects of HIV Antiretroviral Therapy on Sexual and Injecting Risk-Taking Behavior: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2014, 59, 1483-1494.	2.9	33
917	Biomedical Prevention: State of the Science. <i>Clinical Infectious Diseases</i> , 2014, 59, S41-S46.	2.9	10
918	Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence. <i>Clinical Infectious Diseases</i> , 2014, 59, S55-S60.	2.9	108
919	Controlling the HIV Epidemic With Antiretrovirals: Moving From Consensus to Implementation. <i>Clinical Infectious Diseases</i> , 2014, 59, S1-S2.	2.9	10
920	A Paradigm Shift: Focus on the HIV Prevention Continuum. <i>Clinical Infectious Diseases</i> , 2014, 59, S12-S15.	2.9	80
921	The AIDS Pandemic in Historic Perspective. <i>Journal of the History of Medicine and Allied Sciences</i> , 2014, 69, 351-382.	0.1	14
922	Advances in HIV Prevention for Serodiscordant Couples. <i>Current HIV/AIDS Reports</i> , 2014, 11, 434-446.	1.1	49
923	Moving HIV PrEP from research into practice. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 781-783.	4.6	3
924	Towards an integrated framework for accelerating the end of the global HIV epidemic among young people. <i>Sex Education</i> , 2014, 14, 609-621.	1.5	11
925	Examining the Role of Serostatus Disclosure on Unprotected Sex Among People Living with HIV. <i>AIDS Patient Care and STDs</i> , 2014, 28, 677-684.	1.1	17
926	Advancing HIV prevention science: the roads from Cape Town. <i>Lancet</i> , The, 2014, 384, 1725-1727.	6.3	0
927	Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus. <i>Science</i> , 2014, 343, 1151-1154.	6.0	145
928	Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 684-693.	0.6	65
929	Human Immunodeficiency Virus Vaccines. <i>Infectious Disease Clinics of North America</i> , 2014, 28, 615-631.	1.9	5
931	Effects of Hormonal Contraception on Antiretroviral Drug Metabolism, Pharmacokinetics and Pharmacodynamics. <i>American Journal of Reproductive Immunology</i> , 2014, 71, 523-530.	1.2	25
932	Common Sexually Transmitted Infections in Adolescents. <i>Primary Care - Clinics in Office Practice</i> , 2014, 41, 631-650.	0.7	11
933	HIV pre-exposure prophylaxis: Mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model. <i>Virology</i> , 2014, 464-465, 253-263.	1.1	34
934	Self-Perception of HIV Risk and Candidacy for Pre-Exposure Prophylaxis Among Men Who Have Sex with Men Testing for HIV at Commercial Sex Venues in New York City. <i>LGBT Health</i> , 2014, 1, 218-224.	1.8	85

#	ARTICLE	IF	CITATIONS
935	Stakeholder views of ethical guidance regarding prevention and care in HIV vaccine trials. <i>BMC Medical Ethics</i> , 2014, 15, 51.	1.0	8
936	Moving the Bar to the Right Place: Positioning Interventions in HIV Prevention. <i>AIDS and Behavior</i> , 2014, 18, 634-637.	1.4	2
937	Optimizing Content for Pre-exposure Prophylaxis (PrEP) Counseling for Men Who Have Sex with Men: Perspectives of PrEP Users and High-Risk PrEP Naïve Men. <i>AIDS and Behavior</i> , 2014, 18, 871-879.	1.4	68
938	The Impact of Patient Race on Clinical Decisions Related to Prescribing HIV Pre-Exposure Prophylaxis (PrEP): Assumptions About Sexual Risk Compensation and Implications for Access. <i>AIDS and Behavior</i> , 2014, 18, 226-240.	1.4	204
939	Prevalence and Public Health Implications of State Laws that Criminalize Potential HIV Exposure in the United States. <i>AIDS and Behavior</i> , 2014, 18, 997-1006.	1.4	97
940	Impact of an Adherence Intervention on the Effectiveness of Tenofovir Gel in the CAPRISA 004 Trial. <i>AIDS and Behavior</i> , 2014, 18, 841-848.	1.4	20
941	Willingness to Use HIV Pre-Exposure Prophylaxis Among Opiate Users. <i>AIDS and Behavior</i> , 2014, 18, 1694-1700.	1.4	71
942	Preferences for Daily or Intermittent Pre-exposure Prophylaxis Regimens and Ability to Anticipate Sex Among HIV Uninfected Members of Kenyan HIV Serodiscordant Couples. <i>AIDS and Behavior</i> , 2014, 18, 1701-1711.	1.4	15
943	A Mixed-Methods Study of Condom Use and Decision Making Among Adolescent Gay and Bisexual Males. <i>AIDS and Behavior</i> , 2014, 18, 1955-1969.	1.4	36
944	Effects of Messaging About Multiple Biomedical and Behavioral HIV Prevention Methods on Intentions to use Among US MSM: Results of an Experimental Messaging Study. <i>AIDS and Behavior</i> , 2014, 18, 1651-1660.	1.4	19
945	Adaptation of the African couples HIV testing and counseling model for men who have sex with men in the United States: an application of the ADAPT-ITT framework. <i>SpringerPlus</i> , 2014, 3, 249.	1.2	64
946	Pharmacokinetics of Antiretrovirals in Genital Secretions and Anatomic Sites of HIV Transmission: Implications for HIV Prevention. <i>Clinical Pharmacokinetics</i> , 2014, 53, 611-624.	1.6	46
947	Unprotected sex among men who have sex with men living with HIV in Brazil: a cross-sectional study in Rio de Janeiro. <i>BMC Public Health</i> , 2014, 14, 379.	1.2	14
948	Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. <i>BMC Medicine</i> , 2014, 12, 46.	2.3	57
949	Renal Function of Participants in the Bangkok Tenofovir Study--Thailand, 2005-2012. <i>Clinical Infectious Diseases</i> , 2014, 59, 716-724.	2.9	58
950	Correlation between Plasma, Intracellular, and Cervical Tissue Levels of Raltegravir at Steady-State Dosing in Healthy Women. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3360-3365.	1.4	12
951	Formulation and delivery of anti-HIV rectal microbicides: Advances and challenges. <i>Journal of Controlled Release</i> , 2014, 194, 278-294.	4.8	39
952	Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 820-829.	4.6	1,039

#	ARTICLE	IF	CITATIONS
953	Considerations for Implementing Oral Preexposure Prophylaxis: A Literature Review. <i>Journal of the Association of Nurses in AIDS Care</i> , 2014, 25, 496-507.	0.4	13
954	Manufacturing scale-up of electrospun poly(vinyl alcohol) fibers containing tenofovir for vaginal drug delivery. <i>International Journal of Pharmaceutics</i> , 2014, 475, 282-291.	2.6	76
955	Qualitative evaluation of a Positive Prevention training for health care providers in Mozambique. <i>Evaluation and Program Planning</i> , 2014, 43, 38-47.	0.9	7
956	Does tenofovir gel or do other microbicide products affect detection of biomarkers of semen exposure in vitro?. <i>Contraception</i> , 2014, 90, 136-141.	0.8	5
957	Pre-exposure prophylaxis to intensify the fight against HIV. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 443-445.	4.6	7
958	HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial. <i>Journal of Infectious Diseases</i> , 2014, 210, 1217-1227.	1.9	68
959	The development of rectal microbicides for HIV prevention. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 69-82.	2.4	43
960	HIV infection: epidemiology, pathogenesis, treatment, and prevention. <i>Lancet</i> , The, 2014, 384, 258-271.	6.3	616
961	Who mixes with whom among men who have sex with men? Implications for modelling the HIV epidemic in southern India. <i>Journal of Theoretical Biology</i> , 2014, 355, 140-150.	0.8	9
962	Being Unaware of Being HIV-Infected is Associated with Alcohol Use Disorders and High-Risk Sexual Behaviors Among Men Who have Sex with Men in Peru. <i>AIDS and Behavior</i> , 2014, 18, 120-127.	1.4	35
963	Psychosocial factors related to willingness to use pre-exposure prophylaxis for HIV prevention among Black men who have sex with men attending a community event. <i>Sexual Health</i> , 2014, 11, 244.	0.4	83
964	Challenges and potential barriers to the uptake of antiretroviral-based prevention in Asia and the Pacific region. <i>Sexual Health</i> , 2014, 11, 126.	0.4	14
965	Daily Oral Tenofovir and Emtricitabine—Tenofovir Preexposure Prophylaxis Reduces Herpes Simplex Virus Type 2 Acquisition Among Heterosexual HIV-1–Uninfected Men and Women. <i>Annals of Internal Medicine</i> , 2014, 161, 11.	2.0	51
966	HIV pre-exposure prophylaxis and treatment as prevention: a review of awareness and acceptability among men who have sex with men in the Asia-Pacific region and the Americas. <i>Sexual Health</i> , 2014, 11, 166.	0.4	61
967	The key role of adherence for the effectiveness of antiretroviral-based prevention: state of the science and implications for the Asia-Pacific region. <i>Sexual Health</i> , 2014, 11, 155.	0.4	6
968	Acceptability of oral and topical HIV chemoprophylaxis in India: implications for at-risk women and men who have sex with men. <i>Sexual Health</i> , 2014, 11, 171.	0.4	11
969	Pharmacokinetics of Single- and Multiple-Dose Emtricitabine in Healthy Male Chinese Volunteers. <i>Pharmacology</i> , 2014, 93, 166-171.	0.9	2
970	Barriers to uptake and use of pre-exposure prophylaxis (PrEP) among communities most affected by HIV in the UK: findings from a qualitative study in Scotland. <i>BMJ Open</i> , 2014, 4, e005717.	0.8	97

#	ARTICLE	IF	CITATIONS
971	Structural approaches for prevention of sexually transmitted HIV in general populations: definitions and an operational approach. <i>Journal of the International AIDS Society</i> , 2014, 17, 19052.	1.2	51
972	The Truvada wars. <i>BMJ, The</i> , 2014, 348, g3811-g3811.	3.0	18
973	Condom use and HIV testing among men who have sex with men in Jordan. <i>Journal of the International AIDS Society</i> , 2014, 17, 18573.	1.2	17
974	The HIV and AIDS Epidemic and the Challenge Posed to University Education Excellence in Sub-Saharan Africa. <i>Journal of Human Ecology: International, Interdisciplinary Journal of Man-environment Relationship</i> , 2014, 46, 297-308.	0.1	0
975	Pharmacokinetics and Safety of Tenofovir in HIV-Infected Women During Labor and Their Infants During the First Week of Life. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 33-41.	0.9	60
976	Knowledge and Attitudes About Preexposure Prophylaxis (PrEP) Among Sexually Active Men Who Have Sex with Men and Who Participate in New York City Gay Pride Events. <i>LGBT Health</i> , 2014, 1, 93-97.	1.8	22
977	Opportunity Knocks: HIV Prevention in Primary Care. <i>LGBT Health</i> , 2014, 1, 75-78.	1.8	8
978	The First Year of LGBT Health: A Year of LGBT Progress in the United States. <i>LGBT Health</i> , 2014, 1, 239-241.	1.8	0
979	Sexual Risk Trajectories Among MSM in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 579-586.	0.9	67
980	HIV Prevention for Adults With Criminal Justice Involvement: A Systematic Review of HIV Risk-Reduction Interventions in Incarceration and Community Settings. <i>American Journal of Public Health</i> , 2014, 104, e27-e53.	1.5	53
981	Lessons Learned From a Review of Interventions for Adolescent and Young Key Populations in Asia Pacific and Opportunities for Programming. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, S186-S192.	0.9	19
982	Advances at AIDS 2014. What does the future look like and how can we better use the tools we have now?. <i>Journal of Pharmacy Practice and Research</i> , 2014, 44, 183-187.	0.5	1
983	Evidence-Based Programming for Adolescent HIV Prevention and Care. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, S228-S235.	0.9	11
984	Exploratory survey of Florida pharmacists's™ experience, knowledge, and perception of HIV pre-exposure prophylaxis. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2014, 54, 610-617.	0.7	37
985	Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. <i>Aids</i> , 2014, 28, 851-859.	1.0	123
986	Is preexposure prophylaxis ready for prime time use in HIV prevention research?. <i>Aids</i> , 2014, 28, 293-295.	1.0	5
987	CD4+ cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis. <i>Aids</i> , 2014, 28, 223-226.	1.0	22
988	State-level structural sexual stigma and HIV prevention in a national online sample of HIV-uninfected MSM in the United States. <i>Aids</i> , 2015, 29, 837-845.	1.0	138

#	ARTICLE	IF	CITATIONS
990	The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs. <i>Aids</i> , 2015, 29, 819-824.	1.0	77
991	Targeting Pre-Exposure Prophylaxis Among Men Who Have Sex With Men in the United States and Peru. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 119-125.	0.9	25
992	When the science fails and the ethics works: "Fail-safe"™ ethics in the FEM-PrEP study. <i>Anthropology and Medicine</i> , 2015, 22, 309-325.	0.6	4
993	PrEP: A case study. <i>Journal of the American Association of Nurse Practitioners</i> , 2015, 27, 296-299.	0.5	2
994	Monoclonal and Single Domain Antibodies Targeting Î²2-Integrin Subunits Block Sexual Transmission of HIV-1 in In Vitro and In Vivo Model Systems. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 278-285.	0.9	6
995	HIV infection. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15035.	18.1	340
996	Is anyone around me using condoms? Site-specific condom-use norms and their potential impact on condomless sex across various gay venues and websites in the Netherlands.. <i>Health Psychology</i> , 2015, 34, 857-864.	1.3	15
997	Challenges in the diagnosis and prevention of viral infections. <i>Laboratoriums Medizin</i> , 2015, 38, .	0.1	2
998	Preexposure Prophylaxis for HIV Prevention. <i>Annals of Internal Medicine</i> , 2015, 163, 941-948.	2.0	1
999	Homosexual men in HIV serodiscordant relationships: implications for HIV treatment as prevention research. <i>Journal of the International AIDS Society</i> , 2015, 18, 19884.	1.2	10
1000	Passing the baton: Community-based ethnography to design a randomized clinical trial on the effectiveness of oral pre-exposure prophylaxis for HIV prevention among Black men who have sex with men. <i>Contemporary Clinical Trials</i> , 2015, 45, 244-251.	0.8	19
1001	Prevalence of high-risky behaviors in transmission of HIV among high school and college student MSM in China: a meta-analysis. <i>BMC Public Health</i> , 2015, 15, 1272.	1.2	27
1002	MSM and HIV-1 infection in China. <i>National Science Review</i> , 2015, 2, 388-391.	4.6	28
1003	Pre-exposure Prophylaxis for the Prevention of HIV Disease in Heterosexuals. <i>Current Sexual Health Reports</i> , 2015, 7, 205-209.	0.4	0
1004	Unprotected Anal Intercourse With Casual Male Partners in Urban Gay, Bisexual, and Other Men Who Have Sex With Men. <i>American Journal of Public Health</i> , 2015, 105, 103-110.	1.5	20
1005	How many MSM in Europe could benefit from PrEP " a 9 billion Euro question?. <i>International Journal of STD and AIDS</i> , 2015, 26, 988-990.	0.5	9
1006	Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques. <i>Retrovirology</i> , 2015, 12, 69.	0.9	13
1007	Protocol for a systematic review: understanding the motivations and barriers to uptake and use of female-initiated, primary biomedical HIV prevention technologies in sub-Saharan Africa. <i>Systematic Reviews</i> , 2015, 4, 111.	2.5	14

#	ARTICLE	IF	CITATIONS
1008	How Bioethics is Complementing Human Rights in Realizing Health Access for Clinical Trial Participants: The Case of Formative PrEP Access in South Africa. <i>Health and Human Rights</i> , 2015, 17, 58.	1.3	2
1009	Beyond "getting drugs into bodies": social science perspectives on pre-exposure prophylaxis for HIV. <i>Journal of the International AIDS Society</i> , 2015, 18, 19983.	1.2	106
1011	Cabotegravir long-acting for HIV-1 prevention. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 258-263.	1.5	50
1012	Using High-Impact HIV Prevention to Achieve the National HIV/AIDS Strategic Goals in Miami-Dade County, Florida. <i>Journal of Public Health Management and Practice</i> , 2015, 21, 584-593.	0.7	10
1013	Antiretroviral Drug Use and HIV Drug Resistance Among HIV-Infected Black Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 446-452.	0.9	21
1014	Feasibility of a Combination HIV Prevention Program for Men Who Have Sex With Men in Blantyre, Malawi. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 155-162.	0.9	25
1015	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 545-548.	0.9	24
1016	How Stigma Surrounding the Use of HIV Preexposure Prophylaxis Undermines Prevention and Pleasure: A Call to Destigmatize "Truvada Whores". <i>American Journal of Public Health</i> , 2015, 105, 1960-1964.	1.5	231
1017	The road ahead: working towards effective clinical translation of biomedical HIV prevention strategies. <i>Future Virology</i> , 2015, 10, 271-282.	0.9	3
1018	Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers. <i>Aids</i> , 2015, 29, 2149-2154.	1.0	16
1019	Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 264-269.	0.9	67
1020	Considerations for a Human Rights Impact Assessment of a Population Wide Treatment for HIV Prevention Intervention. <i>Developing World Bioethics</i> , 2015, 15, 115-124.	0.6	5
1021	A Brief Screening Tool to Assess the Risk of Contracting HIV Infection Among Active Injection Drug Users. <i>Journal of Addiction Medicine</i> , 2015, 9, 226-232.	1.4	30
1022	The current status of the use of oral medication to prevent HIV transmission. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 226-232.	1.5	26
1023	What do Dutch MSM think of preexposure prophylaxis to prevent HIV-infection? A cross-sectional study. <i>Aids</i> , 2015, 29, 955-964.	1.0	35
1024	Understanding HIV Care Provider Attitudes Regarding Intentions to Prescribe PrEP. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 520-528.	0.9	61
1025	Preference for Condoms, Antiretroviral Preexposure Prophylaxis, or Both Methods to Reduce Risk for HIV Acquisition Among Uninfected US Black and Latino MSM. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, e153-e155.	0.9	16
1026	Achieving Pregnancy Safely in HIV-Affected Individuals and Couples. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, e155-e159.	0.9	7

#	ARTICLE	IF	CITATIONS
1027	Sexual Relationships Outside Primary Partnerships and Abstinence Are Associated With Lower Adherence and Adherence Gaps. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 36-43.	0.9	6
1028	Debating Ethics in HIV Research: Gaps between Policy and Practice in Nigeria. <i>Developing World Bioethics</i> , 2015, 15, 214-225.	0.6	5
1029	Antibodies for HIV prevention in young women. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 183-189.	1.5	9
1030	Disclosure of pharmacokinetic drug results to understand nonadherence. <i>Aids</i> , 2015, 29, 2161-2171.	1.0	71
1031	GSK1265744 Demonstrates Robust In Vitro Activity Against Various Clades of HIV-1. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, e39-e41.	0.9	29
1032	Transition to Adulthood and Antiretroviral Adherence Among HIV-Positive Young Black Men Who Have Sex With Men. <i>American Journal of Public Health</i> , 2015, 105, 725-731.	1.5	26
1033	The Role of Stigma and Medical Mistrust in the Routine Health Care Engagement of Black Men Who Have Sex With Men. <i>American Journal of Public Health</i> , 2015, 105, e75-e82.	1.5	305
1034	The Ryan White HIV/AIDS Program in the Age of Health Care Reform. <i>American Journal of Public Health</i> , 2015, 105, 1078-1085.	1.5	41
1035	Injectable agents for pre-exposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 271-277.	1.5	13
1036	Formulation and pharmacology of long-acting rilpivirine. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 233-238.	1.5	71
1037	Extending access with long-acting antiretroviral therapy. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 216-218.	1.5	3
1038	Condom Use Errors and Problems. <i>Sexually Transmitted Diseases</i> , 2015, 42, 634-636.	0.8	13
1039	Defining success with HIV pre-exposure prophylaxis. <i>Aids</i> , 2015, 29, 1277-1285.	1.0	247
1040	A 15-year study of the impact of community antiretroviral therapy coverage on HIV incidence in Kenyan female sex workers. <i>Aids</i> , 2015, 29, 2279-2286.	1.0	23
1041	Strengthening healthcare providers' skills to improve HIV services for MSM in Kenya. <i>Aids</i> , 2015, 29, S237-S240.	1.0	23
1042	Transmission Networks of HIV-1 Among Men Who Have Sex With Men in East and Southeast Asia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, e28-e30.	0.9	3
1043	Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 385-394.	0.9	8
1044	HIV infection: antiretroviral therapy. , 0, , 645-668.		0

#	ARTICLE	IF	CITATIONS
1045	Sex, human rights and AIDS: an analysis of new technologies for HIV prevention in the Brazilian context. <i>Revista Brasileira De Epidemiologia</i> , 2015, 18, 89-103.	0.3	20
1046	Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review. <i>HIV/AIDS - Research and Palliative Care</i> , 2015, 7, 125.	0.4	34
1047	Preexposure prophylaxis-related stigma: strategies to improve uptake and adherence – a narrative review. <i>HIV/AIDS - Research and Palliative Care</i> , 2015, 7, 241.	0.4	78
1048	HIV and adolescents: focus on young key populations. <i>Journal of the International AIDS Society</i> , 2015, 18, 20076.	1.2	56
1049	Costâ€effectiveness of preâ€exposure prophylaxis targeted to highâ€risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda. <i>Journal of the International AIDS Society</i> , 2015, 18, 20013.	1.2	59
1050	Translating PrEP effectiveness into public health impact: key considerations for decisionâ€makers on costâ€effectiveness, price, regulatory issues, distributive justice and advocacy for access. <i>Journal of the International AIDS Society</i> , 2015, 18, 19973.	1.2	34
1051	PRE-EXPOSURE PROPHYLAXIS (PREP) AS HIV PREVENTION STRATEGY AND PUBLIC HEALTH IMPLICATIONS. <i>International Research Journal of Pharmacy</i> , 2015, 6, 227-230.	0.0	0
1052	What is the benefit of the biomedical and behavioral interventions in preventing HIV transmission?. <i>Revista Brasileira De Epidemiologia</i> , 2015, 18, 26-42.	0.3	3
1053	Technologies for HIV prevention and care: challenges for health services. <i>Revista Brasileira De Epidemiologia</i> , 2015, 18, 104-119.	0.3	18
1054	Rethinking HIV prevention to prepare for oral PrEP implementation for young African women. <i>Journal of the International AIDS Society</i> , 2015, 18, 20227.	1.2	109
1055	Pre-exposure prophylaxis for South African adolescents: What evidence?. <i>South African Medical Journal</i> , 2015, 105, 907.	0.2	21
1056	Diagnosis of Human Immunodeficiency Virus Infection. , 2015, , 1503-1525.e7.		1
1057	Getting to zero: World AIDS Day 2015. <i>British Journal of Healthcare Assistants</i> , 2015, 9, 622-623.	0.1	0
1058	Natural Plant Alkaloid (Emetine) Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity. <i>Molecules</i> , 2015, 20, 11474-11489.	1.7	56
1059	Impact of cocaine abuse on HIV pathogenesis. <i>Frontiers in Microbiology</i> , 2015, 6, 1111.	1.5	51
1060	High Frequency of Transmitted HIV-1 Gag HLA Class I-Driven Immune Escape Variants but Minimal Immune Selection over the First Year of Clade C Infection. <i>PLoS ONE</i> , 2015, 10, e0119886.	1.1	14
1061	Client and Provider Perspectives on New HIV Prevention Tools for MSM in the Americas. <i>PLoS ONE</i> , 2015, 10, e0121044.	1.1	20
1062	Frequency of False Positive Rapid HIV Serologic Tests in African Men and Women Receiving PrEP for HIV Prevention: Implications for Programmatic Roll-Out of Biomedical Interventions. <i>PLoS ONE</i> , 2015, 10, e0123005.	1.1	15

#	ARTICLE	IF	CITATIONS
1063	A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study). PLoS ONE, 2015, 10, e0125363.	1.1	53
1064	Facilitators of Adherence to the Study Pill in the FEM-PrEP Clinical Trial. PLoS ONE, 2015, 10, e0125458.	1.1	66
1065	Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention. PLoS ONE, 2015, 10, e0128857.	1.1	25
1066	Knowledge, Indications and Willingness to Take Pre-Exposure Prophylaxis among Transwomen in San Francisco, 2013. PLoS ONE, 2015, 10, e0128971.	1.1	47
1067	Preparing for the Rollout of Pre-Exposure Prophylaxis (PrEP): A Vignette Survey to Identify Intended Sexual Behaviors among Women in Kenya and South Africa if Using PrEP. PLoS ONE, 2015, 10, e0129177.	1.1	9
1068	Glycerol Monolaurate Microbicide Protection against Repeat High-Dose SIV Vaginal Challenge. PLoS ONE, 2015, 10, e0129465.	1.1	27
1069	Knowledge, Beliefs and Practices Regarding Antiretroviral Medications for HIV Prevention: Results from a Survey of Healthcare Providers in New England. PLoS ONE, 2015, 10, e0132398.	1.1	90
1070	Towards a Science of Community Stakeholder Engagement in Biomedical HIV Prevention Trials: An Embedded Four-Country Case Study. PLoS ONE, 2015, 10, e0135937.	1.1	54
1071	Efficient Identification of HIV Serodiscordant Couples by Existing HIV Testing Programs in South Brazil. PLoS ONE, 2015, 10, e0142638.	1.1	4
1072	Uptake, Accuracy, Safety, and Linkage into Care over Two Years of Promoting Annual Self-Testing for HIV in Blantyre, Malawi: A Community-Based Prospective Study. PLoS Medicine, 2015, 12, e1001873.	3.9	276
1073	Strategies to prevent HIV transmission to serodiscordant couples. Revista Brasileira De Epidemiologia, 2015, 18, 169-182.	0.3	7
1074	HIV pre-exposure prophylaxis and health and community systems in the Global South: Thailand case study. Journal of the International AIDS Society, 2015, 18, 19953.	1.2	30
1075	Cost Effectiveness of "On Demand"™ Hiv Pre-Exposure Prophylaxis for Non-Injection Drug-Using Men Who Have Sex with Men in Canada. Canadian Journal of Infectious Diseases and Medical Microbiology, 2015, 26, 23-29.	0.7	39
1076	Tailored combination prevention packages and PrEP for young key populations. Journal of the International AIDS Society, 2015, 18, 19434.	1.2	78
1077	Pre-exposure prophylaxis for men and transgender women who have sex with men in Brazil: opportunities and challenges. Journal of the International AIDS Society, 2015, 18, 20010.	1.2	14
1078	Antiretroviral Therapy for Human Immunodeficiency Virus Infection. , 2015, , 1622-1641.e6.		7
1079	PrEP Implementation Science: State-of-the-Art and Research Agenda. Journal of the International AIDS Society, 2015, 18, 20527.	1.2	10
1080	Antiretroviral pre-exposure prophylaxis implementation in the United States: a work in progress. Journal of the International AIDS Society, 2015, 18, 19980.	1.2	53

#	ARTICLE	IF	CITATIONS
1081	The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention. <i>Journal of the International AIDS Society</i> , 2015, 18, 19949.	1.2	51
1082	Women want Pre-Exposure Prophylaxis but are Advised Against it by Their HIV-positive Counterparts. <i>Journal of AIDS & Clinical Research</i> , 2015, 6, 1-10.	0.5	54
1083	The Art of HIV Elimination: Past and Present Science. <i>Journal of AIDS & Clinical Research</i> , 2015, 6, .	0.5	10
1084	Pre-exposure prophylaxis in Southern Africa: feasible or not?. <i>Journal of the International AIDS Society</i> , 2015, 18, 19979.	1.2	12
1085	The San Francisco MSM Epidemic: A Retrospective Analysis. <i>Mathematics</i> , 2015, 3, 1083-1094.	1.1	0
1086	Oral PrEP for HIV prevention. It works. <i>Journal of Virus Eradication</i> , 2015, 1, 168-172.	0.3	0
1087	Low incidence of HIV infection in an anonymous HIV counselling and testing clinic cohort in Bangkok, Thailand despite high HIV prevalence and self-report of high-risk behaviour. <i>Journal of Virus Eradication</i> , 2015, 1, 78-88.	0.3	0
1088	The Impact of Modern Antiretroviral Therapy on Lipid Metabolism of HIV-1 Infected Patients. , 2015, , .		1
1089	Estimating HIV Protective Effects of Method Adherence With Combinations of Preexposure Prophylaxis and Condom Use Among African American Men Who Have Sex With Men. <i>Sexually Transmitted Diseases</i> , 2015, 42, 88-92.	0.8	30
1090	Effects of a social network HIV/STD prevention intervention for MSM in Russia and Hungary. <i>Aids</i> , 2015, 29, 583-593.	1.0	38
1091	Preexposure Prophylaxis. <i>JAMA Internal Medicine</i> , 2015, 175, 255.	2.6	1
1092	Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use. <i>Infectious Diseases and Therapy</i> , 2015, 4, 145-157.	1.8	31
1093	Changes in Glomerular Kidney Function Among HIV-1 Uninfected Men and Women Receiving Emtricitabine Tenofovir Disoproxil Fumarate Preexposure Prophylaxis. <i>JAMA Internal Medicine</i> , 2015, 175, 246.	2.6	83
1094	Management of Gender Dysphoria. , 2015, , .		11
1095	Characteristics Associated with HIV Drug Resistance Among Women Screening for an HIV Prevention Trial in KwaZulu-Natal, South Africa. <i>AIDS and Behavior</i> , 2015, 19, 2076-2086.	1.4	2
1096	New Arrivals to New York City: Vulnerability to HIV among Urban Migrant Young Gay Men. <i>Archives of Sexual Behavior</i> , 2015, 44, 2041-2053.	1.2	17
1097	A Qualitative Study of Medical Mistrust, Perceived Discrimination, and Risk Behavior Disclosure to Clinicians by U.S. Male Sex Workers and Other Men Who Have Sex with Men: Implications for Biomedical HIV Prevention. <i>Journal of Urban Health</i> , 2015, 92, 667-686.	1.8	88
1098	Transactional sex and prevalence of STIs: a cross-sectional study of MSM and transwomen screened for an HIV prevention trial. <i>International Journal of STD and AIDS</i> , 2015, 26, 879-886.	0.5	29

#	ARTICLE	IF	CITATIONS
1099	Acceptability of PrEP Uptake Among Racially/Ethnically Diverse Young Men Who Have Sex With Men: The P18 Study. <i>AIDS Education and Prevention</i> , 2015, 27, 112-125.	0.6	142
1100	Population pharmacokinetics of tenofovir and tenofovirâ€diphosphate in healthy women. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 629-638.	1.0	25
1101	Simultaneous Evaluation of Safety, Acceptability, Pericoital Kinetics, and <i>Ex Vivo</i> Pharmacodynamics Comparing Four Rectal Microbicide Vehicle Candidates. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1089-1097.	0.5	12
1102	Motivations for Reducing Other HIV Risk-Reduction Practices if Taking Pre-Exposure Prophylaxis: Findings from a Qualitative Study Among Women in Kenya and South Africa. <i>AIDS Patient Care and STDs</i> , 2015, 29, 503-509.	1.1	15
1103	The Strategic Use of Antiretrovirals to Prevent HIV Infection: A Converging Agenda. <i>Clinical Infectious Diseases</i> , 2015, 60, S159-S160.	2.9	21
1104	Optimizing Adherence to Preexposure and Postexposure Prophylaxis: The Need for an Integrated Biobehavioral Approach. <i>Clinical Infectious Diseases</i> , 2015, 60, S187-S190.	2.9	18
1105	Formulating the Future Research Agenda for Postexposure Prophylaxis for HIV: Methodological Challenges and Potential Approaches. <i>Clinical Infectious Diseases</i> , 2015, 60, S205-S211.	2.9	21
1106	Benefits of PrEP as an Adjunctive Method of HIV Prevention During Attempted Conception Between HIV-uninfected Women and HIV-infected Male Partners. <i>Journal of Infectious Diseases</i> , 2015, 212, 1534-1543.	1.9	22
1107	Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir. <i>Journal of Infectious Diseases</i> , 2015, 212, 1988-1995.	1.9	26
1108	Applying Public Health Principles to the HIV Epidemic â€” How Are We Doing?. <i>New England Journal of Medicine</i> , 2015, 373, 2281-2287.	13.9	84
1109	Pre-exposure and postexposure prophylaxes and the combination HIV prevention methods (The Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3 Open, 2015, 5, e009021.	0.8	21
1110	HIV knowledge, risk perception and pre-exposure prophylaxis interest among Thai university students. <i>International Journal of STD and AIDS</i> , 2015, 26, 1007-1016.	0.5	10
1111	Perceptions of and intentions to adopt HIV pre-exposure prophylaxis among black men who have sex with men in Los Angeles. <i>International Journal of STD and AIDS</i> , 2015, 26, 1040-1048.	0.5	70
1112	I Am Menâ€™s Health. <i>Journal of the International Association of Providers of AIDS Care</i> , 2015, 14, 103-107.	0.6	26
1114	Biomedical HIV Prevention Including Pre-exposure Prophylaxis and Opiate Agonist Therapy for Women Who Inject Drugs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, S169-S175.	0.9	28
1115	Patient Experiences of Men Who Have Sex with Men Using Pre-Exposure Prophylaxis to Prevent HIV Infection. <i>AIDS Patient Care and STDs</i> , 2015, 29, 639-642.	1.1	28
1116	Ensuring the Ethical Implementation of the New World Health Organization Pre-Exposure Prophylaxis Recommendations for Men Who Have Sex with Men. <i>LGBT Health</i> , 2015, 2, 11-13.	1.8	3
1117	Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner. <i>EBioMedicine</i> , 2015, 2, 1145-1152.	2.7	37

#	ARTICLE	IF	CITATIONS
1118	HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. <i>Lancet HIV</i> , 2015, 2, e512-e519.	2.1	225
1119	Uptake and effectiveness of PrEP for transgender women. <i>Lancet HIV</i> , 2015, 2, e502-e503.	2.1	12
1120	The compliance of clinicians and patients cannot be globalized. <i>Clinical Microbiology and Infection</i> , 2015, 21, 391.	2.8	1
1121	Gay Inspiration in the Interim Report of the Bishops' Synod. <i>Linacre quarterly</i> , 2015, 82, 101-107.	0.1	2
1122	Perceptions among Dutch men who have sex with men and their willingness to use rectal microbicides and oral pre-exposure prophylaxis to reduce HIV risk – a preliminary study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2015, 27, 1493-1500.	0.6	11
1123	Combination HIV prevention for female sex workers: what is the evidence?. <i>Lancet</i> , 2015, 385, 72-87.	6.3	182
1124	Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons. <i>Journal of Infectious Diseases</i> , 2015, 211, 1943-1952.	1.9	15
1126	HIV in Thai men who have sex with men: a sustained emergency. <i>Lancet HIV</i> , 2015, 2, e38-e39.	2.1	2
1127	Pre-Exposure Prophylaxis to Prevent HIV Infection: Current Status, Future Opportunities and Challenges. <i>Drugs</i> , 2015, 75, 243-251.	4.9	67
1128	Antiretrovirals for Primary HIV Prevention: the Current Status of Pre- and Post-exposure Prophylaxis. <i>Current HIV/AIDS Reports</i> , 2015, 12, 127-138.	1.1	61
1129	Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1473-1481.	1.3	30
1130	Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial. <i>AIDS and Behavior</i> , 2015, 19, 770-783.	1.4	12
1131	Preventing HIV in Women – Still Trying to Find Their VOICE. <i>New England Journal of Medicine</i> , 2015, 372, 564-566.	13.9	15
1132	Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. <i>New England Journal of Medicine</i> , 2015, 372, 509-518.	13.9	1,094
1133	Temporal trends in HIV-1 incidence and risk behaviours in men who have sex with men in Bangkok, Thailand, 2006–13: an observational study. <i>Lancet HIV</i> , 2015, 2, e64-e70.	2.1	56
1134	A Systematic Review of Recent Smartphone, Internet and Web 2.0 Interventions to Address the HIV Continuum of Care. <i>Current HIV/AIDS Reports</i> , 2015, 12, 173-190.	1.1	289
1135	Can we rely on the antiretroviral treatment as the only means for human immunodeficiency virus prevention? A Public Health perspective. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, e63-e68.	0.3	0
1136	Human rights violations against sex workers: burden and effect on HIV. <i>Lancet</i> , 2015, 385, 186-199.	6.3	253

#	ARTICLE	IF	CITATIONS
1137	Binge drinking and risky sexual behavior among HIV-negative and unknown HIV status men who have sex with men, 20 US cities. <i>Drug and Alcohol Dependence</i> , 2015, 147, 46-52.	1.6	58
1138	Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya. <i>AIDS and Behavior</i> , 2015, 19, 794-801.	1.4	39
1139	Role of Medication Therapy Management in Preexposure Prophylaxis Therapy for HIV Prevention. <i>Journal of Pharmacy Practice</i> , 2015, 28, 10-12.	0.5	7
1140	It's Time: The Case for PrEP as an Active Comparator in HIV Biomedical Prevention Trials. <i>Journal of Bioethical Inquiry</i> , 2015, 12, 239-249.	0.9	3
1141	Care of the HIV-infected pregnant woman in the developed world. <i>Obstetric Medicine</i> , 2015, 8, 13-17.	0.5	0
1142	The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. <i>Science Translational Medicine</i> , 2015, 7, 270ra5.	5.8	64
1143	Attitudes and Perceptions of Biomedical HIV Prevention Methods: Voices from Young Men Who Have Sex with Men. <i>Archives of Sexual Behavior</i> , 2015, 44, 487-497.	1.2	59
1144	Lay Social Resources for Support of Adherence to Antiretroviral Prophylaxis for HIV Prevention Among Serodiscordant Couples in sub-Saharan Africa: A Qualitative Study. <i>AIDS and Behavior</i> , 2015, 19, 811-820.	1.4	21
1145	Acceptability of HIV Pre-exposure Prophylaxis (PrEP) Among People Who Inject Drugs (PWID) in a Canadian Setting. <i>AIDS and Behavior</i> , 2015, 19, 752-757.	1.4	60
1146	Intimacy, Condom Use, and Pre-Exposure Prophylaxis (PrEP) Acceptability among Men Who Have Sex with Men (MSM) in Primary Partnerships: a Comment on Gamarel and Golub. <i>Annals of Behavioral Medicine</i> , 2015, 49, 151-153.	1.7	20
1147	Knowledge, Attitudes, and Likelihood of Pre-Exposure Prophylaxis (PrEP) Use Among US Women at Risk of Acquiring HIV. <i>AIDS Patient Care and STDs</i> , 2015, 29, 102-110.	1.1	299
1148	Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2015, 61, 572-580.	2.9	132
1149	Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6080-6086.	1.4	19
1150	PrEP Works and Is a Valuable Addition to the HIV Prevention Toolkit. <i>Journal of the Association of Nurses in AIDS Care</i> , 2015, 26, 224-226.	0.4	3
1151	Elevated urinary leukocyte esterase as a potential surrogate marker for HIV sexual transmission risks in men receiving antiretroviral therapy. <i>International Journal of STD and AIDS</i> , 2015, 26, 313-321.	0.5	1
1152	Explaining racial disparities in HIV incidence in black and white men who have sex with men in Atlanta, GA: a prospective observational cohort study. <i>Annals of Epidemiology</i> , 2015, 25, 445-454.	0.9	199
1153	Editorial Commentary: Uncoupling Epidemiological Synergy: New Opportunities for HIV Prevention for Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2015, 61, 288-290.	2.9	5
1154	Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward. <i>AIDS Patient Care and STDs</i> , 2015, 29, 389-399.	1.1	54

#	ARTICLE	IF	CITATIONS
1155	Processing, selecting and ritualizing: ambivalent relationships to semen. <i>Reproductive BioMedicine Online</i> , 2015, 30, 443-446.	1.1	2
1156	Prospects for a globally effective HIV-1 vaccine. <i>Vaccine</i> , 2015, 33, D4-D12.	1.7	28
1157	Risk of Drug Resistance Among Persons Acquiring HIV Within a Randomized Clinical Trial of Single- or Dual-Agent Preexposure Prophylaxis. <i>Journal of Infectious Diseases</i> , 2015, 211, 1211-8.	1.9	80
1158	Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. <i>Journal of Infectious Diseases</i> , 2015, 212, 1402-1406.	1.9	62
1159	Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8379-8384.	3.3	14
1160	The Transition From Postexposure Prophylaxis to Preexposure Prophylaxis: An Emerging Opportunity for Biobehavioral HIV Prevention. <i>Clinical Infectious Diseases</i> , 2015, 60, S200-S204.	2.9	37
1161	Weighing the Risk of Drug Resistance With the Benefits of HIV Preexposure Prophylaxis. <i>Journal of Infectious Diseases</i> , 2015, 211, 1202-4.	1.9	15
1162	Configuring the users of new HIV-prevention technologies: the case of HIV pre-exposure prophylaxis. <i>Culture, Health and Sexuality</i> , 2015, 17, 428-439.	1.0	32
1163	Impulsivity as a Risk Factor for HIV Transmission in Men Who Have Sex with Men: A Delay Discounting Approach. <i>Journal of Homosexuality</i> , 2015, 62, 588-603.	1.3	14
1164	“Any Condomless Anal Intercourse” is No Longer an Accurate Measure of HIV Sexual risk Behavior in Gay and Other Men Who have Sex with Men. <i>Frontiers in Immunology</i> , 2015, 6, 86.	2.2	42
1165	Multiple Approaches for Increasing the Immunogenicity of an Epitope-Based Anti-HIV Vaccine. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1077-1088.	0.5	17
1166	Clinician Attitudes Toward CDC Interim Pre-Exposure Prophylaxis (PrEP) Guidance and Operationalizing PrEP for Adolescents. <i>AIDS Patient Care and STDs</i> , 2015, 29, 193-203.	1.1	47
1167	Pharmaceutical HIV prevention technologies in the UK: six domains for social science research. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2015, 27, 796-803.	0.6	17
1168	Streamlining HIV Testing for HIV Preexposure Prophylaxis. <i>Journal of Clinical Microbiology</i> , 2015, 53, 179-183.	1.8	10
1169	Reevaluating HIV Vaccine Clinical Trials Policy for Infants. <i>Journal of Infectious Diseases</i> , 2015, 211, 501-503.	1.9	3
1170	A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. <i>Science Translational Medicine</i> , 2015, 7, 270ra4.	5.8	83
1171	Optimal Treatment Strategies in the Context of “Treatment for Prevention” against HIV-1 in Resource-Poor Settings. <i>PLoS Computational Biology</i> , 2015, 11, e1004200.	1.5	17
1172	Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3913-3919.	1.4	147

#	ARTICLE	IF	CITATIONS
1173	Inclusion of trans women in pre-exposure prophylaxis trials: a review. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2015, 27, 637-641.	0.6	52
1174	Tenofovir alafenamide for HIV infection: is less more?. <i>Lancet, The</i> , 2015, 385, 2559-2560.	6.3	14
1175	Mediated intimacies: Raw sex, Truvada, and the biopolitics of chemoprophylaxis. <i>Sexualities</i> , 2015, 18, 224-246.	0.8	96
1176	Antiretroviral therapy initiation in an Australian cohort: implications for increased use of antiretroviral therapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 253-259.	1.3	0
1177	Male Partner Influence on Women's HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of Understanding. <i>AIDS and Behavior</i> , 2015, 19, 784-793.	1.4	88
1178	Knowledge is Power! Increased Provider Knowledge Scores Regarding Pre-exposure Prophylaxis (PrEP) are Associated with Higher Rates of PrEP Prescription and Future Intent to Prescribe PrEP. <i>AIDS and Behavior</i> , 2015, 19, 802-810.	1.4	155
1179	"If I don't use a condom I would be stressed in my heart that I've done something wrong": Routine Prevention Messages Preclude Safer Conception Counseling for HIV-Infected Men and Women in South Africa. <i>AIDS and Behavior</i> , 2015, 19, 1666-1675.	1.4	28
1180	Willingness to Take PrEP and Potential for Risk Compensation Among Highly Sexually Active Gay and Bisexual Men. <i>AIDS and Behavior</i> , 2015, 19, 2234-2244.	1.4	139
1181	Novel Interventions to Prevent HIV and HCV Among Persons Who Inject Drugs. <i>Current HIV/AIDS Reports</i> , 2015, 12, 145-163.	1.1	18
1182	Measuring the Cost Effectiveness of HIV Prevention Interventions in the US: Pitfalls and Problems. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 129-133.	1.0	1
1183	Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery. <i>Current Treatment Options in Infectious Diseases</i> , 2015, 7, 101-112.	0.8	22
1184	Dispelling myths and focusing on notable concepts in HIV pathogenesis. <i>Trends in Molecular Medicine</i> , 2015, 21, 341-353.	3.5	12
1185	"Why should I take drugs for your infection?" outcomes of formative research on the use of HIV pre-exposure prophylaxis in Nigeria. <i>BMC Public Health</i> , 2015, 15, 349.	1.2	18
1186	Pre-exposure prophylaxis works—it's time to deliver. <i>Lancet, The</i> , 2015, 385, 1482-1484.	6.3	19
1187	HIV-Negative Partnered Men's Willingness to Use Pre-Exposure Prophylaxis and Associated Factors Among an Internet Sample of U.S. HIV-Negative and HIV-Discordant Male Couples. <i>LGBT Health</i> , 2015, 2, 35-40.	1.8	28
1188	<i>Editorial Commentary</i> : Unmasking the Bare Bones of HIV Preexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2015, 61, 581-583.	2.9	3
1189	Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial. <i>Clinical Trials</i> , 2015, 12, 394-402.	0.7	9
1190	Update on the Epidemiology and Prevention of HIV/AIDS in the USA. <i>Current Epidemiology Reports</i> , 2015, 2, 110-119.	1.1	14

#	ARTICLE	IF	CITATIONS
1191	Dose Response for Starting and Stopping HIV Preexposure Prophylaxis for Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2015, 60, 804-810.	2.9	53
1192	Reduced Immune Activation During Tenofovir+Emtricitabine Therapy in HIV-Negative Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 495-501.	0.9	19
1193	Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. <i>Aids</i> , 2015, 29, 331-337.	1.0	37
1194	Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 13-20.	0.9	72
1195	HIV and STI Prevalence and Risk Factors Among Male Sex Workers and Other Men Who Have Sex With Men in Nairobi, Kenya. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 91-96.	0.9	72
1196	High Interest in Preexposure Prophylaxis Among Men Who Have Sex With Men at Risk for HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 439-448.	0.9	171
1197	HIV Therapy—The State of ART. <i>Current Topics in Microbiology and Immunology</i> , 2015, 389, 1-29.	0.7	19
1198	Longitudinal Trends in HIV Nonoccupational Postexposure Prophylaxis Use at a Boston Community Health Center Between 1997 and 2013. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 97-101.	0.9	21
1199	Models for Predicting Effective HIV Chemoprevention in Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 369-376.	0.9	17
1200	The HLA-C*04. <i>Aids</i> , 2015, 29, 507-517.	1.0	33
1201	Pharmacokinetics of antiretrovirals in mucosal tissue. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 893-905.	1.5	30
1202	Antiretroviral Drug Exposures Reported to Texas Poison Centers. <i>Journal of Pharmacy Technology</i> , 2015, 31, 276-281.	0.5	0
1204	A Shot in the Arm for HIV Prevention? Recent Successes and Critical Thresholds. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1055-1059.	0.5	3
1205	Transitioning to HIV Pre-Exposure Prophylaxis (PrEP) from Non-Occupational Post-Exposure Prophylaxis (nPEP) in a Comprehensive HIV Prevention Clinic: A Prospective Cohort Study. <i>AIDS Patient Care and STDs</i> , 2015, 29, 431-436.	1.1	20
1206	Attitudes Towards PrEP and Anticipated Condom Use Among Concordant HIV-Negative and HIV-Discordant Male Couples. <i>AIDS Patient Care and STDs</i> , 2015, 29, 408-417.	1.1	65
1207	A Latent Class Analysis of Risk Factors for Acquiring HIV Among Men Who Have Sex with Men: Implications for Implementing Pre-Exposure Prophylaxis Programs. <i>AIDS Patient Care and STDs</i> , 2015, 29, 597-605.	1.1	48
1208	Estimating Efficacy in a Randomized Trial With Product Nonadherence: Application of Multiple Methods to a Trial of Preexposure Prophylaxis for HIV Prevention. <i>American Journal of Epidemiology</i> , 2015, 182, 848-856.	1.6	21
1209	HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1060-1076.	0.5	29

#	ARTICLE	IF	CITATIONS
1210	Cultural Conundrums: The Ethics of Epidemiology and the Problems of Population in Implementing Pre-Exposure Prophylaxis. <i>Developing World Bioethics</i> , 2015, 15, 27-39.	0.6	8
1211	Caring for sex workers. <i>BMJ, The</i> , 2015, 351, h4011.	3.0	8
1212	Defeating AIDS—advancing global health. <i>Lancet, The</i> , 2015, 386, 171-218.	6.3	234
1213	The Impact of Alcohol Use and Related Disorders on the HIV Continuum of Care: a Systematic Review. <i>Current HIV/AIDS Reports</i> , 2015, 12, 421-436.	1.1	155
1214	Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7762-7770.	1.4	15
1215	Acceptability of HIV Pre-Exposure Prophylaxis (PrEP) and Implementation Challenges Among Men Who Have Sex with Men in India: A Qualitative Investigation. <i>AIDS Patient Care and STDs</i> , 2015, 29, 569-577.	1.1	68
1216	Teachers' Patterns of Implementation of an Evidence-Based Intervention and Their Impact on Student Outcomes: Results from a Nationwide Dissemination over 24-Months Follow-Up. <i>AIDS and Behavior</i> , 2015, 19, 1828-1840.	1.4	5
1217	High Prevalence of Multiple Syndemic Conditions Associated with Sexual Risk Behavior and HIV Infection Among a Large Sample of Spanish- and Portuguese-Speaking Men Who Have Sex with Men in Latin America. <i>Archives of Sexual Behavior</i> , 2015, 44, 1869-1878.	1.2	61
1218	Applying a PrEP Continuum of Care for Men Who Have Sex With Men in Atlanta, Georgia. <i>Clinical Infectious Diseases</i> , 2015, 61, 1590-1597.	2.9	253
1219	Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. <i>Journal of Controlled Release</i> , 2015, 219, 669-680.	4.8	39
1220	No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting: Figure 1.. <i>Clinical Infectious Diseases</i> , 2015, 61, 1601-1603.	2.9	444
1221	A Phase 1 Randomized, Blinded Comparison of the Pharmacokinetics and Colonic Distribution of Three Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated Unprotected Sex (CHARM-02). <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1098-1108.	0.5	20
1222	Primary Care for Men Who Have Sex with Men. <i>New England Journal of Medicine</i> , 2015, 373, 854-862.	13.9	23
1223	Integrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early Treatment. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv126.	0.4	9
1224	An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate. <i>International Journal of Pharmaceutics</i> , 2015, 495, 579-587.	2.6	21
1225	On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2237-2246.	13.9	1,302
1226	Are randomised controlled trials always required?. <i>Lancet HIV,the</i> , 2015, 2, e460-e461.	2.1	2
1227	Prospects for a Globally Effective HIV-1 Vaccine. <i>American Journal of Preventive Medicine</i> , 2015, 49, S307-S318.	1.6	29

#	ARTICLE	IF	CITATIONS
1228	Minimal Awareness and Stalled Uptake of Pre-Exposure Prophylaxis (PrEP) Among at Risk, HIV-Negative, Black Men Who Have Sex with Men. <i>AIDS Patient Care and STDs</i> , 2015, 29, 423-429.	1.1	213
1229	Invited Commentary: Every Good Randomization Deserves Observation. <i>American Journal of Epidemiology</i> , 2015, 182, 857-860.	1.6	13
1230	Awareness of Post-Exposure Prophylaxis (PEP) and Pre-Exposure Prophylaxis (PrEP) Is Low but Interest Is High Among Men Engaging in Condomless Anal Sex With Men in Boston, Pittsburgh, and San Juan. <i>AIDS Education and Prevention</i> , 2015, 27, 289-297.	0.6	77
1231	Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection. <i>Future Microbiology</i> , 2015, 10, 1773-1782.	1.0	34
1232	The effect of risk-taking behaviour in epidemic models. <i>Journal of Biological Dynamics</i> , 2015, 9, 229-246.	0.8	6
1233	Periconception HIV Risk Behavior Among Men and Women Reporting HIV-Serodiscordant Partners in KwaZulu-Natal, South Africa. <i>AIDS and Behavior</i> , 2015, 19, 2291-2303.	1.4	24
1234	The Cost and Intensity of Behavioral Interventions to Promote HIV Treatment for Prevention Among HIV-Positive Men Who Have Sex with Men. <i>Archives of Sexual Behavior</i> , 2015, 44, 1833-1841.	1.2	9
1235	Tailoring biomedical interventions for key populations. <i>Lancet HIV</i> , 2015, 2, e8-e9.	2.1	4
1236	Post-exposure prophylaxis use and recurrent exposure to HIV among men who have sex with men who use crystal methamphetamine. <i>Drug and Alcohol Dependence</i> , 2015, 146, 75-80.	1.6	16
1237	Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials. <i>AIDS and Behavior</i> , 2015, 19, 743-751.	1.4	62
1238	A new HIV prevention network approach: Sociometric peer change agent selection. <i>Social Science and Medicine</i> , 2015, 125, 192-202.	1.8	68
1239	Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection. <i>Annual Review of Medicine</i> , 2015, 66, 423-437.	5.0	150
1240	Mind the gap: An empirical study of post-trial access in HIV biomedical prevention trials. <i>Developing World Bioethics</i> , 2015, 15, 85-97.	0.6	14
1241	Intimacy Motivations and Pre-exposure Prophylaxis (PrEP) Adoption Intentions Among HIV-Negative Men Who Have Sex with Men (MSM) in Romantic Relationships. <i>Annals of Behavioral Medicine</i> , 2015, 49, 177-186.	1.7	125
1242	HIV risk and preventive interventions in transgender women sex workers. <i>Lancet, The</i> , 2015, 385, 274-286.	6.3	297
1243	Global implementation of PrEP as part of combination HIV prevention - Unsolved challenges. <i>Journal of the International AIDS Society</i> , 2016, 19, 21479.	1.2	0
1244	HIV pre-exposure prophylaxis for women. <i>Journal of Virus Eradication</i> , 2016, 2, 149-155.	0.3	63
1245	What's new for antiretroviral treatment in women with HIV. <i>Journal of Virus Eradication</i> , 2016, 2, 67-77.	0.3	7

#	ARTICLE	IF	CITATIONS
1246	Sexual Behavior Patterns and PrEP Dosing Preferences in a Large Sample of North American Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 94-101.	0.9	14
1248	Ten Years of Screening and Testing for Acute HIV Infection in North Carolina. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 111-119.	0.9	21
1249	Perceived Advantages and Disadvantages of Using Pre-Exposure Prophylaxis (PrEP) among Sexually Active Black Women: An Exploratory Study. <i>Journal of Black Sexuality and Relationships</i> , 2016, 3, 1-24.	0.2	39
1250	Community mobilization and empowerment interventions for preventing HIV in low and middle income countries. <i>The Cochrane Library</i> , 0, , .	1.5	2
1251	Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities. <i>Journal of the International AIDS Society</i> , 2016, 19, 20903.	1.2	192
1252	“Since both of us are using antiretrovirals, we have been supportive to each other” facilitators and barriers of pre-exposure prophylaxis use in heterosexual HIV serodiscordant couples in Kisumu, Kenya. <i>Journal of the International AIDS Society</i> , 2016, 19, 21134.	1.2	47
1253	Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE (MTN003D) study. <i>Journal of the International AIDS Society</i> , 2016, 19, 20875.	1.2	65
1254	HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities. <i>Open AIDS Journal</i> , 2016, 10, 34-48.	0.1	595
1255	Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw125.	0.4	9
1256	Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date. <i>HIV/AIDS - Research and Palliative Care</i> , 2016, Volume 8, 157-164.	0.4	29
1257	Recent Insights into the HIV/AIDS Pandemic. <i>Microbial Cell</i> , 2016, 3, 450-474.	1.4	41
1258	A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy. <i>Journal of the International AIDS Society</i> , 2016, 19, 20990.	1.2	5
1259	PrEP as a feature in the optimal landscape of combination HIV prevention in sub-Saharan Africa. <i>Journal of the International AIDS Society</i> , 2016, 19, 21104.	1.2	25
1260	Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN003 (VOICE) study. <i>Journal of the International AIDS Society</i> , 2016, 19, 20642.	1.2	45
1261	Stop stalling and make PrEP for HIV available now. <i>BMJ</i> , The, 2016, 353, i3160.	3.0	0
1262	Sexual transmission of HIV and the law: an Australian medical consensus statement. <i>Medical Journal of Australia</i> , 2016, 205, 409-412.	0.8	6
1263	New Biomedical Technologies and Strategies for Prevention of HIV and Other Sexually Transmitted Infections. <i>Journal of Sexually Transmitted Diseases</i> , 2016, 2016, 1-10.	1.0	1
1264	Therapeutic Drug Monitoring of Antiretrovirals. , 2016, , 135-163.		0

#	ARTICLE	IF	CITATIONS
1265	Optimizing HIV pre-exposure prophylaxis implementation among men who have sex with men in a large urban centre: a dynamic modelling study. <i>Journal of the International AIDS Society</i> , 2016, 19, 20791.	1.2	24
1266	Towards a fair consideration of PrEP as part of combination HIV prevention in Latin America. <i>Journal of the International AIDS Society</i> , 2016, 19, 21113.	1.2	32
1267	Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1 Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda. <i>PLoS Medicine</i> , 2016, 13, e1002099.	3.9	166
1268	Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. <i>Molecules</i> , 2016, 21, 221.	1.7	24
1269	Primary care clinicians' experiences prescribing HIV pre-exposure prophylaxis at a specialized community health centre in Boston: lessons from early adopters. <i>Journal of the International AIDS Society</i> , 2016, 19, 21165.	1.2	20
1270	Antiretroviral pre-exposure prophylaxis for HIV prevention is highly effective in community settings. <i>Evidence-Based Medicine</i> , 2016, 21, 99-99.	0.6	0
1271	Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?. <i>PLoS Biology</i> , 2016, 14, e1002372.	2.6	12
1272	Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption. <i>PLoS Medicine</i> , 2016, 13, e1002132.	3.9	70
1273	HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost. <i>PLoS ONE</i> , 2016, 11, e0145637.	1.1	20
1274	Drivers of Vaginal Drug Delivery System Acceptability from Internet-Based Conjoint Analysis. <i>PLoS ONE</i> , 2016, 11, e0150896.	1.1	15
1275	"How I Wish This Thing Was Initiated 100 Years Ago" - Willingness to Take Daily Oral Pre-Exposure Prophylaxis among Men Who Have Sex with Men in Kenya. <i>PLoS ONE</i> , 2016, 11, e0151716.	1.1	50
1276	PrEP Awareness and Attitudes in a National Survey of Primary Care Clinicians in the United States, 2009-2015. <i>PLoS ONE</i> , 2016, 11, e0156592.	1.1	139
1277	Achieving NHAS 90/90/80 Objectives by 2020: An Interactive Tool Modeling Local HIV Prevalence Projections. <i>PLoS ONE</i> , 2016, 11, e0156888.	1.1	1
1278	Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV Exposures. <i>PLoS ONE</i> , 2016, 11, e0157061.	1.1	28
1279	Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting. <i>PLoS ONE</i> , 2016, 11, e0157742.	1.1	60
1280	The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. <i>Journal of the International AIDS Society</i> , 2016, 19, 21105.	1.2	115
1281	HIV Infection and Infertility. , 0, , .		6
1282	Ending the HIV/AIDS epidemic in low- and middle-income countries by 2030: is it possible?. <i>F1000Research</i> , 2016, 5, 2328.	0.8	20

#	ARTICLE	IF	CITATIONS
1283	Partner Disclosure of PrEP Use and Undetectable Viral Load on Geosocial Networking Apps. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 200-206.	0.9	103
1284	Mucosal Topical Microbicide Candidates Exert Influence on the Subsequent SIV Infection and Survival by Regulating SIV-Specific T-Cell Immune Responses. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 121-129.	0.9	16
1285	The Safety of Tenofovir+Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 281-286.	0.9	25
1286	Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 374-380.	0.9	57
1287	Impact of Peer Support on Behavior Change Among Newly Diagnosed Australian Gay Men. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 72, 565-571.	0.9	15
1288	Nondaily preexposure prophylaxis for HIV prevention. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 94-101.	1.5	36
1289	What people want from sex and preexposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 3-9.	1.5	66
1290	What do we know about the cost+effectiveness of HIV preexposure prophylaxis, and is it affordable?. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 56-66.	1.5	37
1291	Planning for HIV preexposure prophylaxis introduction. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 87-93.	1.5	47
1292	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 191.	3.8	533
1293	Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1287-1294.	1.0	5
1294	Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC. <i>Clinical Infectious Diseases</i> , 2016, 63, 836-843.	2.9	37
1295	The promise and pitfalls of long-acting injectable agents for HIV prevention. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 122-128.	1.5	91
1296	Human Immunodeficiency Virus Prevention With Preexposure Prophylaxis in Sexually Transmitted Disease Clinics. <i>Sexually Transmitted Diseases</i> , 2016, 43, 277-282.	0.8	11
1297	Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities. <i>Aids</i> , 2016, 30, 2131-2133.	1.0	2
1298	Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 287-294.	0.9	42
1299	Clear Links Between Starting Methamphetamine and Increasing Sexual Risk Behavior. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 551-557.	0.9	138
1300	Correlates of Sexual HIV Risk Among African American Men Who Have Sex With Men. <i>American Journal of Public Health</i> , 2016, 106, 96-102.	1.5	16

#	ARTICLE	IF	CITATIONS
1301	Statistical issues in trials of preexposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 116-121.	1.5	5
1302	A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 498-505.	0.9	63
1303	PrEP Adherence Patterns Strongly Affect Individual HIV Risk and Observed Efficacy in Randomized Clinical Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 444-451.	0.9	33
1304	A structurally plastic ribonucleoprotein complex mediates posttranscriptional gene regulation in HIV-1. <i>Wiley Interdisciplinary Reviews RNA</i> , 2016, 7, 470-486.	3.2	25
1305	Guidance for Providing Informed-Choice Counseling on Sexual Health for Women Interested in Pre-Exposure Prophylaxis in Kenya and South Africa. <i>AIDS Patient Care and STDs</i> , 2016, 30, 106-109.	1.1	7
1306	The Promise of Pre-Exposure Prophylaxis for Black Men Who Have Sex with Men: An Ecological Approach to Attitudes, Beliefs, and Barriers. <i>AIDS Patient Care and STDs</i> , 2016, 30, 282-290.	1.1	87
1307	Changes in Familiarity with and Willingness to Take Preexposure Prophylaxis in a Longitudinal Study of Highly Sexually Active Gay and Bisexual Men. <i>LGBT Health</i> , 2016, 3, 252-257.	1.8	28
1308	The preexposure prophylaxis revolution; from clinical trials to programmatic implementation. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 80-86.	1.5	84
1309	The History of the HIV/AIDS Epidemic in Africa. <i>Current HIV/AIDS Reports</i> , 2016, 13, 187-193.	1.1	22
1310	Interventions to strengthen the HIV prevention cascade: a systematic review of reviews. <i>Lancet HIV</i> , 2016, 3, e307-e317.	2.1	120
1311	Forging Collaborative Relationships in Brazil: From AIDS to ZIKV. <i>Cell</i> , 2016, 166, 2-4.	13.5	3
1312	Healthcare providers' knowledge of, attitudes to and practice of pre-exposure prophylaxis for HIV infection. <i>HIV Medicine</i> , 2016, 17, 133-142.	1.0	51
1313	The role of tenofovir alafenamide in future HIV management. <i>HIV Medicine</i> , 2016, 17, 4-16.	1.0	40
1314	Reconciling Epidemiology and Social Justice in the Public Health Discourse Around the Sexual Networks of Black Men Who Have Sex With Men. <i>American Journal of Public Health</i> , 2016, 106, 808-814.	1.5	35
1315	Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation. <i>Aids</i> , 2016, 30, 31-35.	1.0	24
1316	Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, e115-e118.	0.9	29
1317	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 184-188.	0.9	1
1318	Implementation and Operational Research: A Cost-Effective, Clinically Actionable Strategy for Targeting HIV Preexposure Prophylaxis to High-Risk Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, e61-e67.	0.9	29

#	ARTICLE	IF	CITATIONS
1319	Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3759-3766.	1.4	22
1320	Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 49-55.	1.5	54
1321	Predictors of interest in taking pre-exposure prophylaxis among men who have sex with men who used a rapid HIV-testing site in Montreal (Actuel sur Rue). <i>HIV Medicine</i> , 2016, 17, 152-158.	1.0	16
1322	Risk factors associated with incident sexually transmitted infections in <sc>HIV</sc>-positive patients in the Australian <sc>HIV</sc> Observational Database: a prospective cohort study. <i>HIV Medicine</i> , 2016, 17, 623-630.	1.0	4
1323	Ethical Implications of Social Stigma Associated with the Promotion and Use of Pre-Exposure Prophylaxis for HIV Prevention. <i>LGBT Health</i> , 2016, 3, 103-108.	1.8	16
1324	Misunderstanding of Pre-Exposure Prophylaxis Use Among Men Who Have Sex with Men: Public Health and Policy Implications. <i>LGBT Health</i> , 2016, 3, 461-464.	1.8	16
1325	Pre-exposure prophylaxis for HIV infection and new sexually transmitted infections among men who have sex with men. <i>Aids</i> , 2016, 30, 2251-2252.	1.0	157
1326	High Willingness to Use HIV Pre-Exposure Prophylaxis Among Transgender Women in Argentina. <i>Transgender Health</i> , 2016, 1, 266-273.	1.2	22
1327	Preventing HIV among Women – A Step Forward, but Much Farther to Go. <i>New England Journal of Medicine</i> , 2016, 375, 2195-2196.	13.9	4
1328	Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women. <i>New England Journal of Medicine</i> , 2016, 375, 2133-2143.	13.9	368
1329	The Shift to High-Impact HIV Prevention by Health Departments in the United States. <i>Public Health Reports</i> , 2016, 131, 7-10.	1.3	15
1330	Individual-Level, Partnership-Level, and Sexual Event-Level Predictors of Condom Use During Receptive Anal Intercourse Among HIV-Negative Men Who Have Sex with Men in Los Angeles. <i>AIDS and Behavior</i> , 2016, 20, 1315-1326.	1.4	23
1331	Antiretroviral pre-exposure prophylaxis preferences among men who have sex with men in Vietnam: results from a nationwide cross-sectional survey. <i>Sexual Health</i> , 2016, 13, 465.	0.4	23
1332	Awareness and knowledge of HIV pre-exposure prophylaxis among Australian gay and bisexual men: results of a national, online survey. <i>Sexual Health</i> , 2016, 13, 359.	0.4	20
1333	Condom deserts: geographical disparities in condom availability and their relationship with rates of sexually transmitted infections. <i>Sexually Transmitted Infections</i> , 2016, 92, 194-199.	0.8	12
1334	<i>T</i>reatment<i>A</i>nd<i>P</i>revention for female<i>S</i>ex workers in South Africa: protocol for the TAPS Demonstration Project. <i>BMJ Open</i> , 2016, 6, e011595.	0.8	15
1335	Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project<i>PRELUDE</i>. <i>BMJ Open</i> , 2016, 6, e012179.	0.8	19
1336	Lignes directrices canadiennes en mati�re de planification de la grossesse en pr�sence du VIH. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2016, 38, S59-S78.	0.3	1

#	ARTICLE	IF	CITATIONS
1337	Mining Pre-Exposure Prophylaxis Trends in Social Media. , 2016, , .		5
1338	Pre-Exposure Prophylaxis for HIV Prevention. North Carolina Medical Journal, 2016, 77, 361-362.	0.1	1
1339	MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel. Clinical Infectious Diseases, 2017, 64, ciw832.	2.9	42
1340	Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States. Annals of Internal Medicine, 2016, 165, 10.	2.0	45
1341	Reactions and Receptivity to Framing HIV Prevention Message Concepts About Pre-Exposure Prophylaxis for Black and Latino Men Who Have Sex with Men in Three Urban US Cities. AIDS Patient Care and STDs, 2016, 30, 484-489.	1.1	22
1342	Mediation Analysis of the Efficacy of the Eban HIV/STD Risk-Reduction Intervention for African American HIV Serodiscordant Couples. AIDS and Behavior, 2016, 20, 1197-1207.	1.4	10
1343	Systematic review and meta-analysis of the adolescent HIV continuum of care in South Africa: the Cresting Wave. BMJ Global Health, 2016, 1, e000004.	2.0	115
1344	Enhancing PrEP Access for Black and Latino Men Who Have Sex With Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 547-555.	0.9	116
1345	Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S.. AIDS and Behavior, 2016, 20, 1390-1399.	1.4	82
1346	Pre-exposure Prophylaxis (PrEP) Use, Seroadaptation, and Sexual Behavior Among Men Who Have Sex with Men, San Francisco, 2004â€“2014. AIDS and Behavior, 2016, 20, 2791-2797.	1.4	66
1347	Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. Journal of Virology, 2016, 90, 5315-5328.	1.5	12
1348	Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2015. American Journal of Medicine, 2016, 129, 879.e13-879.e18.	0.6	1
1349	Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women. Journal of Infectious Diseases, 2016, 214, 1050-1057.	1.9	40
1350	Antiretroviral Therapy for Prevention of Human Immunodeficiency Virus Infection. Medical Clinics of North America, 2016, 100, 927-950.	1.1	11
1351	Pre-exposure Prophylaxis Awareness Among Gay and Other Men who have Sex with Men in Vancouver, British Columbia, Canada. AIDS and Behavior, 2016, 20, 1408-1422.	1.4	35
1352	ART Adherence as a Key Component of Prevention With Persons Living With HIV in Mozambique. Journal of the Association of Nurses in AIDS Care, 2016, 27, 44-56.	0.4	6
1353	Working Toward 21st Century Interprofessional Workforce Training and Leadership in HIV Care. Journal of the Association of Nurses in AIDS Care, 2016, 27, 199-202.	0.4	0
1354	An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis. Trials, 2016, 17, 163.	0.7	36

#	ARTICLE	IF	CITATIONS
1356	A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. <i>Journal of Infectious Diseases</i> , 2016, 214, 55-64.	1.9	251
1357	Awareness of Pre-exposure Prophylaxis for HIV, Willingness to Use It and Potential Barriers or Facilitators to Uptake Among Men Who Have Sex with Men in Spain. <i>AIDS and Behavior</i> , 2016, 20, 1423-1433.	1.4	29
1358	Cost Effectiveness of HIV Prevention Interventions in the U.S.. <i>American Journal of Preventive Medicine</i> , 2016, 50, 699-708.	1.6	31
1359	HIV-negative male couples' attitudes about pre-exposure prophylaxis (PrEP) and using PrEP with a sexual agreement. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 994-999.	0.6	32
1360	Acceptability of Three Novel HIV Prevention Methods Among Young Male and Transgender Female Sex Workers in Puerto Rico. <i>AIDS and Behavior</i> , 2016, 20, 2192-2202.	1.4	20
1361	Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. <i>Journal of Infectious Diseases</i> , 2016, 213, 1523-1531.	1.9	39
1362	Engagement of Gay Men and Other Men Who Have Sex with Men (MSM) in the Response to HIV: A Critical Step in Achieving an AIDS-Free Generation. <i>AIDS and Behavior</i> , 2016, 20, 330-340.	1.4	22
1363	Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). <i>Biochemical Pharmacology</i> , 2016, 119, 1-7.	2.0	119
1364	Testing the hypothesis that treatment can eliminate HIV: a nationwide, population-based study of the Danish HIV epidemic in men who have sex with men. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 789-796.	4.6	42
1365	HIV moments and pre-exposure prophylaxis " Authors' reply. <i>Lancet</i> , The, 2016, 387, 1508.	6.3	2
1366	HIV moments and pre-exposure prophylaxis. <i>Lancet</i> , The, 2016, 387, 1507-1508.	6.3	11
1367	Evaluating the Impact of the US National HIV/AIDS Strategy, 2010-2015. <i>AIDS and Behavior</i> , 2016, 20, 1383-1389.	1.4	13
1368	Safety and Pharmacokinetics of Quick-Dissolving Polymeric Vaginal Films Delivering the Antiretroviral IQP-0528 for Preexposure Prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4140-4150.	1.4	23
1369	A shot at AIDS. <i>Current Opinion in Biotechnology</i> , 2016, 42, 147-151.	3.3	9
1370	Perceived HIV risk, actual sexual HIV risk and willingness to take pre-exposure prophylaxis among men who have sex with men in Toronto, Canada. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 1378-1385.	0.6	56
1371	UK guideline for the use of HIV Post-Exposure Prophylaxis Following Sexual Exposure, 2015. <i>International Journal of STD and AIDS</i> , 2016, 27, 713-738.	0.5	54
1372	Clinical challenges in HIV/AIDS: Hints for advancing prevention and patient management strategies. <i>Advanced Drug Delivery Reviews</i> , 2016, 103, 5-19.	6.6	26
1373	Uncertainty in Online U.S. News Coverage of Truvada. <i>Health Communication</i> , 2016, 31, 1250-1257.	1.8	19

#	ARTICLE	IF	CITATIONS
1374	Antiretroviral chemoprophylaxis: PROUD and pragmatism. <i>Lancet, The</i> , 2016, 387, 6-7.	6.3	18
1375	Barriers to condom use: Results for men and women enrolled in HIV risk reduction trials in outpatient drug treatment. <i>Journal of HIV/AIDS and Social Services</i> , 2016, 15, 130-146.	0.7	10
1376	Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. <i>Aids</i> , 2016, 30, 1973-1983.	1.0	721
1377	The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study. <i>AIDS and Behavior</i> , 2016, 20, 1527-1534.	1.4	41
1378	HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis. <i>Journal of Virology</i> , 2016, 90, 9855-9861.	1.5	12
1379	Preexposure Prophylaxis and Patient Centeredness. <i>American Journal of Men's Health</i> , 2016, 10, 353-358.	0.7	2
1380	Humanized mice in infectious diseases. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2016, 49, 29-38.	0.7	43
1381	HIV pre-exposure prophylaxis for women and infants prevents vaginal and oral HIV transmission in a preclinical model of HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3185-3194.	1.3	12
1382	Development of peptide inhibitors of HIV transmission. <i>Bioactive Materials</i> , 2016, 1, 109-121.	8.6	22
1383	Predictors of crystal methamphetamine use in a community-based sample of UK men who have sex with men. <i>International Journal of Drug Policy</i> , 2016, 36, 43-46.	1.6	17
1384	Pharmacology supports on-demand PrEP. <i>Lancet HIV,the</i> , 2016, 3, e405-e406.	2.1	17
1385	Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. <i>Lancet HIV,the</i> , 2016, 3, e521-e528.	2.1	66
1386	Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing. <i>Biochemical Pharmacology</i> , 2016, 116, 162-175.	2.0	15
1387	A Medical Care Missed Opportunity: Preexposure Prophylaxis and Young Black Men Who Have Sex With Men. <i>Journal of Adolescent Health</i> , 2016, 59, 725-728.	1.2	42
1388	Impact of the Centers for Disease Control's HIV Preexposure Prophylaxis Guidelines for Men Who Have Sex With Men in the United States. <i>Journal of Infectious Diseases</i> , 2016, 214, 1800-1807.	1.9	174
1389	Combining biomedical preventions for HIV: Vaccines with pre-exposure prophylaxis, microbicides or other HIV preventions. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 3202-3211.	1.4	9
1390	Evaluation of a Computer-Based Recruitment System for Enrolling Men Who Have Sex With Men Into an Observational HIV Behavioral Risk Study. <i>American Journal of Epidemiology</i> , 2016, 184, 477-483.	1.6	7
1391	What Community-Based HIV Prevention Organizations Say About Their Role in Biomedical HIV Prevention. <i>AIDS Education and Prevention</i> , 2016, 28, 426-439.	0.6	14

#	ARTICLE	IF	CITATIONS
1392	Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How. <i>Infectious Diseases and Therapy</i> , 2016, 5, 407-416.	1.8	15
1393	Approaches for targeting cancer stem cells drug resistance. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 1201-1212.	2.5	38
1394	Making an Impact With Preexposure Prophylaxis for Prevention of HIV Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 1787-1789.	1.9	5
1395	Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1423-1429.	4.6	89
1396	Predictive Factors for HIV Seroconversion Among Individuals Attending a Specialized Center After an HIV Risk Exposure: A Caseâ€“Control Study. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 1016-1021.	0.5	4
1397	Development and characterization of a long-acting nanoformulated abacavir prodrug. <i>Nanomedicine</i> , 2016, 11, 1913-1927.	1.7	41
1398	Frequency of <sc>HIV</sc> testing among gay and bisexual men in the <sc>UK</sc>: implications for <sc>HIV</sc> prevention. <i>HIV Medicine</i> , 2016, 17, 683-693.	1.0	38
1399	A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2016, 63, 1495-1504.	2.9	53
1400	Multiscale Systemsâ€“Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIVâ€“1. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 377-387.	1.3	27
1401	Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database. <i>Journal of Clinical Virology</i> , 2016, 83, 48-53.	1.6	5
1402	Rectal Infection With<i>Neisseria gonorrhoeae</i>and<i>Chlamydia trachomatis</i>in Men in the United States. <i>Clinical Infectious Diseases</i> , 2016, 63, 1325-1331.	2.9	16
1403	Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5387-5392.	1.4	11
1404	The benefits and risks of PrEP and kidney function. <i>Lancet HIV</i> ,the, 2016, 3, e501-e502.	2.1	1
1405	New Antiretroviral Treatment for HIV. <i>Infectious Diseases and Therapy</i> , 2016, 5, 329-352.	1.8	16
1406	Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 981-991.	0.5	66
1407	Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 131, 333-344.	1.4	13
1408	Pre-exposure prophylaxis: a useful tool to prevent human immunodeficiency virus infection?. <i>Clinical Microbiology and Infection</i> , 2016, 22, 757-767.	2.8	10
1409	Chemoprophylaxis With Oral Emtricitabine and Tenofovir Alafenamide Combination Protects Macaques From Rectal Simian/Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 1058-1062.	1.9	28

#	ARTICLE	IF	CITATIONS
1410	Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6692-6697.	1.4	59
1411	Combination HIV prevention options for young women in Africa. <i>African Journal of AIDS Research</i> , 2016, 15, 109-121.	0.3	39
1412	Factors Associated with Returning At-Home Specimen Collection Kits for HIV Testing among Internet-Using Men Who Have Sex with Men. <i>Journal of the International Association of Providers of AIDS Care</i> , 2016, 15, 463-469.	0.6	19
1413	HIV Pre-exposure Prophylaxis Indication and Readiness Among HIV-Uninfected Transgender Women in Ho Chi Minh City, Vietnam. <i>AIDS and Behavior</i> , 2016, 20, 365-370.	1.4	26
1414	Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis. <i>AIDS and Behavior</i> , 2016, 20, 357-364.	1.4	10
1415	Antiretrovirals for HIV Treatment and Prevention. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 151.	3.8	7
1416	Can the Heterosexual HIV Epidemic be Eliminated in South Africa Using Combination Prevention? A Modeling Analysis. <i>American Journal of Epidemiology</i> , 2016, 184, 239-248.	1.6	13
1417	Adolescent Human Immunodeficiency Virus Care Providers' Attitudes Toward the Use of Oral Pre-Exposure Prophylaxis in Youth. <i>AIDS Patient Care and STDs</i> , 2016, 30, 339-348.	1.1	41
1418	Reaching High-Risk Patients for HIV Preexposure Prophylaxis. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 211.	3.8	5
1419	HIV Infection, Tenofovir, and Urine β 2-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study. <i>American Journal of Kidney Diseases</i> , 2016, 68, 571-581.	2.1	34
1420	Impact of Population Recruitment on the HIV Epidemics and the Effectiveness of HIV Prevention Interventions. <i>Bulletin of Mathematical Biology</i> , 2016, 78, 2057-2090.	0.9	2
1421	Human Immunodeficiency Virus, Other Sexually Transmitted Infections, and Sexual and Reproductive Health in Lesbian, Gay, Bisexual, Transgender Youth. <i>Pediatric Clinics of North America</i> , 2016, 63, 1027-1055.	0.9	29
1422	National leadership needed on HIV Pre-exposure Prophylaxis (PrEP) access in Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2016, 40, 504-505.	0.8	2
1423	PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305). <i>Journal of Infectious Diseases</i> , 2017, 215, jiw525.	1.9	40
1424	Past, Present, and Future Drug Delivery Systems for Antiretrovirals. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 3471-3482.	1.6	23
1425	Potential impact of pre-exposure prophylaxis for female sex workers and men who have sex with men in Bangalore, India: a mathematical modelling study. <i>Journal of the International AIDS Society</i> , 2016, 19, 20942.	1.2	18
1426	Church-Based HIV Screening in Racial/Ethnic Minority Communities of California, 2011-2012. <i>Public Health Reports</i> , 2016, 131, 676-684.	1.3	7
1427	Funding PrEP for HIV prevention. <i>BMJ, The</i> , 2016, 354, i3515.	3.0	5

#	ARTICLE	IF	CITATIONS
1428	Prevention literacy: community-based advocacy for access and ownership of the HIV prevention toolkit. <i>Journal of the International AIDS Society</i> , 2016, 19, 21092.	1.2	16
1429	PrEP implementation in the Asia-Pacific region: opportunities, implementation and barriers. <i>Journal of the International AIDS Society</i> , 2016, 19, 21119.	1.2	60
1430	An Approach to Achieving the Health Equity Goals of the National HIV/AIDS Strategy for the United States Among Racial/Ethnic Minority Communities. <i>Public Health Reports</i> , 2016, 131, 526-530.	1.3	17
1431	HIV Infection Rates and Risk Behavior among Young Men undergoing community-based Testing in San Diego. <i>Scientific Reports</i> , 2016, 6, 25927.	1.6	34
1432	Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 252-257.	0.9	25
1433	Expanded HIV Testing and Linkage to Care: Conventional vs. Point-of-Care Testing and Assignment of Patient Notification and Linkage to Care to an HIV Care Program. <i>Public Health Reports</i> , 2016, 131, 107-120.	1.3	17
1434	Shifting Resources and Focus to Meet the Goals of the National HIV/AIDS Strategy: The Enhanced Comprehensive HIV Prevention Planning Project, 2010-2013. <i>Public Health Reports</i> , 2016, 131, 52-58.	1.3	14
1435	A practical online tool to estimate antiretroviral coverage for HIV infected and susceptible populations needed to reduce local HIV epidemics. <i>Scientific Reports</i> , 2016, 6, 28707.	1.6	6
1436	Modeling HIV vaccine trials of the future. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 620-627.	1.5	5
1437	Condom use and incarceration among STI clinic attendees in the Deep South. <i>BMC Public Health</i> , 2016, 16, 971.	1.2	13
1438	HIV and Zika: When will we be able to end these epidemics?. <i>Retrovirology</i> , 2016, 13, 80.	0.9	1
1439	Perceptions of pre-exposure prophylaxis (PrEP) among HIV-negative and HIV-positive men who have sex with men (MSM). <i>Cogent Medicine</i> , 2016, 3, 1256850.	0.7	45
1440	Using preexposure prophylaxis, losing condoms? Preexposure prophylaxis promotion may undermine safe sex. <i>Aids</i> , 2016, 30, 2753-2756.	1.0	37
1441	Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 365-373.	0.9	11
1442	Evaluation of Sexual Risk Behavior Among Study Participants in the TDF2 PrEP Study Among Heterosexual Adults in Botswana. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 556-563.	0.9	10
1443	The first 24h. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 561-568.	1.5	10
1444	Knowledge, attitudes, and beliefs about HIV pre-exposure prophylaxis among US Air Force Health Care Providers. <i>Medicine (United States)</i> , 2016, 95, e4511.	0.4	36
1445	Motives of Dutch men who have sex with men for daily and intermittent HIV pre-exposure prophylaxis usage and preferences for implementation. <i>Medicine (United States)</i> , 2016, 95, e4910.	0.4	14

#	ARTICLE	IF	CITATIONS
1446	Prevalence of Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infections Among Transgender Persons Referred to an Italian Center for Total Sex Reassignment Surgery. <i>Sexually Transmitted Diseases</i> , 2016, 43, 407-411.	0.8	18
1447	Perceived Risk Among Human Immunodeficiency Virus Serodiscordant Couples in East Africa Taking Oral Pre-Exposure Prophylaxis. <i>Sexually Transmitted Diseases</i> , 2016, 43, 471-475.	0.8	8
1448	Full House: A Retrospective Analysis of High Sexually Transmitted Infection Prevalence among Adult Film Actors at a Singular Residence. <i>Sexually Transmitted Diseases</i> , 2016, 43, 556-559.	0.8	0
1449	Implementation of Preexposure Prophylaxis for Human Immunodeficiency Virus Prevention Among Men Who Have Sex With Men at a New England Sexually Transmitted Diseases Clinic. <i>Sexually Transmitted Diseases</i> , 2016, 43, 717-723.	0.8	67
1450	Hydroxytyrosol. <i>Aids</i> , 2016, 30, 2767-2776.	1.0	23
1451	Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, S145-S153.	0.9	29
1452	Design Issues in Transgender Studies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, S248-S251.	0.9	16
1453	Behavioral Interventions to Prevent HIV Transmission and Acquisition for Transgender Women: A Critical Review. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, S220-S225.	0.9	43
1454	Transgender People and HIV Prevention: What We Know and What We Need to Know, a Call to Action. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, S207-S209.	0.9	42
1455	Ethical Issues to Consider in the Design of HIV Prevention Trials Involving Transgender People. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, S252-S255.	0.9	5
1456	Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, S226-S229.	0.9	33
1457	Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 313-322.	0.9	89
1458	Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, S230-S234.	0.9	17
1459	Inferring HIV-1 Transmission Dynamics in Germany From Recently Transmitted Viruses. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 356-363.	0.9	22
1460	Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 540-546.	0.9	238
1461	Implementation and Operational Research: Affordable Care Act Implementation in a California Health Care System Leads to Growth in HIV-Positive Patient Enrollment and Changes in Patient Characteristics. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, e76-e82.	0.9	17
1462	A Comparison of HIV-Related Risk Factors Between Black Transgender Women and Black Men Who Have Sex with Men. <i>Transgender Health</i> , 2016, 1, 172-180.	1.2	21
1463	International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK. <i>Journal of the International AIDS Society</i> , 2016, 19, 21487.	1.2	17

#	ARTICLE	IF	CITATIONS
1464	Use of an HIV risk screening tool to identify optimal candidates for PrEP scale-up among men who have sex with men in Toronto, Canada: disconnect between objective and subjective HIV risk. <i>Journal of the International AIDS Society</i> , 2016, 19, 20777.	1.2	97
1465	Occurrence of HIV eradication for preexposure prophylaxis treatment with a deterministic HIV model. <i>IET Systems Biology</i> , 2016, 10, 237-243.	0.8	1
1466	The role of healthcare providers in the roll out of preexposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 41-48.	1.5	116
1467	Feasibility of HIV Pre-Exposure Prophylaxis as Part of Routine Care in Toronto, Canada. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, e80-e81.	0.9	7
1468	Shigellosis in men who have sex with men: an overlooked opportunity to counsel with pre-exposure prophylaxis for HIV. <i>International Journal of STD and AIDS</i> , 2016, 27, 1236-1238.	0.5	3
1469	Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2016, 32, 571-583.	1.0	6
1470	Correlates of Awareness of and Willingness to Use Pre-exposure Prophylaxis (PrEP) in Gay, Bisexual, and Other Men Who Have Sex with Men Who Use Geosocial-Networking Smartphone Applications in New York City. <i>AIDS and Behavior</i> , 2016, 20, 1435-1442.	1.4	67
1471	Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study. <i>AIDS and Behavior</i> , 2016, 20, 1535-1540.	1.4	33
1472	Attitudes Toward HIV Pre-Exposure Prophylaxis in a United States Urban Clinic Population. <i>AIDS and Behavior</i> , 2016, 20, 1443-1450.	1.4	47
1473	Pre-exposure prophylaxis as HIV prevention in the UK. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 150-152.	1.1	3
1474	Differences in Attitudes About HIV Pre-Exposure Prophylaxis Use Among Stimulant Versus Alcohol Using Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2016, 20, 1451-1460.	1.4	46
1475	Perceived Challenges and Rewards of Forming a Sexual Agreement Among HIV-Negative Male Couples. <i>Archives of Sexual Behavior</i> , 2016, 45, 1525-1534.	1.2	19
1476	Educating the Primary Care Clinician on Preexposure Prophylaxis for Human Immunodeficiency Virus. <i>JAMA Internal Medicine</i> , 2016, 176, 890.	2.6	2
1477	Public Health Ethics: Cases Spanning the Globe. <i>Public Health Ethics Analysis</i> , 2016, , .	0.1	26
1478	Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention in South Africa: Is There a Will and a Way?. <i>Journal of Infectious Diseases</i> , 2016, 213, 1519-1520.	1.9	7
1479	Current concepts for PrEP adherence in the PrEP revolution. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 10-17.	1.5	147
1480	Willingness to Self-Pay for Pre-exposure Prophylaxis in Men Who Have Sex With Men: A National Online Survey in Taiwan. <i>AIDS Education and Prevention</i> , 2016, 28, 128-137.	0.6	21
1481	A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis. <i>Pharmaceutical Research</i> , 2016, 33, 1649-1656.	1.7	87

#	ARTICLE	IF	CITATIONS
1482	Seasons of Risk: Anticipated Behavior on Vacation and Interest in Episodic Antiretroviral Pre-exposure Prophylaxis (PrEP) Among a Large National Sample of U.S. Men Who have Sex with Men (MSM). <i>AIDS and Behavior</i> , 2016, 20, 1400-1407.	1.4	91
1483	Correlates and Racial/Ethnic Differences in Bareback Sex Among Men Who Have Sex with Men with Unknown or Negative HIV Serostatus. <i>AIDS and Behavior</i> , 2016, 20, 2798-2811.	1.4	8
1484	When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling. <i>Culture, Health and Sexuality</i> , 2016, 18, 1081-1091.	1.0	52
1485	Comparing the impact of increasing condom use or HIV pre-exposure prophylaxis (PrEP) use among female sex workers. <i>Epidemics</i> , 2016, 14, 62-70.	1.5	17
1486	Sexually transmitted infections and pre-exposure prophylaxis: challenges and opportunities among men who have sex with men in the US. <i>AIDS Research and Therapy</i> , 2016, 13, 5.	0.7	76
1487	Overview of HIV molecular epidemiology among people who inject drugs in Europe and Asia. <i>Infection, Genetics and Evolution</i> , 2016, 46, 256-268.	1.0	26
1488	Willingness to Take, Use of, and Indications for Pre-exposure Prophylaxis Among Men Who Have Sex With Men—20 US Cities, 2014. <i>Clinical Infectious Diseases</i> , 2016, 63, 672-677.	2.9	176
1489	Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa. <i>Clinical Infectious Diseases</i> , 2016, 63, 539-547.	2.9	24
1490	Renal Function and Tenofovir Disoproxil Fumarate for Preexposure Prophylaxis: How Safe Is Safe Enough?. <i>Journal of Infectious Diseases</i> , 2016, 214, 983-985.	1.9	1
1491	Early Adopters: Correlates of HIV Chemoprophylaxis Use in Recent Online Samples of US Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2016, 20, 1489-1498.	1.4	36
1492	Does Adherence Change When No One is Looking? Comparing Announced and Unannounced Tenofovir Levels in a PrEP Trial. <i>AIDS and Behavior</i> , 2016, 20, 2639-2643.	1.4	7
1493	Framing HIV Pre-Exposure Prophylaxis (PrEP) for the General Public: How Inclusive Messaging May Prevent Prejudice from Diminishing Public Support. <i>AIDS and Behavior</i> , 2016, 20, 1499-1513.	1.4	41
1494	Beyond Condoms: Risk Reduction Strategies Among Gay, Bisexual, and Other Men Who Have Sex With Men—Receiving Rapid HIV Testing in Montreal, Canada. <i>AIDS and Behavior</i> , 2016, 20, 2812-2826.	1.4	27
1495	Sharing of Investigational Drug Among Participants in the Voice Trial. <i>AIDS and Behavior</i> , 2016, 20, 2709-2714.	1.4	2
1496	HIV Prevention 2020: a framework for delivery and a call for action. <i>Lancet HIV</i> , 2016, 3, e323-e332.	2.1	54
1497	The preexposure prophylaxis revolution. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 67-73.	1.5	25
1498	Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 452-461.	0.9	92
1499	Performing Drug Safety Research During Pregnancy and Lactation: Biomedical HIV Prevention Research as a Template. <i>Journal of Women's Health</i> , 2016, 25, 761-766.	1.5	8

#	ARTICLE	IF	CITATIONS
1500	High Levels of Concomitant Behavioral Health Disorders Among Patients Presenting for HIV Non-occupational Post-exposure Prophylaxis at a Boston Community Health Center Between 1997 and 2013. <i>AIDS and Behavior</i> , 2016, 20, 1556-1563.	1.4	5
1501	Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions. <i>AIDS and Behavior</i> , 2016, 20, 1541-1548.	1.4	12
1502	Explaining the Efficacy of Pre-exposure Prophylaxis (PrEP) for HIV Prevention: A Qualitative Study of Message Framing and Messaging Preferences Among US Men Who have Sex with Men. <i>AIDS and Behavior</i> , 2016, 20, 1514-1526.	1.4	46
1503	Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. <i>Clinical Infectious Diseases</i> , 2016, 62, 1172-1177.	2.9	40
1504	Preexposure Prophylaxis (PrEP) for HIV Prevention: The Primary Care Perspective. <i>Journal of the American Board of Family Medicine</i> , 2016, 29, 143-151.	0.8	27
1505	Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports. <i>Infectious Diseases and Therapy</i> , 2016, 5, 65-71.	1.8	19
1506	Use of Pharmacokinetic Data in Novel Analyses to Determine the Effect of Topical Microbicides as Preexposure Prophylaxis Against HIV Infection. <i>Journal of Infectious Diseases</i> , 2016, 213, 329-331.	1.9	4
1507	Geospatial analysis of condom availability and accessibility in urban Malawi. <i>International Journal of STD and AIDS</i> , 2016, 27, 44-50.	0.5	3
1508	Preparing for pre-exposure prophylaxis: perceptions and readiness of Canadian pharmacists for the implementation of HIV pre-exposure prophylaxis. <i>International Journal of STD and AIDS</i> , 2016, 27, 608-616.	0.5	15
1509	Non-condom related strategies to reduce the risk of HIV transmission: Perspectives and experiences of gay men with diagnosed HIV. <i>Journal of Health Psychology</i> , 2016, 21, 2562-2571.	1.3	11
1510	Investigation of HIV Incidence Rates in a High-Risk, High-Prevalence Kenyan Population. <i>Journal of the International Association of Providers of AIDS Care</i> , 2016, 15, 42-50.	0.6	8
1511	Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 265-273.	1.0	31
1512	PrEP: A Review for Mental Health Professionals. <i>Journal of Gay and Lesbian Mental Health</i> , 2016, 20, 4-12.	0.8	5
1513	People living with HIV and procreation: 30 years of progress from prohibition to freedom?. <i>Human Reproduction</i> , 2016, 31, 918-925.	0.4	8
1515	HIV Incidence Among Men Who Have Sex With Men After Diagnosis With Sexually Transmitted Infections. <i>Sexually Transmitted Diseases</i> , 2016, 43, 249-254.	0.8	86
1516	HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. <i>AIDS and Behavior</i> , 2016, 20, 2983-2995.	1.4	5
1517	ASHP Guidelines on Pharmacist Involvement in HIV Care. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 468-494.	0.5	47
1518	The European preexposure prophylaxis revolution. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 74-79.	1.5	19

#	ARTICLE	IF	CITATIONS
1519	Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings. <i>Current HIV/AIDS Reports</i> , 2016, 13, 116-124.	1.1	76
1520	HIV providers'™ likelihood to prescribe pre-exposure prophylaxis (PrEP) for HIV prevention differs by patient type: a short report. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 1154-1158.	0.6	95
1521	A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1586-1596.	1.3	28
1522	Screening Yield of HIV Antigen/Antibody Combination and Pooled HIV RNA Testing for Acute HIV Infection in a High-Prevalence Population. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 682.	3.8	46
1523	Gendered differences in the perceived risks and benefits of oral PrEP among HIV-serodiscordant couples in Kenya. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 1000-1006.	0.6	21
1524	HIV transmission in MSM: considerations for PrEP scale-up. <i>Lancet HIV</i> , the, 2016, 3, e62-e63.	2.1	3
1525	Ancient Disease, Modern Epidemiology: A Century of Progress in Understanding and Fighting Tuberculosis. <i>American Journal of Epidemiology</i> , 2016, 183, 407-414.	1.6	9
1526	Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 48-55.	0.6	66
1527	Lesbian, Gay, Bisexual, and Transgender Healthcare. , 2016, , .		15
1528	Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. <i>New England Journal of Medicine</i> , 2016, 375, 2121-2132.	13.9	624
1529	Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection Safer Than Aspirin?. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv221.	0.4	11
1530	Microbicide vaginal rings: Technological challenges and clinical development. <i>Advanced Drug Delivery Reviews</i> , 2016, 103, 33-56.	6.6	81
1531	HIV Risk Behaviors, Perceptions, and Testing and Preexposure Prophylaxis (PrEP) Awareness/Use in Grindr-Using Men Who Have Sex With Men in Atlanta, Georgia. <i>Journal of the Association of Nurses in AIDS Care</i> , 2016, 27, 133-142.	0.4	65
1532	Pre-Exposure Prophylaxis (PrEP) for Safer Conception Among Serodifferent Couples: Findings from Healthcare Providers Serving Patients with HIV in Seven US Cities. <i>AIDS Patient Care and STDs</i> , 2016, 30, 125-133.	1.1	22
1533	Towards preparedness for PrEP: PrEP awareness and acceptability among MSM at high risk of HIV transmission who use sociosexual media in four Celtic nations: Scotland, Wales, Northern Ireland and The Republic of Ireland: an online survey. <i>Sexually Transmitted Infections</i> , 2016, 92, 279-285.	0.8	37
1534	Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel. <i>Mucosal Immunology</i> , 2016, 9, 821-833.	2.7	22
1535	Effect of pre-exposure prophylaxis and combination HIV prevention for men who have sex with men in the UK: a mathematical modelling study. <i>Lancet HIV</i> , the, 2016, 3, e94-e104.	2.1	68
1536	Blocking CXCL9 Decreases HIV-1 Replication and Enhances the Activity of Prophylactic Antiretrovirals in Human Cervical Tissues. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 474-482.	0.9	8

#	ARTICLE	IF	CITATIONS
1537	Antiretroviral therapy: Shifting sands. <i>Medical Journal Armed Forces India</i> , 2016, 72, 54-60.	0.3	6
1538	Distinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2765-2770.	1.4	9
1539	High fidelity simian immunodeficiency virus reverse transcriptase mutants have impaired replication in vitro and in vivo. <i>Virology</i> , 2016, 492, 1-10.	1.1	10
1540	Preferences for HIV Pre-Exposure Prophylaxis (PrEP) Information Among Men Who Have Sex with Men (MSM) at Community Outreach Settings. <i>Journal of Gay and Lesbian Mental Health</i> , 2016, 20, 21-33.	0.8	20
1541	NextGen HIV prevention: new possibilities and questions. <i>Lancet, The</i> , 2016, 387, 1036-1038.	6.3	5
1542	PrEP Whores and HIV Prevention: The Queer Communication of HIV Pre-Exposure Prophylaxis (PrEP). <i>Journal of Homosexuality</i> , 2016, 63, 1685-1697.	1.3	69
1543	Modeling and Cost-Effectiveness in HIV Prevention. <i>Current HIV/AIDS Reports</i> , 2016, 13, 64-75.	1.1	25
1544	“I am not a man”: Trans-specific barriers and facilitators to PrEP acceptability among transgender women. <i>Global Public Health</i> , 2016, 11, 1060-1075.	1.0	201
1545	Correlates of PrEP Indication in a Multi-Site Cohort of Young HIV-Uninfected Transgender Women. <i>AIDS and Behavior</i> , 2016, 20, 1470-1477.	1.4	72
1546	Optimizing Delivery of Preexposure Prophylaxis—The Next Frontier. <i>JAMA Internal Medicine</i> , 2016, 176, 85.	2.6	5
1547	On the extinction probability in models of within-host infection: the role of latency and immunity. <i>Journal of Mathematical Biology</i> , 2016, 73, 787-813.	0.8	17
1548	Mucosal tissue pharmacokinetics of the integrase inhibitor raltegravir in a humanized mouse model: Implications for HIV pre-exposure prophylaxis. <i>Virology</i> , 2016, 489, 173-178.	1.1	8
1549	Sources of HIV infection among men having sex with men and implications for prevention. <i>Science Translational Medicine</i> , 2016, 8, 320ra2.	5.8	106
1550	Estimating Incidence of HIV Infection Among Men Who Have Sex with Men, San Francisco, 2004–2014. <i>AIDS and Behavior</i> , 2016, 20, 17-21.	1.4	9
1551	HIV protection with PrEP—implications for controlling other STIs. <i>Nature Reviews Urology</i> , 2016, 13, 72-74.	1.9	1
1552	Acceptability and Preferences for Hypothetical Rectal Microbicides among a Community Sample of Young Men Who Have Sex with Men and Transgender Women in Thailand: A Discrete Choice Experiment. <i>AIDS and Behavior</i> , 2016, 20, 2588-2601.	1.4	30
1553	Using conjoint analysis to determine the impact of product and user characteristics on acceptability of rectal microbicides for HIV prevention among Peruvian men who have sex with men. <i>Sexually Transmitted Infections</i> , 2016, 92, 200-205.	0.8	14
1554	HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. <i>Infection</i> , 2016, 44, 151-158.	2.3	173

#	ARTICLE	IF	CITATIONS
1555	Low-Cost Method to Monitor Patient Adherence to HIV Antiretroviral Therapy Using Multiplex Cathepsin Zymography. <i>Molecular Biotechnology</i> , 2016, 58, 56-64.	1.3	6
1556	Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. <i>JAMA Internal Medicine</i> , 2016, 176, 75.	2.6	535
1557	Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW). <i>AIDS and Behavior</i> , 2016, 20, 1478-1488.	1.4	38
1558	Diffusion of Newer HIV Prevention Innovations: Variable Practices of Frontline Infectious Diseases Physicians. <i>Clinical Infectious Diseases</i> , 2016, 62, 99-105.	2.9	33
1559	Influence of Partner Type on Acceptability and Likelihood of Use of a Rectal Microbicide Among Young Men Who Have Sex With Men in the United States and Puerto Rico. <i>Journal of Sex Research</i> , 2016, 53, 633-641.	1.6	16
1560	HIV Treatment and Prevention. <i>Medical Decision Making</i> , 2016, 36, 391-409.	1.2	22
1561	Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel. <i>Clinical Infectious Diseases</i> , 2016, 62, 375-382.	2.9	20
1562	Pre-exposure prophylaxis of HIV: A right way to go or a long way to go?. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2016, 44, 201-208.	1.9	7
1563	Optimization of Multicomponent Behavioral and Biobehavioral Interventions for the Prevention and Treatment of HIV/AIDS. <i>AIDS and Behavior</i> , 2016, 20, 197-214.	1.4	125
1564	High HIV incidence among men who have sex with men attending a community-based voluntary counselling and testing service in Barcelona, Spain: results from the ITACA cohort. <i>Sexually Transmitted Infections</i> , 2016, 92, 70-75.	0.8	22
1565	Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. <i>Lancet, The</i> , 2016, 387, 53-60.	6.3	1,493
1566	Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 32-43.	0.5	148
1567	A New Measure of the Perceived Influence of Sexually Explicit Online Media on the Sexual Behaviors of Men Who Have Sex With Men. <i>Journal of Sex Research</i> , 2016, 53, 588-600.	1.6	14
1568	Rectal Douching Prevalence and Practices Among Peruvian Men Who have Sex with Men and Transwomen: Implications for Rectal Microbicides. <i>AIDS and Behavior</i> , 2016, 20, 2555-2564.	1.4	10
1569	Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study. <i>Journal of Infectious Diseases</i> , 2016, 213, 335-342.	1.9	40
1570	Persistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+T-Cell Activation. <i>Journal of Infectious Diseases</i> , 2016, 213, 569-573.	1.9	11
1571	Prediction of HIV Sexual Risk Behaviors Among Disadvantaged African American Adults Using a Syndemic Conceptual Framework. <i>AIDS and Behavior</i> , 2016, 20, 449-460.	1.4	20
1572	Sexual Behavior, Risk Compensation, and HIV Prevention Strategies Among Participants in the San Francisco PrEP Demonstration Project: A Qualitative Analysis of Counseling Notes. <i>AIDS and Behavior</i> , 2016, 20, 1461-1469.	1.4	131

#	ARTICLE	IF	CITATIONS
1573	Persistent Racial Disparities in HIV Infection in the USA: HIV Prevalence Matters. <i>Journal of Racial and Ethnic Health Disparities</i> , 2017, 4, 87-93.	1.8	11
1574	Male circumcision to prevent syphilis in 1855 and HIV in 1986 is supported by the accumulated scientific evidence to 2015: Response to Darby. <i>Global Public Health</i> , 2017, 12, 1315-1333.	1.0	9
1575	Overlapping HIV prevention strategies; case report of pre-exposure and postexposure prophylaxes used for a single risk event between two men. <i>Sexually Transmitted Infections</i> , 2017, 93, 238-239.	0.8	0
1576	HIV epidemic and human rights among men who have sex with men in sub-Saharan Africa: Implications for HIV prevention, care, and surveillance. <i>Global Public Health</i> , 2017, 12, 469-482.	1.0	21
1577	“We Might Get Some Free Beers”: Experience and Motivation for Transactional Sex Among Behaviorally Bisexual Men in Vientiane, Laos. <i>Archives of Sexual Behavior</i> , 2017, 46, 1047-1059.	1.2	8
1578	Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework. <i>AIDS and Behavior</i> , 2017, 21, 1361-1375.	1.4	109
1579	“Life-Steps” for PrEP Adherence: Demonstration of a CBT-Based Intervention to Increase Adherence to Preexposure Prophylaxis (PrEP) Medication Among Sexual-Minority Men at High Risk for HIV Acquisition. <i>Cognitive and Behavioral Practice</i> , 2017, 24, 38-49.	0.9	35
1580	Getting the balance right: Scaling-up treatment and prevention. <i>Global Public Health</i> , 2017, 12, 483-497.	1.0	4
1581	Polarised press reporting about HIV prevention: Social representations of pre-exposure prophylaxis in the UK press. <i>Health (United Kingdom)</i> , 2017, 21, 478-497.	0.9	35
1582	“PrEP is not ready for our community, and our community is not ready for PrEP”: pre-exposure prophylaxis for HIV for people who inject drugs and limits to the HIV prevention response. <i>Addiction</i> , 2017, 112, 572-578.	1.7	34
1583	Couples-Focused Prevention Program to Reduce HIV Risk Among Transgender Women and Their Primary Male Partners: Feasibility and Promise of the Couples HIV Intervention Program. <i>AIDS and Behavior</i> , 2017, 21, 2452-2463.	1.4	37
1584	Influencing Condom Use by Gay and Bisexual Men for Anal Sex Through Social Marketing. <i>Social Marketing Quarterly</i> , 2017, 23, 3-17.	0.9	13
1585	Current views on the potential for development of a HIV vaccine. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 295-303.	1.4	23
1586	HIV Pre-exposure Prophylaxis Programs Incorporating Social Applications Can Reach At-Risk Men Who Have Sex With Men for Successful Linkage to Care in Missouri, USA. <i>Journal of the Association of Nurses in AIDS Care</i> , 2017, 28, 428-430.	0.4	13
1587	Pre-exposure prophylaxis and antiretroviral treatment interventions with drug resistance. <i>Mathematical Biosciences</i> , 2017, 285, 92-101.	0.9	10
1588	Global travel and HIV/STI epidemics among MSM: what does the future hold?. <i>Sexual Health</i> , 2017, 14, 51.	0.4	23
1589	Examining the Acceptability of mHealth Technology in HIV Prevention Among High-Risk Drug Users in Treatment. <i>AIDS and Behavior</i> , 2017, 21, 3100-3110.	1.4	31
1590	Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment. <i>AIDS and Behavior</i> , 2017, 21, 1299-1308.	1.4	52

#	ARTICLE	IF	CITATIONS
1591	Stigma and Conspiracy Beliefs Related to Pre-exposure Prophylaxis (PrEP) and Interest in Using PrEP Among Black and White Men and Transgender Women Who Have Sex with Men. <i>AIDS and Behavior</i> , 2017, 21, 1236-1246.	1.4	190
1592	Young Transgender Women's Attitudes Toward HIV Pre-exposure Prophylaxis. <i>Journal of Adolescent Health</i> , 2017, 60, 549-555.	1.2	64
1593	Complex immune correlates of protection in HIV vaccine efficacy trials. <i>Immunological Reviews</i> , 2017, 275, 245-261.	2.8	95
1594	Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model. <i>Scientific Reports</i> , 2017, 7, 41098.	1.6	8
1595	Psychometric evaluation of the Condom Barriers and Motivations Scale (CBMS). <i>Journal of Behavioral Medicine</i> , 2017, 40, 494-505.	1.1	11
1596	Patterns of drug use and HIV infection among adults in a nationally representative sample. <i>Addictive Behaviors</i> , 2017, 68, 39-44.	1.7	70
1597	Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns. <i>Drug Safety</i> , 2017, 40, 273-283.	1.4	51
1598	Long-acting slow effective release antiretroviral therapy. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 1281-1291.	2.4	53
1599	Prevalence and the associated risk factors of HIV, STIs and HBV among men who have sex with men in Kunming, China. <i>International Journal of STD and AIDS</i> , 2017, 28, 1115-1123.	0.5	27
1600	Adolescent Sexuality. <i>Pediatric Clinics of North America</i> , 2017, 64, 389-411.	0.9	27
1601	HIV in transgender women in Brazil. <i>Lancet HIV</i> , 2017, 4, e144-e146.	2.1	3
1602	Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment. <i>Drug and Alcohol Dependence</i> , 2017, 173, 107-116.	1.6	57
1603	Acceptability of HIV Prevention Information Delivered Through Established Geosocial Networking Mobile Applications to Men Who Have Sex With Men. <i>AIDS and Behavior</i> , 2017, 21, 3122-3128.	1.4	14
1604	Progress in HIV vaccine development. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1018-1030.	1.4	80
1605	Use of Pre-exposure Prophylaxis (PrEP) in Young Men Who Have Sex with Men is Associated with Race, Sexual Risk Behavior and Peer Network Size. <i>AIDS and Behavior</i> , 2017, 21, 1376-1382.	1.4	126
1606	Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 377-383.	0.3	11
1607	Post-exposure prophylaxis awareness and use among men who have sex with men in London who use geosocial-networking smartphone applications. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 579-586.	0.6	8
1608	Prevalence of HIV among Aboriginal and Torres Strait Islander Australians: a systematic review and meta-analysis. <i>Sexual Health</i> , 2017, 14, 201.	0.4	5

#	ARTICLE	IF	CITATIONS
1609	Prevalence and characteristics of users of pre-exposure prophylaxis (PrEP) among men who have sex with men, San Francisco, 2014 in a cross-sectional survey: implications for disparities. <i>Sexually Transmitted Infections</i> , 2017, 93, 52-55.	0.8	62
1610	Willingness to use and have sex with men taking HIV pre-exposure prophylaxis (PrEP): results of online surveys of Australian gay and bisexual men, 2011-2015. <i>Sexually Transmitted Infections</i> , 2017, 93, 438-444.	0.8	31
1611	Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 778-783.	0.5	52
1612	Integrating HIV Prevention and Relationship Education for Young Same-Sex Male Couples: A Pilot Trial of the 2GETHER Intervention. <i>AIDS and Behavior</i> , 2017, 21, 2464-2478.	1.4	74
1613	HIV Pre-Exposure Prophylaxis and Postexposure Prophylaxis in Japan: Context of Use and Directions for Future Research and Action. <i>AIDS Patient Care and STDs</i> , 2017, 31, 60-77.	1.1	3
1614	US Black Women and Human Immunodeficiency Virus Prevention: Time for New Approaches to Clinical Trials. <i>Clinical Infectious Diseases</i> , 2017, 65, 324-327.	2.9	18
1615	Adapting behavioural surveillance to antiretroviral-based HIV prevention: reviewing and anticipating trends in the Australian Gay Community Periodic Surveys. <i>Sexual Health</i> , 2017, 14, 72.	0.4	53
1616	Willingness to distribute free rapid home HIV test kits and to test with social or sexual network associates among men who have sex with men in the United States. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 1499-1503.	0.6	36
1617	An Overview of Research and Evaluation Designs for Dissemination and Implementation. <i>Annual Review of Public Health</i> , 2017, 38, 1-22.	7.6	338
1618	The Roles of Behavioral and Social Science Research in the Fight Against HIV/AIDS: A Functional Framework. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 371-381.	0.9	21
1619	International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic Status. <i>Sexually Transmitted Diseases</i> , 2017, 44, 306-309.	0.8	0
1620	Response to: A double-edged sword: does highly active antiretroviral therapy contribute to syphilis incidence by impairing immunity to <i>Treponema pallidum</i> ?. <i>Sexually Transmitted Infections</i> , 2017, 93, 313-313.	0.8	1
1621	Using a network-based approach and targeted maximum likelihood estimation to evaluate the effect of adding pre-exposure prophylaxis to an ongoing test-and-treat trial. <i>Clinical Trials</i> , 2017, 14, 201-210.	0.7	4
1622	Men who have sex with men with newly-diagnosed HIV are often eligible for HIV pre-exposure prophylaxis. <i>International Journal of STD and AIDS</i> , 2017, 28, 629-629.	0.5	0
1623	Risk, safety and sex among male PrEP users: time for a new understanding. <i>Culture, Health and Sexuality</i> , 2017, 19, 1301-1313.	1.0	75
1624	Dolutegravir with tenofovir disoproxil fumarate+emtricitabine as HIV postexposure prophylaxis in gay and bisexual men. <i>Aids</i> , 2017, 31, 1291-1295.	1.0	16
1625	Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 271-279.	0.9	40
1626	Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 184-188.	1.1	3

#	ARTICLE	IF	CITATIONS
1627	Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users. <i>Aids</i> , 2017, 31, 1709-1714.	1.0	103
1628	The Impact of Preexposure Prophylaxis Among Men Who Have Sex With Men: An Individual-Based Model. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 75, 175-183.	0.9	48
1629	A Multi-US City Assessment of Awareness and Uptake of Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Black Men and Transgender Women Who Have Sex with Men. <i>Prevention Science</i> , 2017, 18, 505-516.	1.5	128
1630	U.S. HIV Incidence and Transmission Goals, 2020 and 2025. <i>American Journal of Preventive Medicine</i> , 2017, 53, 275-281.	1.6	14
1631	M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures. <i>Scientific Reports</i> , 2017, 7, 41018.	1.6	9
1632	Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	25
1633	Incidence of Gonorrhea and Chlamydia Following Human Immunodeficiency Virus Preexposure Prophylaxis Among Men Who Have Sex With Men: A Modeling Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 712-718.	2.9	186
1634	Perspectives on HIV Pre- and Post-Exposure Prophylaxes (PrEP and PEP) Among Female and Male Sex Workers in Mombasa, Kenya: Implications for Integrating Biomedical Prevention into Sexual Health Services. <i>AIDS Education and Prevention</i> , 2017, 29, 141-153.	0.6	58
1635	An Event-Level Analysis of the Interpersonal Factors Associated With Condomless Anal Sex Among Gay, Bisexual, and Other Men Who Have Sex With Men (MSM) With Online-Met Partners. <i>AIDS Education and Prevention</i> , 2017, 29, 154-174.	0.6	35
1636	Tenofovir Inhibits Wound Healing of Epithelial Cells and Fibroblasts from the Upper and Lower Human Female Reproductive Tract. <i>Scientific Reports</i> , 2017, 7, 45725.	1.6	20
1637	HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2171-2183.	1.3	8
1638	Disparities in HIV knowledge and attitudes toward biomedical interventions among the non-medical HIV workforce in the United States. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 1576-1584.	0.6	6
1639	An end to lifetime blood donation ban in Israel for MSM would be a major step toward a science-based policy that reduces stigma. <i>Israel Journal of Health Policy Research</i> , 2017, 6, 15.	1.4	4
1640	Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis. <i>HIV Medicine</i> , 2017, 18, 412-418.	1.0	57
1641	Large cluster outbreaks sustain the HIV epidemic among MSM in Quebec. <i>Aids</i> , 2017, 31, 707-717.	1.0	31
1642	Preliminary evidence of HIV seroconversion among HIV-negative men who have sex with men taking non-prescribed antiretroviral medication for HIV prevention in Miami, Florida, USA. <i>Sexual Health</i> , 2017, 14, 193.	0.4	15
1643	Intent to Use Preexposure Prophylaxis (PrEP), HIV Risk Behaviors, and Self-Report Neurocognitive Symptoms by High-Risk Drug Users: A Mediation Analysis. <i>Journal of the Association of Nurses in AIDS Care</i> , 2017, 28, 612-621.	0.4	9
1644	MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection. <i>Aids</i> , 2017, 31, 1603-1610.	1.0	119

#	ARTICLE	IF	CITATIONS
1645	Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	15
1646	PrEP Awareness, Familiarity, Comfort, and Prescribing Experience among US Primary Care Providers and HIV Specialists. <i>AIDS and Behavior</i> , 2017, 21, 1256-1267.	1.4	229
1647	Distinguishing hypothetical willingness from behavioral intentions to initiate HIV pre-exposure prophylaxis (PrEP): Findings from a large cohort of gay and bisexual men in the U.S.. <i>Social Science and Medicine</i> , 2017, 172, 115-123.	1.8	68
1648	Long acting systemic HIV pre-exposure prophylaxis: an examination of the field. <i>Drug Delivery and Translational Research</i> , 2017, 7, 805-816.	3.0	28
1649	On-demand microbicide products: design matters. <i>Drug Delivery and Translational Research</i> , 2017, 7, 775-795.	3.0	18
1651	Herpes Simplex Virus Type 2 Acquisition Among HIV-1â€“Infected Adults Treated With Tenofovir Disoproxil Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. <i>Journal of Infectious Diseases</i> , 2017, 215, 907-910.	1.9	8
1652	Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 535-539.	0.9	16
1653	Culturally Competent Sexual Healthcare as a Prerequisite for Obtaining Preexposure Prophylaxis: Findings from a Qualitative Study. <i>LGBT Health</i> , 2017, 4, 310-314.	1.8	57
1654	Commercial Sexual Behaviors Among Male Rural-to-Urban Migrants in Western China: Implications for HIV Prevention. <i>Asia-Pacific Journal of Public Health</i> , 2017, 29, 388-400.	0.4	14
1655	Defining the HIV pre-exposure prophylaxis care continuum. <i>Aids</i> , 2017, 31, 731-734.	1.0	245
1656	Is PrEP Needed for MSM in West Africa? HIV Incidence in a Prospective Multicountry Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, e80-e82.	0.9	15
1657	Prevention of HIV in Adolescent Girls and Young Women: Key to an AIDS-Free Generation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, S17-S26.	0.9	80
1658	Awareness, Willingness, and Use of Pre-exposure Prophylaxis Among Men Who Have Sex With Men in Washington, DC and Miami-Dade County, FL: National HIV Behavioral Surveillance, 2011 and 2014. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, S375-S382.	0.9	44
1659	Acceptability and use of a dapivirine vaginal ring in a phase III trial. <i>Aids</i> , 2017, 31, 1159-1167.	1.0	97
1660	Tackling HIV and AIDS: contributions by non-human primate models. <i>Lab Animal</i> , 2017, 46, 259-270.	0.2	25
1661	Exploring evidence for behavioral risk compensation among participants in an HIV vaccine clinical trial. <i>Vaccine</i> , 2017, 35, 3558-3563.	1.7	3
1662	Sidestepping the Elephant in the Classroom. , 2017, , .		31
1663	Assessing the need for a preâ€“exposure prophylaxis programme using the social media app Grindrâ„®. <i>HIV Medicine</i> , 2017, 18, 772-776.	1.0	16

#	ARTICLE	IF	CITATIONS
1664	Stabilization and Sustained Release of HIV Inhibitors by Encapsulation in Silk Fibroin Disks. <i>ACS Biomaterials Science and Engineering</i> , 2017, 3, 1654-1665.	2.6	19
1665	Partnership agreements less likely among young gay and bisexual men in Australia – data from a national online survey of gay and bisexual men’s relationships. <i>Sexual Health</i> , 2017, 14, 355.	0.4	1
1666	To whom is HIV pre-exposure prophylaxis proposed?. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2017, 35, 299-302.	0.2	4
1667	Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. <i>Science</i> , 2017, 356, 938-945.	6.0	348
1668	Quantifying the Harms and Benefits from Serosorting Among HIV-Negative Gay and Bisexual Men: A Systematic Review and Meta-analysis. <i>AIDS and Behavior</i> , 2017, 21, 2835-2843.	1.4	27
1669	HIV preexposure prophylaxis for adolescents and young adults. <i>Current Opinion in Pediatrics</i> , 2017, 29, 399-406.	1.0	33
1670	Correlates of Preexposure Prophylaxis (PrEP) Use among Men Who Have Sex with Men (MSM) in Los Angeles, California. <i>Journal of Urban Health</i> , 2017, 94, 710-715.	1.8	55
1671	Humoral responses against HIV in male genital tract. <i>Aids</i> , 2017, 31, 1055-1064.	1.0	1
1672	Differences in Awareness of Pre-exposure Prophylaxis and Post-exposure Prophylaxis Among Groups At-Risk for HIV in New York State: New York City and Long Island, NY, 2011-2013. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, S383-S391.	0.9	56
1674	Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. <i>Lancet HIV</i> , 2017, 4, e331-e340.	2.1	187
1675	Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. <i>MAbs</i> , 2017, 9, 792-800.	2.6	43
1676	Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1760-1768.	1.3	8
1677	Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1731-1740.	1.3	50
1678	Prevention of Sexually Transmitted Diseases in HIV-Infected Individuals. <i>Current HIV/AIDS Reports</i> , 2017, 14, 41-46.	1.1	6
1679	The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 467-481.	2.0	3
1680	Time to Make the Jump: Translating HIV Pre-exposure Prophylaxis Research Into Real-World Public Health Impact. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, e144-e146.	0.9	3
1681	An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 6248-6265.	1.4	17
1682	HIV Prevention and Treatment: The Evolving Role of the Emergency Department. <i>Annals of Emergency Medicine</i> , 2017, 70, 562-572.e3.	0.3	25

#	ARTICLE	IF	CITATIONS
1683	Using geospatial mapping to design HIV elimination strategies for sub-Saharan Africa. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	41
1684	Recent Recommendations for Management of Human Immunodeficiency Virusâ€“Positive Patients. <i>Dental Clinics of North America</i> , 2017, 61, 365-387.	0.8	6
1685	A challenge to overcome: the maintenance of the global quality of life in patients with advanced or metastatic non-small cell lung cancer. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017, 2, 13-22.	0.6	0
1686	Does a Primary Health Clinic for Formerly Incarcerated Women Increase Linkage to Care?. <i>Women's Health Issues</i> , 2017, 27, 499-508.	0.9	25
1687	Markov Mixed Effects Modeling Using Electronic Adherence Monitoring Records Identifies Influential Covariates to HIV Preexposure Prophylaxis. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 606-615.	1.0	7
1688	Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature. <i>AIDS and Behavior</i> , 2017, 21, 1325-1335.	1.4	151
1689	Sexually transmissible infection control programs for men who have sex with men â€“ what will they look like in 2020?. <i>Sexual Health</i> , 2017, 14, 126.	0.4	4
1690	Reaching Key Populations: PrEP Uptake in an Urban Health Care System in the Bronx, New York. <i>AIDS and Behavior</i> , 2017, 21, 1309-1314.	1.4	23
1691	Maximizing the benefits of ART and PrEP in resource-limited settings. <i>Epidemiology and Infection</i> , 2017, 145, 942-956.	1.0	15
1692	Safe sex includes knowing your partner's HIV Status. <i>Journal of Perinatology</i> , 2017, 37, 1-1.	0.9	3
1693	Disparities in Retention in HIV Care Among HIV-Infected Young Men Who Have Sex with Men in the District of Columbia, 2013. <i>LGBT Health</i> , 2017, 4, 34-41.	1.8	3
1694	HIV incidence among gay men and other men who have sex with men in 2020: where is the epidemic heading?. <i>Sexual Health</i> , 2017, 14, 5.	0.4	38
1695	As through a glass, darkly: the future of sexually transmissible infections among gay, bisexual and other men who have sex with men. <i>Sexual Health</i> , 2017, 14, 18.	0.4	19
1696	Comparing non-occupational post-exposure prophylaxis drug regimens for HIV: insights from a linked HIV surveillance system. <i>Sexual Health</i> , 2017, 14, 179.	0.4	3
1697	Likely impact of pre-exposure prophylaxis on HIV epidemics among men who have sex with men. <i>Sexual Health</i> , 2017, 14, 97.	0.4	10
1698	Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	5
1699	Emtricitabine/tenofovir disoproxil fumarate in HIV-1 pre-exposure prophylaxis: a guide to its once-daily use in the EU. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 8-15.	0.3	0
1700	Exploring Patterns of Awareness and Use of HIV Pre-Exposure Prophylaxis Among Young Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2017, 21, 1288-1298.	1.4	115

#	ARTICLE	IF	CITATIONS
1701	Awareness and Acceptability of Pre-exposure HIV Prophylaxis Among Men Who have Sex with Men in Baltimore. <i>AIDS and Behavior</i> , 2017, 21, 1268-1277.	1.4	49
1702	Facebook network structure and awareness of preexposure prophylaxis among young men who have sex with men. <i>Annals of Epidemiology</i> , 2017, 27, 176-180.	0.9	33
1703	Preexposure Prophylaxis of HIV Infection: the Role of Clinical Practices in Ending the HIV Epidemic. <i>Current HIV/AIDS Reports</i> , 2017, 14, 201-210.	1.1	23
1704	HIV prevention trial design in an era of effective pre-exposure prophylaxis. <i>HIV Clinical Trials</i> , 2017, 18, 177-188.	2.0	19
1705	Preventive Health for Transgender Men and Women. <i>Seminars in Reproductive Medicine</i> , 2017, 35, 426-433.	0.5	9
1706	Brief Report: Context Matters: PrEP Adherence is Associated With Sexual Behavior Among HIV Serodiscordant Couples in East Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 488-492.	0.9	16
1707	Potential Healthcare Insurance and Provider Barriers to Pre-Exposure Prophylaxis Utilization Among Young Men Who Have Sex with Men. <i>AIDS Patient Care and STDs</i> , 2017, 31, 470-478.	1.1	52
1708	Comprehensive Primary Health Care for HIV Positive Gay Men. , 2017, , 27-50.		0
1709	Willingness to use HIV pre-exposure prophylaxis among gay men, other men who have sex with men and transgender women in Myanmar. <i>Journal of the International AIDS Society</i> , 2017, 20, 21885.	1.2	38
1710	Dealing with pre-exposure prophylaxis-associated condom migration: changing the paradigm for men who have sex with men. <i>Sexual Health</i> , 2017, 14, 106.	0.4	11
1711	Awareness and willingness to use HIV pre-exposure prophylaxis among men who have sex with men in low- and middle-income countries: a systematic review and meta-analysis. <i>Journal of the International AIDS Society</i> , 2017, 20, 21580.	1.2	119
1712	Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model. <i>Pharmaceutical Research</i> , 2017, 34, 2749-2755.	1.7	32
1713	Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 501-511.	0.9	60
1714	Awareness and willingness towards pre-exposure prophylaxis against HIV infection among individuals seeking voluntary counselling and testing for HIV in Taiwan: a cross-sectional questionnaire survey. <i>BMJ Open</i> , 2017, 7, e015142.	0.8	19
1715	The social value of candidate HIV cures: actualism versus possibilism. <i>Journal of Medical Ethics</i> , 2017, 43, 118-123.	1.0	14
1716	Clinical and public health implications of acute and early HIV detection and treatment: a scoping review. <i>Journal of the International AIDS Society</i> , 2017, 20, 21579.	1.2	107
1717	Barriers to Access and Adoption of Pre-Exposure Prophylaxis for the Prevention of HIV Among Men Who Have Sex With Men (MSM) in a Relatively Rural State. <i>AIDS Education and Prevention</i> , 2017, 29, 315-329.	0.6	84
1718	Attitudes, Beliefs, and Barriers to PrEP Among Trans Men. <i>AIDS Education and Prevention</i> , 2017, 29, 302-314.	0.6	44

#	ARTICLE	IF	CITATIONS
1719	Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen. <i>Aids</i> , 2017, 31, 2245-2251.	1.0	47
1720	Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women. <i>Annals of Internal Medicine</i> , 2017, 167, 384.	2.0	29
1721	Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, e104-e106.	0.9	64
1722	Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. <i>Lancet HIV,the</i> , 2017, 4, e522-e528.	2.1	69
1723	SÃafilis. Realidad de una epidemia actual. <i>Medicina ClÃnica</i> , 2017, 149, 540-541.	0.3	2
1724	The Complex Road Ahead for Preexposure Prophylaxis: A Primary Care Physician Perspective. <i>American Journal of Public Health</i> , 2017, 107, 1580-1581.	1.5	2
1725	Factors Contributing to the Antiviral Effectiveness of Tenofovir. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 363, 156-163.	1.3	17
1726	Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. <i>JAMA Pediatrics</i> , 2017, 171, 1063.	3.3	178
1727	Pre-exposure prophylaxis for MSM and transgender persons in early adopting countries. <i>Aids</i> , 2017, 31, 2179-2191.	1.0	51
1729	Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study. <i>Lancet HIV,the</i> , 2017, 4, e449-e456.	2.1	44
1730	HIV Treatment and Re-infection Beliefs Predict Sexual Risk Behavior of Men Who Have Sex With Men. <i>AIDS Education and Prevention</i> , 2017, 29, 218-227.	0.6	5
1731	Challenges and emerging opportunities for the HIV prevention, treatment and care cascade in men who have sex with men in Asia Pacific. <i>Sexually Transmitted Infections</i> , 2017, 93, 356-362.	0.8	27
1732	Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. <i>Lancet HIV,the</i> , 2017, 4, e402-e410.	2.1	379
1733	The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion. <i>Aids</i> , 2017, 31, 2007-2016.	1.0	75
1734	Condomless Anal Sex Among HIV-Positive Men Who Have Sex with Men: Biomedical Context Matters. <i>AIDS and Behavior</i> , 2017, 21, 2886-2894.	1.4	10
1735	PrEP on demand or every day?. <i>Lancet HIV,the</i> , 2017, 4, e379-e380.	2.1	6
1736	Challenges in Translating PrEP Interest Into Uptake in an Observational Study of Young Black MSM. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 250-258.	0.9	111
1737	Two, three, and four-drug regimens for HIV post-exposure prophylaxis in a North American sexual assault victim population. <i>American Journal of Emergency Medicine</i> , 2017, 35, 1798-1803.	0.7	7

#	ARTICLE	IF	CITATIONS
1738	At the intersection of criminal justice involvement and sexual orientation: Dynamic networks and health among a population-based sample of young Black men who have sex with men. <i>Social Networks</i> , 2017, 51, 73-87.	1.3	26
1739	HIV/AIDS in Rural Communities. , 2017, , .		2
1740	HIV Prevention Among Transgender Populations: Knowledge Gaps and Evidence for Action. <i>Current HIV/AIDS Reports</i> , 2017, 14, 141-152.	1.1	74
1741	Humanized Mouse Models for Human Immunodeficiency Virus Infection. <i>Annual Review of Virology</i> , 2017, 4, 393-412.	3.0	65
1742	Acceptability of Daily Use of Free Oral Pre-exposure Prophylaxis (PrEP) Among Transgender Women Sex Workers in Shenyang, China. <i>AIDS and Behavior</i> , 2017, 21, 3287-3298.	1.4	43
1743	The accuracy of HIV rapid testing in integrated bio-behavioral surveys of men who have sex with men across 5 Provinces in South Africa. <i>Medicine (United States)</i> , 2017, 96, e7391.	0.4	10
1744	HIV pre-exposure prophylaxis (PrEP): effective but controversial. <i>Trends in Urology & Men's Health</i> , 2017, 8, 9-12.	0.2	8
1745	Trends in HIV Risk, Testing, and Treatment among MSM in Chicago 2004â€“2014: Implications for HIV Elimination Planning. <i>Journal of Urban Health</i> , 2017, 94, 699-709.	1.8	12
1746	When Science and Values Collide: Recalling the Lessons of Evidence-Based HIV Prevention. <i>AIDS and Behavior</i> , 2017, 21, 2807-2810.	1.4	0
1747	Online-to-offline models in HIV service delivery. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 447-457.	1.5	17
1748	Evaluation of the Condom Barriers Scale for Young Black Men Who Have Sex With Men: Reliability and Validity of 3 Subscales. <i>Sexually Transmitted Diseases</i> , 2017, 44, 91-95.	0.8	5
1749	Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission. <i>Aids</i> , 2017, 31, 469-476.	1.0	45
1750	Delivering preexposure prophylaxis to pregnant and breastfeeding women in Sub-Saharan Africa. <i>Aids</i> , 2017, 31, 2193-2197.	1.0	30
1751	Routine Inpatient Human Immunodeficiency Virus Screening. <i>Clinical Nurse Specialist</i> , 2017, 31, 45-51.	0.3	0
1752	Are Centers for Disease Control and Prevention Guidelines for Preexposure Prophylaxis Specific Enough? Formulation of a Personalized HIV Risk Score for Pre-Exposure Prophylaxis Initiation. <i>Sexually Transmitted Diseases</i> , 2017, 44, 49-57.	0.8	36
1753	Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251. <i>Aids</i> , 2017, 31, 461-467.	1.0	37
1754	Brief Report: The Right People, Right Places, and Right Practices: Disparities in PrEP Access Among African American Men, Women, and MSM in the Deep South. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 56-59.	0.9	89
1755	Estimated HIV Incidence in the United States, 2003â€“2010. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 10-14.	0.9	7

#	ARTICLE	IF	CITATIONS
1756	Unpacking the Influence of Sexual Stigma on HIV Risk: Results From a Prospective Study of Men Who Have Sex With Men in Beijing, China. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 74, e38-e44.	0.9	16
1757	Healthcare Access and PrEP Continuation in San Francisco and Miami After the US PrEP Demo Project. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 74, 531-538.	0.9	68
1758	Distribution of Behavioral Patterns Before Infection Among San Francisco Men Who Have Sex With Men Newly Infected With HIV in 2014. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 75, 528-534.	0.9	3
1759	Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, 330-337.	0.9	16
1760	Where next with preexposure prophylaxis?. <i>Current Opinion in Infectious Diseases</i> , 2017, 30, 44-49.	1.3	2
1761	A case study of chewed Truvada® for PrEP maintaining protective drug levels as measured by a novel urine tenofovir assay. <i>Antiviral Therapy</i> , 2017, 22, 639-641.	0.6	4
1762	“I Did Not Want to Give Birth to a Child Who has HIV”: Experiences Using PrEP During Pregnancy Among HIV-Uninfected Kenyan Women in HIV-Serodiscordant Couples. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, 259-265.	0.9	43
1763	Individual Versus Community-Level Risk Compensation Following Preexposure Prophylaxis of HIV. <i>American Journal of Public Health</i> , 2017, 107, 1568-1571.	1.5	48
1764	Sexual Communication and Seroadaptation Practices in HIV-Negative Midlife and Older Men Who Have Sex With Men. <i>Journal of Social Service Research</i> , 2017, 43, 193-204.	0.7	2
1765	Assessing the Performance of 3 Human Immunodeficiency Virus Incidence Risk Scores in a Cohort of Black and White Men Who Have Sex With Men in the South. <i>Sexually Transmitted Diseases</i> , 2017, 44, 297-302.	0.8	32
1766	Kidney Disease in HIV: Moving beyond HIV-Associated Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3142-3154.	3.0	24
1767	HIV Care Providers' Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults. <i>AIDS Patient Care and STDs</i> , 2017, 31, 504-516.	1.1	52
1768	Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. <i>Cmaj</i> , 2017, 189, E1448-E1458.	0.9	149
1769	Substance Use and Cognitive Function as Drivers of Condomless Anal Sex Among HIV-Positive Gay, Bisexual, and Other Men Who Have Sex with Men Aged 50 and Older: The Gold Studies. <i>LGBT Health</i> , 2017, 4, 434-441.	1.8	14
1771	Acute Alcohol Consumption Directly Increases HIV Transmission Risk: A Randomized Controlled Experiment. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, 493-500.	0.9	34
1772	A Longitudinal Analysis of Treatment Optimism and HIV Acquisition and Transmission Risk Behaviors Among Black Men Who Have Sex with Men in HPTN 061. <i>AIDS and Behavior</i> , 2017, 21, 2958-2972.	1.4	18
1773	Sexually transmitted infections: challenges ahead. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e235-e279.	4.6	510
1774	Gay Men's Understanding and Education of New HIV Prevention Technologies in Vancouver, Canada. <i>Qualitative Health Research</i> , 2017, 27, 1775-1791.	1.0	12

#	ARTICLE	IF	CITATIONS
1775	Condomless sex in HIV-diagnosed men who have sex with men in the UK: prevalence, correlates, and implications for HIV transmission. <i>Sexually Transmitted Infections</i> , 2017, 93, 590-598.	0.8	39
1776	Management of Newly Diagnosed HIV Infection. <i>Annals of Internal Medicine</i> , 2017, 167, ITC1.	2.0	7
1777	Asymptomatic anorectal <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> infections are associated with systemic CD8+ T-cell activation. <i>Aids</i> , 2017, 31, 2069-2076.	1.0	7
1778	A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective. <i>Infectious Diseases and Therapy</i> , 2017, 6, 363-382.	1.8	37
1779	Urine tenofovir and emtricitabine concentrations provide biomarker for exposure to HIV preexposure prophylaxis. <i>Aids</i> , 2017, 31, 1647-1650.	1.0	6
1780	A multicentre double-blind randomised controlled trial evaluating the efficacy of daily use of antibacterial mouthwash against oropharyngeal gonorrhoea among men who have sex with men: the OMEGA (Oral Mouthwash use to Eradicate GonorrhoeA) study protocol. <i>BMC Infectious Diseases</i> , 2017, 17, 456.	1.3	44
1781	Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention. <i>Harm Reduction Journal</i> , 2017, 14, 40.	1.3	95
1782	Decisions About Testing for HIV While in a Relationship: Perspectives From an Urban, Convenience Sample of HIV-Negative Male Couples Who Have a Sexual Agreement. <i>Archives of Sexual Behavior</i> , 2017, 46, 1069-1077.	1.2	6
1783	Potential for immune-driven viral polymorphisms to compromise antiretroviral-based preexposure prophylaxis for prevention of HIV-1 infection. <i>Aids</i> , 2017, 31, 1935-1943.	1.0	7
1784	An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 21-29.	0.9	235
1785	Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 177-182.	0.9	25
1786	Willingness to use pre-exposure prophylaxis among Black and White men who have sex with men in Atlanta, Georgia. <i>International Journal of STD and AIDS</i> , 2017, 28, 849-857.	0.5	35
1787	Contextualizing willingness to participate: recommendations for engagement, recruitment & enrolment of Kenyan MSM in future HIV prevention trials. <i>BMC Public Health</i> , 2017, 17, 469.	1.2	13
1788	Disparities in Awareness of HIV Postexposure and Preexposure Prophylaxis Among Notified Partners of HIV-Positive Individuals, New York City 2015-2017. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 132-140.	0.9	35
1789	Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2017, 35, 377-383.	0.2	0
1790	Assessment of HIV Screening Tests for Pre-Exposure Prophylaxis Programs. <i>Journal of Infectious Diseases</i> , 2017, 216, 382-386.	1.9	25
1791	“Knowing Your Status and Knowing Your Partner’s Status Is Really Where It Starts”: A Qualitative Exploration of the Process by Which a Sexual Partner’s HIV Status Can Influence Sexual Decision Making. <i>Journal of Sex Research</i> , 2017, 54, 784-794.	1.6	7
1792	Drugs for HIV Infection. , 2017, , 1293-1308.e2.		17

#	ARTICLE	IF	CITATIONS
1793	Uptake of HIV Preexposure Prophylaxis Among Commercially Insured Persons—United States, 2010–2014. <i>Clinical Infectious Diseases</i> , 2017, 64, 144-149.	2.9	109
1794	Preexposure Prophylaxis in the United States: An Evolving HIV Prevention Opportunity. <i>Clinical Infectious Diseases</i> , 2017, 64, 150-151.	2.9	2
1795	Pre-Exposure Prophylaxis: A Narrative Review of Provider Behavior and Interventions to Increase PrEP Implementation in Primary Care. <i>Journal of General Internal Medicine</i> , 2017, 32, 192-198.	1.3	88
1797	Changing Clinician Practices and Attitudes Regarding the Use of Antiretroviral Therapy for HIV Treatment and Prevention. <i>Journal of the International Association of Providers of AIDS Care</i> , 2017, 16, 81-90.	0.6	5
1798	Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2017, 21, 1336-1349.	1.4	103
1799	A Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians. <i>Journal of General Internal Medicine</i> , 2017, 32, 62-70.	1.3	131
1800	Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 734-740.	0.6	6
1801	Low Awareness and Use of Preexposure Prophylaxis in a Diverse Online Sample of Men Who Have Sex With Men in New York City. <i>Journal of the Association of Nurses in AIDS Care</i> , 2017, 28, 27-33.	0.4	20
1802	Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B). <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 339-346.	0.5	32
1803	Epithelium-innate immune cell axis in mucosal responses to SIV. <i>Mucosal Immunology</i> , 2017, 10, 508-519.	2.7	35
1804	Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. <i>Virus Research</i> , 2017, 239, 1-9.	1.1	50
1805	The “Safe Sex” Conundrum: Anticipated Stigma From Sexual Partners as a Barrier to PrEP Use Among Substance Using MSM Engaging in Transactional Sex. <i>AIDS and Behavior</i> , 2017, 21, 300-306.	1.4	62
1806	Informal pre-exposure prophylaxis use in France: results from the Flash PrEP survey (2014). <i>HIV Medicine</i> , 2017, 18, 308-310.	1.0	17
1807	The Impact of HIV Pre-exposure Prophylaxis (PrEP) Use on the Sexual Health of Men Who Have Sex with Men: A Qualitative Study in Seattle, WA. <i>International Journal of Sexual Health</i> , 2017, 29, 55-68.	1.2	63
1808	Mathematical assessment of the role of pre-exposure prophylaxis on HIV transmission dynamics. <i>Applied Mathematics and Computation</i> , 2017, 293, 168-193.	1.4	15
1809	Healthcare Provider Contact and Pre-exposure Prophylaxis in Baltimore Men Who Have Sex With Men. <i>American Journal of Preventive Medicine</i> , 2017, 52, 55-63.	1.6	29
1810	Awareness and Willingness to Use Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex with Men and Transgender Women in Brazil. <i>AIDS and Behavior</i> , 2017, 21, 1278-1287.	1.4	76
1811	Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 478-485.	1.3	37

#	ARTICLE	IF	CITATIONS
1812	¿A quiÃ©n proponer la profilaxis preexposiciÃ³n al virus de la inmunodeficiencia humana?. Enfermedades Infecciosas Y MicrobiologÃ­a ClÃ­nica, 2017, 35, 299-302.	0.3	14
1813	Epidemiology of HIV Infection. , 2017, , 812-823.e2.		0
1814	Bio-behavioral Interventions to Prevent HIV Transmission. , 2017, , 824-828.e2.		0
1815	HIV/AIDS-Related Problems in Low- and Middle-Income Countries. , 2017, , 888-895.e1.		0
1816	Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study. Lancet HIV,the, 2017, 4, e59-e66.	2.1	46
1817	Commitment issues: PrEP adherence in injecting drug users. Lancet HIV,the, 2017, 4, e52-e53.	2.1	4
1818	Optimizing Pre-Exposure Antiretroviral Prophylaxis Adherence in Men Who Have Sex with Men: Results of a Pilot Randomized Controlled Trial of "Life-Steps for PrEP" AIDS and Behavior, 2017, 21, 1350-1360.	1.4	72
1819	Doxycycline in the management of sexually transmitted infections. Journal of Antimicrobial Chemotherapy, 2018, 73, 553-563.	1.3	29
1820	Top Questions in ID: Pre-exposure Prophylaxis for HIV. Open Forum Infectious Diseases, 2017, 4, ofx185.	0.4	1
1821	Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: a case report and review of the literature. Antiviral Therapy, 2017, 23, 379-382.	0.6	0
1822	Promoting Pre-exposure Prophylaxis to Prevent HIV Infections Among Sexual and Gender Minority Hispanics/Latinxs. AIDS Education and Prevention, 2017, 29, 389-400.	0.6	28
1823	Syphilis. Status of a current epidemic. Medicina ClÃ­nica (English Edition), 2017, 149, 540-541.	0.1	1
1824	Recent advances in pre-exposure prophylaxis for HIV. BMJ: British Medical Journal, 2017, 359, j5011.	2.4	101
1825	Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+T cells. Scientific Reports, 2017, 7, 17697.	1.6	10
1826	Facilitators and Barriers to Pre-Exposure Prophylaxis Willingness Among Young Men Who Have Sex with Men Who Use Geosocial Networking Applications in California. AIDS Patient Care and STDs, 2017, 31, 517-527.	1.1	84
1828	Sociodemographic and Clinical Factors Associated With Increasing Bacterial Sexually Transmitted Infection Diagnoses in Men Who Have Sex With Men Accessing Care at a Boston Community Health Center (2005-2015). Open Forum Infectious Diseases, 2017, 4, ofx214.	0.4	26
1829	Differentiating Nonoccupational Postexposure Prophylaxis Seroconverters and Non-Seroconverters in a Community-Based Clinic in Los Angeles, California. Open Forum Infectious Diseases, 2017, 4, ofx061.	0.4	10
1830	Preventing the Spread of HIV/AIDS in Botswana. , 0, , 998-1019.		0

#	ARTICLE	IF	CITATIONS
1831	Implementing National HIV/AIDS Strategy 2015 Treatment Targets Is Cost-effective and Would Save Lives: What Other Evidence Do We Need?. <i>Journal of Infectious Diseases</i> , 2017, 216, 787-789.	1.9	1
1832	Expanding the domain of drug delivery for HIV prevention: exploration of the transdermal route. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2017, 34, 551-587.	1.2	13
1833	Economic evaluation of HIV pre-exposure prophylaxis among men-who-have-sex-with-men in England in 2016. <i>Eurosurveillance</i> , 2017, 22, .	3.9	14
1834	InterPrEP. Internet-based pre-exposure prophylaxis with generic tenofovir DF/emtricitabine in London: an analysis of outcomes in 641 patients. <i>Journal of Virus Eradication</i> , 2017, 3, 218-222.	0.3	14
1836	New Antiretrovirals for HIV and Antivirals for HBV. , 2017, , 628-664.		1
1837	Editorial: HIV and Antiretroviral Drugs: Current Status and New Challenges. <i>Current Pharmaceutical Design</i> , 2017, 23, 2551.	0.9	0
1838	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. <i>Statistical Communications in Infectious Diseases</i> , 2017, 9, .	0.2	62
1839	Developing an Integrated, Brief Biobehavioral HIV Prevention Intervention for High-Risk Drug Users in Treatment: The Process and Outcome of Formative Research. <i>Frontiers in Immunology</i> , 2017, 8, 561.	2.2	25
1840	Stigma and the "Social Epidemic" of HIV: Understanding Bidirectional Mechanisms of Risk and Resilience. , 0, , 457-476.		3
1841	Adolescent pre-exposure prophylaxis for HIV prevention: current perspectives. <i>Adolescent Health, Medicine and Therapeutics</i> , 2017, Volume 8, 137-148.	0.7	20
1842	Feasibility and acceptability of HIV self-testing among pre-exposure prophylaxis users in Kenya. <i>Journal of the International AIDS Society</i> , 2017, 20, 21234.	1.2	66
1843	Pre-exposure prophylaxis for HIV prevention in women: current perspectives. <i>International Journal of Women's Health</i> , 2017, Volume 9, 391-401.	1.1	41
1844	Alcohol-antiretroviral interactive toxicity beliefs as a potential barrier to HIV pre-exposure prophylaxis among men who have sex with men. <i>Journal of the International AIDS Society</i> , 2017, 20, 21534.	1.2	15
1845	Acceptability of an open-label wait-listed trial design: Experiences from the PROUD PrEP study. <i>PLoS ONE</i> , 2017, 12, e0175596.	1.1	6
1846	Optimal costs of HIV pre-exposure prophylaxis for men who have sex with men. <i>PLoS ONE</i> , 2017, 12, e0178170.	1.1	25
1847	Impact of insurance coverage on utilization of pre-exposure prophylaxis for HIV prevention. <i>PLoS ONE</i> , 2017, 12, e0178737.	1.1	75
1848	PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection. <i>PLoS ONE</i> , 2017, 12, e0181433.	1.1	9
1849	High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women. <i>PLoS ONE</i> , 2017, 12, e0181607.	1.1	25

#	ARTICLE	IF	CITATIONS
1850	Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model. <i>PLoS ONE</i> , 2017, 12, e0185946.	1.1	26
1851	A novel Online-to-Offline (O2O) model for pre-exposure prophylaxis and HIV testing scale up. <i>Journal of the International AIDS Society</i> , 2017, 20, 21326.	1.2	49
1852	Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice. <i>PLoS ONE</i> , 2017, 12, e0184303.	1.1	18
1853	Long-Acting HIV Treatment and Prevention: Closer to the Threshold. <i>Global Health, Science and Practice</i> , 2017, 5, 182-187.	0.6	23
1854	Patterns of HIV testing practices among young gay and bisexual men living in Scotland: a qualitative study. <i>BMC Public Health</i> , 2017, 17, 660.	1.2	14
1855	Project LifeSkills - a randomized controlled efficacy trial of a culturally tailored, empowerment-based, and group-delivered HIV prevention intervention for young transgender women: study protocol. <i>BMC Public Health</i> , 2017, 17, 713.	1.2	36
1856	Primary Care of Men Who Have Sex With Men in the U.S. Military in the Post-Don't Ask, Don't Tell Era: A Review of Recent Progress, Health Needs, and Challenges. <i>Military Medicine</i> , 2017, 182, e1603-e1611.	0.4	5
1857	A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study. <i>BMC Infectious Diseases</i> , 2017, 17, 496.	1.3	20
1858	HIV infected men who have sex with men in Israel: knowledge, attitudes and sexual behavior. <i>BMC Infectious Diseases</i> , 2017, 17, 679.	1.3	3
1859	Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians. <i>BMC Infectious Diseases</i> , 2017, 17, 734.	1.3	4
1860	Prevalence and correlates of condom use among sexually active men who have sex with men in the United States: findings from the National Survey of Family Growth, 2002, 2006-10 and 2011-13. <i>Sexual Health</i> , 2017, 14, 363.	0.4	13
1861	High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project. <i>Journal of the International AIDS Society</i> , 2017, 20, 21472.	1.2	98
1862	Stigma, Partners, Providers and Costs: Potential Barriers to PrEP Uptake among US Women. <i>Journal of AIDS & Clinical Research</i> , 2017, 08, .	0.5	128
1863	Prescribing of Human Immunodeficiency Virus (HIV) Pre-exposure Prophylaxis by HIV Medical Providers in the United States, 2013-2014. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx003.	0.4	11
1864	Review of HIV Interventions among Young and Adolescent Key Populations in Low to Middle Income Countries. <i>Journal of AIDS & Clinical Research</i> , 2017, 8, .	0.5	0
1865	How common and frequent is heterosexual anal intercourse among South Africans? A systematic review and meta-analysis. <i>Journal of the International AIDS Society</i> , 2017, 20, 21162.	1.2	15
1866	Summary of Guidelines for the Use of Pre-Exposure Prophylaxis for HIV in Korea. <i>Infection and Chemotherapy</i> , 2017, 49, 243.	1.0	7
1868	Stigma, access to healthcare, and HIV risks among men who sell sex to men in Nigeria. <i>Journal of the International AIDS Society</i> , 2017, 20, 21489.	1.2	55

#	ARTICLE	IF	CITATIONS
1870	Illuminating the Context and Circumstances of Male Couples Establishing a Sexual Agreement in Their Relationship. <i>American Journal of Men's Health</i> , 2017, 11, 600-609.	0.7	12
1871	Preexposure Prophylaxis "a New Addition to the Armamentarium Against Human Immunodeficiency Virus. <i>Clinical Medicine Insights Therapeutics</i> , 2017, 9, 1179559X1771524.	0.4	0
1872	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 175-179.	0.9	34
1873	Facilitators and Barriers to Pre-Exposure Prophylaxis (PrEP) Use Among Black Individuals in the United States: Results from the National Survey on HIV in the Black Community (NSHBC). <i>AIDS and Behavior</i> , 2018, 22, 3576-3587.	1.4	99
1874	Old Pathogen, New Challenges: A Narrative Review of the Multilevel Drivers of Syphilis Increasing in American Men Who Have Sex With Men. <i>Sexually Transmitted Diseases</i> , 2018, 45, S38-S41.	0.8	15
1875	Molecular Epidemiology of HIV-1 Subtype B Reveals Heterogeneous Transmission Risk: Implications for Intervention and Control. <i>Journal of Infectious Diseases</i> , 2018, 217, 1522-1529.	1.9	32
1876	"Where Did This [PrEP] Come From?" African American Mother/Daughter Perceptions Related to Adolescent Preexposure Prophylaxis (PrEP) Utilization and Clinical Trial Participation. <i>Journal of Empirical Research on Human Research Ethics</i> , 2018, 13, 173-184.	0.6	29
1877	Current levels of gonorrhoea screening in MSM in Belgium may have little effect on prevalence: a modelling study. <i>Epidemiology and Infection</i> , 2018, 146, 333-338.	1.0	25
1878	Co-occurring psychosocial problems predict HIV status and increased health care costs and utilization among sexual minority men. <i>Journal of Behavioral Medicine</i> , 2018, 41, 450-457.	1.1	7
1879	PrEP Stigma: Implicit and Explicit Drivers of Disparity. <i>Current HIV/AIDS Reports</i> , 2018, 15, 190-197.	1.1	235
1880	Whose Responsibility Is It? Beliefs About Preventing HIV Transmission Among Men Who Have Sex With Men. <i>Sexually Transmitted Diseases</i> , 2018, 45, e43-e48.	0.8	5
1881	Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. <i>Nature Medicine</i> , 2018, 24, 491-496.	15.2	123
1882	HIV Coinfection Among Persons Diagnosed As Having Sexually Transmitted Diseases, San Francisco, 2007 to 2014. <i>Sexually Transmitted Diseases</i> , 2018, 45, 563-572.	0.8	11
1883	Is Screening for Chlamydia and Gonorrhea in Men Who Have Sex With Men Associated With Reduction of the Prevalence of these Infections? A Systematic Review of Observational Studies. <i>Sexually Transmitted Diseases</i> , 2018, 45, 615-622.	0.8	52
1884	Nurse-Led HIV PEP Program Used by Men at High Risk for HIV Seroconversion. <i>Journal of the Association of Nurses in AIDS Care</i> , 2018, 29, 550-559.	0.4	17
1885	Does HIV pre-exposure prophylaxis use lead to a higher incidence of sexually transmitted infections? A case-crossover study of men who have sex with men in Los Angeles, California. <i>Sexually Transmitted Infections</i> , 2018, 94, 457-462.	0.8	60
1886	Perceptions of HIV Self-Testing Among Men Who Have Sex With Men in the United States: A Qualitative Analysis. <i>AIDS Education and Prevention</i> , 2018, 30, 47-62.	0.6	22
1887	US Guidelines That Empower Women to Prevent HIV With Preexposure Prophylaxis. <i>Sexually Transmitted Diseases</i> , 2018, 45, e38-e39.	0.8	13

#	ARTICLE	IF	CITATIONS
1888	The Changing Paradigm of Sexually Transmitted Disease Prevention. <i>Sexually Transmitted Diseases</i> , 2018, 45, 573-575.	0.8	2
1889	Preexposure Prophylaxis Initiation and Retention in Care Over 5 Years, 2012â€“2017: Are Quarterly Visits Too Much?. <i>Clinical Infectious Diseases</i> , 2018, 67, 283-287.	2.9	71
1890	Amplifying the Population Health Benefits of PrEP for HIV Prevention. <i>Journal of Infectious Diseases</i> , 2018, 217, 1509-1511.	1.9	9
1891	Effects of Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection on Sexual Risk Behavior in Men Who Have Sex With Men: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2018, 67, 676-686.	2.9	326
1892	Meta-Analysis of Alcohol and Serodiscordant Condomless Sex Among People Living with HIV. <i>Archives of Sexual Behavior</i> , 2018, 47, 1351-1366.	1.2	7
1893	Sex Differences in HIV Infection. <i>Current HIV/AIDS Reports</i> , 2018, 15, 136-146.	1.1	128
1894	Impact of Improved HIV Care and Treatment on PrEP Effectiveness in the United States, 2016â€“2020. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 399-405.	0.9	31
1895	Perceived Social Norms About Oral PrEP Use: Differences Between Africanâ€“American, Latino and White Gay, Bisexual and Other Men Who Have Sex with Men in Texas. <i>AIDS and Behavior</i> , 2018, 22, 3588-3602.	1.4	28
1896	Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City. <i>AIDS and Behavior</i> , 2018, 22, 3627-3636.	1.4	79
1897	Skating on thin ice: stimulant use and subâ€optimal adherence to <scp>HIV</scp> preâ€exposure prophylaxis. <i>Journal of the International AIDS Society</i> , 2018, 21, e25103.	1.2	53
1898	A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis. <i>AIDS Patient Care and STDs</i> , 2018, 32, 104-111.	1.1	68
1899	Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 413-420.	1.9	28
1900	Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. <i>Lancet HIV,the</i> , 2018, 5, e136-e145.	2.1	130
1901	Â¡PrEP Ya! Latin America wants PrEP, and Brazil leads the way. <i>Lancet HIV,the</i> , 2018, 5, e110-e112.	2.1	14
1902	Efficacy of a Clinic-Based Safer Sex Program for Human Immunodeficiency Virusâ€Uninfected and Human Immunodeficiency Virusâ€Infected Young Black Men Who Have Sex With Men: A Randomized Controlled Trial. <i>Sexually Transmitted Diseases</i> , 2018, 45, 169-176.	0.8	17
1903	HIV Pre-exposure Prophylaxis Program Implementation Using Intervention Mapping. <i>American Journal of Preventive Medicine</i> , 2018, 54, 519-529.	1.6	7
1904	The Importance of Human Immunodeficiency Virus Research for Transgender and Gender-Nonbinary Individuals. <i>Clinical Infectious Diseases</i> , 2018, 66, 1460-1466.	2.9	8
1905	Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. <i>Clinical Infectious Diseases</i> , 2018, 67, 411-419.	2.9	50

#	ARTICLE	IF	CITATIONS
1906	Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 1712-1721.	2.9	48
1907	HIV preexposure prophylaxis: An essential, safe and effective prevention tool for sexual health. <i>MÃ©decine Et Maladies Infectieuses</i> , 2018, 48, 318-326.	5.1	5
1908	In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs?. <i>Aids</i> , 2018, 32, 809-818.	1.0	13
1909	Correlates of Linkage to HIV Preexposure Prophylaxis Among HIV-Testing Clients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 365-372.	0.9	20
1910	Care continuum entry interventions. <i>Aids</i> , 2018, 32, 407-417.	1.0	14
1911	Laboratory Testing of a Cohort of Commercially Insured Users of HIV Preexposure Prophylaxis in the United States, 2011â€”2015. <i>Journal of Infectious Diseases</i> , 2018, 217, 617-621.	1.9	12
1912	Cost-effectiveness of alternative strategies for provision of HIV preexposure prophylaxis for people who inject drugs. <i>Aids</i> , 2018, 32, 663-672.	1.0	15
1913	Temporal Fluctuations in Behavior, Perceived HIV Risk, and Willingness to Use Pre-Exposure Prophylaxis (PrEP). <i>Archives of Sexual Behavior</i> , 2018, 47, 2109-2121.	1.2	44
1914	Sex Venue-Based Network Analysis to Identify HIV Prevention Dissemination Targets for Men Who Have Sex with Men. <i>LGBT Health</i> , 2018, 5, 78-85.	1.8	5
1916	The relationship between Black and gay community involvement and HIV-related risk behaviors among Black men who have sex with men. <i>Journal of Gay and Lesbian Social Services</i> , 2018, 30, 64-81.	0.9	24
1917	The Preparation Phase of MOST. <i>Statistics for Social and Behavioral Sciences</i> , 2018, , 35-65.	0.3	1
1918	Preventing New Human Immunodeficiency Virus Infections With Pre-exposure Prophylaxis. <i>Journal for Nurse Practitioners</i> , 2018, 14, 376-382.	0.4	3
1919	Insights on transmission of HIV from phylogenetic analysis to locally optimize HIV prevention strategies. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 95-101.	1.5	11
1920	2016 United Kingdom national guideline on the sexual health care of men who have sex with men. <i>International Journal of STD and AIDS</i> , 2018, , 095646241774689.	0.5	40
1921	Trends in Awareness and Use of HIV PrEP Among Gay, Bisexual, and Other Men who have Sex with Men in Vancouver, Canada 2012â€”2016. <i>AIDS and Behavior</i> , 2018, 22, 3550-3565.	1.4	37
1922	Who Starts the Conversation and Who Receives Preexposure Prophylaxis (PrEP)? A Brief Online Survey of Medical Providers' PrEP Practices. <i>Health Education and Behavior</i> , 2018, 45, 723-729.	1.3	20
1923	HIV Infection and Drug Resistance with Unsupervised Use of HIV Pre-Exposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 329-330.	0.5	9
1924	Implementing Generalized Additive Models to Estimate the Expected Value of Sample Information in a Microsimulation Model: Results of Three Case Studies. <i>Medical Decision Making</i> , 2018, 38, 189-199.	1.2	6

#	ARTICLE	IF	CITATIONS
1925	Do You PrEP? A Review of Primary Care Provider Knowledge of PrEP and Attitudes on Prescribing PrEP. <i>Journal of the Association of Nurses in AIDS Care</i> , 2018, 29, 83-92.	0.4	48
1926	Targeting Human Immunodeficiency Virus Pre-Exposure Prophylaxis to Adolescent Sexual Minority Males in Higher Prevalence Areas of the United States: A Modeling Study. <i>Journal of Adolescent Health</i> , 2018, 62, 311-319.	1.2	27
1927	No. 354-Canadian HIV Pregnancy Planning Guidelines. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2018, 40, 94-114.	0.3	34
1928	N o 354 " Lignes directrices canadiennes en matiÃre de planification de la grossesse en prÃsence du VIH. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2018, 40, 115-137.	0.3	0
1929	Potential kidney toxicity from the antiviral drug tenofovir. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 102-112.	1.0	17
1930	Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States. <i>AIDS and Behavior</i> , 2018, 22, 3540-3549.	1.4	39
1931	HIV Pre-exposure Prophylaxis Prescribing Through Telehealth. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, e40-e42.	0.9	49
1932	Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV. <i>Aids</i> , 2018, 32, 523-530.	1.0	109
1933	Factors Supporting and Hindering Adherence to Rectal Microbicide Gel Use with Receptive Anal Intercourse in a Phase 2 Trial. <i>AIDS and Behavior</i> , 2018, 22, 388-401.	1.4	7
1934	Body/Selves and Beyond: Men's Narratives of Sexual Behavior on PrEP. <i>Medical Anthropology: Cross Cultural Studies in Health and Illness</i> , 2018, 37, 387-400.	0.6	27
1935	Can we afford to offer pre-exposure prophylaxis to MSM in Catalonia? Cost-effectiveness analysis and budget impact assessment. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 784-792.	0.6	8
1936	Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States. <i>Clinical Infectious Diseases</i> , 2018, 66, 213-219.	2.9	82
1937	Utility of Different Adherence Measures for PrEP: Patterns and Incremental Value. <i>AIDS and Behavior</i> , 2018, 22, 1165-1173.	1.4	51
1938	Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy. <i>Nature Communications</i> , 2018, 9, 2.	5.8	180
1939	Wild-type HIV infection despite PrEP: a lot to learn from a case report. <i>Lancet HIV,the</i> , 2018, 5, e10.	2.1	0
1940	HIV Education and Sexual Risk Behaviors Among Young Men Who Have Sex with Men. <i>LGBT Health</i> , 2018, 5, 131-138.	1.8	33
1941	Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial. <i>BMC Public Health</i> , 2018, 18, 210.	1.2	49
1942	High HIV risk and syndemic burden regardless of referral source among MSM screening for a PrEP demonstration project in Toronto, Canada. <i>BMC Public Health</i> , 2018, 18, 292.	1.2	12

#	ARTICLE	IF	CITATIONS
1943	Acceptability of Antiretroviral Pre-exposure Prophylaxis from a Cohort of Sexually Experienced Young Transgender Women in Two U.S. Cities. <i>AIDS and Behavior</i> , 2018, 22, 3649-3657.	1.4	25
1944	Physiologically-based pharmacokinetic model of vaginally administered dapivirine ring and film formulations. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1950-1969.	1.1	16
1945	The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. <i>Journal of the International AIDS Society</i> , 2018, 21, e25096.	1.2	24
1946	Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2116-2127.	1.4	17
1947	Missed Opportunities to Prescribe HIV Pre-Exposure Prophylaxis by Primary Care Providers in Saint Louis, Missouri. <i>LGBT Health</i> , 2018, 5, 250-256.	1.8	23
1948	Expanding opportunities to educate and deliver HIV pre-exposure prophylaxis training for gay, bisexual and other men who have sex with men. <i>International Journal of STD and AIDS</i> , 2018, 29, 622-622.	0.5	0
1949	Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017. <i>AIDS and Behavior</i> , 2018, 22, 986-995.	1.4	9
1950	HIV Risk and Protective Factors in the Context of Alcohol and Substance Use During Pride. <i>AIDS and Behavior</i> , 2018, 22, 2797-2806.	1.4	8
1951	Editorial. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 291-293.	1.5	8
1952	High Adherence to HIV Pre-Exposure Prophylaxis among Veterans. <i>Journal of General Internal Medicine</i> , 2018, 33, 253-255.	1.3	4
1953	Treatment and prevention of HIV infection with long-acting antiretrovirals. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 507-517.	1.3	38
1954	Blue Is, Blue Does: A Performance about Truvada in Several Interactions. , 2018, , 301-322.		1
1955	Acceptability of a Tenofovir Disoproxil Fumarate Vaginal Ring for HIV Prevention Among Women in New York City. <i>AIDS and Behavior</i> , 2018, 22, 421-436.	1.4	11
1956	Subsequent HIV Diagnosis Risk After Syphilis in a Southern Black Population. <i>Sexually Transmitted Diseases</i> , 2018, 45, 643-647.	0.8	8
1957	The cost-effectiveness of multi-purpose <sc>HIV</sc> and pregnancy prevention technologies in South Africa. <i>Journal of the International AIDS Society</i> , 2018, 21, e25064.	1.2	23
1958	Promoting positive condom use experiences among young black MSM: a randomized controlled trial of a brief, clinic-based intervention. <i>Health Education Research</i> , 2018, 33, 197-204.	1.0	11
1959	Acute Trigeminal Neuralgia Associated with Initiation of Emtricitabine/Tenofovir for HIV Pre-Exposure Prophylaxis. <i>Journal of the International Association of Providers of AIDS Care</i> , 2018, 17, 232595821876084.	0.6	2
1960	HIV Preexposure Prophylaxis. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1261.	3.8	206

#	ARTICLE	IF	CITATIONS
1961	An Informationâ€“Motivationâ€“Behavioral Skills Model of PrEP Uptake. <i>AIDS and Behavior</i> , 2018, 22, 3603-3616.	1.4	70
1962	Viral Dramaturgies. , 2018, , .		0
1963	Risk behavior score: a practical approach for assessing risk among men who have sex with men in Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2018, 22, 113-122.	0.3	14
1964	What qualities in a potential HIV pre-exposure prophylaxis service are valued by black men who have sex with men in London? A qualitative acceptability study. <i>International Journal of STD and AIDS</i> , 2018, 29, 760-765.	0.5	11
1965	Implementing preexposure prophylaxis among key populations. <i>Aids</i> , 2018, 32, 829-830.	1.0	6
1966	Prescription of Preexposure Prophylaxis to Men Who Have Sex With Men Diagnosed and Reported With Gonorrhoea, STD Surveillance Network, 2016. <i>Sexually Transmitted Diseases</i> , 2018, 45, e57-e60.	0.8	2
1967	A Latent Class Analysis of Seroadaptation Among Gay and Bisexual Men. <i>Archives of Sexual Behavior</i> , 2018, 47, 95-106.	1.2	20
1968	Modelling the UNAIDS 90-90-90 treatment cascade for gay, bisexual and other men who have sex with men in South Africa: using the findings of a data triangulation process to map a way forward. <i>AIDS and Behavior</i> , 2018, 22, 853-859.	1.4	10
1969	Behavioral Changes Following Uptake of HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in a Clinical Setting. <i>AIDS and Behavior</i> , 2018, 22, 1075-1079.	1.4	54
1970	A Global Estimate of the Acceptability of Pre-exposure Prophylaxis for HIV Among Men Who have Sex with Men: A Systematic Review and Meta-analysis. <i>AIDS and Behavior</i> , 2018, 22, 1063-1074.	1.4	137
1971	Prevention Strategies Against HIV Transmission: A Proactive Approach. <i>Journal of Pharmacy Practice</i> , 2018, 31, 82-90.	0.5	3
1972	Perceived HIV Prevalence Accuracy and Sexual Risk Behavior Among Gay, Bisexual, and Other Men Who Have Sex with Men in the United States. <i>AIDS and Behavior</i> , 2018, 22, 1849-1857.	1.4	8
1973	Gay Menâ€™s Health and Identity: Social Change and the Life Course. <i>Archives of Sexual Behavior</i> , 2018, 47, 59-74.	1.2	77
1974	InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtricitabine in London - analysis of pharmacokinetics, safety and outcomes. <i>HIV Medicine</i> , 2018, 19, 1-6.	1.0	28
1975	How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe. <i>AIDS and Behavior</i> , 2018, 22, 877-886.	1.4	7
1976	An Evaluation of a Clinical Preâ€“Exposure Prophylaxis Education Intervention among Men Who Have Sex with Men. <i>Health Services Research</i> , 2018, 53, 2249-2267.	1.0	17
1977	Health and budget impact of combined HIV prevention â€“ first results of the BELHIVPREV model. <i>Acta Clinica Belgica</i> , 2018, 73, 54-67.	0.5	8
1978	â€œWe Need to Deploy Them Very Thoughtfully and Carefullyâ€: Perceptions of Analytical Treatment Interruptions in HIV Cure Research in the United Statesâ€”A Qualitative Inquiry. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 67-79.	0.5	53

#	ARTICLE	IF	CITATIONS
1979	Interest in Long-Acting Injectable PrEP in a Cohort of Men Who have Sex with Men in China. <i>AIDS and Behavior</i> , 2018, 22, 1217-1227.	1.4	51
1980	Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. <i>Lancet HIV</i> , 2018, 5, e68-e78.	2.1	96
1981	Working towards HIV prevention choices for women. <i>Lancet HIV</i> , 2018, 5, e60-e61.	2.1	1
1982	Predictors of Over-Reporting HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Young Men Who Have Sex With Men (YMSM) in Self-Reported Versus Biomarker Data. <i>AIDS and Behavior</i> , 2018, 22, 1174-1183.	1.4	36
1983	HIV sero disclosure among men who have sex with men and transgender women on HIV pre-exposure prophylaxis. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 466-472.	0.6	4
1984	The Effect of PrEP on HIV Incidence Among Men Who Have Sex With Men in the Context of Condom Use, Treatment as Prevention, and Seroadaptive Practices. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 31-40.	0.9	54
1985	Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 193-205.	0.5	17
1986	Belief in Treatment as Prevention and Its Relationship to HIV Status and Behavioral Risk. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 8-16.	0.9	34
1987	Sexual Identity Disclosure and Awareness of HIV Prevention Methods Among Black Men Who Have Sex With Men. <i>Journal of Sex Research</i> , 2018, 55, 975-983.	1.6	23
1988	Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation. <i>Lancet Infectious Diseases</i> , 2018, 18, 85-94.	4.6	80
1989	Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 193-198.	0.9	35
1990	HIV Preexposure Prophylaxis Implementation at Local Health Departments: A Statewide Assessment of Activities and Barriers. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 72-77.	0.9	26
1991	Early detection of HIV infection and of asymptomatic sexually transmitted infections among men who have sex with men. <i>Clinical Microbiology and Infection</i> , 2018, 24, 540-545.	2.8	13
1992	Ethical public health issues for the use of informal PrEP. <i>Global Public Health</i> , 2018, 13, 1382-1387.	1.0	16
1993	Negotiating sexual safety in the era of biomedical HIV prevention: relationship dynamics among male couples using pre-exposure prophylaxis. <i>Culture, Health and Sexuality</i> , 2018, 20, 658-672.	1.0	34
1994	HIV/AIDS conspiracy beliefs and intention to adopt preexposure prophylaxis among black men who have sex with men in Los Angeles. <i>International Journal of STD and AIDS</i> , 2018, 29, 375-381.	0.5	46
1995	Exploring strategies for PrEP adherence and dosing preferences in the context of sexualized recreational drug use among MSM: a qualitative study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 191-198.	0.6	49
1996	Factors Associated with Pre-exposure Prophylaxis in a Highly Insured Population of Urban Men Who Have Sex with Men, 2014. <i>AIDS and Behavior</i> , 2018, 22, 1201-1208.	1.4	9

#	ARTICLE	IF	CITATIONS
1997	Perceived need of, and interest in, HIV pre-exposure prophylaxis amongst men who have sex with men attending three sexual health clinics in London, UK. <i>International Journal of STD and AIDS</i> , 2018, 29, 435-442.	0.5	15
1998	Social Interaction and Safer Sex at Sex Parties: Collective and Individual Norms at Gay Group Sex Venues in NYC. <i>Sexuality Research and Social Policy</i> , 2018, 15, 329-341.	1.4	11
1999	HIV Disease and AIDS. , 2018, , 180-190.e2.		0
2000	Parentsâ€™ Perspectives About Adolescent Boysâ€™ Involvement in Biomedical HIV Prevention Research. <i>Archives of Sexual Behavior</i> , 2018, 47, 1923-1935.	1.2	21
2001	Hypo-osmolar Formulation of Tenofovir (TFV) Enema Promotes Uptake and Metabolism of TFV in Tissues, Leading to Prevention of SHIV/SIV Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	17
2002	A Closer Look at Racism and Heterosexism in Medical Studentsâ€™ Clinical Decision-Making Related to HIV Pre-Exposure Prophylaxis (PrEP): Implications for PrEP Education. <i>AIDS and Behavior</i> , 2018, 22, 1122-1138.	1.4	65
2003	Sex Practices by HIV Awareness and Engagement in the Continuum of Care Among MSM: A National HIV Behavioral Surveillance Analysis in 21 U.S. Cities. <i>AIDS and Behavior</i> , 2018, 22, 840-847.	1.4	10
2004	A cross-sectional study examining associations between substance use frequency, problematic use and STIs among youth living with HIV. <i>Sexually Transmitted Infections</i> , 2018, 94, 304-308.	0.8	15
2005	Pre-Exposure Prophylaxis (PrEP) Use and Condomless Anal Sex: Evidence of Risk Compensation in a Cohort of Young Men Who Have Sex with Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 358-364.	0.9	90
2006	MSM at Highest Risk for HIV Acquisition Express Greatest Interest and Preference for Injectable Antiretroviral PrEP Compared to Daily, Oral Medication. <i>AIDS and Behavior</i> , 2018, 22, 1158-1164.	1.4	37
2007	Preferences for Injectable PrEP Among Young U.S. Cisgender Men and Transgender Women and Men Who Have Sex with Men. <i>Archives of Sexual Behavior</i> , 2018, 47, 2101-2107.	1.2	50
2008	Are Anal Sex Roles Associated with Preferences for Pre-Exposure Prophylaxis Administration Modalities Among Men Who Have Sex with Men?. <i>Archives of Sexual Behavior</i> , 2018, 47, 2123-2133.	1.2	8
2009	Preexposure prophylaxis guidelines have low sensitivity for identifying seroconverters in a sample of young Black MSM in Chicago. <i>Aids</i> , 2018, 32, 383-392.	1.0	66
2010	Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. <i>Lancet Infectious Diseases, The</i> , 2018, 18, 308-317.	4.6	175
2011	Accuracy of HIV Risk Perceptions Among Episodic Substance-Using Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2018, 22, 1932-1943.	1.4	8
2012	Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	182
2013	Evolving Models and Ongoing Challenges for HIV Preexposure Prophylaxis Implementation in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 119-127.	0.9	108
2014	Network Viral Load: A Critical Metric for HIV Elimination. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 167-174.	0.9	8

#	ARTICLE	IF	CITATIONS
2015	CONTENTS. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 2-2.	0.9	20
2016	Sexual Risk Behaviors and Perceptions of Men Who Go to Gay Sex Parties in New York City: Comparisons Between Three HIV Groups. <i>Journal of Sex Research</i> , 2018, 55, 880-891.	1.6	8
2017	The role of menopause in tenofovir diphosphate and emtricitabine triphosphate concentrations in cervical tissue. <i>Aids</i> , 2018, 32, 11-15.	1.0	8
2018	HIV Prevention Among Young Women in South Africa: Understanding Multiple Layers of Risk. <i>Archives of Sexual Behavior</i> , 2018, 47, 1969-1982.	1.2	21
2019	Brief Report: Frequency of Monitoring Kidney Function in HIV-Uninfected Persons Using Daily Oral Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 206-211.	0.9	23
2020	Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05). <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 175-182.	0.9	23
2021	HIV Prevalence and Related Risk Factors in Men Who Have Sex with Men in Bamako, Mali: Findings from a Bio-behavioral Survey Using Respondent-Driven Sampling. <i>AIDS and Behavior</i> , 2018, 22, 2079-2088.	1.4	23
2022	Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users. <i>AIDS and Behavior</i> , 2018, 22, 1228-1238.	1.4	31
2023	Validation of the HIV Risk Assessment of Sexual Partnerships (H-RASP): Comparison to a 2-Month Prospective Diary Study. <i>Archives of Sexual Behavior</i> , 2018, 47, 121-131.	1.2	25
2024	Dyadic Qualitative Analysis of Condom Use Scripts Among Emerging Adult Gay Male Couples. <i>Journal of Sex and Marital Therapy</i> , 2018, 44, 269-280.	1.0	13
2025	Lessons for Patient Education Around Long-Acting Injectable PrEP: Findings from a Mixed-Method Study of Phase II Trial Participants. <i>AIDS and Behavior</i> , 2018, 22, 1209-1216.	1.4	23
2026	Female and younger subjects have lower adherence in PrEP trials: a meta-analysis with implications for the uptake of PrEP service to prevent HIV. <i>Sexually Transmitted Infections</i> , 2018, 94, 163-168.	0.8	36
2027	Effects of Counselling on Adherence to Antiretroviral Treatment Among People with HIV in Estonia: A Randomized Controlled Trial. <i>AIDS and Behavior</i> , 2018, 22, 224-233.	1.4	9
2028	Rectal Douching Among Men Who Have Sex with Men in Paris: Implications for HIV/STI Risk Behaviors and Rectal Microbicide Development. <i>AIDS and Behavior</i> , 2018, 22, 379-387.	1.4	17
2029	Does pre-exposure prophylaxis for HIV prevention in men who have sex with men change risk behaviour? A systematic review. <i>Journal of Clinical Nursing</i> , 2018, 27, 3254-3265.	1.4	47
2030	Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine. <i>Aids</i> , 2018, 32, 2189-2194.	1.0	14
2031	Patterns and Correlates of Participant Retention in a Multi-City Pre-Exposure Prophylaxis Demonstration Project. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 79, 62-69.	0.9	23
2032	Effect of Depression on Adherence to Oral PrEP Among Men and Women in East Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 79, 330-338.	0.9	20

#	ARTICLE	IF	CITATIONS
2033	Pre-exposure prophylaxis rollout in a national public sector program: the Kenyan case study. <i>Sexual Health</i> , 2018, 15, 578.	0.4	60
2034	Canadian guidelines on HIV pre-exposure prophylaxis (PrEP) and non-occupational post-exposure prophylaxis (nPEP): Discussion beyond the guidelines and commentary on the role of infectious diseases specialists. <i>Jammi</i> , 2018, 3, 165-177.	0.3	3
2035	Role of Preexposure Prophylaxis in the Reproductive Health of Women at Risk for Human Immunodeficiency Virus Infection. <i>Obstetrics and Gynecology</i> , 2018, 132, 687-691.	1.2	14
2036	1295. Advancing the PrEP Continuum: A Novel Collaboration Between a Public Health Department and a Federally Qualified Healthcare Center in the Southern United States. <i>Open Forum Infectious Diseases</i> , 2018, 5, S395-S396.	0.4	0
2037	Advancing HIV Biomedical Prevention Research for At-Risk Adolescents. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 535-542.	0.9	7
2038	PrEP: pre-exposure prophylaxis for HIV prevention. <i>Trends in Urology & Men's Health</i> , 2018, 9, 22-24.	0.2	0
2039	Cost and anonymity as factors for the effective implementation of pre-exposure prophylaxis: an observational study among gay, bisexual and other men who have sex with men in Singapore. <i>Sexual Health</i> , 2018, 15, 533.	0.4	9
2040	HIV Preexposure Prophylaxis, by Race and Ethnicity â€” United States, 2014â€“2016. <i>Morbidity and Mortality Weekly Report</i> , 2018, 67, 1147-1150.	9.0	318
2041	Acceptability and tolerability of and adherence to HIV preexposure prophylaxis among Toronto gay and bisexual men: a pilot study. <i>CMAJ Open</i> , 2018, 6, E611-E617.	1.1	4
2042	The DREAMS core package of interventions: A comprehensive approach to preventing HIV among adolescent girls and young women. <i>PLoS ONE</i> , 2018, 13, e0208167.	1.1	198
2043	Effect of Racial Inequities in Pre-exposure Prophylaxis Use on Racial Disparities in HIV Incidence Among Men Who Have Sex With Men: A Modeling Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 323-329.	0.9	45
2044	Choosing Between Daily and Event-Driven Pre-exposure Prophylaxis: Results of a Belgian PrEP Demonstration Project. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 186-194.	0.9	72
2045	Targeting Fallible Men: Communication Strategies and Moral Issues in a Pre-exposure Prophylaxis Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, S13-S19.	0.9	4
2046	PrEParing for the unexpected: mechanisms and management of HIV pre-exposure prophylaxis failure. <i>Future Virology</i> , 2018, 13, 747-759.	0.9	3
2047	A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China. <i>BMC Infectious Diseases</i> , 2018, 18, 600.	1.3	30
2048	Elevated HIV Prevalence and Correlates of PrEP Use Among a Community Sample of Black Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 339-346.	0.9	39
2049	Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018. <i>Journal of Virus Eradication</i> , 2018, 4, 143-159.	0.3	39
2051	Schwartz-Jampel Syndrome (SJS1), Type 1 a Novel Variant in the HSPG2 Gene. <i>Journal of Clinical Case Reports</i> , 2018, 08, .	0.0	0

#	ARTICLE	IF	CITATIONS
2052	Delivery of TDF/FTC for Pre-exposure Prophylaxis to Prevent HIV-1 Acquisition in Young Adult Men Who Have Sex With Men and Transgender Women of Color Using a Urine Adherence Assay. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 79, 173-178.	0.9	22
2053	Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studies. <i>Clinical and Translational Medicine</i> , 2018, 7, 37.	1.7	6
2054	Evaluation of the awareness, knowledge and use of pre-exposure prophylaxis (PrEP) among the serodiscordant partners of HIV infected individuals on ART in an urban HIV clinic. <i>Cogent Medicine</i> , 2018, 5, 1475124.	0.7	1
2055	Increasing prevalence of self-reported HIV preexposure prophylaxis use in published surveys. <i>Aids</i> , 2018, 32, 2633-2635.	1.0	27
2056	Outcomes of Preexposure Prophylaxis Referrals From Public STI Clinics and Implications for the Preexposure Prophylaxis Continuum. <i>Sexually Transmitted Diseases</i> , 2018, 45, 50-55.	0.8	32
2057	Impact of Providing Preexposure Prophylaxis for Human Immunodeficiency Virus at Clinics for Sexually Transmitted Infections in Baltimore City: An Agent-based Model. <i>Sexually Transmitted Diseases</i> , 2018, 45, 791-797.	0.8	11
2058	Screening Peter to Save Paul: The Population-Level Effects of Screening Men Who Have Sex With Men for Gonorrhea and Chlamydia. <i>Sexually Transmitted Diseases</i> , 2018, 45, 623-625.	0.8	12
2059	Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care. <i>Sexual Health</i> , 2018, 15, 556.	0.4	90
2060	Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. <i>PLoS Medicine</i> , 2018, 15, e1002690.	3.9	126
2061	Sexual Risk Behaviors in Adolescent Sexual Minority Males: A Systematic Review and Meta-Analysis. <i>Journal of Primary Prevention</i> , 2018, 39, 619-645.	0.8	19
2062	A systematic review of adherence to oral pre-exposure prophylaxis for HIV – how can we improve uptake and adherence?. <i>BMC Infectious Diseases</i> , 2018, 18, 581.	1.3	146
2063	HIV pre-exposure prophylaxis in South East Asia: A focused review on present situation. <i>International Journal of Infectious Diseases</i> , 2018, 77, 113-117.	1.5	13
2064	Brief Report: HIV Pre-exposure Prophylaxis Engagement Among Adolescent Men Who Have Sex With Men: The Role of Parent – Adolescent Communication About Sex. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 79, 453-457.	0.9	30
2065	Marcus et al. Respond. <i>American Journal of Public Health</i> , 2018, 108, e27-e28.	1.5	0
2066	Foreign Aid and HIV/AIDS in Latin America and the Caribbean: Should We Adjust the Degree of Response?. <i>Atlantic Economic Journal</i> , 2018, 46, 337-349.	0.3	0
2067	Associations between perceived barriers and benefits of using HIV pre-exposure prophylaxis and medication adherence among men who have sex with men in Western China. <i>BMC Infectious Diseases</i> , 2018, 18, 575.	1.3	14
2068	“œl Don't Need PrEP Right Now” A Qualitative Exploration of the Barriers to PrEP Care Engagement Through the Application of the Health Belief Model. <i>AIDS Education and Prevention</i> , 2018, 30, 369-381.	0.6	28
2069	Knowledge about HIV/AIDS and implications of establishing partnerships among Hornet® users. <i>Revista Brasileira De Enfermagem</i> , 2018, 71, 1949-1955.	0.2	19

#	ARTICLE	IF	CITATIONS
2070	HIV Preexposure Prophylaxis. American Journal of Public Health, 2018, 108, e27-e27.	1.5	1
2071	Exploring Gender Differences in PrEP Interest Among Individuals Testing HIV Negative in an Urban Emergency Department. AIDS Education and Prevention, 2018, 30, 382-392.	0.6	14
2072	Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis. Aids, 2018, 32, 2161-2169.	1.0	45
2073	The effect of demand-side financial incentives for increasing linkage into HIV treatment and voluntary medical male circumcision: A systematic review and meta-analysis of randomised controlled trials in low- and middle-income countries. PLoS ONE, 2018, 13, e0207263.	1.1	20
2074	Pre-Exposure Prophylaxis Knowledge and Perceived Effectiveness to Prevent HIV Among Deaf Gay, Bisexual, and Queer Men. LGBT Health, 2018, 5, 469-476.	1.8	8
2075	Potential Impact of HIV Preexposure Prophylaxis Among Black and White Adolescent Sexual Minority Males. American Journal of Public Health, 2018, 108, S284-S291.	1.5	26
2076	Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV, the, 2018, 5, e629-e637.	2.1	273
2077	Knowledge, interest, and anticipated barriers of pre-exposure prophylaxis uptake and adherence among gay, bisexual, and men who have sex with men who are incarcerated. PLoS ONE, 2018, 13, e0205593.	1.1	35
2078	Pre-exposure prophylaxis for HIV prevention preferences among young adult African American men who have sex with men. PLoS ONE, 2018, 13, e0209484.	1.1	23
2079	Improving the impact of HIV pre-exposure prophylaxis implementation in small urban centers among men who have sex with men: An agent-based modelling study. PLoS ONE, 2018, 13, e0199915.	1.1	14
2080	Serodiscordant partnerships and opportunities for pre-exposure prophylaxis among partners of women and men living with HIV in St. Petersburg, Russia. PLoS ONE, 2018, 13, e0207402.	1.1	3
2081	“The Time Has Arrived”: Perceptions of Behavioral Adjustments in the Context of Pre-Exposure Prophylaxis Availability Among Adolescents in South Africa. AIDS Education and Prevention, 2018, 30, 463-473.	0.6	10
2082	PrEP Eligibility and Interest Among Clinic- and Community-Recruited Young Black Women in Atlanta, Georgia, USA. Current HIV Research, 2018, 16, 250-255.	0.2	24
2083	Project ECHO: telementoring to educate and support prescribing of HIV pre-exposure prophylaxis by community medical providers. Sexual Health, 2018, 15, 601.	0.4	32
2084	No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305. PLoS ONE, 2018, 13, e0206577.	1.1	3
2085	Pre-Exposure Prophylaxis (PrEP) Awareness and Acceptability Among Men Who Have Sex With Men in Taiwan. AIDS Education and Prevention, 2018, 30, 490-501.	0.6	7
2086	Use of antiretroviral drugs to prevent the transmission and acquisition of HIV. British Journal of Hospital Medicine (London, England: 2005), 2018, 79, 544-545.	0.2	0
2087	A Group-Based Trajectory Model for Changes in Pre-Exposure Prophylaxis and Condom Use Among Men Who Have Sex with Men Participating in the ANRS IPERGAY Trial. AIDS Patient Care and STDs, 2018, 32, 495-510.	1.1	8

#	ARTICLE	IF	CITATIONS
2088	Midwest pharmacists's familiarity, experience, and willingness to provide pre-exposure prophylaxis (PrEP) for HIV. PLoS ONE, 2018, 13, e0207372.	1.1	20
2089	Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1. Emerging Infectious Diseases, 2018, 24, .	2.0	38
2090	Qualitative Insights Into Adherence to HIV Pre-Exposure Prophylaxis (PrEP) Among Australian Gay and Bisexual Men. AIDS Patient Care and STDs, 2018, 32, 519-528.	1.1	10
2091	Perceptions of HIV Pre-Exposure Prophylaxis Among Young, Black Men Who Have Sex with Men. AIDS Patient Care and STDs, 2018, 32, 511-518.	1.1	46
2092	Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection – A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis. PLoS ONE, 2018, 13, e0208107.	1.1	79
2093	Global and national guidance for the use of pre-exposure prophylaxis during peri-conception, pregnancy and breastfeeding. Sexual Health, 2018, 15, 501.	0.4	25
2094	Going global: the adoption of the World Health Organization's enabling recommendation on oral pre-exposure prophylaxis for HIV. Sexual Health, 2018, 15, 489.	0.4	52
2095	Physicians' preparedness for pre-exposure prophylaxis: results of an online survey in Belgium. Sexual Health, 2018, 15, 606.	0.4	12
2096	Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. HIV Clinical Trials, 2018, 19, 129-138.	2.0	51
2097	PrEP Continuation, HIV and STI Testing Rates, and Delivery of Preventive Care in a Clinic-Based Cohort. AIDS Education and Prevention, 2018, 30, 393-405.	0.6	25
2098	Acceptability of HIV self-testing to support pre-exposure prophylaxis among female sex workers in Uganda and Zambia: results from two randomized controlled trials. BMC Infectious Diseases, 2018, 18, 503.	1.3	37
2099	A Systematic Evaluation of Effect of Adherence Patterns on the Sample Size and Power of a Clinical Study. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 818-828.	1.3	11
2100	Gendered Social Institutions and Preventive Healthcare Seeking for Black Men Who Have Sex with Men: The Promise of Biomedical HIV Prevention. Archives of Sexual Behavior, 2018, 47, 2091-2100.	1.2	24
2101	Princess PrEP program: the first key population-led model to deliver pre-exposure prophylaxis to key populations by key populations in Thailand. Sexual Health, 2018, 15, 542.	0.4	88
2102	Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial. PLoS Medicine, 2018, 15, e1002655.	3.9	27
2103	Repeated False-Positive HIV Test Results in a Patient Taking HIV Pre-Exposure Prophylaxis. Open Forum Infectious Diseases, 2018, 5, ofy197.	0.4	12
2104	HIV-1 genetic transmission networks among men who have sex with men in Kunming, China. PLoS ONE, 2018, 13, e0196548.	1.1	31
2105	Ultra-long-acting removable drug delivery system for HIV treatment and prevention. Nature Communications, 2018, 9, 4156.	5.8	70

#	ARTICLE	IF	CITATIONS
2106	Acceptability of pharmacotherapy for hazardous alcohol use among men who have sex with men: Findings from a qualitative study. <i>Addictive Behaviors Reports</i> , 2018, 8, 122-127.	1.0	1
2107	Engaging United States Black Communities in HIV Pre-exposure Prophylaxis: Analysis of a PrEP Engagement Cascade. <i>Journal of the National Medical Association</i> , 2018, 110, 480-485.	0.6	23
2108	Predictors of Art and PrEP Adherence and Medication-Taking Practices and Preferences to Inform Development of a Wrist-Worn Adherence System. <i>AIDS Education and Prevention</i> , 2018, 30, 357-368.	0.6	3
2109	Incident HIV infection has fallen rapidly in men who have sex with men in Melbourne, Australia (2013-2017) but not in the newly-arrived Asian-born. <i>BMC Infectious Diseases</i> , 2018, 18, 410.	1.3	53
2110	Gaps in Preexposure Prophylaxis Uptake for HIV Prevention in the Veterans Health Administration. <i>American Journal of Public Health</i> , 2018, 108, S305-S310.	1.5	21
2111	A systematic evaluation of mobile apps to improve the uptake of and adherence to HIV pre-exposure prophylaxis. <i>Sexual Health</i> , 2018, 15, 587.	0.4	24
2112	Vaginal washing and lubrication among female sex workers in the Mexico-US border region: implications for the development of vaginal PrEP for HIV prevention. <i>BMC Public Health</i> , 2018, 18, 1009.	1.2	6
2113	Daily HIV pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine reduced <i>Streptococcus</i> and increased <i>Erysipelotrichaceae</i> in rectal microbiota. <i>Scientific Reports</i> , 2018, 8, 15212.	1.6	24
2114	Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice. <i>The Open Virology Journal</i> , 2018, 12, 1-13.	1.8	11
2115	Repeated rectal application of a hyperosmolar lubricant is associated with microbiota shifts but does not affect PrEP drug concentrations: results from a randomized trial in men who have sex with men. <i>Journal of the International AIDS Society</i> , 2018, 21, e25199.	1.2	13
2116	Perspectives of South African youth in the development of an implant for HIV prevention. <i>Journal of the International AIDS Society</i> , 2018, 21, e25170.	1.2	27
2117	Knowledge and use of HIV pre-exposure prophylaxis among men who have sex with men in Berlin – A multicentre, cross-sectional survey. <i>PLoS ONE</i> , 2018, 13, e0204067.	1.1	22
2118	Ending the HIV/AIDS Pandemic. <i>Emerging Infectious Diseases</i> , 2018, 24, 413-416.	2.0	109
2119	Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence. <i>EClinicalMedicine</i> , 2018, 2-3, 22-28.	3.2	42
2120	Estimating the contribution of key populations towards the spread of HIV in Dakar, Senegal. <i>Journal of the International AIDS Society</i> , 2018, 21, e25126.	1.2	30
2121	Efficacy and Safety of Oral TDF-Based Pre-exposure Prophylaxis for Men Who Have Sex With Men: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2018, 9, 799.	1.6	51
2122	Adherence to pre-exposure prophylaxis among men who have sex with men: A prospective cohort study. <i>International Journal of Infectious Diseases</i> , 2018, 75, 52-59.	1.5	30
2123	Lessons from a decade of voluntary medical male circumcision implementation and their application to HIV pre-exposure prophylaxis scale up. <i>International Journal of STD and AIDS</i> , 2018, 29, 1432-1443.	0.5	13

#	ARTICLE	IF	CITATIONS
2124	Management of Human Immunodeficiency Virus in the Emergency Department. <i>Emergency Medicine Clinics of North America</i> , 2018, 36, 777-794.	0.5	3
2125	HIV testing and pre-exposure prophylaxis (PrEP) use, familiarity, and attitudes among gay and bisexual men in the United States: A national probability sample of three birth cohorts. <i>PLoS ONE</i> , 2018, 13, e0202806.	1.1	62
2126	<sc>HIV</sc> Antiretroviral Pre-Exposure Prophylaxis: Development Challenges and Pipeline Promise. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1082-1097.	2.3	21
2127	Stigma and Shame Experiences by MSM Who Take PrEP for HIV Prevention: A Qualitative Study. <i>American Journal of Men's Health</i> , 2018, 12, 1843-1854.	0.7	134
2128	Awareness and Acceptance of HIV Pre-exposure Prophylaxis among Medical Personnel and Men Who Have Sex with Men in Korea. <i>Journal of Korean Medical Science</i> , 2018, 33, e91.	1.1	4
2129	Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trial. <i>Aids</i> , 2018, 32, 2353-2361.	1.0	10
2130	A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 367, 245-251.	1.3	14
2131	Effects of Sexual Network Connectivity and Antimicrobial Drug Use on Antimicrobial Resistance in <i>Neisseria gonorrhoeae</i> . <i>Emerging Infectious Diseases</i> , 2018, 24, 1195-1203.	2.0	72
2132	Geographic and Individual Associations with PrEP Stigma: Results from the RADAR Cohort of Diverse Young Men Who have Sex with Men and Transgender Women. <i>AIDS and Behavior</i> , 2018, 22, 3044-3056.	1.4	78
2133	HIV pre-exposure prophylaxis: Exploring the potential for expanding the role of pharmacists in public health. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2018, 58, 412-420.e3.	0.7	30
2134	Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 169-174.	0.9	20
2135	Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 175-182.	0.9	9
2136	Reasons for nonadherence to the dapivirine vaginal ring. <i>Aids</i> , 2018, 32, 1517-1525.	1.0	33
2137	Effects of gel volume on pharmacokinetics for vaginal and rectal applications of combination DuoGel-IQB4012, a dual chamber-dual drug HIV microbicide gel, in pigtailed macaques. <i>Drug Delivery and Translational Research</i> , 2018, 8, 1180-1190.	3.0	7
2138	Preventing Mother-to-Child Transmission (PMTCT): Prevention of HIV. , 2018, , 1698-1704.		0
2139	Response to the Hammoud et al paper on "the new MTV generation". <i>International Journal of Drug Policy</i> , 2018, 55, 205-206.	1.6	2
2140	Provider Adherence to Pre-exposure Prophylaxis Monitoring Guidelines in a Large Primary Care Network. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy099.	0.4	26
2141	Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to <sc>HIV</sc> serodiscordant couples in East Africa: a qualitative evaluation study in Uganda. <i>Journal of the International AIDS Society</i> , 2018, 21, e25113.	1.2	19

#	ARTICLE	IF	CITATIONS
2142	Estimating Prevalent Diagnoses and Rates of New Diagnoses of HIV at the State Level by Age Group Among Men who Have Sex With Men in the United States. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy124.	0.4	5
2143	Missed Opportunities for HIV Prevention: Individuals Who HIV Seroconverted Despite Accessing Healthcare. <i>AIDS and Behavior</i> , 2018, 22, 3519-3524.	1.4	7
2144	The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2018, 22, 3673-3680.	1.4	33
2145	Medical students reflect on the future of Pre-Exposure Prophylaxis use among adolescents and young adults. <i>Preventive Medicine</i> , 2018, 113, 122-123.	1.6	2
2146	The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. <i>Annals of Epidemiology</i> , 2018, 28, 841-849.	0.9	295
2147	Preventing HIV Infection in High-Risk Adolescents Using Preexposure Prophylaxis (PrEP). <i>Journal of the Association of Nurses in AIDS Care</i> , 2018, 29, 770-774.	0.4	6
2148	The Evolution of HIV Prevention Programming: Moving From Intervention to System. <i>AIDS Education and Prevention</i> , 2018, 30, 187-198.	0.6	3
2149	Overlap between harm reduction and HIV service utilisation among PWID in India: Implications for HIV combination prevention. <i>International Journal of Drug Policy</i> , 2018, 57, 111-118.	1.6	5
2150	Advancing independent adolescent consent for participation in HIV prevention research. <i>Journal of Medical Ethics</i> , 2018, 44, 431-433.	1.0	9
2151	Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017. <i>Annals of Epidemiology</i> , 2018, 28, 833-840.	0.9	168
2152	Early HIV Infection Predictions: Role of Viral Replication Errors. <i>SIAM Journal on Applied Mathematics</i> , 2018, 78, 1863-1890.	0.8	7
2153	Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067. <i>PLoS ONE</i> , 2018, 13, e0195764.	1.1	12
2154	Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2018, 67, 962-964.	2.9	35
2155	Trajectories and Predictors of Longitudinal Preexposure Prophylaxis Adherence Among Men Who Have Sex With Men. <i>Journal of Infectious Diseases</i> , 2018, 218, 1551-1559.	1.9	28
2156	Understanding willingness to use oral pre-exposure prophylaxis for HIV prevention among men who have sex with men in China. <i>PLoS ONE</i> , 2018, 13, e0199525.	1.1	21
2157	Exploring the Use of Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among High-Risk People Who Use Drugs in Treatment. <i>Frontiers in Public Health</i> , 2018, 6, 195.	1.3	33
2158	HIV Prevention Drug's Slow Uptake Undercuts Its Early Promise. <i>Health Affairs</i> , 2018, 37, 178-180.	2.5	6
2159	Pre-exposure prophylaxis (PrEP) for MSM in low HIV incidence places: should high risk individuals be targeted?. <i>Scientific Reports</i> , 2018, 8, 11641.	1.6	18

#	ARTICLE	IF	CITATIONS
2160	The Acceptability of Pre-Exposure Prophylaxis: Beliefs of Health-Care Professionals Working in Sexually Transmitted Infections Clinics and HIV Treatment Centers. <i>Frontiers in Public Health</i> , 2018, 6, 5.	1.3	15
2161	HIV Prevention After Discontinuing Pre-Exposure Prophylaxis: Conclusions From a Case Study. <i>Frontiers in Public Health</i> , 2018, 6, 137.	1.3	8
2162	Protocol for an HIV Pre-exposure Prophylaxis (PrEP) Population Level Intervention Study in Victoria Australia: The PrEPX Study. <i>Frontiers in Public Health</i> , 2018, 6, 151.	1.3	35
2163	HIV. <i>Lancet</i> , The, 2018, 392, 685-697.	6.3	219
2164	Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 835-837.	0.5	12
2166	Interest in HIV pre-exposure prophylaxis in men who have sex with men in West Africa (Cohort MSM ANRS 12324 "Expertise France"). <i>Tropical Medicine and International Health</i> , 2018, 23, 1084-1091.	1.0	15
2167	Editorial: Challenges in HIV Epidemiology, Prevention and Treatment. <i>Current HIV Research</i> , 2018, 15, 384-385.	0.2	1
2168	Pharmaceutical Approaches to HIV Treatment and Prevention. <i>Advanced Therapeutics</i> , 2018, 1, 1800054.	1.6	14
2169	The ethics of ordinary and exact justification in blood donation deferral categories for men who have sex with men. <i>Bioethics</i> , 2018, 32, 445-453.	0.7	4
2170	Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes. <i>PLoS Computational Biology</i> , 2018, 14, e1006155.	1.5	19
2171	Leveraging a Legacy of Activism: Black Lives Matter and the Future of HIV Prevention for Black MSM. <i>AIDS Education and Prevention</i> , 2018, 30, 208-212.	0.6	2
2173	Decentralizing the delivery of HIV pre-exposure prophylaxis (PrEP) through family physicians and sexual health clinic nurses: a dissemination and implementation study protocol. <i>BMC Health Services Research</i> , 2018, 18, 513.	0.9	23
2174	Statewide Evaluation of New HIV Diagnoses in Rhode Island: Implications for Prevention. <i>Public Health Reports</i> , 2018, 133, 489-496.	1.3	2
2175	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). <i>Lancet</i> , The, 2018, 392, 232-243.	6.3	269
2176	How to do it: setting up a PrEP service in an integrated sexual reproductive health service setting. <i>Sexually Transmitted Infections</i> , 2018, 94, 327-330.	0.8	3
2177	Women and HIV in the Twenty-First Century: How Can We Reach the UN 2030 Goal?. <i>AIDS Education and Prevention</i> , 2018, 30, 213-224.	0.6	4
2178	Prevention paradox: Medical students are less inclined to prescribe HIV pre-exposure prophylaxis for patients in highest need. <i>Journal of the International AIDS Society</i> , 2018, 21, e25147.	1.2	43
2179	Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. <i>Lancet HIV</i> , the, 2018, 5, e438-e447.	2.1	337

#	ARTICLE	IF	CITATIONS
2180	<sc>HIV</sc> health care providers are ready to introduce pre-exposure prophylaxis in Central and Eastern Europe and neighbouring countries: data from the Euroguidelines in Central and Eastern Europe (<sc>ECEE</sc>) Network Group. HIV Medicine, 2018, 19, 629-633.	1.0	8
2181	Pre-exposure prophylaxis for men who have sex with men in China: challenges for routine implementation. Journal of the International AIDS Society, 2018, 21, e25166.	1.2	23
2182	HIV (Human Immunodeficiency Virus) ă†. , 2018, , 218-218.		4
2183	PrEParing Women to Prevent HIV: An Integrated Theoretical Framework to PrEP Black Women in the United States. Journal of the Association of Nurses in AIDS Care, 2018, 29, 835-848.	0.4	48
2184	Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	104
2185	HIV Preexposure Prophylaxis as a Gateway to Primary Care. American Journal of Public Health, 2018, 108, 1418-1420.	1.5	34
2186	Treatment of HIV for the Prevention of Transmission in Discordant Couples and at the Population Level. Advances in Experimental Medicine and Biology, 2018, 1075, 125-162.	0.8	12
2187	Efficacy of a Small-Group Intervention for Post-Incarcerated Black Men Who Have Sex with Men and Women (MSMW). Journal of Urban Health, 2018, 95, 159-170.	1.8	6
2188	Pre-exposure Prophylaxis for HIV Infection in the Older Patient: What can be Recommended?. Drugs and Aging, 2018, 35, 485-491.	1.3	16
2189	Poppers and PrEP: Use of Pre-exposure Prophylaxis Among Men Who Have Sex with Men Who Use Inhaled Nitrites. AIDS and Behavior, 2018, 22, 3658-3672.	1.4	19
2190	Where Are They Now? Assessing if Persons Returned to HIV Care Following Loss to Follow-Up by Public Health Case Workers Were Engaged in Care in Follow-Up Years. AIDS Patient Care and STDs, 2018, 32, 181-190.	1.1	12
2191	Seroconversion on preexposure prophylaxis. Aids, 2018, 32, 1199-1200.	1.0	0
2192	Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry. Clinical Mass Spectrometry, 2018, 8, 8-20.	1.9	10
2193	The cost-effectiveness of oral HIV pre-exposure prophylaxis and early antiretroviral therapy in the presence of drug resistance among men who have sex with men in San Francisco. BMC Medicine, 2018, 16, 58.	2.3	25
2194	Threefold Increase in PrEP Uptake Over Time with High Adherence Among Young Men Who Have Sex With Men in Chicago. AIDS and Behavior, 2018, 22, 3637-3644.	1.4	44
2195	High Rate of Discontinuation May Diminish PrEP Coverage Among Young Men Who Have Sex with Men. AIDS and Behavior, 2018, 22, 3645-3648.	1.4	77
2196	Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention in Adolescents and Young Adults. Current Pediatrics Reports, 2018, 6, 114-122.	1.7	11
2197	Evaluation of Preexposure (PrEP) Eligibility Criteria, Using Sexually Transmissible Infections as Markers of Human Immunodeficiency Virus (HIV) Risk at Enrollment in PrEPX, a Large Australian HIV PrEP Trial. Clinical Infectious Diseases, 2018, 67, 1847-1852.	2.9	9

#	ARTICLE	IF	CITATIONS
2198	Cabotegravir. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 334-340.	1.5	14
2199	The intention to use HIV-pre-exposure prophylaxis (PrEP) among men who have sex with men in Switzerland: testing an extended explanatory model drawing on the unified theory of acceptance and use of technology (UTAUT). <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2018, 26, 247-259.	0.8	7
2200	Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 1566-1572.	2.9	77
2201	Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 645-656.	0.5	23
2202	Anti-CD20 monoclonal antibodies: reviewing a revolution. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2820-2841.	1.4	68
2203	Challenges and Successes in Evaluating HIV Prevention for Young Transgender Women—Building Skills, Maintaining Trust. <i>JAMA Pediatrics</i> , 2018, 172, 908.	3.3	0
2204	Birth Cohort Variations Across Functional Knowledge of HIV Prevention Strategies, Perceived Risk, and HIV-Associated Behaviors Among Gay, Bisexual, and Other Men Who Have Sex With Men in the United States. <i>American Journal of Men's Health</i> , 2018, 12, 1824-1834.	0.7	15
2205	Fatores associados à coinfeção por HIV em casos de sífilis adquirida notificados em um Centro de Referência de Doenças Sexualmente Transmissíveis e Aids no município de São Paulo, 2014*. <i>Epidemiologia E Servicos De Saude: Revista Do Sistema Unico De Saude Do Brasil</i> , 2018, 27, e20171678.	0.3	12
2206	Acceptability of Injectable and On-Demand Pre-Exposure Prophylaxis Among an Online Sample of Young Men Who Have Sex with Men in California. <i>LGBT Health</i> , 2018, 5, 341-349.	1.8	19
2207	DIY HIV prevention: Formative qualitative research with men who have sex with men who source PrEP outside of clinical trials. <i>PLoS ONE</i> , 2018, 13, e0202830.	1.1	21
2208	Implementation of a Test, Treat, and Prevent HIV program among men who have sex with men and transgender women in Thailand, 2015-2016. <i>PLoS ONE</i> , 2018, 13, e0201171.	1.1	30
2209	HIV Preexposure Prophylaxis Initiation at a Large Community Clinic: Differences Between Eligibility, Awareness, and Uptake. <i>American Journal of Public Health</i> , 2018, 108, 1408-1417.	1.5	34
2210	Progress and pitfalls in measuring HIV preexposure prophylaxis coverage in the United States. <i>Annals of Epidemiology</i> , 2018, 28, 830-832.	0.9	13
2211	Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand. <i>Journal of the International AIDS Society</i> , 2018, 21, e25129.	1.2	25
2212	Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis. <i>Journal of Controlled Release</i> , 2018, 286, 315-325.	4.8	66
2213	“It’s just an excuse to slut around”: gay and bisexual men’s constructions of HIV pre-exposure prophylaxis (PrEP) as a social problem. <i>Sociology of Health and Illness</i> , 2018, 40, 1391-1403.	1.1	30
2214	Behavioural and demographic correlates of undiagnosed HIV infection in a MSM sample recruited in 13 European cities. <i>BMC Infectious Diseases</i> , 2018, 18, 368.	1.3	15
2215	Assessing HIV Stigma on Prevention Strategies for Black Men Who Have Sex with Men in the United States. <i>AIDS and Behavior</i> , 2018, 22, 3879-3886.	1.4	18

#	ARTICLE	IF	CITATIONS
2216	The ANRS-Ipergay trial, an opportunity to use qualitative research to understand the perception of the participant-physician relationship. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 41-47.	0.6	5
2217	Lessons learned from the experiences of informal PrEP users in France: results from the ANRS-PrEPage study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 48-53.	0.6	14
2218	An Empiric Risk Score to Guide PrEP Targeting Among MSM in Coastal Kenya. <i>AIDS and Behavior</i> , 2018, 22, 35-44.	1.4	32
2219	Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study. <i>Lancet HIV</i> , 2018, 5, e498-e505.	2.1	37
2220	Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial. <i>PLoS ONE</i> , 2018, 13, e0190118.	1.1	18
2221	Contexts of vulnerability and the acceptability of new biomedical HIV prevention technologies among key populations in South Africa: A qualitative study. <i>PLoS ONE</i> , 2018, 13, e0191251.	1.1	37
2222	Improving PrEP Implementation Through Multilevel Interventions: A Synthesis of the Literature. <i>AIDS and Behavior</i> , 2018, 22, 3681-3691.	1.4	158
2223	Suspected unexpected and other adverse reactions to antiretroviral drugs used as post-exposure prophylaxis of HIV infection – five-year experience from clinical practice. <i>Archives of Medical Science</i> , 2018, 14, 547-553.	0.4	4
2224	Human Immunodeficiency Virus Vaccines. , 2018, , 400-429.e25.		0
2225	The Role of Religious Service Attendance, Psychosocial and Behavioral Determinants of Antiretroviral Therapy (ART) Adherence: Results from HPTN 063 Cohort Study. <i>AIDS and Behavior</i> , 2019, 23, 459-474.	1.4	6
2226	Changes in Sexual Behavior and STI Diagnoses Among MSM Initiating PrEP in a Clinic Setting. <i>AIDS and Behavior</i> , 2019, 23, 548-555.	1.4	101
2227	Persistent stigmatizing and negative perceptions of pre-exposure prophylaxis (PrEP) users: implications for PrEP adoption among Latino men who have sex with men. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 427-435.	0.6	33
2228	Prevalence and Correlates of Unhealthy Alcohol and Drug Use Among Men Who Have Sex with Men Prescribed HIV Pre-exposure Prophylaxis in Real-World Clinical Settings. <i>AIDS and Behavior</i> , 2019, 23, 190-200.	1.4	19
2229	Club drug users had higher odds of reporting a bacterial STI compared with non-club drug users: results from a cross-sectional analysis of gay and bisexual men on HIV pre-exposure prophylaxis. <i>Sexually Transmitted Infections</i> , 2019, 95, 626-628.	0.8	18
2230	Preexposure prophylaxis comprehension and the certainty of willingness to use preexposure prophylaxis among men who have sex with men in China. <i>International Journal of STD and AIDS</i> , 2019, 30, 4-11.	0.5	17
2231	Fecal Coliform Bacterial Detection to Assess Enema Adherence in HIV Prevention Clinical Studies. <i>AIDS and Behavior</i> , 2019, 23, 252-258.	1.4	1
2232	Medical Mistrust and PrEP Perceptions Among Transgender Women: A Cluster Analysis. <i>Behavioral Medicine</i> , 2019, 45, 143-152.	1.0	44
2233	Topical Inserts: A Versatile Delivery Form for HIV Prevention. <i>Pharmaceutics</i> , 2019, 11, 374.	2.0	22

#	ARTICLE	IF	CITATIONS
2234	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response. <i>Oncolmunology</i> , 2019, 8, e1617588.	2.1	41
2235	Empowerment Evaluation: A Case Study of Citywide Implementation Within an HIV Prevention Context. <i>American Journal of Evaluation</i> , 2019, 40, 318-334.	0.6	5
2236	Impact of Tenofovir-Based Pre-exposure Prophylaxis on Biomarkers of Bone Formation, Bone Resorption, and Bone Mineral Metabolism in HIV-Negative Adults. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz338.	0.4	3
2237	Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA. <i>Journal of the International AIDS Society</i> , 2019, 22, e25373.	1.2	6
2238	Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. <i>PLoS ONE</i> , 2019, 14, e0219142.	1.1	58
2239	Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP). <i>BMC Infectious Diseases</i> , 2019, 19, 721.	1.3	26
2240	Acceptability and Feasibility of a Pharmacist-Led Human Immunodeficiency Virus Pre-Exposure Prophylaxis Program in the Midwestern United States. <i>Open Forum Infectious Diseases</i> , 2019, 6, .	0.4	56
2241	Use and Acceptability of HIV Self-Testing Among First-Time Testers at Risk for HIV in Senegal. <i>AIDS and Behavior</i> , 2019, 23, 130-141.	1.4	35
2242	Electronic health record tools to catalyse PrEP conversations. <i>Lancet HIV</i> , 2019, 6, e644-e645.	2.1	7
2243	PrEP for HIV: grade A for evidence but pending for impact. <i>Nature Reviews Urology</i> , 2019, 16, 570-571.	1.9	1
2244	Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa. <i>BMC Public Health</i> , 2019, 19, 996.	1.2	14
2245	Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study. <i>PLoS ONE</i> , 2019, 14, e0221281.	1.1	24
2246	Are current guidelines adapted for patient eligibility to PrEP? A case report. <i>BMC Infectious Diseases</i> , 2019, 19, 601.	1.3	1
2247	A Promising PrEP Navigation Intervention for Transgender Women and Men Who Have Sex with Men Experiencing Multiple Syndemic Health Disparities. <i>Journal of Community Health</i> , 2019, 44, 1193-1203.	1.9	50
2248	Historical and Current Trends in HIV Criminalization in South Carolina: Implications for the Southern HIV Epidemic. <i>AIDS and Behavior</i> , 2019, 23, 233-241.	1.4	12
2249	Pre-exposure prophylaxis access in federally qualified health centers across 11 United States metropolitan statistical areas. <i>International Journal of STD and AIDS</i> , 2019, 30, 978-984.	0.5	11
2250	Biopolitiken â€“ Regierungen des Lebens heute. <i>Politologische Aufklârung - Konstruktivistische Perspektiven</i> , 2019, , .	0.4	1
2251	HIV-1 self-testing to improve the efficiency of pre-exposure prophylaxis delivery: a randomized trial in Kenya. <i>Trials</i> , 2019, 20, 396.	0.7	20

#	ARTICLE	IF	CITATIONS
2252	Expanding Knowledge About Implementation of Pre-exposure Prophylaxis (PrEP): A Methodological Review. <i>AIDS and Behavior</i> , 2019, 23, 2761-2778.	1.4	30
2253	Suboptimal HIV Pre-exposure Prophylaxis Awareness and Willingness to Use Among Women Who Use Drugs in the United States: A Systematic Review and Meta-analysis. <i>AIDS and Behavior</i> , 2019, 23, 2641-2653.	1.4	21
2254	Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. <i>Journal of the International AIDS Society</i> , 2019, 22, e25338.	1.2	66
2255	Incidence of cutaneous adverse events after exposure to tenofovir-emtricitabine in HIV-uninfected vs HIV-infected patients: pharmacovigilance within a large Midwestern U.S. patient population from the Research on Adverse Drug events And Reports program. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e470-e471.	1.3	1
2256	HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory. <i>Oncolmmunology</i> , 2019, 8, e1629259.	2.1	58
2257	Antiretroviral Therapy Administration in Healthy Rhesus Macaques Is Associated with Transient Shifts in Intestinal Bacterial Diversity and Modest Immunological Perturbations. <i>Journal of Virology</i> , 2019, 93, .	1.5	13
2258	Using HIV Risk Prediction Tools to Identify Candidates for Pre-Exposure Prophylaxis: Perspectives from Patients and Primary Care Providers. <i>AIDS Patient Care and STDs</i> , 2019, 33, 372-378.	1.1	21
2259	Antiretroviral Medications for the Prevention of HIV Infection. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 629-646.	1.9	6
2260	Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP). <i>Pharmaceutics</i> , 2019, 11, 315.	2.0	62
2261	A Mixed Methods Evaluation of an Inclusive Sexual History Taking and HIV Prevention Curriculum for Trainees. <i>Journal of General Internal Medicine</i> , 2019, 34, 1279-1288.	1.3	34
2262	Mathematical modeling of HIV-1 transmission risk from condomless anal intercourse in HIV-infected MSM by the type of initial ART. <i>PLoS ONE</i> , 2019, 14, e0219802.	1.1	3
2263	Negative and Positive Selection Pressure During Sexual Transmission of Transmitted Founder HIV-1. <i>Frontiers in Immunology</i> , 2019, 10, 1599.	2.2	14
2264	Comparing Self-Report Pre-Exposure Prophylaxis Adherence Questions to Pharmacologic Measures of Recent and Cumulative Pre-Exposure Prophylaxis Exposure. <i>Frontiers in Pharmacology</i> , 2019, 10, 721.	1.6	28
2265	HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. <i>Journal of the International AIDS Society</i> , 2019, 22, e25298.	1.2	150
2266	What matters to me! User conceptions of value in specialist cancer care. <i>Public Management Review</i> , 2019, 21, 1687-1706.	3.4	29
2267	Geographic Access to Preexposure Prophylaxis Clinics Among Men Who Have Sex With Men in the United States. <i>American Journal of Public Health</i> , 2019, 109, 1216-1223.	1.5	82
2268	Location of Pre-exposure Prophylaxis Services Across New York City Neighborhoods: Do Neighborhood Socio-demographic Characteristics and HIV Incidence Matter?. <i>AIDS and Behavior</i> , 2019, 23, 2795-2802.	1.4	6
2269	Designing & Conducting Trials to Reliably Evaluate HIV Prevention Interventions. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	1

#	ARTICLE	IF	CITATIONS
2270	Same-Day HIV Pre-Exposure Prophylaxis (PrEP) Initiation During Drop-in Sexually Transmitted Diseases Clinic Appointments Is a Highly Acceptable, Feasible, and Safe Model that Engages Individuals at Risk for HIV into PrEP Care. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz310.	0.4	47
2271	Willingness to Use and Adhere to HIV Pre-Exposure Prophylaxis (PrEP) among Men Who Have Sex with Men (MSM) in China. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2620.	1.2	38
2272	Infrared Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry Imaging of Human Hair to Characterize Longitudinal Profiles of the Antiretroviral Maraviroc for Adherence Monitoring. <i>Analytical Chemistry</i> , 2019, 91, 10816-10822.	3.2	17
2273	Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis. <i>Viruses</i> , 2019, 11, 569.	1.5	2
2274	NZPrEP Demonstration Project: protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) to determine feasibility, acceptability, adverse and behavioural effects of PrEP provision to gay and bisexual men in publicly funded sexual health clinics in Auckland, New Zealand. <i>BMJ Open</i> , 2019, 9, e026363.	0.8	6
2275	Cohort profile: ACTUAL Pre-Exposure Prophylaxis (PrEP) Cohort study in Montreal, Canada. <i>BMJ Open</i> , 2019, 9, e028768.	0.8	40
2276	Pre-Exposure Prophylaxis Counseling in a Community Sexual Health Clinic for Men Who Have Sex with Men in Lisbon, Portugal. <i>Acta Medica Portuguesa</i> , 2019, 32, 441.	0.2	4
2277	Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection. <i>Bioconjugate Chemistry</i> , 2019, 30, 2216-2227.	1.8	13
2278	Toward a Set of Criteria to Decide Which STIs to Screen for in PrEP Cohorts. <i>Frontiers in Public Health</i> , 2019, 7, 154.	1.3	10
2279	Heterogeneous antiretroviral drug distribution and HIV/SHIV detection in the gut of three species. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	38
2280	Development and validation of an automated HIV prediction algorithm to identify candidates for pre-exposure prophylaxis: a modelling study. <i>Lancet HIV</i> , 2019, 6, e696-e704.	2.1	87
2281	Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy. <i>Journal of the International AIDS Society</i> , 2019, 22, e25355.	1.2	85
2282	Pleasure and HIV biomedical discourse: The structuring of sexual and drug-related risks for gay and bisexual men who Party-n-Play. <i>International Journal of Drug Policy</i> , 2019, 74, 181-190.	1.6	21
2283	Underutilization of Pre-Exposure Prophylaxis Services Among Transgender and Nonbinary Youth: Findings from Project Moxie and TechStep. <i>Transgender Health</i> , 2019, 4, 217-221.	1.2	12
2284	The Heart Team Approach: What is the Role of the Surgeon?. <i>Structural Heart</i> , 2019, 3, 469-470.	0.2	0
2285	Attitudes and referral practices for pre-exposure prophylaxis (PrEP) among HIV rapid testers and case managers in Philadelphia: A mixed methods study. <i>PLoS ONE</i> , 2019, 14, e0223486.	1.1	4
2286	Give PrEP a chance: moving on from the "risk compensation" concept. <i>Journal of the International AIDS Society</i> , 2019, 22, e25351.	1.2	57
2287	HIV and sexually transmitted infections: reconciling estranged bedfellows in the U=U and PrEP era. <i>Journal of the International AIDS Society</i> , 2019, 22, e25357.	1.2	6

#	ARTICLE	IF	CITATIONS
2288	Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial. <i>Journal of the International AIDS Society</i> , 2019, 22, e25381.	1.2	13
2289	Motives for choosing, switching and stopping daily or event-driven pre-exposure prophylaxis – a qualitative analysis. <i>Journal of the International AIDS Society</i> , 2019, 22, e25389.	1.2	42
2290	The impact, cost and cost-effectiveness of oral pre-exposure prophylaxis in sub-Saharan Africa: a scoping review of modelling contributions and way forward. <i>Journal of the International AIDS Society</i> , 2019, 22, e25390.	1.2	24
2291	Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men. <i>Journal of the International AIDS Society</i> , 2019, 22, e25405.	1.2	55
2292	Pre-Exposure Prophylaxis (PrEP) Use is Associated With Health Risk Behaviors Among Moderate- and Heavy-Drinking MSM. <i>AIDS Education and Prevention</i> , 2019, 31, 452-462.	0.6	12
2293	Global implementation of PrEP for HIV prevention: setting expectations for impact. <i>Journal of the International AIDS Society</i> , 2019, 22, e25370.	1.2	45
2294	High risk and low uptake of pre-exposure prophylaxis to prevent <sc>HIV</sc> acquisition in a national online sample of transgender men who have sex with men in the United States. <i>Journal of the International AIDS Society</i> , 2019, 22, e25391.	1.2	55
2295	Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076). <i>Journal of the International AIDS Society</i> , 2019, 22, e25408.	1.2	33
2296	Transactional Sex, Substance Use, and Sexual Risk: Comparing Pay Direction for an Internet-Based U.S. Sample of Men Who Have Sex with Men. <i>Sexuality Research and Social Policy</i> , 2019, 16, 255-267.	1.4	30
2297	High Prevalence of Anal and Oral High-Risk Human Papillomavirus in Human Immunodeficiency Virus-Uninfected French Men Who Have Sex With Men and Use Preexposure Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz291.	0.4	17
2298	Impact of HIV risk perception on both pre-exposure prophylaxis and condom use. <i>Journal of Health Psychology</i> , 2021, 26, 1575-1586.	1.3	11
2299	Electronic Health Record Use in Public Health Infectious Disease Surveillance, USA, 2018-2019. <i>Current Infectious Disease Reports</i> , 2019, 21, 32.	1.3	17
2301	Iowa TelePrEP: A Public-Health-Partnered Telehealth Model for Human Immunodeficiency Virus Preexposure Prophylaxis Delivery in a Rural State. <i>Sexually Transmitted Diseases</i> , 2019, 46, 507-512.	0.8	83
2302	Community awareness of, use of and attitudes towards HIV pre-exposure prophylaxis (PrEP) among men who have sex with men in Vancouver, Canada: preparing health promotion for a publicly funded PrEP program. <i>Sexual Health</i> , 2019, 16, 180-186.	0.4	12
2303	Perceived barriers to pre-exposure prophylaxis use among HIV-negative men who have sex with men in Tijuana, Mexico: A latent class analysis. <i>PLoS ONE</i> , 2019, 14, e0221558.	1.1	14
2304	The PrEP Care Continuum and Black Men Who Have Sex with Men: A Scoping Review of Published Data on Awareness, Uptake, Adherence, and Retention in PrEP Care. <i>AIDS and Behavior</i> , 2019, 23, 2654-2673.	1.4	91
2305	Experiences of Pre-Exposure Prophylaxis Stigma, Social Support, and Information Dissemination Among Black and Latina Transgender Women Who Are Using Pre-Exposure Prophylaxis. <i>Transgender Health</i> , 2019, 4, 188-196.	1.2	30
2306	Human Immunodeficiency Virus Diagnosis After a Syphilis, Gonorrhea, or Repeat Diagnosis Among Males Including non-Men Who Have Sex With Men: What Is the Incidence?. <i>Sexually Transmitted Diseases</i> , 2019, 46, 271-277.	0.8	18

#	ARTICLE	IF	CITATIONS
2307	Providing competent, comprehensive and inclusive sexual health services for men who have sex with men in low- and middle-income countries: a scoping review. <i>Sexual Health</i> , 2019, 16, 320.	0.4	12
2308	Rising HIV prevalence among men who have sex with men in Nigeria: a trend analysis. <i>BMC Public Health</i> , 2019, 19, 1201.	1.2	26
2309	Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors. <i>PLoS ONE</i> , 2019, 14, e0222183.	1.1	1
2310	Faith and healthcare providers' perspectives about enhancing HIV biomedical interventions in Western Kenya. <i>Global Public Health</i> , 2019, 14, 1744-1756.	1.0	4
2311	Advancing Novel PrEP Products – Alternatives to Non-Inferiority. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	7
2312	What will it take for the Global Plan priority countries in Sub-Saharan Africa to eliminate mother-to-child transmission of HIV?. <i>BMC Infectious Diseases</i> , 2019, 19, 783.	1.3	19
2313	Primary Care Physician Attitudes and Intentions Toward the Use of HIV Pre-exposure Prophylaxis in Adolescents in One Metropolitan Region. <i>Journal of Adolescent Health</i> , 2019, 64, 581-588.	1.2	26
2314	Decisional Balance and Contemplation Ladder to Support Interventions for HIV Pre-Exposure Prophylaxis Uptake and Persistence. <i>AIDS Patient Care and STDs</i> , 2019, 33, 67-78.	1.1	11
2315	Neighbourhoods, networks and pre-exposure prophylaxis awareness: a multilevel analysis of a sample of young black men who have sex with men. <i>Sexually Transmitted Infections</i> , 2019, 95, 228-235.	0.8	21
2316	US Guideline Criteria for Human Immunodeficiency Virus Preexposure Prophylaxis: Clinical Considerations and Caveats. <i>Clinical Infectious Diseases</i> , 2019, 69, 884-889.	2.9	20
2317	Understanding women's motivations to participate in MTN-003/VOICE, a phase 2b HIV prevention trial with low adherence. <i>BMC Women's Health</i> , 2019, 19, 18.	0.8	12
2318	Association of HIV pre-exposure prophylaxis awareness, preferred Spanish (vs. English) language use, and sociodemographic variables among Hispanic/Latino men who have sex with men. <i>Annals of Epidemiology</i> , 2019, 31, 8-10.	0.9	6
2319	Evaluation of the Performance of the Cobas CT/NG Test for Use on the Cobas 6800/8800 Systems for Detection of <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> in Male and Female Urogenital Samples. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	16
2320	Optimizing HIV prevention and care for transgender adults. <i>Aids</i> , 2019, 33, 363-375.	1.0	16
2321	Accompagnement médical et communautaire dans un essai de prévention biomédicale: vers une nouvelle forme d'éducation?. <i>Pratiques Psychologiques</i> , 2019, 25, 367-381.	0.4	0
2322	Provision of online HIV-related information to gay, bisexual and other men who have sex with men: a health literacy-informed critical appraisal of Canadian agency websites. <i>Sexual Health</i> , 2019, 16, 39.	0.4	10
2323	Progress in the HIV epidemic: Identifying goals and measuring success. <i>PLoS Medicine</i> , 2019, 16, e1002729.	3.9	51
2324	2-Hydroxypropyl- β -cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis. <i>Journal of Controlled Release</i> , 2019, 306, 89-96.	4.8	49

#	ARTICLE	IF	CITATIONS
2325	A descriptive analysis of transgender participants in phase 1-2a trials of the HIV Vaccine Trials Network (HVTN) in the United States and Peru. <i>Vaccine</i> , 2019, 37, 3911-3917.	1.7	4
2326	First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2752-2758.	1.3	20
2327	HIV pre-exposure prophylaxis and the "problems" of reduced condom use and sexually transmitted infections in Australia: a critical analysis from an evidence-making intervention perspective. <i>Sociology of Health and Illness</i> , 2019, 41, 1535-1548.	1.1	20
2328	Integration of Telehealth Services in the Healthcare System: With Emphasis on the Experience of Patients Living with HIV. <i>Journal of Investigative Medicine</i> , 2019, 67, 815-820.	0.7	25
2329	Update on HIV Preexposure Prophylaxis: Effectiveness, Drug Resistance, and Risk Compensation. <i>Current Infectious Disease Reports</i> , 2019, 21, 28.	1.3	36
2330	Nonoccupational Postexposure Prophylaxis and Preexposure Prophylaxis for Human Immunodeficiency Virus Prevention in Adolescents and Young Adults. <i>Advances in Pediatrics</i> , 2019, 66, 245-261.	0.5	3
2331	Global dynamics and cost-effectiveness analysis of HIV pre-exposure prophylaxis and structured treatment interruptions based on a multi-scale model. <i>Applied Mathematical Modelling</i> , 2019, 75, 162-200.	2.2	10
2332	Implementation Strategies to Increase PrEP Uptake in the South. <i>Current HIV/AIDS Reports</i> , 2019, 16, 259-269.	1.1	132
2333	Preexposure Prophylaxis for the Prevention of HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2214.	3.8	172
2334	Preexposure Prophylaxis for the Prevention of HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2203.	3.8	219
2335	Confronting Rising STIs in the Era of PrEP and Treatment as Prevention. <i>Current HIV/AIDS Reports</i> , 2019, 16, 244-256.	1.1	47
2336	"No strings attached": A qualitative exploration of gay and bisexual men's motivations for and attitudes toward engaging in casual sex while on vacation. <i>Journal of Gay and Lesbian Social Services</i> , 2019, 31, 397-415.	0.9	4
2337	Mapping the study topics and characteristics of HIV pre-exposure prophylaxis research literature: a protocol for a scoping review. <i>BMJ Open</i> , 2019, 9, e024212.	0.8	3
2338	Human Immunodeficiency Virus in Transgender Persons. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019, 48, 453-464.	1.2	5
2339	Diverse Large HIV-1 Non-subtype B Clusters Are Spreading Among Men Who Have Sex With Men in Spain. <i>Frontiers in Microbiology</i> , 2019, 10, 655.	1.5	31
2340	A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 794-804.	0.5	5
2341	Characteristics of the Provider-Patient Encounter Associated With Awareness of and Willingness to Take PrEP Among Young Minority Urban Males in Baltimore City. <i>AIDS Education and Prevention</i> , 2019, 31, 237-245.	0.6	0
2342	Community-Based Care in the ANRS-IPERGAY Trial: The Challenges of Combination Prevention. <i>AIDS Education and Prevention</i> , 2019, 31, 259-272.	0.6	4

#	ARTICLE	IF	CITATIONS
2343	The Pre-exposure Prophylaxis (PrEP) Continuum of Care and Correlates to Initiation Among HIV-Negative Men Recruited at Miami Gay Pride 2018. <i>Journal of Urban Health</i> , 2019, 96, 835-844.	1.8	13
2344	Provider Knowledge Gaps in HIV PrEP Affect Practice Patterns in the US Navy. <i>Military Medicine</i> , 2019, 185, e117-e124.	0.4	4
2345	Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	2
2346	Pr<sc>EP</sc> interest and <sc>HIV</sc> incidence among <sc>MSM</sc> and transgender women in coastal Kenya. <i>Journal of the International AIDS Society</i> , 2019, 22, e25323.	1.2	47
2347	Modeling the joint effects of adolescent and adult PrEP for sexual minority males in the United States. <i>PLoS ONE</i> , 2019, 14, e0217315.	1.1	10
2348	Tenofovir-Diphosphate as a Marker of HIV Pre-exposure Prophylaxis Use Among East African Men and Women. <i>Frontiers in Pharmacology</i> , 2019, 10, 401.	1.6	9
2349	Effect of a Community-Level HIV Prevention Intervention on Psychosocial Determinants of HIV Risk Behaviors among Young Black Men Who Have Sex with Men (YBMSM). <i>AIDS and Behavior</i> , 2019, 23, 2361-2374.	1.4	11
2350	The Pharmacist's Expanding Role in HIV Pre-Exposure Prophylaxis. <i>AIDS Patient Care and STDs</i> , 2019, 33, 207-213.	1.1	42
2351	Recent HIV Risk Behavior and Partnership Type Predict HIV Pre-Exposure Prophylaxis Adherence in Men Who Have Sex with Men. <i>AIDS Patient Care and STDs</i> , 2019, 33, 220-226.	1.1	4
2352	Interest in Pre-exposure Prophylaxis (PrEP) for HIV is Limited Among Women in a General Obstetrics & Gynecology Setting. <i>AIDS and Behavior</i> , 2019, 23, 2741-2748.	1.4	20
2353	Distinct Profiles of Consumers of Psychoactive Substances in People Attending French Sexual Transmitted Infections Centers. <i>AIDS and Behavior</i> , 2019, 23, 3375-3383.	1.4	1
2354	Acceptability and willingness of HIV pre-exposure prophylaxis amongst female sex workers in China. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 1555-1564.	0.6	12
2355	Awareness and Acceptability of pre-exposure prophylaxis (PrEP) among gay, bisexual and other men who have sex with men (GBMSM) in Kenya. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 1185-1192.	0.6	29
2356	Quantification of tenofovir disoproxil fumarate and emtricitabine in generic pre-exposure prophylaxis tablets obtained from the internet. <i>International Journal of STD and AIDS</i> , 2019, 30, 765-768.	0.5	4
2357	Resurgence of Syphilis. <i>Advances in Pediatrics</i> , 2019, 66, 231-244.	0.5	8
2358	Association between rectal douching and HIV and other sexually transmitted infections among men who have sex with men: a systematic review and meta-analysis. <i>Sexually Transmitted Infections</i> , 2019, 95, 428-436.	0.8	19
2359	Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2352-2359.	1.3	9
2360	Demographic characteristics associated with the use of HIV pre-exposure prophylaxis (PrEP) in an urban, community health center. <i>Preventive Medicine Reports</i> , 2019, 15, 100889.	0.8	12

#	ARTICLE	IF	CITATIONS
2361	Relational Empathy. <i>International Journal of Philosophical Studies</i> , 2019, 27, 162-179.	0.2	0
2362	Epidemiology and prevention of sexually transmitted infections in men who have sex with men at risk of HIV. <i>Lancet HIV</i> , 2019, 6, e396-e405.	2.1	114
2363	Development and validation of plasma miRNA biomarker signature panel for the detection of early HIV-1 infection. <i>EBioMedicine</i> , 2019, 43, 307-316.	2.7	61
2364	Having children outside a heterosexual relationship: options for persons living with HIV. <i>Sexually Transmitted Infections</i> , 2019, 95, 99-101.	0.8	4
2365	Healthcare providers' knowledge, readiness, prescribing behaviors, and perceived barriers regarding routine HIV testing and pre-exposure prophylaxis in DeLand, Florida. <i>SAGE Open Medicine</i> , 2019, 7, 205031211983603.	0.7	8
2366	HIV pre-exposure prophylaxis (PrEP) awareness and acceptability among trans women: a review. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 1234-1240.	0.6	29
2367	Implementing pre-exposure prophylaxis could prevent most new HIV infections in transsexual women and men who have sex with men. <i>Revista Colombiana Espanola</i> , 2019, 219, 360-366.	0.3	2
2368	Intimate partner violence, depression, and sexual behaviour among gay, bisexual and other men who have sex with men in the PROUD trial. <i>BMC Public Health</i> , 2019, 19, 431.	1.2	50
2369	Correlates of nonadherence to key population-led HIV pre-exposure prophylaxis services among Thai men who have sex with men and transgender women. <i>BMC Public Health</i> , 2019, 19, 328.	1.2	22
2370	A Cross-sectional Survey of Internal Medicine Resident Knowledge, Attitudes, Behaviors, and Experiences Regarding Pre-Exposure Prophylaxis for HIV Infection. <i>Journal of General Internal Medicine</i> , 2019, 34, 1258-1278.	1.3	18
2371	Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 1228-1233.	0.6	17
2372	Making Meaning of the Impact of Pre-Exposure Prophylaxis (PrEP) on Public Health and Sexual Culture: Narratives of Three Generations of Gay and Bisexual Men. <i>Archives of Sexual Behavior</i> , 2019, 48, 1041-1058.	1.2	25
2373	Awareness, knowledge, and attitudes towards human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) among pharmacy students. <i>Currents in Pharmacy Teaching and Learning</i> , 2019, 11, 352-360.	0.4	23
2374	HIV Infection in Transgender Persons. <i>Contemporary Endocrinology</i> , 2019, , 239-281.	0.3	0
2375	Public health's social contract: An obstacle in the advancement of effective HIV technologies. <i>Global Public Health</i> , 2019, 14, 1264-1274.	1.0	1
2376	Contrasting Self-Perceived Need and Guideline-Based Indication for HIV Pre-Exposure Prophylaxis Among Young, Black Men Who Have Sex with Men Offered Pre-Exposure Prophylaxis in Atlanta, Georgia. <i>AIDS Patient Care and STDs</i> , 2019, 33, 112-119.	1.1	31
2377	Public Awareness of HIV Pre-Exposure Prophylaxis in Durham, North Carolina. <i>North Carolina Medical Journal</i> , 2019, 80, 7-11.	0.1	3
2378	Engagement in Mental Health Care is Associated with Higher Cumulative Drug Exposure and Adherence to Antiretroviral Therapy. <i>AIDS and Behavior</i> , 2019, 23, 3493-3502.	1.4	16

#	ARTICLE	IF	CITATIONS
2379	Antibody repertoire analysis of mouse immunization protocols using microfluidics and molecular genomics. <i>MAbs</i> , 2019, 11, 870-883.	2.6	29
2380	US Human Immunodeficiency Virus (HIV) Practitionersâ€™ Recommendations Regarding Condomless Sex in the Era of HIV Pre-Exposure Prophylaxis and Treatment as Prevention. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz082.	0.4	5
2381	Racial and Ethnic Disparities in HIV Pre-exposure Prophylaxis Awareness Among Men Who have Sex with Men. <i>AIDS and Behavior</i> , 2019, 23, 2706-2709.	1.4	42
2382	Using discrete choice experiments to inform the design of complex interventions. <i>Trials</i> , 2019, 20, 157.	0.7	16
2383	Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions. <i>Journal of the International AIDS Society</i> , 2019, 22, e25247.	1.2	15
2384	BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018. <i>HIV Medicine</i> , 2019, 20, s2-s80.	1.0	30
2385	Simulated vaccine efficacy trials to estimate HIV incidence for actual vaccine clinical trials in key populations in Uganda. <i>Vaccine</i> , 2019, 37, 2065-2072.	1.7	14
2386	Moving Metaphors: Shifting Institutional Responsibilities and Evidentiary Boundaries in the Commissioning of Pre-Exposure Prophylaxis for HIV. <i>Qualitative Health Research</i> , 2019, 29, 1408-1418.	1.0	2
2387	Tenofovir and emtricitabine resistance among antiretroviral-naïve patients in the Canadian Observational Cohort Collaboration: implications for PrEP. <i>Antiviral Therapy</i> , 2019, 24, 211-220.	0.6	2
2388	Acceptability of HIV Pre-exposure Prophylaxis (PrEP) and Opinions on PrEP Service Delivery Among Men Who Have Sex With Men in Singapore: A Qualitative Study. <i>AIDS Education and Prevention</i> , 2019, 31, 152-162.	0.6	7
2389	Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1380.	3.8	266
2390	Generalizing from the results of randomized studies of treatment: Can non-randomized studies be of help?. <i>European Journal of Epidemiology</i> , 2019, 34, 715-718.	2.5	10
2391	Factors Associated with PrEP Refusal Among Transgender Women in Northeastern Brazil. <i>AIDS and Behavior</i> , 2019, 23, 2710-2718.	1.4	6
2392	Drug Resistance During HIV Pre-Exposure Prophylaxis. <i>Drugs</i> , 2019, 79, 609-619.	4.9	54
2393	Best practices for identifying men who have sex with men for corrections-based pre-exposure prophylaxis provision. <i>Health and Justice</i> , 2019, 7, 7.	0.9	4
2394	The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 199.	1.6	14
2395	Training health care providers to provide PrEP for HIV serodiscordant couples attending public health facilities in Kenya. <i>Global Public Health</i> , 2019, 14, 1524-1534.	1.0	12
2396	Barriers to HIV pre-exposure prophylaxis among African, Caribbean and Black men in Toronto, Canada. <i>PLoS ONE</i> , 2019, 14, e0213740.	1.1	15

#	ARTICLE	IF	CITATIONS
2397	In-depth Sampling of High-risk Populations to Characterize HIV Transmission Epidemics Among Young MSM Using PrEP in France and Quebec. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz080.	0.4	12
2398	Predictive factors for HIV infection among men who have sex with men and who are seeking PrEP: a secondary analysis of the PROUD trial. <i>Sexually Transmitted Infections</i> , 2019, 95, 449-454.	0.8	14
2399	The epidemiology of HIV and other sexually transmitted infections in African, Caribbean and Black men in Toronto, Canada. <i>BMC Infectious Diseases</i> , 2019, 19, 294.	1.3	16
2400	Participation in community groups increases the likelihood of PrEP awareness: New Orleans NHBS-MSM Cycle, 2014. <i>PLoS ONE</i> , 2019, 14, e0213022.	1.1	19
2401	Mind the gaps: prescription coverage and HIV incidence among patients receiving pre-exposure prophylaxis from a large federally qualified health center in Los Angeles, California. <i>AIDS and Behavior</i> , 2019, 23, 2730-2740.	1.4	34
2402	Integrated HIV prevention and care for key populations. <i>Lancet HIV</i> , 2019, 6, e270-e271.	2.1	8
2403	Community Levels of PrEP Use Among Men Who Have Sex with Men by Race/Ethnicity, San Francisco, 2017. <i>AIDS and Behavior</i> , 2019, 23, 2687-2693.	1.4	11
2404	Data-Driven Goals for Curbing the U.S. HIV Epidemic by 2030. <i>AIDS and Behavior</i> , 2019, 23, 557-563.	1.4	26
2405	The Impact of Pre-Exposure Prophylaxis (PrEP) Use on Sexual Anxiety, Satisfaction, and Esteem Among Gay and Bisexual Men. <i>Journal of Sex Research</i> , 2019, 56, 1128-1135.	1.6	38
2406	Studying treatment-effect heterogeneity in precision medicine through induced subgroups. <i>Journal of Biopharmaceutical Statistics</i> , 2019, 29, 491-507.	0.4	8
2407	Selecting Evidence-Based HIV Prevention Behavioral Interventions for HIV-Negative Persons for National Dissemination. <i>AIDS and Behavior</i> , 2019, 23, 2226-2237.	1.4	3
2408	Scaling-up PrEP Delivery in Sub-Saharan Africa: What Can We Learn from the Scale-up of ART?. <i>Current HIV/AIDS Reports</i> , 2019, 16, 141-150.	1.1	51
2409	Access to HIV Pre-exposure Prophylaxis in Practice Settings: a Qualitative Study of Sexual and Gender Minority Adults' Perspectives. <i>Journal of General Internal Medicine</i> , 2019, 34, 535-543.	1.3	18
2410	HIV Prevention Interventions for Adolescents. <i>Current HIV/AIDS Reports</i> , 2019, 16, 120-128.	1.1	66
2411	Knowledge and willingness to use pre-exposure prophylaxis among men who have sex with men in Northeastern Brazil. <i>Global Public Health</i> , 2019, 14, 1098-1111.	1.0	20
2412	Condoms are like public transit. It's something you want everyone else to take. Perceptions and use of condoms among HIV negative gay men in Vancouver, Canada in the era of biomedical and seroadaptive prevention. <i>BMC Public Health</i> , 2019, 19, 120.	1.2	12
2413	No Easy Answers: Avoiding Potential Pitfalls of Deimplementation. <i>American Journal of Community Psychology</i> , 2019, 63, 239-242.	1.2	5
2414	The role of sexual risk behaviors on PrEP awareness and interest among men who have sex with men in Latin America. <i>International Journal of STD and AIDS</i> , 2019, 30, 542-549.	0.5	9

#	ARTICLE	IF	CITATIONS
2415	Acceptability and Predictors of Uptake of Anti-retroviral Pre-exposure Prophylaxis (PrEP) Among Fishing Communities in Uganda: A Cross-Sectional Discrete Choice Experiment Survey. <i>AIDS and Behavior</i> , 2019, 23, 2674-2686.	1.4	24
2416	Patterns and clinical consequences of discontinuing <scp>HIV</scp> preexposure prophylaxis during primary care. <i>Journal of the International AIDS Society</i> , 2019, 22, e25250.	1.2	74
2417	Dermatologic care for lesbian, gay, bisexual, and transgender persons. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 591-602.	0.6	53
2418	“No one’s driving this bus” qualitative analysis of PrEP health promotion for Aboriginal and Torres Strait Islander gay and bisexual men. <i>Australian and New Zealand Journal of Public Health</i> , 2019, 43, 18-23.	0.8	9
2419	Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States. <i>Pharmacotherapy</i> , 2019, 39, 486-500.	1.2	19
2421	Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017. <i>Journal of the International AIDS Society</i> , 2019, 22, e25252.	1.2	99
2422	Routine screening for hepatitis C in MSM on HIV PrEP. <i>Nature Reviews Urology</i> , 2019, 16, 272-274.	1.9	2
2423	Pre-exposure prophylaxis initiation and adherence among Black men who have sex with men (<scp>MSM</scp>) in three US cities: results from the <scp>HPTN</scp> 073 study. <i>Journal of the International AIDS Society</i> , 2019, 22, e25223.	1.2	81
2424	“Little Tablets of Gold”: An Examination of the Psychological and Social Dimensions of PrEP Among LGBTQ Communities. <i>AIDS Education and Prevention</i> , 2019, 31, 51-62.	0.6	16
2425	Epithelial Cells and Fibroblasts from the Human Female Reproductive Tract Accumulate and Release TFV and TAF to Sustain Inhibition of HIV Infection of CD4+ T cells. <i>Scientific Reports</i> , 2019, 9, 1864.	1.6	8
2426	PrEP in Prisons: HIV prevention in incarcerated populations. <i>International Journal of Prisoner Health</i> , 2019, 16, 199-206.	0.5	5
2427	HIV-1 genetic diversity to estimate time of infection and infer adherence to preexposure prophylaxis. <i>Aids</i> , 2019, 33, 2299-2307.	1.0	3
2429	Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz463.	0.4	9
2430	Knowledge and attitudes of syphilis and syphilis pre-exposure prophylaxis (PrEP) among men who have sex with men in Vancouver, Canada: a qualitative study. <i>BMJ Open</i> , 2019, 9, e031239.	0.8	6
2431	Ten Things We Need to Do to Achieve the Goals of the End the HIV Epidemic Plan for America. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, S94-S98.	0.9	12
2432	Estimation of new HIV diagnosis rates among high-risk, PrEP-eligible individuals using HIV surveillance data at the Metropolitan Statistical Area level in the United States. <i>Journal of the International AIDS Society</i> , 2019, 22, e25433.	1.2	10
2433	Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 72-77.	0.9	50
2434	Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa. <i>BMJ Open</i> , 2019, 9, e027227.	0.8	12

#	ARTICLE	IF	CITATIONS
2435	Treatment of Functional Mitral Regurgitation in Heart Failure. <i>Current Cardiology Reports</i> , 2019, 21, 139.	1.3	1
2436	Congruence between Hypothetical Willingness to Use Pre-Exposure Prophylaxis (PrEP) and Eligibility: An Online Survey among Belgian Men Having Sex with Men. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4411.	1.2	6
2437	Progreso en Salud: Findings from Two Adapted Social Network HIV Risk Reduction Interventions for Latina Seasonal Workers. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4530.	1.2	9
2438	Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	2
2439	Audit of patient retention in pre-exposure prophylaxis (PrEP) services in an integrated sexual reproductive health service setting. <i>International Journal of STD and AIDS</i> , 2019, 30, 1432-1435.	0.5	4
2440	Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 252-256.	0.9	12
2441	From surviving to thriving. <i>Aids</i> , 2019, 33, S1-S4.	1.0	13
2442	Differences Between Groups of Pre-exposure Prophylaxis (PrEP) Using Couples in HIV-Negative/Unknown Relationships. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 419-428.	0.9	9
2443	The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 542-550.	0.9	37
2444	Prepared for PrEP: preferences for HIV pre-exposure prophylaxis among Chinese men who have sex with men in an online national survey. <i>BMC Infectious Diseases</i> , 2019, 19, 1057.	1.3	7
2445	Awareness, willingness to use, and history of HIV PrEP use among gay, bisexual, and other men who have sex with men in Nigeria. <i>PLoS ONE</i> , 2019, 14, e0226384.	1.1	26
2446	Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review. <i>Journal of the International AIDS Society</i> , 2019, 22, e25419.	1.2	49
2447	Is reaching 90â€“90â€“90 enough to end AIDS? Lessons from Amsterdam. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 455-463.	1.5	10
2448	Sexual and reproductive health considerations among transgender and gender-expansive youth. <i>Current Problems in Pediatric and Adolescent Health Care</i> , 2019, 49, 100684.	0.8	25
2449	Silver bullets and structural impediments to HIV prevention. <i>Lancet HIV</i> , 2019, 6, e729-e732.	2.1	3
2450	Interventions to improve the HIV continuum of care in China. <i>Current HIV/AIDS Reports</i> , 2019, 16, 448-457.	1.1	29
2451	How Big Data Science Can Improve Linkage and Retention in Care. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 807-815.	1.9	7
2452	Unspeakable PrEP: a qualitative study of sexual communication, problematic integration, and uncertainty management among men who have sex with men in Taiwan. <i>Journal of Applied Communication Research</i> , 2019, 47, 611-627.	0.7	9

#	ARTICLE	IF	CITATIONS
2453	Transformation of Australian Community Pharmacies Into Good Clinical Practice Compliant Trial Pharmacies for HIV Pre-Exposure Prophylaxis. <i>Frontiers in Pharmacology</i> , 2019, 10, 1269.	1.6	2
2454	Estimating Human Immunodeficiency Virus (HIV) Prevention Effects in Low-incidence Settings. <i>Epidemiology</i> , 2019, 30, 358-364.	1.2	5
2455	Global Challenges to Human Immunodeficiency Virus Prevention. <i>Health Care Manager</i> , 2019, 38, 74-81.	1.4	1
2456	Behavioral Interventions to Enhance PrEP Uptake Among Black Men Who Have Sex With Men. <i>Journal of the Association of Nurses in AIDS Care</i> , 2019, 30, 151-163.	0.4	18
2457	Characteristics of a cohort of high-risk men who have sex with men on pre-exposure prophylaxis reporting transgender sexual partners. <i>Medicine (United States)</i> , 2019, 98, e18232.	0.4	3
2458	Changes in Disparities in Estimated HIV Incidence Rates Among Black, Hispanic/Latino, and White Men Who Have Sex With Men (MSM) in the United States, 2010â€”2015. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 57-62.	0.9	35
2459	PrEP Discontinuation and Prevention-Effective Adherence: Experiences of PrEP Users in Ugandan HIV Serodiscordant Couples. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 265-274.	0.9	20
2460	Comprehensive HIV risk reduction interventions for 2020 and beyond. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 423-432.	1.5	16
2461	Factors Associated With Increased Syphilis Screening Among People Living With Human Immunodeficiency Virus. <i>Sexually Transmitted Diseases</i> , 2019, 46, 521-526.	0.8	1
2462	Preexposure prophylaxis use continues to evolve. <i>Aids</i> , 2019, 33, N5.	1.0	0
2463	â€œThis is mine, this is for meâ€™. <i>Aids</i> , 2019, 33, S45-S52.	1.0	22
2464	Racial/ethnic and HIV risk category disparities in preexposure prophylaxis discontinuation among patients in publicly funded primary care clinics. <i>Aids</i> , 2019, 33, 2189-2195.	1.0	55
2465	Comfort Discussing HIV Pre-exposure Prophylaxis With Patients Among Physicians in an Urban Emergency Department. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, e49-e52.	0.9	7
2466	Vulnerable Periods: Characterizing Patterns of Sexual Risk and Substance Use During Lapses in Adherence to HIV Pre-exposure Prophylaxis Among Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 276-283.	0.9	20
2467	Baseline Characteristics Explain Differences in Effectiveness of Randomization to Daily Oral TDF/FTC PrEP Between Transgender Women and Cisgender Men Who Have Sex With Men in the iPrEx Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, e94-e98.	0.9	13
2468	Adherence to PrEP Among Young Men Who Have Sex With Men Participating in a Sexual Health Services Demonstration Project in Alameda County, California. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 406-413.	0.9	11
2469	Brief Report: Routine Use of Oral PrEP in a Phase 2 Rectal Microbicide Study of Tenofovir Reduced-Glycerin 1% Gel (MTN-017). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 516-520.	0.9	1
2470	A Field Evaluation of Point-of-Care Creatinine Testing Within a Large PrEP Implementation Program in Western Kenya. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, e8-e10.	0.9	7

#	ARTICLE	IF	CITATIONS
2471	Regulatory Perspectives for Streamlining HIV Prevention Trials. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	4
2472	Update on HIV integrase inhibitors for the treatment of HIV-1 infection. <i>Future Virology</i> , 2019, 14, 693-709.	0.9	6
2473	HIV Seroconversion in the Era of Pharmacologic Prevention: A Caseâ€“Control Study at a San Francisco STD Clinic. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 159-165.	0.9	7
2474	Mapping the Study Characteristics and Topics of HIV Pre-Exposure Prophylaxis Research Literature: A Scoping Review. <i>AIDS Education and Prevention</i> , 2019, 31, 505-522.	0.6	4
2475	Study on Pre-Exposure Prophylaxis Regimens among Men Who Have Sex with Men: A Prospective Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4996.	1.2	4
2476	STD Partner Services to Monitor and Promote HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 533-541.	0.9	32
2477	Clinical trials of antiretroviral treatment interruption in HIV-infected individuals. <i>Aids</i> , 2019, 33, 773-791.	1.0	34
2478	Brief Report: Role of Sociobehavioral Factors in Subprotective TFV-DP Levels Among YMSM Enrolled in 2 PrEP Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 160-165.	0.9	13
2479	Brief Report: Quantitative Assessment of Brief Messages About HIV Pre-exposure Prophylaxis Among HIV-Infected and HIV-Uninfected Black/African American and Hispanic/Latino MSM. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 31-35.	0.9	7
2480	The HIV epidemic in Latin America. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 366-373.	1.5	56
2481	PrEP-RN. <i>Journal of the Association of Nurses in AIDS Care</i> , 2019, 30, 301-311.	0.4	33
2482	PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, S113-S117.	0.9	19
2483	Mosaic effectiveness: measuring the impact of novel PrEP methods. <i>Lancet HIV</i> , 2019, 6, e800-e806.	2.1	15
2484	Drawing from the Theory of Planned Behaviour to examine pre-exposure prophylaxis uptake intentions among heterosexuals in high HIV prevalence neighbourhoods in Philadelphia, Pennsylvania, USA: an observational study. <i>Sexual Health</i> , 2019, 16, 218-224.	0.4	9
2485	Pre-exposure prophylaxis differentially alters circulating and mucosal immune cell activation in herpes simplex virus type 2 seropositive women. <i>Aids</i> , 2019, 33, 2125-2136.	1.0	5
2486	Predictors of Long-Term HIV Pre-exposure Prophylaxis Adherence After Study Participation in Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 166-174.	0.9	15
2487	Factors Associated With Sex-Related Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men in New York City in HPTN 067. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 551-558.	0.9	24
2488	A Gap Between Willingness and Uptake: Findings From Mixed Methods Research on HIV Prevention Among Black and Latina Transgender Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 131-140.	0.9	78

#	ARTICLE	IF	CITATIONS
2489	Brief Report: Incidence of HIV in a Nationwide Cohort Receiving Pre-exposure Prophylaxis for HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, 427-430.	0.9	9
2490	Current and Future Challenges in Trial Design for Pre-Exposure Prophylaxis in HIV Prevention. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	2
2491	Global Epidemiologic Characteristics of Sexually Transmitted Infections Among Individuals Using Preexposure Prophylaxis for the Prevention of HIV Infection. <i>JAMA Network Open</i> , 2019, 2, e1917134.	2.8	102
2492	Incentivized Screening to Reduce Sexually Transmitted Infection Risk and Prevalence. <i>Sexually Transmitted Diseases</i> , 2019, 46, 654-656.	0.8	0
2493	Differences in sexually transmitted infection risk comparing preexposure prophylaxis users and propensity score matched historical controls in a clinic setting. <i>Aids</i> , 2019, 33, 1773-1780.	1.0	16
2494	Perceived Versus Calculated HIV Risk: Implications for Pre-exposure Prophylaxis Uptake in a Randomized Trial of Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 80, e23-e29.	0.9	55
2495	Brief Report: Cocaine Use and Pre-exposure Prophylaxis: Adherence, Care Engagement, and Kidney Function. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, 78-82.	0.9	18
2496	Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, 149-158.	0.9	12
2497	Eliminating the HIV epidemic. <i>Aids</i> , 2019, 33, 1951-1952.	1.0	0
2498	Implementing Pre-exposure Prophylaxis for HIV Prevention at an Urban Youth Clinic. <i>Journal of the Association of Nurses in AIDS Care</i> , 2019, 30, 232-237.	0.4	2
2499	Proportion of Incident Human Immunodeficiency Virus Cases Among Men Who Have Sex With Men Attributable to Gonorrhea and Chlamydia: A Modeling Analysis. <i>Sexually Transmitted Diseases</i> , 2019, 46, 357-363.	0.8	60
2500	Impact of Q-Griffithsin anti-HIV microbicide gel in non-human primates: In situ analyses of epithelial and immune cell markers in rectal mucosa. <i>Scientific Reports</i> , 2019, 9, 18120.	1.6	19
2501	HIV pharmacogenetics and pharmacogenomics: From bench to bedside. , 2019, , 185-222.		0
2502	Risk Perception and Interest in HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men with Rectal Gonorrhea and Chlamydia Infection. <i>Archives of Sexual Behavior</i> , 2019, 48, 1185-1190.	1.2	21
2503	Advancing the case for nurse practitioner-based models to accelerate scale-up of HIV pre-exposure prophylaxis. <i>Journal of Clinical Nursing</i> , 2019, 28, 351-361.	1.4	26
2504	A Randomized Controlled Pilot Study of a Culturally-Tailored Counseling Intervention to Increase Uptake of HIV Pre-exposure Prophylaxis Among Young Black Men Who Have Sex with Men in Washington, DC. <i>AIDS and Behavior</i> , 2019, 23, 105-115.	1.4	29
2505	Oral and vaginal HIV pre-exposure prophylaxis product attribute preferences among female sex workers in the Mexico-US border region. <i>International Journal of STD and AIDS</i> , 2019, 30, 45-55.	0.5	15
2506	Transcatheter Aortic Valve Replacement in the Presence of Mitral Prosthesis or Ring. <i>Structural Heart</i> , 2019, 3, 134-137.	0.2	0

#	ARTICLE	IF	CITATIONS
2507	Applying the Information-Motivation-Behavioral Skills Model to Understand PrEP Intentions and Use Among Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2019, 23, 1904-1916.	1.4	69
2508	Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 545-553.	0.6	54
2509	Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission. <i>Journal of Controlled Release</i> , 2019, 294, 216-225.	4.8	37
2510	Sexual safety and HIV prevention in travel medicine: Practical considerations and new approaches. <i>Travel Medicine and Infectious Disease</i> , 2019, 28, 68-73.	1.5	9
2511	Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, G12q and G12S and kill uveal melanoma cells. <i>Cancer Biology and Therapy</i> , 2019, 20, 700-710.	1.5	37
2512	A Pilot Intervention Trial to Promote Sexual Health and Stress Management Among HIV-Infected Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2019, 23, 48-59.	1.4	13
2513	Short Message Service (SMS) Surveys Assessing Pre-exposure Prophylaxis (PrEP) Adherence and Sexual Behavior are Highly Acceptable Among HIV-Uninfected Members of Serodiscordant Couples in East Africa: A Mixed Methods Study. <i>AIDS and Behavior</i> , 2019, 23, 1267-1276.	1.4	13
2514	Modern Human Immunodeficiency Virus Therapy: Progress and Prospects. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 61-70.	2.3	15
2515	Stigma, the Media, and Pre-exposure Prophylaxis for HIV Prevention: Observations for Enhancing Knowledge Translation and Resisting Stigma in the Canadian Context. <i>AIDS and Behavior</i> , 2019, 23, 1877-1887.	1.4	15
2516	Rectal Douching Practices Associated with Anal Intercourse: Implications for the Development of a Behaviorally Congruent HIV-Prevention Rectal Microbicide Douche. <i>AIDS and Behavior</i> , 2019, 23, 1484-1493.	1.4	14
2517	Cancer and AIDS. , 2019, , .		0
2518	Network Modeling of PrEP Uptake on Referral Networks and Health Venue Utilization Among Young Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2019, 23, 1698-1707.	1.4	11
2519	Is HIV prevention creating new biosocialities among gay men? Treatment as prevention and pre-exposure prophylaxis in Canada. <i>Sociology of Health and Illness</i> , 2019, 41, 484-501.	1.1	29
2520	The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM. <i>Aids</i> , 2019, 33, 237-246.	1.0	17
2521	Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	12
2522	Predicting Pharmacist Dispensing Practices and Comfort Related to Pre-exposure Prophylaxis for HIV Prevention (PrEP). <i>AIDS and Behavior</i> , 2019, 23, 1925-1938.	1.4	16
2523	HIV Both Starts and Stops with Me™: Configuring the Neoliberal Sexual Actor in HIV Prevention. <i>Sexuality and Culture</i> , 2019, 23, 657-673.	1.1	6
2524	Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, e9-e13.	0.9	33

#	ARTICLE	IF	CITATIONS
2525	Genetic variation of kinases and activation of nucleotide analog reverse transcriptase inhibitor tenofovir. <i>Pharmacogenomics</i> , 2019, 20, 105-111.	0.6	7
2526	Experiences of Anticipated and Enacted Pre-exposure Prophylaxis (PrEP) Stigma Among Latino MSM in Los Angeles. <i>AIDS and Behavior</i> , 2019, 23, 1964-1973.	1.4	61
2527	Pre-exposure Prophylaxis for HIV Infection: Preventing Disease or Promoting Sexual Health?. <i>Journal of Community Health</i> , 2019, 44, 423-427.	1.9	3
2528	Self-initiated continuation of and adherence to HIV pre-exposure prophylaxis (PrEP) after PrEP demonstration project roll-off in men who have sex with men: associations with risky decision making, impulsivity/disinhibition, and sensation seeking. <i>Journal of NeuroVirology</i> , 2019, 25, 324-330.	1.0	11
2529	Adolescent Preexposure Prophylaxis Administration: An Education Curriculum for Health Care Providers. <i>Journal of Pediatric Health Care</i> , 2019, 33, 288-295.	0.6	8
2530	Barriers to preexposure prophylaxis use among individuals with recently acquired HIV infection in Northern California. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 536-544.	0.6	45
2531	Timing and Sequence of Events: HIV Status Disclosure, Condomless Anal Sex, and Sexual Agreement Formation Among Same-Sex Male Couples. <i>Journal of Sex Research</i> , 2019, 56, 728-739.	1.6	4
2532	The role of public health units in the delivery of HIV pre-exposure prophylaxis (PrEP). <i>Canadian Journal of Public Health</i> , 2019, 110, 72-75.	1.1	9
2533	Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring. <i>Clinical Infectious Diseases</i> , 2019, 69, 523-529.	2.9	8
2534	PrEP awareness, eligibility, and interest among people who inject drugs in Baltimore, Maryland. <i>Drug and Alcohol Dependence</i> , 2019, 195, 148-155.	1.6	75
2535	Addressing Gaps in HIV Preexposure Prophylaxis Care to Reduce Racial Disparities in HIV Incidence in the United States. <i>American Journal of Epidemiology</i> , 2019, 188, 743-752.	1.6	76
2536	The Context of Sexual Risk Behaviour Among Men Who Have Sex with Men Seeking PrEP, and the Impact of PrEP on Sexual Behaviour. <i>AIDS and Behavior</i> , 2019, 23, 1708-1720.	1.4	56
2537	A Review of Approaches Used to Increase Awareness of Pre-exposure Prophylaxis (PrEP) in the United States. <i>AIDS and Behavior</i> , 2019, 23, 1749-1770.	1.4	31
2538	Towards an Integration of PrEP into a Safe Sex Ethics Framework for Men Who Have Sex with Men. <i>Public Health Ethics</i> , 2019, 12, 54-63.	0.4	9
2539	Predictors of Daily Adherence to HIV Pre-exposure Prophylaxis in Gay/Bisexual Men in the PRELUDE Demonstration Project. <i>AIDS and Behavior</i> , 2019, 23, 1287-1296.	1.4	14
2540	Trends in Attitudes to and the Use of HIV Pre-exposure Prophylaxis by Australian Gay and Bisexual Men, 2011-2017: Implications for Further Implementation from a Diffusion of Innovations Perspective. <i>AIDS and Behavior</i> , 2019, 23, 1939-1950.	1.4	47
2541	Health Care Facility Characteristics are Associated with Variation in Human Immunodeficiency Virus Pre-exposure Prophylaxis Initiation in Veteran's Health Administration. <i>AIDS and Behavior</i> , 2019, 23, 1803-1811.	1.4	8
2542	Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. <i>Lancet HIV</i> , 2019, 6, e43-e50.	2.1	43

#	ARTICLE	IF	CITATIONS
2543	Adaptive non-inferiority margins under observable non-constancy. <i>Statistical Methods in Medical Research</i> , 2019, 28, 3318-3332.	0.7	18
2544	Increases in Pre-exposure Prophylaxis Use and Decreases in Condom Use: Behavioral Patterns Among HIV-Negative San Francisco Men Who have Sex with Men, 2004-2017. <i>AIDS and Behavior</i> , 2019, 23, 1841-1845.	1.4	39
2545	Promoting "Equitable Access"™ to PrEP in Australia: Taking Account of Stakeholder Perspectives. <i>AIDS and Behavior</i> , 2019, 23, 1846-1857.	1.4	17
2546	Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 2010-2017.	2.9	96
2547	Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048. <i>Clinical Infectious Diseases</i> , 2019, 68, 1129-1135.	2.9	14
2548	Representations of Pre-exposure Prophylaxis, Informal Antiretroviral Medication Use for HIV Prevention, and Diversion on Geosocial Networking Apps among Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2019, 23, 1790-1796.	1.4	13
2549	A New Era of HIV Risk: It's Not What You Know, It's Who You Know (and How Infectious). <i>Annual Review of Psychology</i> , 2019, 70, 673-701.	9.9	13
2550	Institutional distrust among gay, bisexual, and other men who have sex with men as a barrier to accessing pre-exposure prophylaxis (PrEP). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 364-369.	0.6	25
2551	Perceived Candidacy for Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex with Men in Paris, France. <i>AIDS and Behavior</i> , 2019, 23, 1771-1779.	1.4	9
2552	Factors Associated with Awareness of Pre-exposure Prophylaxis for HIV Among Persons Who Inject Drugs in Philadelphia: National HIV Behavioral Surveillance, 2015. <i>AIDS and Behavior</i> , 2019, 23, 1833-1840.	1.4	34
2553	Learning to address multiple syndemics for people living with HIV through client perspectives on CBT. <i>Psychotherapy Research</i> , 2019, 29, 492-502.	1.1	5
2554	Considerable interest in pre-exposure prophylaxis uptake among men who have sex with men recruited from a popular geosocial-networking smartphone application in London. <i>Global Public Health</i> , 2019, 14, 112-121.	1.0	11
2555	Transactional Sex and Preferences for Pre-Exposure Prophylaxis (PrEP) Administration Modalities Among Men Who Have Sex With Men (MSM). <i>Journal of Sex Research</i> , 2019, 56, 650-658.	1.6	9
2556	Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 138, 75-91.	2.0	36
2557	Capturing public interest toward new tools for controlling human immunodeficiency virus (HIV) infection exploiting data from Google Trends. <i>Health Informatics Journal</i> , 2019, 25, 1383-1397.	1.1	20
2558	Viewpoint: Why you should provide HIV pre-exposure prophylaxis (PrEP) at your college health center. <i>Journal of American College Health</i> , 2020, 68, 119-123.	0.8	1
2559	Assessing Mozambicans'™ willingness and determinants to use pre-exposure prophylactic HIV medication. <i>Journal of Health Psychology</i> , 2020, 25, 1954-1964.	1.3	5
2560	PrEP Awareness in the Context of HIV/AIDS Conspiracy Beliefs Among Black/African American and Hispanic/Latino MSM in Three Urban US Cities. <i>Journal of Homosexuality</i> , 2020, 67, 833-843.	1.3	26

#	ARTICLE	IF	CITATIONS
2561	Correlations Between Human Immunodeficiency Virus (HIV) Infection and Rectal Gonorrhea Incidence in Men Who Have Sex With Men: Implications for Future HIV Preexposure Prophylaxis Trials. <i>Journal of Infectious Diseases</i> , 2020, 221, 214-217.	1.9	25
2562	Novel Approaches for Development of Human Immunodeficiency Virus Preexposure Prophylaxis Agents. <i>Journal of Infectious Diseases</i> , 2020, 221, 172-174.	1.9	1
2563	Open pilot trial of a brief motivational interviewing-based HIV pre-exposure prophylaxis intervention for men who have sex with men: preliminary effects, and evidence of feasibility and acceptability. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 406-410.	0.6	13
2564	Facilitators and barriers affecting PrEP adherence among Thai men who have sex with men (MSM) in the HPTN 067/ADAPT Study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 249-254.	0.6	25
2565	Acceptability of pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) in Benin: a qualitative study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 242-248.	0.6	7
2566	Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077. <i>Clinical Infectious Diseases</i> , 2020, 70, 319-322.	2.9	31
2567	Experiences of Pre-Exposure Prophylaxis (PrEP)-Related Stigma among Black MSM PrEP Users in Los Angeles. <i>Journal of Urban Health</i> , 2020, 97, 679-691.	1.8	61
2568	Perceived barriers to pre-exposure prophylaxis use and the role of syndemic factors among female sex workers in the Mexico-United States border region: <i>a latent class analysis</i>. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 557-566.	0.6	17
2569	Next-Generation Preexposure Prophylaxis: Choices For Effective HIV Prevention. <i>Journal of Infectious Diseases</i> , 2020, 221, 1387-1389.	1.9	3
2570	A Serial, Cross-Sectional Comparison of Condomless Anal Sex and HIV Testing Among Young MSM in Beirut, Lebanon. <i>Archives of Sexual Behavior</i> , 2020, 49, 321-330.	1.2	3
2571	Misclassification of sexual health risks in a self-identified low risk cohort of men who have sex with men (MSM) enrolled in a community based PrEP program. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 230-237.	0.6	11
2572	Social Network Organization, Structure, and Patterns of Influence Within a Community of Transgender Women in Lima, Peru: Implications for Biomedical HIV Prevention. <i>AIDS and Behavior</i> , 2020, 24, 233-245.	1.4	19
2573	Pre-exposure Prophylaxis Persistence Is a Critical Issue in PrEP Implementation. <i>Clinical Infectious Diseases</i> , 2020, 71, 583-585.	2.9	29
2574	Predicting the impact of clustered risk and testing behaviour patterns on the population-level effectiveness of pre-exposure prophylaxis against HIV among gay, bisexual and other men who have sex with men in Greater Vancouver, Canada. <i>Epidemics</i> , 2020, 30, 100360.	1.5	1
2575	Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention - 2018 update. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 1-10.	1.5	16
2576	What do we say about condoms in 2019?. <i>Lancet HIV,the</i> , 2020, 7, e82-e83.	2.1	0
2577	Do Try To Use Condoms, But Knowledge and Interest in PrEP Among Male Sex Workers in Mexico City. <i>Archives of Sexual Behavior</i> , 2020, 49, 355-363.	1.2	13
2578	Knowledge and Acceptability of HIV pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) in Ghana. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 330-336.	0.6	33

#	ARTICLE	IF	CITATIONS
2579	Syndemics and the PrEP Cascade: Results from a Sample of Young Latino Men Who Have Sex with Men. Archives of Sexual Behavior, 2020, 49, 125-135.	1.2	42
2580	HIV Pre-exposure Prophylaxis for People Who Inject Drugs: The Context of Co-occurring Injection- and Sexual-Related HIV Risk in the U.S. Northeast. Substance Use and Misuse, 2020, 55, 525-533.	0.7	10
2581	Combined Sexual Behavioral Profiles in HIV-Seronegative Men Who have Sex with Men in West Africa (CohMSM ANRS 12324-Expertise France). Archives of Sexual Behavior, 2020, 49, 331-345.	1.2	9
2582	How Male Sex Workers and Their Clients Shifted from Reluctance About HIV Pre-exposure Prophylaxis to Advocating for Its Use: A Longitudinal Mixed Methods Study. AIDS and Behavior, 2020, 24, 782-790.	1.4	8
2583	Human Immunodeficiency Virus Infection. , 2020, , 232-266.		3
2584	Human Immunodeficiency Virus Pre-exposure Prophylaxis and Increased Incidence of Sexually Transmitted Infections in the United States. Clinical Infectious Diseases, 2020, 70, 1884-1890.	2.9	13
2585	Once-Weekly Oral Dosing of MK-8591 Protects Male Rhesus Macaques From Intrarectal Challenge With SHIV109CP3. Journal of Infectious Diseases, 2020, 221, 1398-1406.	1.9	31
2586	Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study). Clinical Infectious Diseases, 2020, 70, 2143-2151.	2.9	24
2587	Mieux comprendre les défis de la médicalisation de la prévention du VIH en France : la prophylaxie pré-exposition au prisme des sciences sociales. Global Health Promotion, 2020, 27, 149-153.	0.7	4
2588	Increasing PrEP uptake and adherence among MSM and TW sex workers in Lima, Peru: what and whom do different patients trust?. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 255-260.	0.6	11
2589	PrEP Use and Sexually Transmitted Infections Are Not Associated Longitudinally in a Cohort Study of Young Men Who Have Sex with Men and Transgender Women in Chicago. AIDS and Behavior, 2020, 24, 1334-1341.	1.4	10
2590	Predicted Effectiveness of Daily and Nondaily Preexposure Prophylaxis for Men Who Have Sex With Men Based on Sex and Pill-taking Patterns From the Human Immuno Virus Prevention Trials Network 067/ADAPT Study. Clinical Infectious Diseases, 2020, 71, 249-255.	2.9	7
2591	Some of us, we don't know where we're going to be tomorrow. Contextual factors affecting PrEP use and adherence among a diverse sample of transgender women in San Francisco. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 585-593.	0.6	19
2592	Understanding the impact of a syndemic on the use of pre-exposure prophylaxis in a community-based sample of behaviorally PrEP-eligible BSM in the United States. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 551-556.	0.6	12
2593	Using a student-led, community-specific training module to increase PrEP uptake amongst at-risk populations: results from an exploratory pilot implementation. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 546-550.	0.6	5
2594	No Evidence of Sexual Risk Compensation Following PrEP Initiation Among Heterosexual HIV Serodiscordant Couples in Kenya and Uganda. AIDS and Behavior, 2020, 24, 1365-1375.	1.4	11
2595	Prevention of HIV Transmission and the HPTN 052 Study. Annual Review of Medicine, 2020, 71, 347-360.	5.0	25
2596	Inhibitory Effects of Probenecid on Pharmacokinetics of Tenofovir Disoproxil Fumarate and Emtricitabine for On-Demand HIV Preexposure Prophylaxis. Clinical Pharmacology and Therapeutics, 2020, 107, 1200-1208.	2.3	3

#	ARTICLE	IF	CITATIONS
2597	The Equal Curriculum. , 2020, , .		4
2598	Roadblocks to PrEP: What Medical Records Reveal About Access to HIV Pre-exposure Prophylaxis. Journal of General Internal Medicine, 2020, 35, 832-838.	1.3	30
2599	Interindividual Differences in Treatment Effects Based on Structural Equation Models with Latent Variables: An EffectLiteR Tutorial. Structural Equation Modeling, 2020, 27, 798-816.	2.4	8
2600	Age at first HIV test for MSM at a community health clinic in Los Angeles. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 186-192.	0.6	0
2602	Meeting the Sexual Health Needs of Bisexual Men in the Age of Biomedical HIV Prevention: Gaps and Priorities. Archives of Sexual Behavior, 2020, 49, 217-232.	1.2	28
2603	Topical Microbicides in HIV Prevention: State of the Promise. Annual Review of Medicine, 2020, 71, 361-377.	5.0	30
2604	Defining Sexual Risk in the Era of Biomedical HIV Prevention: Implications for HIV Research and Practice. Archives of Sexual Behavior, 2020, 49, 91-102.	1.2	4
2605	Stimulant Use and Study Protocol Completion: Assessing the Ability of Men Who Have Sex with Men to Collect Dried Blood Spots for Laboratory Measurement of HIV Viral Load. Archives of Sexual Behavior, 2020, 49, 195-209.	1.2	4
2606	Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading?. Journal of the International AIDS Society, 2020, 23, e25426.	1.2	67
2607	Direct quantitation of tenofovir diphosphate in human blood with mass spectrometry for adherence monitoring. Analytical and Bioanalytical Chemistry, 2020, 412, 1243-1249.	1.9	17
2608	Barriers and Facilitators to PrEP Use Among People Who Inject Drugs in Rural Appalachia: A Qualitative Study. AIDS and Behavior, 2020, 24, 1942-1950.	1.4	47
2609	The Role of Social Support in HIV Testing and PrEP Awareness among Young Black Men and Transgender Women Who Have Sex with Men or Transgender Women. Journal of Urban Health, 2020, 97, 715-727.	1.8	29
2610	Responsibilization and Sexual Stigma Under Austerity: Surveying Public Support for Government-Funded PrEP in England. Sexuality Research and Social Policy, 2020, 17, 643-653.	1.4	2
2611	Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV. Lancet HIV, the, 2020, 7, e443-e448.	2.1	27
2612	Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. International Journal of Infectious Diseases, 2020, 92, 71-77.	1.5	43
2613	The HIV Pre-exposure Prophylaxis (PrEP) Cascade at NYC Sexual Health Clinics: Navigation Is the Key to Uptake. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 357-364.	0.9	40
2614	Identifying Missed Opportunities for Human Immunodeficiency Virus Pre-exposure Prophylaxis During Preventive Care and Reproductive Visits in Adolescents in the Deep South. Sexually Transmitted Diseases, 2020, 47, 88-95.	0.8	9
2615	Preexposure Prophylaxis for Human Immunodeficiency Virus Infection for Men Who Have Sex with Men and Transgender Persons:. Dermatologic Clinics, 2020, 38, 233-238.	1.0	0

#	ARTICLE	IF	CITATIONS
2616	Use of PrEP, sexual behaviors and mental health correlates in a sample of gay, bisexual and other men who have sex with men. <i>Journal of Gay and Lesbian Mental Health</i> , 2020, 24, 94-111.	0.8	7
2617	HIV Preexposure Prophylaxis—The Role of Primary Care Clinicians in Ending the HIV Epidemic. <i>JAMA Internal Medicine</i> , 2020, 180, 126.	2.6	11
2618	Implementation of pre-exposure prophylaxis at a community pharmacy through a collaborative practice agreement with San Francisco Department of Public Health. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 138-144.	0.7	42
2619	Factors Associated with General Sexual Functioning and Sexual Satisfaction among People Living with HIV: A Systematic Review. <i>Journal of Sex Research</i> , 2020, 57, 824-835.	1.6	14
2620	Implementation of a fidelity monitoring process to assess delivery of an evidence-based adherence counseling intervention in a multi-site biomedical HIV prevention study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 1082-1091.	0.6	6
2621	Area-level HIV risk and socioeconomic factors associated with willingness to use PrEP among Black people in the U.S. South. <i>Annals of Epidemiology</i> , 2020, 42, 33-41.	0.9	19
2622	Preferences for implementation of HIV pre-exposure prophylaxis (PrEP): Results from a survey of primary care providers. <i>Preventive Medicine Reports</i> , 2020, 17, 101012.	0.8	18
2623	Introduction. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 1-3.	1.5	0
2624	Validation and implementation of an ultrasensitive liquid chromatographic-tandem mass spectrometric (LC-MS/MS) assay for dapivirine quantitation in breast milk. <i>Clinical Biochemistry</i> , 2020, 82, 66-72.	0.8	0
2625	Escape expectancies and sexualized substance use among gay, bisexual, and other men who have sex with men. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 1489-1497.	0.6	8
2626	Predictors of Awareness, Accessibility and Acceptability of Pre-exposure Prophylaxis (PrEP) Among English- and Spanish-Speaking Latino Men Who have Sex with Men in Los Angeles, California. <i>Journal of Immigrant and Minority Health</i> , 2020, 22, 708-716.	0.8	18
2627	HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health. <i>Aids</i> , 2020, 34, 699-706.	1.0	12
2628	HIV treatment and prevention 2019. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 4-12.	1.5	52
2629	Could Intensive Screening for Gonorrhea/Chlamydia in Preexposure Prophylaxis Cohorts Select for Resistance? Historical Lessons From a Mass Treatment Campaign in Greenland. <i>Sexually Transmitted Diseases</i> , 2020, 47, 24-27.	0.8	13
2630	Biomedical HIV Protection Among Gay and Bisexual Men Who Use Crystal Methamphetamine. <i>AIDS and Behavior</i> , 2020, 24, 1400-1413.	1.4	25
2631	Relationship Characteristics Associated with Perceptions of Partners' HIV Testing Behavior Among Male Couples. <i>AIDS and Behavior</i> , 2020, 24, 516-531.	1.4	3
2632	Cost-Effectiveness of Pre-Exposure Prophylaxis Among Adolescent Sexual Minority Males. <i>Journal of Adolescent Health</i> , 2020, 66, 100-106.	1.2	16
2633	Developing a Typology of HIV/STI Testing Patterns Among Gay, Bisexual, and Queer Men: A Framework to Guide Interventions. <i>Qualitative Health Research</i> , 2020, 30, 610-621.	1.0	4

#	ARTICLE	IF	CITATIONS
2634	Tenofovir Urine Assay to Monitor Adherence to HIV Pre-exposure Prophylaxis. <i>Current Clinical Pharmacology</i> , 2020, 15, 102-104.	0.2	6
2635	On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. <i>Lancet HIV</i> , 2020, 7, e113-e120.	2.1	54
2636	Considerations and challenges in developing novel long-acting antiretrovirals modalities for treatment and prevention of HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 61-65.	1.5	6
2637	Long-acting injectable cabotegravir for the prevention of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 19-26.	1.5	71
2638	Topical delivery of long-acting antiretrovirals to prevent HIV acquisition. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 42-48.	1.5	12
2639	Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities. <i>Aids</i> , 2020, 34, 559-567.	1.0	3
2640	Eligibility for Pre-exposure Prophylaxis According to Different Guidelines in a Cohort of HIV-Negative Men Who Have Sex with Men in Lisbon, Portugal. <i>Sexuality Research and Social Policy</i> , 2020, 17, 688-699.	1.4	4
2641	PrEP Nonadherence, White Coat Dosing, and HIV Risk Among a Cohort of MSM. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa329.	0.4	3
2642	Acute Weight Gain After Switch to Emtricitabine/Tenofovir Alafenamide for Human Immunodeficiency Virus Pre-Exposure Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa454.	0.4	3
2643	Exploring nurse-led HIV Pre-Exposure Prophylaxis in a community health care clinic. <i>Public Health Nursing</i> , 2020, 37, 871-879.	0.7	5
2644	<i>In Vitro</i> Exposure of Leukocytes to HIV Preexposure Prophylaxis Decreases Mitochondrial Function and Alters Gene Expression Profiles. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	8
2645	Knowledge, Attitudes, and Intentions towards HIV Pre-Exposure Prophylaxis among Nursing Students in Spain. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 7151.	1.2	4
2646	PrEP4Love: The Role of Messaging and Prevention Advocacy in PrEP Attitudes, Perceptions, and Uptake Among YMSM and Transgender Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 450-456.	0.9	28
2647	Awareness and use of HIV pre-exposure prophylaxis among people who engage in sex work presenting to a sexually transmitted infection clinic. <i>International Journal of STD and AIDS</i> , 2020, 31, 1055-1062.	0.5	3
2648	Uptake, retention, and outcomes in a demonstration project of pre-exposure prophylaxis among female sex workers in public health centers in Senegal. <i>International Journal of STD and AIDS</i> , 2020, 31, 1063-1072.	0.5	26
2649	Brief Report: Associations Between Self-Reported Substance Use Behaviors and PrEP Acceptance and Adherence Among Black MSM in the HPTN 073 Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 23-29.	0.9	36
2650	PrEP is like an adult using floaties™: meanings and new identities of PrEP among a niche sample of gay men. <i>Culture, Health and Sexuality</i> , 2022, 24, 153-166.	1.0	10
2651	Learning from combination HIV prevention programmes to face COVID-19 emerging pandemic. <i>Colombia Medica</i> , 2020, 51, 1-13.	0.7	1

#	ARTICLE	IF	CITATIONS
2652	Adolescent girls and young women: Policy-to-implementation gaps for addressing sexual and reproductive health needs in South Africa. <i>South African Medical Journal</i> , 2020, 110, 855.	0.2	6
2653	Law Everywhere: A Causal Framework for Law and Infectious Disease. <i>Public Health Reports</i> , 2020, 135, 25S-31S.	1.3	5
2654	Small-area spatial-temporal changes in pre-exposure prophylaxis (PrEP) use in the general population and among men who have sex with men in the United States between 2012 and 2018. <i>Annals of Epidemiology</i> , 2020, 49, 1-7.	0.9	12
2655	Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis. <i>Journal of the International AIDS Society</i> , 2020, 23, e25624.	1.2	7
2656	Lamivudine/Tenofovir Disoproxil Fumarate is an Appropriate PrEP Regimen. <i>Drugs</i> , 2020, 80, 1881-1888.	4.9	5
2657	Nondaily Use of HIV Preexposure Prophylaxis in a Large Online Survey of Primarily Men Who Have Sex With Men in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 182-188.	0.9	11
2659	Pre-exposure prophylaxis during the SARS-CoV-2 pandemic: can PrEP prevent COVID-19-related symptoms?. <i>Epidemiology and Infection</i> , 2020, 148, e231.	1.0	9
2660	Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e485-e493.	2.9	55
2661	Improving the HIV PrEP continuum of care using an intervention for healthcare providers: a stepped-wedge study protocol. <i>BMJ Open</i> , 2020, 10, e040734.	0.8	18
2662	Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2020, 396, 239-254.	6.3	245
2663	Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 1087-1089.	13.9	30
2664	Trends in Human Immunodeficiency Virus and Sexually Transmitted Infection Testing Among Gay, Bisexual, and Other Men Who Have Sex With Men After Rapid Scale-up of Preexposure Prophylaxis in Victoria, Australia. <i>Sexually Transmitted Diseases</i> , 2020, 47, 516-524.	0.8	4
2665	Evaluating statewide HIV preexposure prophylaxis implementation using All-Payer Claims Data. <i>Annals of Epidemiology</i> , 2020, 44, 1-7.e2.	0.9	5
2666	Recent declines in HIV infections at Silom Community Clinic Bangkok, Thailand corresponding to HIV prevention scale up: An open cohort assessment 2005-2018. <i>International Journal of Infectious Diseases</i> , 2020, 99, 131-137.	1.5	10
2667	Elevated Perceived Risk for HIV as a Barrier to Accessing Health Care Among Black Men Who Have Sex with Men. <i>Prevention Science</i> , 2020, 21, 917-925.	1.5	1
2668	Point-of-care and Near Real-time Testing for Antiretroviral Adherence Monitoring to HIV Treatment and Prevention. <i>Current HIV/AIDS Reports</i> , 2020, 17, 487-498.	1.1	19
2669	Pre-exposure Prophylaxis Uptake Among Men Who Have Sex With Men Who Used nPEP: A Longitudinal Analysis of Attendees at a Large Sexual Health Clinic in Montréal (Canada). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 408-415.	0.9	9
2670	Adherence to recommendations for ART and targeted PrEP use among HIV serodiscordant couples in East Africa: the PrEP as a bridge to ART strategy. <i>BMC Public Health</i> , 2020, 20, 1621.	1.2	9

#	ARTICLE	IF	CITATIONS
2671	Design of a care pathway for pharmacy-based PrEP delivery in Kenya: results from a collaborative stakeholder consultation. <i>BMC Health Services Research</i> , 2020, 20, 1034.	0.9	31
2672	Alcohol consumption, substance use, and depression in relation to HIV Pre-Exposure Prophylaxis (PrEP) nonadherence among gay, bisexual, and other men-who-have-sex-with-men. <i>BMC Public Health</i> , 2020, 20, 1782.	1.2	33
2673	National Trends in Drug Payments for HIV Preexposure Prophylaxis in the United States, 2014 to 2018. <i>Annals of Internal Medicine</i> , 2020, 173, 799-805.	2.0	18
2674	Consensus statement on human immunodeficiency virus pre-exposure prophylaxis in China. <i>Chinese Medical Journal</i> , 2020, 133, 2840-2846.	0.9	8
2675	Inflammation, HIV, and Immune Quiescence: Leveraging on Immunomodulatory Products to Reduce HIV Susceptibility. <i>AIDS Research and Treatment</i> , 2020, 2020, 1-16.	0.3	3
2676	Attitudes about community pharmacy access to HIV prevention medications in California. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, e179-e183.	0.7	14
2677	Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2117-e2123.	2.9	33
2678	Sexual desire and pleasure in the context of the HIV pre-exposure prophylaxis (PrEP). <i>Sexualities</i> , 2020, 23, 1400-1416.	0.8	13
2679	DISCOVER: much accomplished, but not yet for all. <i>Lancet, The</i> , 2020, 396, 214-215.	6.3	6
2680	Trial designs for evaluating combination HIV prevention approaches. <i>HIV Research and Clinical Practice</i> , 2020, 21, 72-82.	1.1	2
2681	<p>Current Perspectives on the Impact of Pre-Exposure Prophylaxis Stigma Regarding Men Who Have Sex with Men in the United States</p>. <i>HIV/AIDS - Research and Palliative Care</i> , 2020, Volume 12, 187-192.	0.4	5
2682	Abrocitinib for atopic dermatitis: a step forward. <i>Lancet, The</i> , 2020, 396, 215-217.	6.3	10
2683	HIV Pre-Exposure Prophylaxis (PrEP) Counseling in Germany: Knowledge, Attitudes and Practice in Non-governmental and in Public HIV and STI Testing and Counseling Centers. <i>Frontiers in Public Health</i> , 2020, 8, 298.	1.3	5
2684	HIV risk, risk perception, and PrEP interest among adolescent girls and young women in Lilongwe, Malawi: operationalizing the PrEP cascade. <i>Journal of the International AIDS Society</i> , 2020, 23, e25502.	1.2	31
2685	HIV Testing and PrEP Use in a National Probability Sample of Sexually Active Transgender People in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 437-442.	0.9	46
2686	Trauma-informed Human Immunodeficiency Virus Prevention for Black Men Who Have Sex With Men: A Critical Need. <i>Sexually Transmitted Diseases</i> , 2020, 47, 447-449.	0.8	0
2687	Simulating the End of AIDS in New York: Using Participatory Dynamic Modeling to Improve Implementation of the Ending the Epidemic Initiative. <i>Public Health Reports</i> , 2020, 135, 158S-171S.	1.3	5
2688	Sexual Subcultures and HIV Prevention Methods: An Assessment of Condom Use, PrEP, and TasP Among Gay, Bisexual, and Other Men Who Have Sex with Men Using a Social and Sexual Networking Smartphone Application. <i>Archives of Sexual Behavior</i> , 2021, 50, 1781-1792.	1.2	5

#	ARTICLE	IF	CITATIONS
2689	Growth in Proportion and Disparities of HIV PrEP Use Among Key Populations Identified in the United States National Goals: Systematic Review and Meta-analysis of Published Surveys. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 84, 379-386.	0.9	33
2690	Highly synergistic drug combination prevents vaginal HIV infection in humanized mice. <i>Scientific Reports</i> , 2020, 10, 12995.	1.6	3
2691	Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs. <i>Journal of Substance Abuse Treatment</i> , 2020, 117, 108058.	1.5	24
2692	Pathopolitics: Pathologies and Biopolitics of PrEP. <i>Frontiers in Sociology</i> , 2020, 5, 53.	1.0	5
2693	Real-time monitoring and just-in-time intervention for adherence to pre-exposure prophylaxis among men who have sex with men in China: a multicentre RCT study protocol. <i>BMC Public Health</i> , 2020, 20, 1160.	1.2	8
2694	Understanding HIV Sexual Protection and Its Association With Substance Use During Sex Among MSM in an Era of Multiple Primary Prevention Products. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 85, e67-e67.	0.9	5
2695	Model-Based Predictions of HIV Incidence Among African Women Using HIV Risk Behaviors and Community-Level Data on Male HIV Prevalence and Viral Suppression. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 85, 423-429.	0.9	7
2696	Designing HIV Vaccine Efficacy Trials in the Context of Highly Effective Non-vaccine Prevention Modalities. <i>Statistics in Biosciences</i> , 2020, 12, 468-494.	0.6	5
2697	HIV Pre-Exposure Prophylaxis Prevention Awareness, Willingness, and Perceived Barriers among People Who Inject Drugs in Los Angeles and San Francisco, CA, 2016-2018. <i>Substance Use and Misuse</i> , 2020, 55, 2409-2419.	0.7	24
2698	Sustained, Low Prevalence of Undiagnosed HIV Among Gay and Bisexual Men in Sydney, Australia Coincident With Increased Testing and Pre-exposure Prophylaxis Use: Results From Repeated, Bio-Behavioral Studies 2014-2018. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 85, e41-e47.	0.9	0
2699	Perceptions of black men who have sex with men about accessing and taking PrEP: A qualitative study. <i>Journal of HIV/AIDS and Social Services</i> , 2020, 19, 263-282.	0.7	3
2700	The paradox of HIV prevention: did biomedical prevention trials show how effective behavioral prevention can be?. <i>Aids</i> , 2020, 34, 2007-2011.	1.0	4
2701	A Bayesian averted infection framework for PrEP trials with low numbers of HIV infections: application to the results of the DISCOVER trial. <i>Lancet HIV</i> , 2020, 7, e791-e796.	2.1	13
2702	Delivering PrEP to adults with low or no HIV risk and youth: experiences and perspectives of PrEP providers. <i>Culture, Health and Sexuality</i> , 2022, 24, 95-108.	1.0	6
2703	Outcomes of a PrEP Demonstration Project with LGBTQ Youth in a Community-Based Clinic Setting with Integrated Gender-Affirming Care. <i>Transgender Health</i> , 2020, 5, 75-79.	1.2	8
2704	Brief Report: Discrepancies Between Self-Reported Adherence and a Biomarker of Adherence in Real-World Settings. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 85, 454-457.	0.9	17
2705	Meta-synthesis of Qualitative Research of Pre-exposure Prophylaxis (PrEP) Adherence Among Men Who Have Sex With Men (MSM). <i>AIDS Education and Prevention</i> , 2020, 32, 416-431.	0.6	13
2706	Acceptability of pre-exposure prophylaxis for HIV prevention: facilitators, barriers and impact on sexual risk behaviors among men who have sex with men in Benin. <i>BMC Public Health</i> , 2020, 20, 1267.	1.2	18

#	ARTICLE	IF	CITATIONS
2707	Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases consensus panel. <i>Aids</i> , 2020, 34, 1699-1711.	1.0	21
2708	Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development. <i>Nature Communications</i> , 2020, 11, 4737.	5.8	31
2709	Perspectives on Social Support and Stigma in PrEP-related Care among Gay and Bisexual Men: A Qualitative Investigation. <i>Journal of Homosexuality</i> , 2022, 69, 254-276.	1.3	10
2710	A stepped-wedge randomized trial and qualitative survey of HIV pre-exposure prophylaxis uptake in the Eswatini population. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	11
2711	Combating HIV stigma in low- and middle-income healthcare settings: a scoping review. <i>Journal of the International AIDS Society</i> , 2020, 23, e25553.	1.2	33
2712	Feasibility of Short-Term PrEP Uptake for Men Who Have Sex With Men With Episodic Periods of Increased HIV Risk. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 508-513.	0.9	6
2713	A Review of HIV Pre-exposure Prophylaxis Streamlining Strategies. <i>Current HIV/AIDS Reports</i> , 2020, 17, 643-653.	1.1	35
2714	Pharmacokinetic and Pharmacodynamic Impacts of Depot Medroxyprogesterone Acetate Use on HIV Pre-exposure Prophylaxis in Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 182-188.	0.9	3
2715	Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study. <i>Scientific Reports</i> , 2020, 10, 14609.	1.6	10
2716	The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa. <i>Aids</i> , 2020, 34, 883-891.	1.0	18
2717	Factors Associated with Being PrEP-Naïve Among a U.S. National Cohort of Former-PrEP and PrEP-Naïve Participants Meeting Objective Criteria for PrEP Care. <i>Archives of Sexual Behavior</i> , 2021, 50, 1793-1803.	1.2	7
2718	Uptake and retention on HIV pre-exposure prophylaxis among key and priority populations in South-Central Uganda. <i>Journal of the International AIDS Society</i> , 2020, 23, e25588.	1.2	32
2719	Assessing the performance of international pre-exposure prophylaxis (PrEP) eligibility guidelines in a cohort of Chinese MSM, Beijing, China 2009 to 2016. <i>Journal of the International AIDS Society</i> , 2020, 23, e25653.	1.2	7
2720	Evaluating family physicians'™ willingness to prescribe PrEP. <i>Médecine Et Maladies Infectieuses</i> , 2020, 50, 606-610.	5.1	4
2721	Knowledge needs for implementing HIV pre-exposure prophylaxis among primary care providers in a safety-net health system. <i>Preventive Medicine Reports</i> , 2020, 20, 101266.	0.8	10
2722	Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial. <i>Journal of the International AIDS Society</i> , 2020, 23, e25634.	1.2	49
2723	Utilizing emergency departments for pre-exposure prophylaxis (PrEP). <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 1427-1435.	0.4	10
2724	Transactional Sex Is Associated with Income Level and Psychosocial Health Problems among Gay and Bisexual Men (GBM) in Nigeria, Africa. <i>Journal of Sex Research</i> , 2020, 58, 1-7.	1.6	2

#	ARTICLE	IF	CITATIONS
2725	Patterns of PrEP Retention Among HIV Pre-exposure Prophylaxis Users in Baltimore City, Maryland. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 85, 593-600.	0.9	13
2726	Experiencing Intimate Partner Violence (IPV) Is Associated with Psychosocial Health Problems Among Gay, Bisexual, and Other Men Who Have Sex with Men (GBMSM) in Nigeria, Africa. <i>Journal of Interpersonal Violence</i> , 2022, 37, NP7394-NP7425.	1.3	11
2727	Understanding the role of nurse practitioners, physician assistants and other nursing staff in HIV pre-exposure prophylaxis care in the United States: a systematic review and meta-analysis. <i>BMC Nursing</i> , 2020, 19, 117.	0.9	11
2729	Risk factors for loss to follow-up among at-risk HIV negative men who have sex with men participating in a research cohort with access to pre-exposure prophylaxis in coastal Kenya. <i>Journal of the International AIDS Society</i> , 2020, 23, e25593.	1.2	15
2730	Regional Disparities in Qualified Health Plans'™ Prior Authorization Requirements for HIV Pre-exposure Prophylaxis in the United States. <i>JAMA Network Open</i> , 2020, 3, e207445.	2.8	10
2731	Sexual health needs of female sex workers in CÔte d'Ivoire: a mixed-methods study to prepare the future implementation of pre-exposure prophylaxis (PrEP) for HIV prevention. <i>BMJ Open</i> , 2020, 10, e028508.	0.8	17
2732	Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	9
2733	â€œI'm doing this test so I can benefit from PrEPâ€ exploring HIV testing barriers/facilitators and implementation of pre-exposure prophylaxis among South African adolescents. <i>African Journal of AIDS Research</i> , 2020, 19, 101-108.	0.3	5
2734	Influence of hair treatments on detection of antiretrovirals by mass spectrometry imaging. <i>Analyst</i> , 2020, 145, 4540-4550.	1.7	6
2735	Correlation of pre-exposure prophylaxis adherence to a mental health diagnosis or experience of childhood trauma in high-risk youth. <i>International Journal of STD and AIDS</i> , 2020, 31, 440-446.	0.5	8
2736	â€œA Good Habitâ€ Telehealth PrEP Users Find Benefit in Quarterly Monitoring Requirements. <i>Journal of the International Association of Providers of AIDS Care</i> , 2020, 19, 232595822091926.	0.6	12
2737	Estimated Number of Men Who Have Sex With Men With Indications for HIV Pre-exposure Prophylaxis in a National Sexual Network Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 84, 10-17.	0.9	12
2738	Characteristics of gay and bisexual men who rarely use HIV risk reduction strategies during condomless anal intercourse: Results from the FLUX national online cohort study. <i>PLoS ONE</i> , 2020, 15, e0233922.	1.1	7
2739	PrEP rollout in Africa: status and opportunity. <i>Nature Medicine</i> , 2020, 26, 655-664.	15.2	71
2740	Social-Environmental Resilience, PrEP Uptake, and Viral Suppression among Young Black Men Who Have Sex with Men and Young Black Transgender Women: the Neighborhoods and Networks (N2) Study in Chicago. <i>Journal of Urban Health</i> , 2020, 97, 728-738.	1.8	26
2741	On assessing control actions for epidemic models on temporal networks. , 2020, , 1-1.		13
2742	Estimating the impact of HIV combination prevention in men who have sex with men, the Bangkok MSM Cohort Study, Thailand. <i>International Journal of STD and AIDS</i> , 2020, 31, 637-641.	0.5	1
2743	Lost in translation: College students'™ knowledge of HIV and PrEP in relation to their sexual health behaviors. <i>Journal of American College Health</i> , 2022, 70, 561-567.	0.8	5

#	ARTICLE	IF	CITATIONS
2744	HIV Antiretroviral Treatment and Pre-exposure Prophylaxis in Transgender Individuals. <i>Drugs</i> , 2020, 80, 965-972.	4.9	15
2745	Impact of PrEP on a STI clinic in a Belgian context: a provider's perspective. <i>Acta Clinica Belgica</i> , 2020, 76, 1-5.	0.5	0
2746	Cost-Effectiveness of HIV Pre-exposure Prophylaxis Among Heterosexual Men in South Africa: A Cost-Utility Modeling Analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 173-181.	0.9	18
2747	Attitude of infectious diseases physicians in Turkey about HIV pre-exposure prophylaxis: results of an online survey. <i>International Journal of STD and AIDS</i> , 2020, 31, 665-670.	0.5	3
2748	Quarterly screening optimizes detection of sexually transmitted infections when prescribing HIV pre-exposure prophylaxis. <i>Aids</i> , 2020, 34, 1181-1186.	1.0	16
2749	A novel method to estimate the indirect community benefit of HIV interventions using a microsimulation model of HIV disease. <i>Journal of Biomedical Informatics</i> , 2020, 107, 103475.	2.5	5
2750	Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 323-330.	0.9	26
2751	Standardised patient encounters to improve quality of counselling for pre-exposure prophylaxis (PrEP) in adolescent girls and young women (AGYW) in Kenya: study protocol of a cluster randomised controlled trial. <i>BMJ Open</i> , 2020, 10, e035689.	0.8	11
2752	Pre-exposure prophylaxis for HIV: A powerful preventive tool still underused. <i>Medicina Clínica (English Edition)</i> , 2020, 154, 348-350.	0.1	0
2753	Interest in Taking HIV Pre-exposure Prophylaxis Is Associated with Behavioral Risk Indicators and Self-Perceived HIV Risk Among Men Who Have Sex with Men Attending HIV Testing Venues in Sweden. <i>Archives of Sexual Behavior</i> , 2020, 49, 2165-2177.	1.2	8
2754	Update on HIV prevention and preexposure prophylaxis. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2020, 33, 12-17.	0.1	1
2755	Perspectives on HIV PrEP care in Germany: qualitative insights from primary care physicians and specialists. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 994-1000.	0.6	5
2756	Unlocking HIV Pre-Exposure Prophylaxis Delivery: Examining the Role of HIV Providers in Pre-Exposure Prophylaxis Care. <i>AIDS Patient Care and STDs</i> , 2020, 34, 251-258.	1.1	4
2757	Considerations for Research on Sexually Transmitted Infections (STIs): Reflections of an STI Clinician-Researcher. <i>Archives of Sexual Behavior</i> , 2020, 49, 1863-1873.	1.2	0
2758	Health Care-Seeking Behaviors and Perceptions of Provider-Initiated Discussion of Pre-exposure Prophylaxis Among PrEP-Naïve HIV-Negative Men Who Have Sex With Men in Atlanta, Georgia. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa165.	0.4	3
2759	Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 1227-1238.	2.4	30
2760	Community pharmacy delivered PrEP to STOP HIV transmission: An opportunity NOT to miss!. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, e18-e24.	0.7	13
2761	Validation of the HIV Pre-exposure Prophylaxis Stigma Scale: Performance of Likert and Semantic Differential Scale Versions. <i>AIDS and Behavior</i> , 2020, 24, 2637-2649.	1.4	36

#	ARTICLE	IF	CITATIONS
2762	â€”â€™m waiting for thatâ€™: Interest in the use of PrEP for safer conception in Botswana. <i>Global Public Health</i> , 2020, 15, 1200-1211.	1.0	4
2765	Are PrEP services in France reaching all those exposed to HIV who want to take PrEP? MSM respondents who are eligible but not using PrEP (EMIS 2017). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 47-56.	0.6	32
2766	Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide. <i>Frontiers in Pharmacology</i> , 2020, 11, 286.	1.6	8
2767	The influence of HIVâ€™related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. <i>Journal of the International AIDS Society</i> , 2020, 23, e25463.	1.2	115
2768	Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077. <i>AIDS and Behavior</i> , 2020, 24, 2520-2531.	1.4	41
2770	Increase in the overall level of protected anal sex in men who have sex with men in France: results from the repeated cross-sectional survey Rapport au Sexe, France, 2017â€™2019. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 162-169.	0.6	9
2771	Administrative and Related Barriers to Covering the Costs of Preexposure Prophylaxis at a Safety-net Clinic in Seattle, Washington. <i>Clinical Infectious Diseases</i> , 2020, 71, 2509-2512.	2.9	5
2772	Tenofovir alafenamide use in pregnant and lactating women living with HIV. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 333-342.	1.5	28
2773	Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel. <i>BMC Public Health</i> , 2020, 20, 271.	1.2	9
2774	Outâ€™ofâ€™pocket costs and HIV preâ€™exposure prophylaxis persistence in a US multicity demonstration project. <i>Health Services Research</i> , 2020, 55, 524-530.	1.0	10
2775	Exploring the Pre-exposure Prophylaxis (PrEP) Health Care Experiences Among Men Who Have Sex With Men (MSM) Who Live in Rural Areas of the Midwest. <i>AIDS Education and Prevention</i> , 2020, 32, 51-66.	0.6	28
2776	Social network intervention to increase pre-exposure prophylaxis (PrEP) awareness, interest, and use among African American men who have sex with men. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 40-46.	0.6	36
2777	Pre-exposure Prophylaxis Awareness and Use Among Cisgender Men Who Have Sex With Men and Use Methamphetamine in 3 Western US Cities. <i>Sexually Transmitted Diseases</i> , 2020, 47, 217-223.	0.8	5
2778	PrEP Interest Among Men Who Have Sex with Men in the Netherlands: Covariates and Differences Across Samples. <i>Archives of Sexual Behavior</i> , 2020, 49, 2155-2164.	1.2	10
2779	<i>Homo adhaerens</i>: Risk and adherence in biomedical HIV prevention research. <i>Social Studies of Science</i> , 2020, 50, 860-880.	1.5	1
2780	Clinical targeting of HIV capsid protein with a long-acting small molecule. <i>Nature</i> , 2020, 584, 614-618.	13.7	192
2781	Pre-exposure prophylaxis among men who have sex with men in CÃ”te dâ€™Ivoire: a quantitative study of acceptability. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 1228-1236.	0.6	8
2782	Provider-Patient Communication on Pre-Exposure Prophylaxis (Prep) for HIV Prevention: An Exploration of Healthcare Provider Challenges. <i>Health Communication</i> , 2021, 36, 1677-1686.	1.8	28

#	ARTICLE	IF	CITATIONS
2783	A review of HIV pre-exposure prophylaxis (PrEP) programmes by delivery models in the Asia-Pacific through the healthcare accessibility framework. <i>Journal of the International AIDS Society</i> , 2020, 23, e25531.	1.2	12
2784	Implementing PrEP in the pharmacy. <i>Pharmacy Today</i> , 2020, 26, 39-53.	0.0	3
2785	Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies. <i>Nature Communications</i> , 2020, 11, 3195.	5.8	15
2786	Masculine ideology and Black men who have sex with men's interest in HIV pre-exposure prophylaxis (PrEP). <i>Journal of Health Psychology</i> , 2021, 26, 2908-2920.	1.3	7
2787	Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications. <i>International Journal of Pharmaceutics</i> , 2020, 587, 119623.	2.6	10
2788	Effects of Internalized Homonegativity and Face Visibility on HIV-Risk-Taking Behaviour in Gay Men Who Had Casual Sex Using Online-Dating Applications. <i>International Journal of Sexual Health</i> , 2020, 32, 165-170.	1.2	6
2789	Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. <i>Lancet HIV</i> , 2020, 7, e472-e481.	2.1	97
2790	Factors Associated With Weight Gain in People Treated With Dolutegravir. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa195.	0.4	47
2791	Sexually transmitted infections and sexual behaviors of men who have sex with men in an American Deep South PrEP clinic. <i>International Journal of STD and AIDS</i> , 2020, 31, 127-135.	0.5	7
2792	A new grounded theory model of sexual adjustment to HIV: facilitators of sexual adjustment and recommendations for clinical practice. <i>BMC Infectious Diseases</i> , 2020, 20, 31.	1.3	6
2793	Real-World Eligibility for HIV Pre-exposure Prophylaxis Among People Who Inject Drugs. <i>AIDS and Behavior</i> , 2020, 24, 2400-2408.	1.4	3
2794	Disclosure of HIV Status and HIV Sexual Transmission Behaviors among HIV-Positive Black Men Who Have Sex with Men in the BROTHERS (HPTN 061) Study. <i>Journal of Urban Health</i> , 2020, 97, 692-703.	1.8	6
2795	STI in times of PrEP: high prevalence of chlamydia, gonorrhoea, and mycoplasma at different anatomic sites in men who have sex with men in Germany. <i>BMC Infectious Diseases</i> , 2020, 20, 110.	1.3	108
2796	Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate + emtricitabine for HIV pre-exposure prophylaxis. <i>Journal of the International AIDS Society</i> , 2020, 23, e25420.	1.2	13
2797	Has Pre-exposure Prophylaxis Made a Difference at a Population Level? Jury Is Still Out. <i>Clinical Infectious Diseases</i> , 2020, 71, 3152-3153.	2.9	8
2798	Human papillomavirus vaccination and sexual practices among men who have sex with men in Melbourne, Australia: a cross-sectional study. <i>International Journal of STD and AIDS</i> , 2020, 31, 312-317.	0.5	4
2799	The role of syringe exchange programs and sexual identity in awareness of pre-exposure prophylaxis (PrEP) for male persons who inject drugs. <i>International Journal of Drug Policy</i> , 2020, 77, 102671.	1.6	27
2800	Understanding PrEP Persistence: Provider and Patient Perspectives. <i>AIDS and Behavior</i> , 2020, 24, 2509-2519.	1.4	48

#	ARTICLE	IF	CITATIONS
2801	HIV infection risk and condom use among sex workers in Senegal: evidence from the list experiment method. <i>Health Policy and Planning</i> , 2020, 35, 408-415.	1.0	9
2802	Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1242-1249.	1.3	17
2803	Modeling HIV Pre-Exposure Prophylaxis. <i>Frontiers in Pharmacology</i> , 2020, 10, 1514.	1.6	6
2804	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. <i>PLoS Computational Biology</i> , 2020, 16, e1007626.	1.5	20
2805	Student Education About Pre-exposure Prophylaxis (PrEP) Varies Between Regions of the United States. <i>Journal of General Internal Medicine</i> , 2020, 35, 2873-2881.	1.3	15
2806	Health Care Provider Barriers to HIV Pre-Exposure Prophylaxis in the United States: A Systematic Review. <i>AIDS Patient Care and STDs</i> , 2020, 34, 111-123.	1.1	127
2807	Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries. <i>Journal of the International AIDS Society</i> , 2020, 23, e25451.	1.2	20
2808	Lessons on PrEP from the SEARCH study in east Africa. <i>Lancet HIV</i> , 2020, 7, e219-e220.	2.1	7
2809	Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictions. <i>Annals of Epidemiology</i> , 2020, 44, 16-30.	0.9	28
2810	Human immunodeficiency virus prevention strategies in China. <i>Chinese Medical Journal</i> , 2020, 133, 318-325.	0.9	8
2811	Prevalence and correlates of anal intercourse among female sex workers in eSwatini. <i>PLoS ONE</i> , 2020, 15, e0228849.	1.1	4
2812	Interprofessional Collaboration Improves the Odds of Educating Patients About PrEP over Time. <i>Journal of General Internal Medicine</i> , 2020, 35, 1444-1451.	1.3	6
2813	Key barriers and enablers associated with uptake and continuation of oral pre-exposure prophylaxis (PrEP) in the public sector in Zimbabwe: Qualitative perspectives of general population clients at high risk for HIV. <i>PLoS ONE</i> , 2020, 15, e0227632.	1.1	55
2814	On-Demand Oral Pre-exposure Prophylaxis with Tenofovir/Emtricitabine: What Every Clinician Needs to Know. <i>Journal of General Internal Medicine</i> , 2020, 35, 1285-1288.	1.3	15
2815	A Thematic Analysis of Pre-Exposure Prophylaxis (PrEP) YouTube Videos. <i>Journal of Homosexuality</i> , 2021, 68, 1877-1898.	1.3	12
2816	Community perspectives on barriers and challenges to HIV pre-exposure prophylaxis access by men who have sex with men and female sex workers access in Nigeria. <i>BMC Public Health</i> , 2020, 20, 69.	1.2	50
2817	Acceptability of HIV Pre-Exposure Prophylaxis Among Transgender Women in India: A Qualitative Investigation. <i>AIDS Patient Care and STDs</i> , 2020, 34, 92-98.	1.1	28
2818	Feasibility and Acceptability of an mHealth-Based Approach as an HIV Prevention Strategy Among People Who Use Drugs on Pre-Exposure Prophylaxis. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 107-118.	0.8	12

#	ARTICLE	IF	CITATIONS
2819	A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	49
2820	The Effect of Depression on Adherence to HIV Pre-exposure Prophylaxis Among High-Risk South African Women in HPTN 067/ADAPT. <i>AIDS and Behavior</i> , 2020, 24, 2178-2187.	1.4	13
2821	Interference with HIV infection of the first cell is essential for viral clearance at sub-optimal levels of drug inhibition. <i>PLoS Computational Biology</i> , 2020, 16, e1007482.	1.5	5
2822	Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY Trial. <i>AIDS and Behavior</i> , 2020, 24, 3244-3251.	1.4	6
2823	Age-Period-Cohort Analysis of HIV Mortality in China: Data from the Global Burden of Disease Study 2016. <i>Scientific Reports</i> , 2020, 10, 7065.	1.6	11
2824	Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. <i>Annual Review of Immunology</i> , 2020, 38, 673-703.	9.5	74
2825	Greater Levels of Self-Reported Adherence to Pre-Exposure Prophylaxis (PrEP) are Associated with Increased Condomless Sex Among Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2020, 24, 3192-3204.	1.4	7
2826	Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate. <i>Pharmaceutical Research</i> , 2020, 37, 83.	1.7	30
2827	Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex with Men (MSM): A Scoping Review on PrEP Service Delivery and Programming. <i>AIDS and Behavior</i> , 2020, 24, 3056-3070.	1.4	50
2828	Responding to Pandemics: What Weâ€™ve Learned from HIV/AIDS. <i>AIDS and Behavior</i> , 2020, 24, 1980-1982.	1.4	20
2829	Facilitators and Barriers of Pre-exposure Prophylaxis (PrEP) Uptake Among Rural Men who have Sex with Men Living in the Midwestern U.S.. <i>Archives of Sexual Behavior</i> , 2020, 49, 2179-2191.	1.2	38
2830	An Exploration of Pre-exposure Prophylaxis (PrEP) Initiation Among Women Who Inject Drugs. <i>Archives of Sexual Behavior</i> , 2020, 49, 2205-2212.	1.2	20
2831	PrEP in Student Health Servicesâ€™a Call to Action. <i>Journal of General Internal Medicine</i> , 2020, 35, 3689-3690.	1.3	2
2832	Racialized Sexual Risk Perceptions of Pre-exposure Prophylaxis in Men Who have Sex with Men. <i>Sexuality and Culture</i> , 2020, 24, 1738-1755.	1.1	1
2833	Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review. <i>Advances in Therapy</i> , 2020, 37, 1778-1811.	1.3	187
2834	PrEP for HIV Prevention: Evidence, Global Scale-up, and Emerging Options. <i>Cell Host and Microbe</i> , 2020, 27, 502-506.	5.1	30
2835	Thematic synthesis HIV prevention qualitative studies in men who have sex with men (MSM). <i>Colombia Medica</i> , 2020, 50, 201-2014.	0.7	3
2836	How can we improve uptake of oral HIV pre-exposure prophylaxis for transgender individuals?. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 835-838.	2.0	5

#	ARTICLE	IF	CITATIONS
2837	Uptake and willingness to use PrEP among Chinese gay, bisexual and other men who have sex with men with experience of sexualized drug use in the past year. <i>BMC Infectious Diseases</i> , 2020, 20, 299.	1.3	27
2838	Male partners' influence on women's acceptance and use of PrEP products across two high HIV-burdened districts in South Africa. <i>African Journal of AIDS Research</i> , 2020, 19, 93-100.	0.3	5
2839	Knowledge and practices of Parisian family physicians for the management of men who have sex with men in the era of HIV pre-exposure prophylaxis. <i>Médecine Et Maladies Infectieuses</i> , 2020, 50, 597-605.	5.1	3
2840	Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	6
2841	Changes in Sexual Behaviors in Men Who Have Sex with Men: A Comparison Between the Double-Blind and Open-Label Extension Phases of the ANRS-IPERGAY Trial. <i>AIDS and Behavior</i> , 2020, 24, 3093-3106.	1.4	7
2842	HIV Post-Exposure Prophylaxis (PEP) Awareness and Non-Occupational PEP (nPEP) Prescribing History Among U.S. Healthcare Providers. <i>AIDS and Behavior</i> , 2020, 24, 3124-3131.	1.4	11
2843	Implementation of HIV Preexposure Prophylaxis in a Homeless Primary Care Setting at the Veterans Affairs. <i>Journal of Primary Care and Community Health</i> , 2020, 11, 215013272090837.	1.0	10
2844	Ethical issues in cluster randomized trials conducted in low- and middle-income countries: an analysis of two case studies. <i>Trials</i> , 2020, 21, 314.	0.7	9
2845	Acceptability of electronic healthcare predictive analytics for HIV prevention: a qualitative study with men who have sex with men in New York City. <i>MHealth</i> , 2020, 6, 11-11.	0.9	4
2846	Traditional Machismo, Caballerismo, and the Pre-Exposure Prophylaxis (PrEP) Cascade Among a Sample of Latino Sexual Minority Men. <i>Journal of Sex Research</i> , 2021, 58, 21-28.	1.6	15
2847	"Now that PrEP is reducing the risk of transmission of HIV, why then do you still insist that we use condoms?" the condom quandary among PrEP users and health care providers in Kenya. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 92-100.	0.6	12
2848	Perspectives on and Preferences for On-Demand and Long-Acting PrEP Among Sexual and Gender Minority Adolescents Assigned Male at Birth. <i>Sexuality Research and Social Policy</i> , 2021, 18, 39-53.	1.4	29
2849	Earlier treatment initiation is associated with a decreased number of HIV-1 subtype A1 transmissions in Greece. <i>Sexually Transmitted Infections</i> , 2021, 97, 232-237.	0.8	2
2850	Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015-2018). <i>Canadian Journal of Public Health</i> , 2021, 112, 89-96.	1.1	11
2851	Experienced barriers to adherence to pre-exposure prophylaxis for HIV prevention among MSM: a systematic review and meta-ethnography of qualitative studies. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 697-705.	0.6	45
2852	Needed: A Life Course Perspective on Maintaining Pre-exposure Prophylaxis Use. <i>Clinical Infectious Diseases</i> , 2021, 72, 386-387.	2.9	3
2853	Factors Associated with Preferred Pre-Exposure Prophylaxis Dosing Regimen Among Men Who Have Sex with Men in Real-World Settings: A Mixed-Effect Model Analysis. <i>AIDS and Behavior</i> , 2021, 25, 249-258.	1.4	9
2854	A review of reported cases of HIV pre-exposure prophylaxis failure with resultant breakthrough HIV infections. <i>HIV Medicine</i> , 2021, 22, 75-82.	1.0	13

#	ARTICLE	IF	CITATIONS
2855	Number, type and cost of microbiological tests during HIV Pre-Exposure Prophylaxis: The experience of a French hospital. <i>Infectious Diseases Now</i> , 2021, 51, 357-361.	0.7	1
2856	Where are we with pre-exposure prophylaxis use in Central and Eastern Europe? Data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group. <i>HIV Medicine</i> , 2021, 22, 67-72.	1.0	8
2857	Community-Based Participatory Approaches to Knowledge Translation: HIV Prevention Case Study of the Investigaytors Program. <i>Archives of Sexual Behavior</i> , 2021, 50, 105-117.	1.2	5
2858	A Pilot Study to Evaluate a Novel Pre-exposure Prophylaxis Peer Outreach and Navigation Intervention for Women at High Risk for HIV Infection. <i>AIDS and Behavior</i> , 2021, 25, 1411-1422.	1.4	29
2859	Pre-exposure prophylaxis for HIV infection and new sexually transmitted infections among men who have sex with men: real-life experience from three sexual health clinics in France. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e94-e96.	1.3	0
2860	Factors associated with awareness and use of pre-exposure prophylaxis (PrEP) among Black men who have sex with men with a recent STI diagnosis. <i>Behavioral Medicine</i> , 2021, 47, 161-169.	1.0	4
2861	CDC's Community-Based Organization Behavioral Outcomes Project: Perspectives for Researchers, Implementers and Funders. <i>AIDS and Behavior</i> , 2021, 25, 284-293.	1.4	5
2862	Betamethasone induces potent immunosuppression and reduces HIV infection in a PBMC in vitro model. <i>Journal of Investigative Medicine</i> , 2021, 69, 28-40.	0.7	4
2863	Risk compensation in HIV PrEP adherence among Black men who have sex with men in HPTN 073 study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 633-638.	0.6	7
2864	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2021, 72, e835-e843.	2.9	103
2865	DOT Diary: Developing a Novel Mobile App Using Artificial Intelligence and an Electronic Sexual Diary to Measure and Support PrEP Adherence Among Young Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2021, 25, 1001-1012.	1.4	29
2866	Design and Delivery of Real-Time Adherence Data to Men Who Have Sex with Men Using Antiretroviral Pre-exposure Prophylaxis via an Ingestible Electronic Sensor. <i>AIDS and Behavior</i> , 2021, 25, 1661-1674.	1.4	16
2867	Low awareness of and willingness to use PrEP in the Chinese YMSM: An alert in YMSM HIV prevention. <i>HIV Medicine</i> , 2021, 22, 185-193.	1.0	12
2868	Addressing Unhealthy Alcohol Use and the HIV Pre-exposure Prophylaxis Care Continuum in Primary Care: A Scoping Review. <i>AIDS and Behavior</i> , 2021, 25, 1777-1789.	1.4	14
2869	Perspectives on pre-exposure prophylaxis for people who inject drugs in the context of an hiv outbreak: A qualitative study.. <i>International Journal of Drug Policy</i> , 2021, 88, 103033.	1.6	13
2870	Fully synthetic injectable depots with high drug content and tunable pharmacokinetics for long-acting drug delivery. <i>Journal of Controlled Release</i> , 2021, 329, 257-269.	4.8	11
2871	Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 421-428.	0.5	12
2872	Pre-exposure Prophylaxis (PrEP) Awareness and Prescribing Behaviors Among Primary Care Providers: DocStyles Survey, 2016-2020, United States. <i>AIDS and Behavior</i> , 2021, 25, 1267-1275.	1.4	11

#	ARTICLE	IF	CITATIONS
2873	Reviewing PrEP's Effect on STI Incidence Among Men Who Have sex with Men "Balancing Increased STI Screening and Potential Behavioral Sexual Risk Compensation. <i>AIDS and Behavior</i> , 2021, 25, 1810-1818.	1.4	15
2874	Optimal Allocation of Societal HIV Prevention Resources to Reduce HIV Incidence in the United States. <i>American Journal of Public Health</i> , 2021, 111, 150-158.	1.5	10
2875	A Pragmatic Randomized Controlled Trial to Increase PrEP Uptake for HIV Prevention: 55-Week Results From PrEPChicago. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 31-37.	0.9	26
2876	Predictors of HIV Preexposure Prophylaxis Initiation Among Public Health Clients in Rural and Small Urban Areas in Iowa. <i>Public Health Reports</i> , 2021, 136, 172-182.	1.3	4
2877	Socio-Sexual Experiences and Access to Healthcare Among Informal PrEP Users in the Netherlands. <i>AIDS and Behavior</i> , 2021, 25, 1236-1246.	1.4	9
2878	Development and Psychometric Evaluation of the PrEP Sexual Expectancies (PSEXS) Scale. <i>AIDS and Behavior</i> , 2021, 25, 1192-1198.	1.4	0
2879	Two-dose emtricitabine/tenofovir alafenamide plus bicitgravir prophylaxis protects macaques against SHIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 692-698.	1.3	8
2880	Persistence of oral pre-exposure prophylaxis (PrEP) among adolescent girls and young women initiating PrEP for HIV prevention in Kenya. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 712-720.	0.6	27
2881	Early impact of COVID-19 social distancing measures on reported sexual behaviour of HIV pre-exposure prophylaxis users in Wales. <i>Sexually Transmitted Infections</i> , 2021, 97, 85-87.	0.8	23
2882	Modeling the Impact of PrEP Programs for Adolescent Sexual Minority Males Based on Empirical Estimates for the PrEP Continuum of Care. <i>Journal of Adolescent Health</i> , 2021, 68, 488-496.	1.2	8
2883	Impact of Medicaid Expansion on PrEP Utilization in the US: 2012-2018. <i>AIDS and Behavior</i> , 2021, 25, 1103-1111.	1.4	15
2884	Altered Antibody Responses in Persons Infected with HIV-1 While Using Preexposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 189-195.	0.5	4
2885	Sharing Objective Measures of Adherence to a Vaginal Microbicide Promotes Candor About Actual Use and Bolsters Motivation to Prevent HIV. <i>AIDS and Behavior</i> , 2021, 25, 721-731.	1.4	4
2886	Interpersonal and Intrapersonal Influences on Sexual Satisfaction in Young Male Couples: Analyses of Actor-Partner Interdependence Models. <i>Journal of Sex Research</i> , 2021, 58, 183-194.	1.6	10
2887	Projected Impact of Concurrently Available Long-Acting Injectable and Daily-Oral Human Immunodeficiency Virus Preexposure Prophylaxis: A Mathematical Model. <i>Journal of Infectious Diseases</i> , 2021, 223, 72-82.	1.9	18
2888	Exploration of the Complex Relationships Among Multilevel Predictors of PrEP Use Among Men Who Have Sex with Men in the United States. <i>AIDS and Behavior</i> , 2021, 25, 798-808.	1.4	6
2889	Integrating Pre- and Post-exposure Prophylaxes Programs for HIV Prevention Guidelines in Manila, Philippines. <i>Sexuality Research and Social Policy</i> , 2021, 18, 672-681.	1.4	2
2890	Interest in Long-Acting Injectable Pre-exposure Prophylaxis (LAI PrEP) Among Women in the Women's Interagency HIV Study (WIHS): A Qualitative Study Across Six Cities in the United States. <i>AIDS and Behavior</i> , 2021, 25, 667-678.	1.4	35

#	ARTICLE	IF	CITATIONS
2891	Missed Prevention Opportunities: Why Young, Black MSM with Recent HIV Diagnosis did not Access HIV Pre-exposure Prophylaxis Services. <i>AIDS and Behavior</i> , 2021, 25, 1464-1473.	1.4	25
2892	Intersecting Barriers to PrEP Awareness and Uptake in Black Men Who Have Sex with Men in Atlanta, GA: a Syndemic Perspective. <i>International Journal of Behavioral Medicine</i> , 2021, 28, 349-359.	0.8	9
2893	Client-Centered Adherence Counseling with Adherence Measurement Feedback to Support Use of the Dapivirine Ring in MTN-025 (The HOPE Study). <i>AIDS and Behavior</i> , 2021, 25, 447-458.	1.4	14
2894	Impure policies: controversy in HIV prevention and the making of evidence. <i>Critical Policy Studies</i> , 2021, 15, 21-36.	1.4	5
2895	Gearing up for PrEP in the Middle East and North Africa: An Initial Look at Willingness to Take PrEP among Young Men Who Have Sex with Men in Beirut, Lebanon. <i>Behavioral Medicine</i> , 2021, 47, 111-119.	1.0	5
2896	Molecular Transmission Dynamics of Primary HIV Infections in Lazio Region, Years 2013-2020. <i>Viruses</i> , 2021, 13, 176.	1.5	4
2897	A rapid review of pre-exposure prophylaxis for HIV in the Asia-Pacific region: recommendations for scale up and future directions. <i>Sexual Health</i> , 2021, 18, 31.	0.4	10
2898	Progression and transmission of HIV (PATH 4.0)-A new agent-based evolving network simulation for modeling HIV transmission clusters. <i>Mathematical Biosciences and Engineering</i> , 2021, 18, 2150-2181.	1.0	7
2899	Examining the Longitudinal Predictive Relationship Between HIV Treatment Outcomes and Pre-exposure Prophylaxis Use by Serodiscordant Male Couples. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 38-45.	0.9	1
2900	Population-level effectiveness of a national HIV preexposure prophylaxis programme in MSM. <i>Aids</i> , 2021, 35, 665-673.	1.0	38
2901	SIEs motivational CQ on job satisfaction: A two-study examination of power distance and role clarity. <i>International Journal of Intercultural Relations</i> , 2021, 80, 158-169.	1.0	8
2902	Control and prevention of infectious diseases from a One Health perspective. <i>Genetics and Molecular Biology</i> , 2021, 44, e20200256.	0.6	38
2903	Trajectories of PrEP Adherence Among Young Women Aged 16 to 25 in Cape Town, South Africa. <i>AIDS and Behavior</i> , 2021, 25, 2046-2053.	1.4	19
2904	Pre-Exposure Prophylaxis Care Continuum, Barriers, and Facilitators among Black Men Who Have Sex with Men in the United States: A Systematic Review and Meta-Analysis. <i>AIDS and Behavior</i> , 2021, 25, 2278-2288.	1.4	24
2905	Recommendations for Increasing Physician Provision of Pre-Exposure Prophylaxis: Implications for Medical Student Training. <i>Inquiry (United States)</i> , 2021, 58, 004695802110176.	0.5	5
2906	The case for an HIV cure and how to get there. <i>Lancet HIV</i> , 2021, 8, e51-e58.	2.1	46
2907	Multilevel Barriers to HIV PrEP Uptake and Adherence Among Black and Hispanic/Latinx Transgender Women in Southern California. <i>AIDS and Behavior</i> , 2021, 25, 2301-2315.	1.4	52
2908	The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review. <i>Pan African Medical Journal</i> , 2021, 38, 308.	0.3	1

#	ARTICLE	IF	CITATIONS
2909	Estimating the percentage of European MSM eligible for PrEP: insights from a bio-behavioural survey in thirteen cities. <i>Sexually Transmitted Infections</i> , 2021, 97, sextrans-2020-054786.	0.8	3
2910	Barriers and facilitators to pre-exposure prophylaxis among African migrants in high income countries: a systematic review. <i>Sexual Health</i> , 2021, 18, 130-139.	0.4	12
2911	Microbial mismanagement: how inadequate treatments for vaginal dysbiosis drive the HIV epidemic in women. <i>Seminars in Immunology</i> , 2021, 51, 101482.	2.7	9
2912	United States Ending the Human Immunodeficiency Virus (HIV) Epidemic Plan: Evaluation of the Role of Industry Funding in Published Pre-Exposure Prophylaxis (PrEP) Literature. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2913	Are New Antiretroviral Treatments Increasing the Risk of Weight Gain?. <i>Drugs</i> , 2021, 81, 299-315.	4.9	34
2914	Agency, Pleasure and Justice: A Public Health Ethics Perspective on the Use of PrEP by Gay and Other Homosexually-Active Men. <i>Social Aspects of HIV</i> , 2021, , 131-141.	0.1	0
2915	The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?. <i>Journal of the International Association of Providers of AIDS Care</i> , 2021, 20, 232595822110090.	0.6	35
2916	Implementation Science or "Show" Trial? England's PrEP Impact Study. <i>Social Aspects of HIV</i> , 2021, , 159-172.	0.1	2
2917	Imagined Futures and Unintended Consequences in the Making of PrEP: An Evidence-Making Intervention Perspective. <i>Social Aspects of HIV</i> , 2021, , 249-264.	0.1	2
2918	Pre-exposure prophylaxis makes it possible to better live one's sexuality and guide men who have sex with men towards a responsible approach to their health: a phenomenological qualitative study about primary motivations for PrEP. <i>AIDS Research and Therapy</i> , 2021, 18, 2.	0.7	5
2919	HIV/AIDS Global Epidemic. , 2021, , 1-30.		0
2920	Evaluation of the Microbiome in Men Taking Pre-exposure Prophylaxis for HIV Prevention. <i>AIDS and Behavior</i> , 2021, 25, 2005-2013.	1.4	9
2921	HIV-Infektion " PrÄvalenz, Bedeutung und Implikationen fr die PrÄvention und Gesundheitsfrderung. <i>The Springer Reference Pfliegerapie, Gesundheit</i> , 2021, , 1001-1006.	0.2	0
2922	Patient-Led Decision-Making for HIV Preexposure Prophylaxis. <i>Current HIV/AIDS Reports</i> , 2021, 18, 48-56.	1.1	15
2923	A Scoping Review of HIV Pre-exposure Prophylaxis Stigma and Implications for Stigma-Reduction Interventions for Men and Transwomen Who Have Sex with Men. <i>AIDS and Behavior</i> , 2021, 25, 2054-2070.	1.4	31
2924	HIV non-occupational post-exposure prophylaxis (nPEP) awareness and promotion among five key populations in China: A cross-sectional study. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 7, 100086.	1.3	3
2925	Assessment of PrEP Awareness, PrEP Discussion with a Provider, and PrEP Use by Transmission Risk Group with an Emphasis on the Southern United States. <i>AIDS and Behavior</i> , 2021, 25, 2985-2991.	1.4	12
2926	Equity considerations in outcome measures of the HIV pre-exposure prophylaxis care continuum in high-income countries: a systematic review protocol. <i>BMJ Open</i> , 2021, 11, e040701.	0.8	1

#	ARTICLE	IF	CITATIONS
2927	The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques. <i>Antiviral Research</i> , 2021, 186, 105001.	1.9	2
2928	Attitudes and Practices of a Sample of Nova Scotian Physicians for the Implementation of HIV Pre-Exposure Prophylaxis. <i>HIV/AIDS - Research and Palliative Care</i> , 2021, Volume 13, 157-170.	0.4	4
2929	Brief Report: Seroadaptive Behaviors Varied Among Geographically Diverse iPrEx Participants. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, e43-e47.	0.9	2
2930	Long-Acting Injection and Implant Preferences and Trade-Offs for HIV Prevention Among South African Male Youth. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 928-936.	0.9	9
2931	Low use of condom and high STI incidence among men who have sex with men in PrEP programs. <i>PLoS ONE</i> , 2021, 16, e0245925.	1.1	15
2932	Characterizing Biomedical HIV Prevention Awareness and Use Among Black Transgender Women in the United States. <i>AIDS and Behavior</i> , 2021, 25, 2929-2940.	1.4	9
2933	Preference for daily versus on-demand pre-exposure prophylaxis for HIV and correlates among men who have sex with men: the China Real-world Oral PrEP Demonstration study. <i>Journal of the International AIDS Society</i> , 2021, 24, e25667.	1.2	20
2934	Slow Uptake of PrEP: Behavioral Predictors and the Influence of Price on PrEP Uptake Among MSM with a High Interest in PrEP. <i>AIDS and Behavior</i> , 2021, 25, 2382-2390.	1.4	20
2935	Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma. <i>PLoS ONE</i> , 2021, 16, e0246994.	1.1	2
2936	Referral linkage to pre-exposure prophylaxis (PrEP) care and persistence on PrEP in an integrated healthcare system. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, 918-927.	0.9	8
2937	Pharmacotherapy considerations in transgender individuals living with human immunodeficiency virus. <i>Pharmacotherapy</i> , 2021, 41, 299-314.	1.2	5
2938	Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. <i>Lancet HIV</i> , 2021, 8, e87-e95.	2.1	70
2939	HIV risk management among sexual minority men in China: context, lived experience, and implications for pre-exposure prophylaxis implementation. <i>Culture, Health and Sexuality</i> , 2022, 24, 797-811.	1.0	4
2940	Transporting Subgroup Analyses of Randomized Controlled Trials for Planning Implementation of New Interventions. <i>American Journal of Epidemiology</i> , 2021, 190, 1671-1680.	1.6	8
2941	Possible risk compensation, attitudes, and beliefs among Brazilian individuals potentially eligible for pre-exposure prophylaxis. <i>International Journal of STD and AIDS</i> , 2021, 32, 806-815.	0.5	3
2942	HIV Prevention Responsibility Beliefs Among Men Who Have Sex with Men in the PrEP Era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, e222-e228.	0.9	2
2943	In vitro Study on Synergistic Interactions Between Free and Encapsulated Q-Griffithsin and Antiretrovirals Against HIV-1 Infection. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 1189-1206.	3.3	8
2944	Successful integration of HIV pre-exposure prophylaxis into a community-based HIV prevention program for female sex workers in Kolkata, India. <i>International Journal of STD and AIDS</i> , 2021, 32, 638-647.	0.5	4

#	ARTICLE	IF	CITATIONS
2945	Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday. <i>Molecules</i> , 2021, 26, 923.	1.7	21
2946	Real-Time Monitoring and Point-of-Care Testing: A Review of the Current Landscape of PrEP Adherence Monitoring. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 259-269.	0.8	14
2947	HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda. <i>PLoS Medicine</i> , 2021, 18, e1003492.	3.9	35
2949	Missed opportunities for sexually transmitted infections testing for HIV pre-exposure prophylaxis users: a systematic review. <i>Journal of the International AIDS Society</i> , 2021, 24, e25673.	1.2	22
2950	The Impact of Pre-exposure Prophylaxis on Sexual Well-Being Among Men Who Have Sex with Men. <i>Archives of Sexual Behavior</i> , 2021, 50, 1829-1841.	1.2	9
2951	Awareness of and willingness to use pre-exposure prophylaxis (PrEP) among people who inject drugs and men who have sex with men in India: Results from a multi-city cross-sectional survey. <i>PLoS ONE</i> , 2021, 16, e0247352.	1.1	20
2952	A Mechanistic In Vivo / Ex Vivo Pharmacokinetic-Pharmacodynamic Model of Tenofovir for HIV Prevention. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 179-187.	1.3	2
2953	Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review. <i>Infectious Diseases and Therapy</i> , 2021, 10, 165-186.	1.8	13
2954	Sexually Transmitted Infection Testing and Prevalence Before and After Preexposure Prophylaxis Initiation Among Men Aged ≥18 Years in US Private Settings. <i>Sexually Transmitted Diseases</i> , 2021, 48, 515-520.	0.8	3
2955	A Review of Recent HIV Prevention Interventions and Future Considerations for Nursing Science. <i>Journal of the Association of Nurses in AIDS Care</i> , 2021, 32, 373-391.	0.4	2
2956	From training wheels to chemical condoms: Exploring narratives of PrEP discontinuation. <i>Health (United Kingdom)</i> , 2021, , 136345932110051.	0.9	1
2957	Kidney injury biomarkers during exposure to tenofovir-based preexposure prophylaxis. <i>Aids</i> , 2021, 35, 1147-1149.	1.0	1
2958	“The Main Concern is HIV, Everything Else is Fixable” Indifference Toward Sexually Transmitted Infections in the Era of Biomedical HIV Prevention. <i>AIDS and Behavior</i> , 2021, 25, 2657-2660.	1.4	7
2959	Effect of Medicaid Expansions on HIV Diagnoses and Pre-Exposure Prophylaxis Use. <i>American Journal of Preventive Medicine</i> , 2021, 60, 335-342.	1.6	9
2960	Drug Injection-Related and Sexual Behavior Changes in Drug Injecting Networks after the Transmission Reduction Intervention Project (TRIP): A Social Network-Based Study in Athens, Greece. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2388.	1.2	3
2961	Mathematical modelling of the influence of serosorting on the population-level HIV transmission impact of pre-exposure prophylaxis. <i>Aids</i> , 2021, 35, 1113-1125.	1.0	10
2962	Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. <i>Journal of Infectious Diseases</i> , 2021, 224, 1581-1592.	1.9	72
2963	PrEP Awareness, Use, Intention to Use, and Information Source Among Geosocial Networking Application Users in Mexico in 2018-2019. <i>AIDS and Behavior</i> , 2021, 25, 2743-2754.	1.4	8

#	ARTICLE	IF	CITATIONS
2964	A Randomized Trial of a Brief Behavioral Intervention for PrEP Uptake Among Men Who Have Sex With Men at Increased Risk for HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 87, 937-943.	0.9	11
2965	Inflammatory Markers During Early Treatment of Seroconverters in a Randomized Placebo-Controlled Trial of PrEP (ANRS-IPERGAY). <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab085.	0.4	0
2966	Early Colorectal Responses to HIV-1 and Modulation by Antiretroviral Drugs. <i>Vaccines</i> , 2021, 9, 231.	2.1	7
2967	Development and Evaluation of a Mobile App Designed to Increase HIV Testing and Pre-exposure Prophylaxis Use Among Young Men Who Have Sex With Men in the United States: Open Pilot Trial. <i>Journal of Medical Internet Research</i> , 2021, 23, e25107.	2.1	29
2968	Harm Reduction in Sexual Medicine. <i>Sexual Medicine Reviews</i> , 2022, 10, 3-22.	1.5	21
2969	Primary HIV-1 infection in users of pre-exposure prophylaxis. <i>Lancet HIV</i> , 2021, 8, e166-e174.	2.1	23
2970	It's Time to Expand Chlamydia Treatment for Gay and Bisexual Men. <i>Annals of Family Medicine</i> , 2021, 19, 168-170.	0.9	1
2971	Antiretroviral Drug Treatment of Individuals that Used Preexposure Prophylaxis (PrEP) Before Diagnosis. <i>Current Treatment Options in Infectious Diseases</i> , 2021, 13, 141-152.	0.8	0
2972	Expression, Activity, and Regulation of Phosphorylating Enzymes in Tissues and Cells Relevant to HIV-1 Sexual Transmission. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 22-32.	0.5	6
2973	Factors Predicting Uptake of Sexually Transmitted Infections Testing among Men Who Have Sex with Men Who Are "Pre-Exposure Prophylaxis Tourists" An Observational Prospective Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3582.	1.2	9
2974	Call to action: how can the US Ending the HIV Epidemic initiative succeed?. <i>Lancet, The</i> , 2021, 397, 1151-1156.	6.3	24
2975	Cannabis and Alcohol Co-Use and Condomless Anal Sex Among Men Who have Sex with Men Living with HIV: An Event-Level Analysis. <i>AIDS and Behavior</i> , 2021, 25, 3770-3781.	1.4	5
2976	Infection with antiretroviral-susceptible HIV in an individual adherent to pre-exposure prophylaxis: strategies for treatment initiation. <i>International Journal of STD and AIDS</i> , 2021, 32, 578-581.	0.5	1
2977	Community Legal Systems: Targeting PrEP and HIV Education to Decrease Risk of HIV Transmission. <i>AIDS and Behavior</i> , 2021, 25, 2578-2590.	1.4	2
2978	The Pre-Exposure Prophylaxis Cascade in At-Risk Transgender Men Who Have Sex with Men in the United States. <i>LGBT Health</i> , 2021, 8, 116-124.	1.8	30
2979	Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019. <i>Sexually Transmitted Infections</i> , 2022, 98, 132-135.	0.8	10
2980	Mixed-Methods Evaluation of the Incorporation of Home Specimen Self-Collection Kits for Laboratory Testing in a Telehealth Program for HIV Pre-exposure Prophylaxis. <i>AIDS and Behavior</i> , 2021, 25, 2463-2482.	1.4	18
2982	Implementing Implementation Research: Teaching Implementation Research to HIV Researchers. <i>Current HIV/AIDS Reports</i> , 2021, 18, 186-197.	1.1	4

#	ARTICLE	IF	CITATIONS
2984	HIV Pathogenesis in the Human Female Reproductive Tract. <i>Current HIV/AIDS Reports</i> , 2021, 18, 139-156.	1.1	10
2985	Patient perspectives of pharmacists prescribing HIV pre-exposure prophylaxis: A survey of patients receiving antiretroviral therapy. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021, 61, e75-e79.	0.7	11
2986	Preexposure prophylaxis care continuum among transgender women at a patient-centered preexposure prophylaxis program in Atlanta, Georgia. <i>Aids</i> , 2021, 35, 524-526.	1.0	3
2987	The persistent and evolving HIV epidemic in American men who have sex with men. <i>Lancet, The</i> , 2021, 397, 1116-1126.	6.3	53
2988	Geographic Density and Uptake of Pre-exposure Prophylaxis (PrEP) Among Young Gay, Bisexual and Other Sexual Minority Men: A Global Positioning System (GPS) Study. <i>AIDS and Behavior</i> , 2021, 25, 155-164.	1.4	6
2989	Knowledge, Attitudes and Practices Regarding Pre-Exposure Prophylaxis (PrEP) in a Sample of Italian Men Who Have SEX with MEN (MSM). <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 4772.	1.2	8
2990	Sexual Dysfunction in Men Who Have Sex With Men. <i>Sexual Medicine Reviews</i> , 2022, 10, 130-141.	1.5	13
2991	The Past, Present, and Future of PrEP implementation Among People Who Use Drugs. <i>Current HIV/AIDS Reports</i> , 2021, 18, 328-338.	1.1	22
2992	Cross-cultural adaptation of the Perceived Risk of HIV Scale in Brazilian Portuguese. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 117.	1.0	9
2993	AIDS in the Heartland—“Hemophilia Was the Harbinger of Things to Come. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 517-522.	0.9	1
2994	A Systematic Review of the Social Network Strategy to Optimize HIV Testing in Key Populations to End the Epidemic in the United States. <i>AIDS and Behavior</i> , 2021, 25, 2680-2698.	1.4	13
2995	Primary Care Providers’ Perspectives on Using Automated HIV Risk Prediction Models to Identify Potential Candidates for Pre-exposure Prophylaxis. <i>AIDS and Behavior</i> , 2021, 25, 3651-3657.	1.4	8
2996	Pilot evaluation of an enzymatic assay for rapid measurement of antiretroviral drug concentrations. <i>Virology Journal</i> , 2021, 18, 77.	1.4	5
2997	HIV Pre-exposure Prophylaxis (PrEP): Knowledge, attitudes and counseling practices among physicians in Germany – A cross-sectional survey. <i>PLoS ONE</i> , 2021, 16, e0250895.	1.1	1
2998	Structural Issues Associated with Pre-exposure Prophylaxis Use in Men Who Have Sex with Men. <i>International Journal of Behavioral Medicine</i> , 2021, 28, 759-767.	0.8	7
2999	Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1245-1251.	0.9	2
3000	Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis. <i>Aids</i> , 2021, 35, 1585-1595.	1.0	10
3001	Increased targeted HIV testing and reduced undiagnosed HIV infections among gay and bisexual men. <i>HIV Medicine</i> , 2021, 22, 605-616.	1.0	9

#	ARTICLE	IF	CITATIONS
3002	Awareness of and Preferences for Preexposure Prophylaxis (PrEP) among MSM at High Risk of HIV Infection in Southern China: Findings from the T2T Study. <i>BioMed Research International</i> , 2021, 2021, 1-11.	0.9	8
3003	Segmented intravaginal ring for the combination delivery of hydroxychloroquine and anti-CCR5 siRNA nanoparticles as a potential strategy for preventing HIV infection. <i>Drug Delivery and Translational Research</i> , 2022, 12, 816-825.	3.0	2
3004	Correlates of PrEP Uptake Among Young Sexual Minority Men and Transgender Women in New York City: The Need to Reframe "Risk" Messaging and Normalize Preventative Health. <i>AIDS and Behavior</i> , 2021, 25, 3057-3073.	1.4	15
3005	Differences in PrEP Awareness, Discussions with Healthcare Providers, and Use Among Men Who Have Sex with Men in the United States by Urbanicity and Region: A Cross-sectional Analysis. <i>AIDS and Behavior</i> , 2021, 25, 4102-4114.	1.4	14
3006	Imperfect adherence in real life: a prevention-effective perspective on adherence to daily and event-driven HIV pre-exposure prophylaxis among men who have sex with men – a prospective cohort study in Taiwan. <i>Journal of the International AIDS Society</i> , 2021, 24, e25733.	1.2	18
3007	HIV PrEP implementation: A multi-level systems approach. <i>Evaluation and Program Planning</i> , 2022, 90, 101966.	0.9	9
3008	Facilitators and barriers of 2-1-1 HIV pre-exposure prophylaxis. <i>PLoS ONE</i> , 2021, 16, e0251917.	1.1	11
3009	Pre-exposure prophylaxis for HIV with oral tenofovir disoproxil fumarate/emtricitabine in men who have sex with men: Slovenian national demonstration project. <i>International Journal of STD and AIDS</i> , 2021, 32, 1060-1065.	0.5	3
3010	Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1367-1373.	1.0	11
3011	Pilot randomised controlled trial of a patient navigation intervention to enhance engagement in the PrEP continuum among young Latino MSM: a protocol paper. <i>BMJ Open</i> , 2021, 11, e040955.	0.8	5
3012	HIV Treatment Cascade and PrEP Care Continuum Among Serodiscordant Male Couples in the United States. <i>AIDS and Behavior</i> , 2021, 25, 3563-3573.	1.4	1
3013	Sociodemographic Characteristics of HIV Pre-Exposure Prophylaxis Use and Reasons for Nonuse Among Gay, Bisexual, and Other Men Who Have Sex with Men from Three US Cities. <i>AIDS Patient Care and STDs</i> , 2021, 35, 158-166.	1.1	21
3014	Urban sexual health clinic patients with "undetermined risk" for HIV are less likely to receive PrEP. <i>Sexually Transmitted Diseases</i> , 2021, Publish Ahead of Print, 881-886.	0.8	0
3015	The Role of Alcohol-Related Behavioral Research in the Design of HIV Secondary Prevention Interventions in the Era of Antiretroviral Therapy: Targeted Research Priorities Moving Forward. <i>AIDS and Behavior</i> , 2021, 25, 365-380.	1.4	5
3016	A qualitative assessment in acceptability and barriers to use pre-exposure prophylaxis (PrEP) among men who have sex with men: implications for service delivery in Vietnam. <i>BMC Infectious Diseases</i> , 2021, 21, 472.	1.3	11
3017	Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virus. <i>Aids</i> , 2021, 35, 1567-1574.	1.0	6
3018	Preferences for pre-exposure prophylaxis among U.S. military men who have sex with men: results of an adaptive choice based conjoint analysis study. <i>Military Medical Research</i> , 2021, 8, 32.	1.9	5
3019	Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background HIV incidence: a secondary analysis of a randomized, controlled trial. <i>Journal of the International AIDS Society</i> , 2021, 24, e25744.	1.2	12

#	ARTICLE	IF	CITATIONS
3020	Recurrent Sexually Transmitted Infections Among a Cohort of Men Who Have Sex With Men Using Preexposure Prophylaxis in Belgium Are Highly Associated With Sexualized Drug Use. Sexually Transmitted Diseases, 2021, 48, 726-732.	0.8	5
3021	Antiretroviral drug exposure in urethral and glans surface sampling of the penis. Journal of Antimicrobial Chemotherapy, 2021, 76, 2368-2374.	1.3	5
3022	Tempering hope with Intimate Knowledge: Contrasting emergences of the concept "uninfectious" in HIV. Sociology of Health and Illness, 2021, 43, 1100-1116.	1.1	2
3023	Pre-Exposure Prophylaxis (PrEP) for HIV Infection in Cisgender and Transgender Women in the U.S.: A Narrative Review of the Literature. Archives of Sexual Behavior, 2021, 50, 1713-1728.	1.2	19
3024	Awareness and acceptability of HIV pre-exposure prophylaxis (PrEP) among students at two historically Black universities (HBCU): a cross-sectional survey. BMC Public Health, 2021, 21, 943.	1.2	4
3025	Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP). Journal of Antimicrobial Chemotherapy, 2021, 76, 2129-2136.	1.3	10
3026	HIV Pre-Exposure Prophylaxis, Condoms, or Both? Insights on Risk Compensation Through a Discrete Choice Experiment and Latent Class Analysis Among Men Who Have Sex With Men. Value in Health, 2021, 24, 714-723.	0.1	8
3027	Substantial Need for Preexposure Prophylaxis Among Men Who Have Sex With Men in Hanoi, Vietnam. Sexually Transmitted Diseases, 2021, 48, e56-e58.	0.8	2
3028	Inflammatory cytologic alterations in the oral epithelium associated with HIV pre-exposure prophylaxis: a preliminary study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2021, 131, 534-539.	0.2	2
3029	Experiencia de un programa de profilaxis preexposici3n en una unidad de virus de la inmunodeficiencia humana hospitalaria. Descripci3n del perfil basal del usuario e identificaci3n de oportunidades de mejora. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2023, 41, 24-28.	0.3	7
3030	Long-Acting Cabotegravir for HIV/AIDS Prophylaxis. Biochemistry, 2021, 60, 1731-1740.	1.2	12
3031	The Value of Assessing Self-Reported and Biological Indicators of Outcomes in Evaluating HIV Programs. Current HIV/AIDS Reports, 2021, 18, 365-376.	1.1	1
3032	A comparison of covariate selection techniques applied to pre-exposure prophylaxis (PrEP) drug concentration data in men and transgender women at risk for HIV. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 655-669.	0.8	1
3034	The impact of condom use on the HIV epidemic. Gates Open Research, 2021, 5, 91.	2.0	3
3035	Predictors of HIV Status Disclosure to Sexual Partners Among People Living with HIV in Brazil. AIDS and Behavior, 2021, 25, 3538-3546.	1.4	2
3036	How Alcohol Influences Mechanisms of Sexual Risk Behavior Change: Contributions of Alcohol Challenge Research to the Development of HIV Prevention Interventions. AIDS and Behavior, 2021, 25, 314-332.	1.4	8
3037	Intervening for HIV prevention and mental health: a review of global literature. Journal of the International AIDS Society, 2021, 24, e25710.	1.2	20
3038	Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention. AIDS and Behavior, 2021, 25, 2801-2814.	1.4	5

#	ARTICLE	IF	CITATIONS
3039	PrEP University: A Multi-Disciplinary University-Based HIV Prevention Education Program. <i>Journal of Community Health</i> , 2021, 46, 1213-1220.	1.9	5
3040	Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission. <i>Nature Communications</i> , 2021, 12, 3343.	5.8	15
3041	Tonse Pamodzi: Developing a combination strategy to support adherence to antiretroviral therapy and HIV pre-exposure prophylaxis during pregnancy and breastfeeding. <i>PLoS ONE</i> , 2021, 16, e0253280.	1.1	8
3042	Combination adherence strategy to support HIV antiretroviral therapy and pre-exposure prophylaxis adherence during pregnancy and breastfeeding: protocol for a pair of pilot randomised trials. <i>BMJ Open</i> , 2021, 11, e046032.	0.8	8
3043	HIV and COVID-19: Lessons From HIV and STI Harm Reduction Strategies. <i>Current HIV/AIDS Reports</i> , 2021, 18, 261-270.	1.1	5
3044	Considerations for the Design of Pre-exposure Prophylaxis (PrEP) Interventions for Women: Lessons Learned from the Implementation of a Novel PrEP Intervention. <i>AIDS and Behavior</i> , 2021, 25, 3987-3999.	1.4	21
3045	Adherence to daily HIV pre-exposure prophylaxis in a large-scale implementation study in New South Wales, Australia. <i>Aids</i> , 2021, 35, 1987-1996.	1.0	15
3046	Increased immune activation and signs of neuronal injury in HIV-negative people on preexposure prophylaxis. <i>Aids</i> , 2021, 35, 2129-2136.	1.0	6
3047	Messaging matters: achieving equity in the HIV response through public health communication. <i>Lancet HIV</i> , 2021, 8, e376-e386.	2.1	11
3048	Assessing longitudinal patterns of depressive symptoms and the influence of symptom trajectories on HIV pre-exposure prophylaxis adherence among adolescent girls in the HPTN 082 randomized controlled trial. <i>Journal of the International AIDS Society</i> , 2021, 24, e25731.	1.2	17
3049	Defining the optimal cut-point of self-reported ART adherence to achieve viral suppression in the era of contemporary HIV therapy: a cross-sectional study. <i>AIDS Research and Therapy</i> , 2021, 18, 36.	0.7	18
3050	Changing the PrEP Narrative: A Call to Action to Increase PrEP Uptake among Women. <i>Women</i> , 2021, 1, 120-127.	0.5	7
3051	Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial. <i>EClinicalMedicine</i> , 2021, 36, 100893.	3.2	27
3052	Evidence of an untamed HIV epidemic among MSM and TGW in Rio de Janeiro, Brazil: a 2018 to 2020 cross-sectional study using recent infection testing. <i>Journal of the International AIDS Society</i> , 2021, 24, e25743.	1.2	16
3053	Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 409-420.	0.5	20
3054	HIV Risk and Pre-Exposure Prophylaxis Eligibility Among Emergency Department Patients. <i>AIDS Patient Care and STDs</i> , 2021, 35, 211-219.	1.1	12
3055	Can the combination of TasP and PrEP eliminate HIV among MSM in British Columbia, Canada?. <i>Epidemics</i> , 2021, 35, 100461.	1.5	3
3056	Reflections on 40 Years of AIDS. <i>Emerging Infectious Diseases</i> , 2021, 27, 1553-1560.	2.0	49

#	ARTICLE	IF	CITATIONS
3057	Estimating the HIV Effective Reproduction Number in the United States and Evaluating HIV Elimination Strategies. <i>Journal of Public Health Management and Practice</i> , 2021, Publish Ahead of Print, .	0.7	1
3058	Pre-exposure Prophylaxis in LGBT Communities. <i>Primary Care - Clinics in Office Practice</i> , 2021, 48, 299-310.	0.7	1
3059	HIV pre-exposure prophylaxis (PrEP) knowledge, familiarity, and attitudes among United States healthcare professional students: A cross-sectional study. <i>Preventive Medicine Reports</i> , 2021, 22, 101334.	0.8	10
3060	Effects of condom use on HIV transmission among adolescent sexual minority males in the United States. <i>Sexually Transmitted Diseases</i> , 2021, Publish Ahead of Print, 973-980.	0.8	5
3061	Cost-Effectiveness Analysis of a National Pre-Exposure Prophylaxis (PrEP) Program in Ireland. <i>Value in Health</i> , 2021, 24, 948-956.	0.1	3
3062	Mathematical Modelling of the Molecular Mechanisms of Interaction of Tenofovir with Emtricitabine against HIV. <i>Viruses</i> , 2021, 13, 1354.	1.5	4
3063	Initial implementation of PrEP in Zambia: health policy development and service delivery scale-up. <i>BMJ Open</i> , 2021, 11, e047017.	0.8	19
3064	Tracking elimination of HIV transmission in men who have sex with men in England: a modelling study. <i>Lancet HIV</i> , 2021, 8, e440-e448.	2.1	11
3065	Factors associated with self-reported adherence to daily oral pre-exposure prophylaxis among men who have sex with man and transgender women: PrEP Brasil study. <i>International Journal of STD and AIDS</i> , 2021, 32, 1231-1241.	0.5	5
3066	Integration of HIV Prevention With Sexual and Reproductive Health Services: Evidence for Contraceptive Options and HIV Outcomes Study Experience of Integrating Oral Pre-exposure HIV Prophylaxis in Family Planning Services in Lusaka, Zambia. <i>Frontiers in Reproductive Health</i> , 2021, 3, .	0.6	4
3067	Beyond the Magic Bullet: What Will It Take to End the AIDS Epidemic?. <i>American Journal of Public Health</i> , 2021, 111, 1234-1236.	1.5	3
3068	Maternal PrEP Use in HIV-Uninfected Pregnant Women in South Africa: Role of Stigma in PrEP Initiation, Retention and Adherence. <i>AIDS and Behavior</i> , 2022, 26, 205-217.	1.4	30
3069	The Community PrEP Study: a randomized control trial leveraging community-based platforms to improve access and adherence to pre-exposure prophylaxis to prevent HIV among adolescent girls and young women in South Africaâ€”study protocol. <i>Trials</i> , 2021, 22, 489.	0.7	14
3070	Qualitative Assessment of Barriers and Facilitators of PrEP Use Before and After Rollout of a PrEP Program for Priority Populations in South-central Uganda. <i>AIDS and Behavior</i> , 2021, 25, 3547-3562.	1.4	18
3071	Implementation and evaluation of patient navigation in Chicago: Insights on addressing the social determinants of health and integrating HIV prevention and care services. <i>Evaluation and Program Planning</i> , 2022, 90, 101977.	0.9	3
3072	Longitudinal pre-exposure prophylaxis (PrEP) acceptability, initiation and adherence among criminal justice-involved adults in the USA: the Southern PrEP Cohort Study (SPECS) protocol. <i>BMJ Open</i> , 2021, 11, e047340.	0.8	6
3074	â€œShades of riskâ€: Understanding current PrEP usersâ€™ sexually transmitted infection perceptions. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, , 1-6.	0.6	2
3075	Delivering PrEP to Young Women in a Low-Income Setting in South Africa: Lessons for Providing Both Convenience and Support. <i>AIDS and Behavior</i> , 2022, 26, 147-159.	1.4	9

#	ARTICLE	IF	CITATIONS
3076	Factors associated with methamphetamine dependency among men who have sex with men engaging in chemsex: Findings from the COMeT study in Taiwan. <i>International Journal of Drug Policy</i> , 2021, 93, 103119.	1.6	19
3077	Loss to Follow-Up and Re-Engagement in HIV Pre-Exposure Prophylaxis Care in the United States, 2013–2019. <i>AIDS Patient Care and STDs</i> , 2021, 35, 271-277.	1.1	13
3078	Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2675-2680.	1.3	6
3079	mHealth for pre-exposure prophylaxis adherence by young adult men who have sex with men. <i>MHealth</i> , 2021, 7, 44-44.	0.9	9
3080	Renal impairment in a large-scale HIV pre-exposure prophylaxis implementation cohort. <i>Aids</i> , 2021, Publish Ahead of Print, 2319-2326.	1.0	5
3081	Sexually Transmitted Infections Treatment Guidelines, 2021. <i>MMWR Recommendations and Reports</i> , 2021, 70, 1-187.	26.7	841
3082	HIV pre-exposure prophylaxis: scaling up for impact now and in the future. <i>Lancet Public Health</i> , The, 2021, 6, e528-e533.	4.7	67
3083	A cross-sectional survey of general practitioner knowledge, attitudes, and clinical experience of HIV PrEP. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 0, , 1.	0.8	0
3084	Factors associated with PrEP adherence among MSM living in Jackson, Mississippi. <i>Journal of HIV/AIDS and Social Services</i> , 2021, 20, 246-261.	0.7	6
3085	The association between social and spatial closeness with PrEP conversations among Latino men who have sex with men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, 366-375.	0.9	4
3086	Internet-Based HIV Self-Testing Among Men Who Have Sex With Men Through Pre-exposure Prophylaxis: 3-Month Prospective Cohort Analysis From China. <i>Journal of Medical Internet Research</i> , 2021, 23, e23978.	2.1	8
3087	Pre-exposure prophylaxis awareness, use, and intention to use in a regional sample of Latin American geosocial networking application users in 2018–2019. <i>International Journal of STD and AIDS</i> , 2021, 32, 1261-1267.	0.5	3
3088	Pre-Exposure Prophylaxis (PrEP) Awareness Among Black Men Who Have Sex with Men with a History of Criminal Justice Involvement in Six U.S. Cities: Findings from the HPTN 061 Study. <i>Archives of Sexual Behavior</i> , 2021, 50, 2943-2946.	1.2	2
3090	Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study. <i>Lancet HIV</i> , the, 2021, 8, e486-e494.	2.1	54
3092	Case Report: Reversal of Integrase Inhibitor- and Tenofovir Alafenamide-Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab403.	0.4	3
3093	Reaching Those Most at Risk for HIV Acquisition: Evaluating Racial/Ethnic Disparities in the Preexposure Prophylaxis Care Continuum in Baltimore City, Maryland. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 1145-1153.	0.9	14
3094	Are men who have sex with men at higher risk for HIV in Latin America more aware of PrEP?. <i>PLoS ONE</i> , 2021, 16, e0255557.	1.1	7
3095	Health Service- and Provider-Level Factors Influencing Engagement in HIV Pre-Exposure Prophylaxis Care Among Male Sex Workers. <i>AIDS Patient Care and STDs</i> , 2021, 35, 279-287.	1.1	12

#	ARTICLE	IF	CITATIONS
3096	Trends in the Number and Characteristics of HIV Pre-Exposure Prophylaxis Providers in the United States, 2014–2019. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 88, 282-289.	0.9	13
3097	Brief Report: Low Incidence of Hepatitis C Among a Cohort of HIV-Negative Gay and Bisexual Men Using HIV Pre-exposure Prophylaxis (PrEP) in Melbourne, Australia, and the Contribution of Sexual Transmission. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 87, 1011-1015.	0.9	4
3098	Implementation and Access to Pre-exposure Prophylaxis for Human Immunodeficiency Virus by Men Who Have Sex With Men in Europe. <i>Frontiers in Medicine</i> , 2021, 8, 722247.	1.2	2
3099	Association of positive psychobehavioral factors and structural disadvantage with condomless sex in men who have sex men with childhood sexual abuse histories. <i>Journal of Behavioral Medicine</i> , 2021, , 1.	1.1	0
3100	Failure of pre-exposure prophylaxis with on-demand tenofovir disoproxil fumarate/emtricitabine resulting in emergence of antiretroviral resistance. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 755-757.	1.5	1
3101	PrEPing Memphis: A qualitative process evaluation of peer navigation support. <i>Evaluation and Program Planning</i> , 2022, 90, 101989.	0.9	8
3102	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. <i>New England Journal of Medicine</i> , 2021, 385, 595-608.	13.9	359
3103	Multipurpose Prevention Technologies: Opportunities and Challenges to Ensure Advancement of the Most Promising MPTs. <i>Frontiers in Reproductive Health</i> , 2021, 3, .	0.6	14
3104	Análise da oferta e eficácia da profilaxia a prÃ©-exposiÃ£o sexual (PrEP) para o enfrentamento do HIV/AIDS no Brasil. <i>Research, Society and Development</i> , 2021, 10, e22101219095.	0.0	1
3105	Perceived HIV Acquisition Risk and Low Uptake of PrEP Among a Cohort of Transgender Women With PrEP Indication in the Eastern and Southern United States. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 88, 10-18.	0.9	18
3106	Pre-exposure Prophylaxis Persistence Among Greek Sexual Minority Men: Results from PrEP for Greece (P4G) Study. <i>AIDS and Behavior</i> , 2021, , 1.	1.4	1
3107	An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 279-287.	0.5	7
3108	Brief Report: No Difference in Urine Tenofovir Levels in Patients Living With HIV on Unboosted Versus Dose-Adjusted Boosted Tenofovir Alafenamide. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 88, 57-60.	0.9	3
3109	Alcohol Use and the Risk of Communicable Diseases. <i>Nutrients</i> , 2021, 13, 3317.	1.7	23
3110	Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate. <i>Aids</i> , 2021, 35, 2481-2487.	1.0	8
3112	Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward. <i>Vaccines</i> , 2021, 9, 1001.	2.1	2
3113	Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 290-302.	1.3	47
3115	The wisdom of mistrust: qualitative insights from transgender women who participated in PrEP research in Lima, Peru. <i>Journal of the International AIDS Society</i> , 2021, 24, e25769.	1.2	9

#	ARTICLE	IF	CITATIONS
3116	Awareness, knowledge and comfort of pharmacy students on pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) for HIV prevention. <i>Pharmacy Education</i> , 0, , 517-527.	0.2	2
3117	Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 88, 86-95.	0.9	15
3118	Brief Report: “I Didn’t Really Have a Primary Care Provider Until I Got PrEP” Patients’ Perspectives on HIV Preexposure Prophylaxis as a Gateway to Health Care. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 88, 31-35.	0.9	8
3119	Merging care and prevention: preventive properties of antiretroviral drugs and HIV chronification in the case of Switzerland. <i>Anthropology and Medicine</i> , 2021, , 1-15.	0.6	0
3120	The spatiotemporal distribution of pre-exposure prophylaxis accessibility in the United States, 2016–2020. <i>Annals of Epidemiology</i> , 2021, 64, 102-110.	0.9	10
3121	Pre-Exposure Prophylaxis Among Gay, Bisexual, and Other Men Who Have Sex With Men in Ottawa: A Real World View With Benefits Beyond HIV Risk Reduction. <i>International Journal of Sexual Health</i> , 0, , 1-13.	1.2	0
3122	Global scoping review of HIV prevention research with transgender people: Transcending from trans- to trans-centered research. <i>Journal of the International AIDS Society</i> , 2021, 24, e25786.	1.2	11
3123	Genital mucosal drug concentrations and anti-HIV activity in tenofovir-based PrEP products. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, Publish Ahead of Print, 87-97.	0.9	6
3124	Impact of dosing strategies on plasma concentrations of tenofovir: Implications in HIV pre-exposure prophylaxis in China. <i>Journal of Infection and Public Health</i> , 2021, 14, 1169-1173.	1.9	0
3125	Reddit on PrEP: Posts About Pre-exposure Prophylaxis for HIV from Reddit Users, 2014–2019. <i>AIDS and Behavior</i> , 2022, 26, 1084-1094.	1.4	6
3126	Naturally Occurring Mutations to Muscle-Type Creatine Kinase Impact Its Canonical and Pharmacological Activities in a Substrate-Dependent Manner In Vitro. <i>Molecular Pharmacology</i> , 2021, 100, 588-596.	1.0	5
3127	Comparison between daily and on-demand PrEP (pre-exposure prophylaxis) regimen in covering condomless anal intercourse for men who have sex with men in Hong Kong: A randomized, controlled, open-label, crossover trial. <i>Journal of the International AIDS Society</i> , 2021, 24, e25795.	1.2	13
3128	HIV-1 Nucleic Acids Identify Rectal HIV Exposures in Self-Collected Rectal Swabs, Whereas Y-Chromosome Single Tandem Repeat Mixtures Are Not Reliable Biomarkers of Condomless Receptive Anal Intercourse. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 88, 138-148.	0.9	0
3129	HIV Viral Suppression and Pre-exposure Prophylaxis in HIV and Syphilis Contact Tracing Networks: An Analysis of Disease Surveillance and Prescription Claims Data. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 88, 157-164.	0.9	0
3130	Living While Black, Gay, and Poor: The Association of Race, Neighborhood Structural Disadvantage, and Prep Utilization Among a Sample of Black Men Who Have Sex With Men in the Deep South. <i>AIDS Education and Prevention</i> , 2021, 33, 395-410.	0.6	13
3131	Exchanging a “Gnawing Thought for “Taking a Pill Once a Day”: Examining Sexual Minority Men’s Experiences With PrEP and Mental Health in a Universal PrEP Access Context. <i>AIDS Education and Prevention</i> , 2021, 33, 411-423.	0.6	3
3132	Drug resistance mutations in HIV: new bioinformatics approaches and challenges. <i>Current Opinion in Virology</i> , 2021, 51, 56-64.	2.6	23
3133	Exploring real-world experiences of early PrEP adopters in southern Germany. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 754-759.	0.6	2

#	ARTICLE	IF	CITATIONS
3134	An Unfinished History: A Story of Ongoing Events and Mutating HIV Problems. <i>Social Aspects of HIV</i> , 2021, , 289-302.	0.1	0
3135	PrEP Is a Programme™: What Does this Mean for Policy. <i>Social Aspects of HIV</i> , 2021, , 21-34.	0.1	1
3136	The Political Life of PrEP in England: An Ethnographic Account. <i>Social Aspects of HIV</i> , 2021, , 145-158.	0.1	2
3137	TransPrEP: Results from the Pilot Study of a Social Network-Based Intervention to Support PrEP Adherence Among Transgender Women in Lima, Peru. <i>AIDS and Behavior</i> , 2021, 25, 1873-1883.	1.4	15
3138	Pre-Exposure Prophylaxis Training among Medical Schools in the United States. <i>Journal of Primary Care and Community Health</i> , 2021, 12, 215013272110287.	1.0	5
3139	Acquired immune deficiency syndrome (AIDS) and late presentation in Poland – data from Test and Keep in Care (TAK) Polska project. <i>HIV Medicine</i> , 2021, 22, 387-396.	1.0	12
3140	Acesso a PrEP por homens cisgênero e transexuais: Um estudo de abordagem qualitativa. <i>Research, Society and Development</i> , 2021, 10, e44310111843.	0.0	0
3141	A qualitative study to identify critical attributes and attribute-levels for a discrete choice experiment on oral pre-exposure prophylaxis (PrEP) delivery among young people in Cape Town and Johannesburg, South Africa. <i>BMC Health Services Research</i> , 2021, 21, 17.	0.9	13
3142	The continuing HIV epidemic among men who have sex with men and transgender women in the ASEAN region: implications for HIV policy and service programming. <i>Sexual Health</i> , 2021, 18, 21.	0.4	11
3143	Bibliometric analysis of the top 100 cited articles on HIV/AIDS. <i>Annals of Infection</i> , 0, 5, 6-6.	0.0	2
3144	Preventive Efficacy of a Tenofovir Alafenamide Fumarate Nanofluidic Implant in SHIV-Challenged Nonhuman Primates. <i>Advanced Therapeutics</i> , 2021, 4, 2000163.	1.6	28
3145	Beyond HIV prevention: everyday life priorities and demand for PrEP among Ugandan HIV serodiscordant couples. <i>Journal of the International AIDS Society</i> , 2019, 22, e25225.	1.2	34
3146	Couple-Based HIV Prevention and Treatment: State of Science, Gaps, and Future Directions. , 2012, , 153-172.		11
3147	Animal Models of HIV Transmission Through Breastfeeding and Pediatric HIV Infection. <i>Advances in Experimental Medicine and Biology</i> , 2012, 743, 89-108.	0.8	5
3148	The New Public Health and STD/HIV Prevention. , 2013, , .		4
3149	Enhancing Women's Sexual Health: Prevention Measures in Diverse Populations of Women. , 2013, , 197-219.		1
3151	Advances, Promises, and Challenges in HIV Prevention. , 2014, , 3-28.		1
3152	Implementing Biomedical HIV Prevention Advances in Ecuador and Peru. , 2014, , 251-266.		2

#	ARTICLE	IF	CITATIONS
3154	Adherence to HIV Treatment as Prevention and Preexposure Prophylaxis. , 2014, , 69-108.		2
3155	Mental Health and Substance Use in the Scale-Up of HIV Prevention. , 2014, , 139-159.		1
3156	Revolution or Evolution? What Can Approaches Based on the Use of Antiretroviral Drugs Contribute to HIV Prevention in Gay Communities in High-Income Countries?. , 2014, , 181-204.		3
3157	The Clinical Spectrum of Human Immunodeficiency Virus Infection. , 2020, , 295-317.		1
3158	Topics in Global LGBTQ Health. , 2020, , 261-288.		3
3159	Sexually Transmitted Infections in LGBT Populations. , 2016, , 233-262.		3
3160	Understanding the HIV/AIDS Epidemic in the United States—The Role of Syndemics in Shaping the Public’s Health. Social Disparities in Health and Health Care, 2016, , 1-17.	0.0	2
3161	Prevention of Sexually Transmitted Infections Among Adolescents. , 2017, , 183-205.		4
3162	Stigma, Sex and Family Life: Serodiscordance in Henan Province, China. Social Aspects of HIV, 2017, , 125-138.	0.1	1
3164	The Democratic Biopolitics of PrEP. Politologische Aufklärung - Konstruktivistische Perspektiven, 2019, , 121-153.	0.4	14
3165	Trends in Sexual Behavior Among Men Who have Sex with Men (MSM) in High-Income Countries, 1990–2013: A Systematic Review. AIDS and Behavior, 2017, 21, 2811-2834.	1.4	77
3166	The Influence of Relationship Dynamics and Sexual Agreements on Perceived Partner Support and Benefit of PrEP Use Among Same-Sex Male Couples in the U.S.. AIDS and Behavior, 2020, 24, 2169-2177.	1.4	14
3167	Risk Perception, Sexual Behaviors, and PrEP Adherence Among Substance-Using Men Who Have Sex with Men: a Qualitative Study. Prevention Science, 2017, 18, 737-747.	1.5	104
3168	Role of Social and Sexual Network Factors in PrEP Utilization Among YMSM and Transgender Women in Chicago. Prevention Science, 2019, 20, 1089-1097.	1.5	31
3169	Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions. Current HIV/AIDS Reports, 2020, 17, 301-314.	1.1	83
3170	La implementaci3n de la profilaxis preexposici3n podr3a evitar la mayor3a de las nuevas infecciones por el VIH en hombres que tienen sexo con hombres y mujeres transexuales. Revista Clinica Espanola, 2019, 219, 360-366.	0.2	8
3171	Geospatial perspectives on health: The PrEP4Love campaign and the role of local context in health promotion messaging. Social Science and Medicine, 2020, 265, 113497.	1.8	10
3172	Global PrEP roll-out: recommendations for programmatic success. Lancet HIV,the, 2019, 6, e137-e140.	2.1	66

#	ARTICLE	IF	CITATIONS
3173	Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies. <i>Lancet HIV</i> , 2020, 7, e721-e730.	2.1	38
3174	Sexuality and HIV/AIDS prevention.. , 2014, , 697-724.		1
3175	HIV risk and multiple sources of heterosexism among young Black men who have sex with men.. <i>Journal of Consulting and Clinical Psychology</i> , 2017, 85, 1122-1130.	1.6	15
3176	Cognitive influences on sexual risk and risk appraisals in men who have sex with men.. <i>Health Psychology</i> , 2014, 33, 690-698.	1.3	30
3177	Syndemic conditions and HIV transmission risk behavior among HIV-negative gay and bisexual men in a U.S. national sample.. <i>Health Psychology</i> , 2017, 36, 695-703.	1.3	60
3178	Health care discrimination, sex behavior disclosure, and awareness of pre-exposure prophylaxis among Black men who have sex with men.. <i>Stigma and Health</i> , 2018, 3, 330-337.	1.2	19
3180	Transforming Australiaâ€™s HIV prevention and treatment efforts to achieve an AIDS-free generation: the United Nations Political Declaration on HIV/AIDS and the Melbourne Declaration â€“ Action on HIVâ€™. <i>Sexual Health</i> , 2014, 11, 101.	0.4	3
3181	Baseline characteristics of gay and bisexual men in a HIV pre-exposure prophylaxis demonstration project with equity quotas in Auckland, New Zealand. <i>Sexual Health</i> , 2019, 16, 47.	0.4	7
3182	Early experience of implementing a national HIV pre-exposure prophylaxis service in Wales, United Kingdom 2017. <i>Sexual Health</i> , 2019, 16, 56.	0.4	7
3183	Long-term follow-up of HIV seroconverters in microbicide trials â€“ rationale, study design, and challenges in MTN-015. <i>HIV Clinical Trials</i> , 2016, 17, 204-211.	2.0	7
3184	Can gut microbiota of men who have sex with men influence HIV transmission?. <i>Gut Microbes</i> , 2020, 11, 610-619.	4.3	18
3185	Differing Experiences with Pre-Exposure Prophylaxis in Boston Among Lesbian, Gay, Bisexual, and Transgender Specialists and Generalists in Primary Care: Implications for Scale-Up. <i>AIDS Patient Care and STDs</i> , 2017, 31, 297-304.	1.1	39
3186	Disseminated Effects in Agent-Based Models: A Potential Outcomes Framework and Application to Inform Preexposure Prophylaxis Coverage Levels for HIV Prevention. <i>American Journal of Epidemiology</i> , 2021, 190, 939-948.	1.6	12
3187	Attitudes Among Men and Women Regarding Pre-exposure Prophylaxis to Prevent HIV Acquisition in an Urban HIV-Prevalent Setting in the United States. <i>Open Forum Infectious Diseases</i> , 2015, 2, .	0.4	2
3188	HIV-1 treatment as prevention: the good, the bad, and the challenges. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 1.	1.5	66
3189	Health Profession Studentsâ€™ Awareness, Knowledge, and Confidence Regarding Preexposure Prophylaxis: Results of a National, Multidisciplinary Survey. <i>Sexually Transmitted Diseases</i> , 2021, 48, 25-31.	0.8	9
3190	Dramatic increase in preexposure prophylaxis use among MSM in King County, Washington. <i>Aids</i> , 2015, 30, 1.	1.0	70
3191	Decision-making regarding condom use among daily and event-driven users of preexposure prophylaxis in the Netherlands. <i>Aids</i> , 2020, 34, 2295-2304.	1.0	16

#	ARTICLE	IF	CITATIONS
3192	Mathematical Model Impact Analysis of a Real-Life Pre-exposure Prophylaxis and Treatment-As-Prevention Study Among Female Sex Workers in Cotonou, Benin. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 86, e28-e42.	0.9	5
3193	How actively should we screen for chlamydia and gonorrhoea in MSM and other high-ST-prevalence populations as we enter the era of increasingly untreatable infections? A viewpoint. <i>Journal of Medical Microbiology</i> , 2019, 68, 132-135.	0.7	11
3202	Couples-based approach to HIV prevention for transgender women and their partners: study protocol for a randomised controlled trial testing the efficacy of the "It Takes Two"™ intervention. <i>BMJ Open</i> , 2020, 10, e038723.	0.8	7
3203	Challenges in optimizing preexposure prophylaxis development, engagement, and access for HIV prevention. <i>Journal of Clinical Investigation</i> , 2019, 129, 5071-5073.	3.9	2
3204	Rare serotype adenoviral vectors for HIV vaccine development. <i>Journal of Clinical Investigation</i> , 2012, 122, 25-27.	3.9	15
3205	ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions. <i>Journal of Clinical Investigation</i> , 2016, 126, 892-904.	3.9	30
3206	Evaluation of Algorithms Used for PrEP Surveillance Using a Reference Population From New York City, July 2016–June 2018. <i>Public Health Reports</i> , 2020, 135, 202-210.	1.3	17
3207	Pleasure and PrEP: Pleasure-Seeking Plays a Role in Prevention Choices and Could Lead to PrEP Initiation. <i>American Journal of Men's Health</i> , 2019, 13, 155798831982739.	0.7	54
3208	- Microbicide Formulation Development: Scale-Up, Affordability, and Intellectual Property Issues. , 2014, , 558-571.		7
3209	Screening is not associated with reduced incidence of gonorrhoea or chlamydia in men who have sex with men (MSM); an ecological study of 23 European countries. <i>F1000Research</i> , 2019, 8, 160.	0.8	8
3210	Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa. <i>Gates Open Research</i> , 2017, 1, 3.	2.0	71
3211	Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa. <i>Gates Open Research</i> , 2017, 1, 3.	2.0	75
3212	Community Inclusion in PrEP Demonstration Projects: Lessons for Scaling Up. <i>Gates Open Research</i> , 0, 3, 1504.	2.0	15
3213	Community Inclusion in PrEP Demonstration Projects: Lessons for Scaling Up. <i>Gates Open Research</i> , 2019, 3, 1504.	2.0	17
3214	Evaluation of a behavior-centered design strategy for creating demand for oral PrEP among young women in Cape Town, South Africa. <i>Gates Open Research</i> , 2020, 4, 29.	2.0	16
3215	Evaluation of a behavior-centered design strategy for creating demand for oral PrEP among young women in Cape Town, South Africa. <i>Gates Open Research</i> , 2020, 4, 29.	2.0	14
3216	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. <i>PLoS Medicine</i> , 2017, 14, e1002417.	3.9	186
3217	Implementation science and the Health Resources and Services Administration's Ryan White HIV/AIDS Program's work towards ending the HIV epidemic in the United States. <i>PLoS Medicine</i> , 2020, 17, e1003128.	3.9	16

#	ARTICLE	IF	CITATIONS
3218	Evaluating the Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) and Its Impact on HIV-1 Transmission in South Africa. PLoS ONE, 2010, 5, e13646.	1.1	120
3219	Rising Population Cost for Treating People Living with HIV in the UK, 1997-2013. PLoS ONE, 2010, 5, e15677.	1.1	37
3220	HIV Quasispecies Dynamics during Pro-Active Treatment Switching: Impact on Multi-Drug Resistance and Resistance Archiving in Latent Reservoirs. PLoS ONE, 2011, 6, e18204.	1.1	35
3221	T Cell Chemo-Vaccination Effects after Repeated Mucosal SHIV Exposures and Oral Pre-Exposure Prophylaxis. PLoS ONE, 2011, 6, e19295.	1.1	16
3222	HIV Pre-Exposure Prophylaxis (PrEP) – A Quantitative Ethics Appraisal. PLoS ONE, 2011, 6, e22497.	1.1	3
3223	First Phase 1 Double-Blind, Placebo-Controlled, Randomized Rectal Microbicide Trial Using UC781 Gel with a Novel Index of Ex Vivo Efficacy. PLoS ONE, 2011, 6, e23243.	1.1	79
3224	Enrollment Characteristics and Risk Behaviors of Injection Drug Users Participating in the Bangkok Tenofovir Study, Thailand. PLoS ONE, 2011, 6, e25127.	1.1	35
3225	An Inducible Cell-Cell Fusion System with Integrated Ability to Measure the Efficiency and Specificity of HIV-1 Entry Inhibitors. PLoS ONE, 2011, 6, e26731.	1.1	32
3226	Using HIV Transmission Networks to Investigate Community Effects in HIV Prevention Trials. PLoS ONE, 2011, 6, e27775.	1.1	34
3227	Modeling the Population-Level Effects of Male Circumcision as an HIV-Preventive Measure: A Gendered Perspective. PLoS ONE, 2011, 6, e28608.	1.1	19
3228	Willingness to Accept HIV Pre-Exposure Prophylaxis among Chinese Men Who Have Sex with Men. PLoS ONE, 2012, 7, e32329.	1.1	78
3229	Limited Awareness and Low Immediate Uptake of Pre-Exposure Prophylaxis among Men Who Have Sex with Men Using an Internet Social Networking Site. PLoS ONE, 2012, 7, e33119.	1.1	222
3230	Pharmacokinetics and Pharmacodynamics of the Reverse Transcriptase Inhibitor Tenofovir and Prophylactic Efficacy against HIV-1 Infection. PLoS ONE, 2012, 7, e40382.	1.1	57
3231	Universal Access to HIV Treatment versus Universal “Test and Treat”: Transmission, Drug Resistance & Treatment Costs. PLoS ONE, 2012, 7, e41212.	1.1	49
3232	The Meaning of Adherence When Behavioral Risk Patterns Vary: Obscured Use- and Method-Effectiveness in HIV-Prevention Trials. PLoS ONE, 2012, 7, e44029.	1.1	6
3233	Ambiguity, Ambivalence, and Apprehensions of Taking HIV-1 Pre-Exposure Prophylaxis among Male Couples in San Francisco: A Mixed Methods Study. PLoS ONE, 2012, 7, e50061.	1.1	79
3234	What Drives the US and Peruvian HIV Epidemics in Men Who Have Sex with Men (MSM)? PLoS ONE, 2012, 7, e50522.	1.1	296
3235	In Captive Rhesus Macaques, Cervicovaginal Inflammation Is Common but Not Associated with the Stable Polymicrobial Microbiome. PLoS ONE, 2012, 7, e52992.	1.1	16

#	ARTICLE	IF	CITATIONS
3236	MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments. PLoS ONE, 2013, 8, e55013.	1.1	174
3237	Rectal Transmission of Transmitted/Founder HIV-1 Is Efficiently Prevented by Topical 1% Tenofovir in BLT Humanized Mice. PLoS ONE, 2013, 8, e60024.	1.1	54
3238	Sexual Healthcare Preferences among Gay and Bisexual Men: A Qualitative Study in San Francisco, California. PLoS ONE, 2013, 8, e71546.	1.1	36
3239	Population-Level Benefits from Providing Effective HIV Prevention Means to Pregnant Women in High Prevalence Settings. PLoS ONE, 2013, 8, e73770.	1.1	6
3240	Analytic Review of Modeling Studies of ARV Based PrEP Interventions Reveals Strong Influence of Drug-Resistance Assumptions on the Population-Level Effectiveness. PLoS ONE, 2013, 8, e80927.	1.1	12
3241	No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis. PLoS ONE, 2013, 8, e81997.	1.1	193
3242	Pre-Exposure Prophylaxis for the Prevention of HIV Infection in High Risk Populations: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2014, 9, e87674.	1.1	55
3243	Women's Experiences with Oral and Vaginal Pre-Exposure Prophylaxis: The VOICE-C Qualitative Study in Johannesburg, South Africa. PLoS ONE, 2014, 9, e89118.	1.1	228
3244	Bone Mineral Density Changes among HIV-Uninfected Young Adults in a Randomised Trial of Pre-Exposure Prophylaxis with Tenofovir-Emtricitabine or Placebo in Botswana. PLoS ONE, 2014, 9, e90111.	1.1	69
3245	Daily Oral Emtricitabine/Tenofovir Preexposure Prophylaxis and Herpes Simplex Virus Type 2 among Men Who Have Sex with Men. PLoS ONE, 2014, 9, e91513.	1.1	27
3246	Risk Behaviors and Risk Factors for HIV Infection among Participants in the Bangkok Tenofovir Study, an HIV Pre-Exposure Prophylaxis Trial among People Who Inject Drugs. PLoS ONE, 2014, 9, e92809.	1.1	21
3247	The Sexual Risk Context among the FEM-PrEP Study Population in Bondo, Kenya and Pretoria, South Africa. PLoS ONE, 2014, 9, e106410.	1.1	11
3248	HIV Transmission among Men Who Have Sex with Men due to Condom Failure. PLoS ONE, 2014, 9, e107540.	1.1	12
3249	Combination HIV Prevention among MSM in South Africa: Results from Agent-based Modeling. PLoS ONE, 2014, 9, e112668.	1.1	42
3250	HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy?. PLoS ONE, 2014, 9, e113031.	1.1	21
3251	High Interest in a Long-Acting Injectable Formulation of Pre-Exposure Prophylaxis for HIV in Young Men Who Have Sex with Men in NYC: A P18 Cohort Substudy. PLoS ONE, 2014, 9, e114700.	1.1	74
3252	Estimating the Cost-Effectiveness of Pre-Exposure Prophylaxis to Reduce HIV-1 and HSV-2 Incidence in HIV-Serodiscordant Couples in South Africa. PLoS ONE, 2015, 10, e0115511.	1.1	17
3253	Immune Activation in the Female Genital Tract: Expression Profiles of Soluble Proteins in Women at High Risk for HIV Infection. PLoS ONE, 2016, 11, e0143109.	1.1	51

#	ARTICLE	IF	CITATIONS
3254	Knowledge, Attitudes, and Acceptability of Pre-Exposure Prophylaxis among Individuals Living with HIV in an Urban HIV Clinic. PLoS ONE, 2016, 11, e0145670.	1.1	22
3255	Who Will Use Pre-Exposure Prophylaxis (PrEP) and Why?: Understanding PrEP Awareness and Acceptability amongst Men Who Have Sex with Men in the UK – A Mixed Methods Study. PLoS ONE, 2016, 11, e0151385.	1.1	47
3256	Integration of Social, Cultural, and Biomedical Strategies into an Existing Couple-Based Behavioral HIV/STI Prevention Intervention: Voices of Latino Male Couples. PLoS ONE, 2016, 11, e0152361.	1.1	42
3257	Comparing the Information and Support Needs of Different Population Groups in Preparation for 2015 Government Approval for HIV Self-testing in France. PLoS ONE, 2016, 11, e0152567.	1.1	10
3258	What Is Required to End the AIDS Epidemic as a Public Health Threat by 2030? The Cost and Impact of the Fast-Track Approach. PLoS ONE, 2016, 11, e0154893.	1.1	163
3259	PEP and TasP Awareness among Italian MSM, PLWHA, and High-Risk Heterosexuals and Demographic, Behavioral, and Social Correlates. PLoS ONE, 2016, 11, e0157339.	1.1	32
3260	How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact. PLoS ONE, 2016, 11, e0158620.	1.1	19
3261	Prioritizing Risk in Preparation for a Demonstration Project: A Mixed Methods Feasibility Study of Oral Pre-Exposure Prophylaxis (PREP) among Female Sex Workers in South India. PLoS ONE, 2016, 11, e0166889.	1.1	28
3262	Individual HIV Risk versus Population Impact of Risk Compensation after HIV Preexposure Prophylaxis Initiation among Men Who Have Sex with Men. PLoS ONE, 2017, 12, e0169484.	1.1	35
3263	Generational analysis of trends in unprotected sex in France among men who have sex with men: The major role of context-driven evolving patterns. PLoS ONE, 2017, 12, e0171493.	1.1	14
3264	Social, structural, behavioral and clinical factors influencing retention in Pre-Exposure Prophylaxis (PrEP) care in Mississippi. PLoS ONE, 2017, 12, e0172354.	1.1	160
3265	Awareness and attitudes of pre-exposure prophylaxis for HIV prevention among physicians in Guatemala: Implications for country-wide implementation. PLoS ONE, 2017, 12, e0173057.	1.1	24
3266	An intravaginal ring for real-time evaluation of adherence to therapy. PLoS ONE, 2017, 12, e0174729.	1.1	5
3267	The potential impact and cost of focusing HIV prevention on young women and men: A modeling analysis in western Kenya. PLoS ONE, 2017, 12, e0175447.	1.1	17
3268	HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial. PLoS ONE, 2017, 12, e0178594.	1.1	4
3269	Willingness of community-recruited men who have sex with men in Washington, DC to use long-acting injectable HIV pre-exposure prophylaxis. PLoS ONE, 2017, 12, e0183521.	1.1	30
3270	Validation of participant eligibility for pre-exposure prophylaxis: Baseline data from the PRELUDE demonstration project. PLoS ONE, 2017, 12, e0185398.	1.1	7
3271	HIV transmission and pre-exposure prophylaxis in a high risk MSM population: A simulation study of location-based selection of sexual partners. PLoS ONE, 2017, 12, e0189002.	1.1	4

#	ARTICLE	IF	CITATIONS
3272	Home-based pre-exposure prophylaxis (PrEP) services for gay and bisexual men: An opportunity to address barriers to PrEP uptake and persistence. PLoS ONE, 2017, 12, e0189794.	1.1	53
3273	Prevalence of actual uptake and willingness to use pre-exposure prophylaxis to prevent HIV acquisition among men who have sex with men in Hong Kong, China. PLoS ONE, 2018, 13, e0191671.	1.1	40
3274	“You can’t have a PrEP program without a PrEP Coordinator” Implementation of a PrEP panel management intervention. PLoS ONE, 2020, 15, e0240745.	1.1	14
3275	PrEP discontinuation among Latino/a and Black MSM and transgender women: A need for PrEP support services. PLoS ONE, 2020, 15, e0241340.	1.1	35
3276	Longitudinal trends in PrEP familiarity, attitudes, use and discontinuation among a national probability sample of gay and bisexual men, 2016–2018. PLoS ONE, 2020, 15, e0244448.	1.1	20
3277	Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission. PLoS Pathogens, 2015, 11, e1005075.	2.1	60
3278	Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus. PLoS Pathogens, 2016, 12, e1005619.	2.1	97
3279	Advances in Nucleotide Antiviral Development from Scientific Discovery to Clinical Applications: Tenofovir Disoproxil Fumarate for Hepatitis B. Journal of Clinical and Translational Hepatology, 2013, 1, 33-8.	0.7	10
3280	Tackling the social and structural drivers of HIV in Canada. Canada Communicable Disease Report, 2015, 41, 322-326.	0.6	4
3281	Setting the stage for expanding HIV pre-exposure prophylaxis use in Canada. Canada Communicable Disease Report, 2017, 43, 272-278.	0.6	17
3282	Vital Signs: Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition – United States, 2015. Morbidity and Mortality Weekly Report, 2015, 64, 1291-1295.	9.0	293
3283	HIV Preexposure Prophylaxis in the U.S. Military Services – 2014–2016. Morbidity and Mortality Weekly Report, 2018, 67, 569-574.	9.0	15
3284	Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020. MMWR Recommendations and Reports, 2020, 69, 1-12.	26.7	56
3285	Beyond Men, Women, or Both: A Comprehensive, LGBTQ-Inclusive, Implicit-Bias-Aware, Standardized-Patient-Based Sexual History Taking Curriculum. MedEdPORTAL: the Journal of Teaching and Learning Resources, 2017, 13, 10634.	0.5	43
3286	A Guide for Designing Student-Led, Interprofessional Community Education Initiatives About HIV Risk and Pre-Exposure Prophylaxis. MedEdPORTAL: the Journal of Teaching and Learning Resources, 2019, 15, 10818.	0.5	17
3287	Major Infectious Diseases: Key Messages from Disease Control Priorities, Third Edition. , 2017, , 1-27.		28
3288	Sexually Transmitted Infections: Impact and Cost-Effectiveness of Prevention. , 2017, , 203-232.		26
3289	Cost-Effectiveness of Interventions to Prevent HIV Acquisition. , 2017, , 137-155.		8

#	ARTICLE	IF	CITATIONS
3290	Tailoring the Local HIV/AIDS Response to Local HIV/AIDS Epidemics. , 2017, , 157-178.		6
3291	Current Trends in HIV/AIDS. Journal of HIV/AIDS and Infectious Diseases, 2013, , 1-2.	0.0	3
3292	Updating the management of sexually transmitted infections. Australian Prescriber, 2015, 38, 204-208.	0.5	3
3293	Microbicides for topical immunoprevention of HIV infection. Bulletin of Siberian Medicine, 2019, 18, 49-59.	0.1	5
3294	Global Efforts against HIV Epidemic and HIV Vaccine Development. Tropical Medicine and Health, 2014, 42, S91-S92.	1.0	3
3295	HIV-Antigens Charged on Phosphorus Dendrimers as Tools for Tolerogenic Dendritic Cells-Based Immunotherapy. Current Medicinal Chemistry, 2014, 21, 1898-1909.	1.2	19
3296	Inhibitors of HIV-1 Entry. Current Pharmaceutical Design, 2013, 19, 1784-1799.	0.9	8
3297	Lessons Learned from HIV Vaccine Clinical Efficacy Trials. Current HIV Research, 2014, 11, 441-449.	0.2	38
3298	Social Justice and HIV Vaccine Research in the Age of Pre-Exposure Prophylaxis and Treatment as Prevention. Current HIV Research, 2014, 11, 473-480.	0.2	9
3299	Protein-Based HIV-1 Microbicides. Current HIV Research, 2014, 11, 576-594.	0.2	9
3300	PrEP Awareness and Perceived Barriers Among Single Young Men who have Sex with Men. Current HIV Research, 2014, 11, 520-527.	0.2	204
3301	Pre-Exposure Prophylaxis (PrEP) in Men Who have Sex with Men in BouakÃ©, CÃ´te d'Ivoire: A Qualitative Evaluation of Acceptability. Open AIDS Journal, 2019, 13, 49-58.	0.1	7
3302	University of North Carolina/Emory Center for Innovative Technology (iTech) for Addressing the HIV Epidemic Among Adolescents and Young Adults in the United States: Protocol and Rationale for Center Development. JMIR Research Protocols, 2018, 7, e10365.	0.5	40
3303	A Multilevel Tailored Web App-Based Intervention for Linking Young Men Who Have Sex With Men to Quality Care (Get Connected): Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e10444.	0.5	43
3304	Testing the Efficacy of a Social Networking Gamification App to Improve Pre-Exposure Prophylaxis Adherence (P3: Prepared, Protected, emPowered): Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e10448.	0.5	54
3305	Smartphone-Based Contingency Management Intervention to Improve Pre-Exposure Prophylaxis Adherence: Pilot Trial. JMIR MHealth and UHealth, 2018, 6, e10456.	1.8	43
3306	Developing a Mobile App (LYNX) to Support Linkage to HIV/Sexually Transmitted Infection Testing and Pre-Exposure Prophylaxis for Young Men Who Have Sex With Men: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2019, 8, e10659.	0.5	46
3307	A Pre-Exposure Prophylaxis Adherence Intervention (LifeSteps) for Young Men Who Have Sex With Men: Protocol for a Pilot Randomized Controlled Trial. JMIR Research Protocols, 2019, 8, e10661.	0.5	13

#	ARTICLE	IF	CITATIONS
3308	A Mobile-Based App (MyChoices) to Increase Uptake of HIV Testing and Pre-Exposure Prophylaxis by Young Men Who Have Sex With Men: Protocol for a Pilot Randomized Controlled Trial. JMIR Research Protocols, 2019, 8, e10694.	0.5	59
3309	Using eHealth to Reach Black and Hispanic Men Who Have Sex With Men Regarding Treatment as Prevention and Preexposure Prophylaxis: Protocol for a Small Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e11047.	0.5	12
3310	Empowering With PrEP (E-PrEP), a Peer-Led Social Media-Based Intervention to Facilitate HIV Preexposure Prophylaxis Adoption Among Young Black and Latinx Gay and Bisexual Men: Protocol for a Cluster Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e11375.	0.5	65
3311	Using Partially-Observed Facebook Networks to Develop a Peer-Based HIV Prevention Intervention: Case Study. Journal of Medical Internet Research, 2018, 20, e11652.	2.1	7
3312	The PrEP You Want: A Web-Based Survey of Online Cross-Border Shopping for HIV Prophylaxis Medications. Journal of Medical Internet Research, 2019, 21, e12076.	2.1	2
3313	Spatial Access and Willingness to Use Pre-Exposure Prophylaxis Among Black/African American Individuals in the United States: Cross-Sectional Survey. JMIR Public Health and Surveillance, 2019, 5, e12405.	1.2	33
3314	Acceptability and Feasibility of Self-Collecting Biological Specimens for HIV, Sexually Transmitted Infection, and Adherence Testing Among High-Risk Populations (Project Caboodle!): Protocol for an Exploratory Mixed-Methods Study. JMIR Research Protocols, 2019, 8, e13647.	0.5	13
3315	Factors Associated With Willingness to Use Pre-Exposure Prophylaxis in Brazil, Mexico, and Peru: Web-Based Survey Among Men Who Have Sex With Men. JMIR Public Health and Surveillance, 2019, 5, e13771.	1.2	58
3316	An Electronic Pre-Exposure Prophylaxis Initiation and Maintenance Home Care System for Nonurban Young Men Who Have Sex With Men: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2019, 8, e13982.	0.5	41
3317	Testing a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to Preexposure Prophylaxis in Kenya (PUMA): Protocol for a Pilot Randomized Controlled Trial. JMIR Research Protocols, 2020, 9, e15029.	0.5	14
3318	A Web-Based Intervention to Reduce Decision Conflict Regarding HIV Pre-Exposure Prophylaxis: Protocol for a Clinical Trial. JMIR Research Protocols, 2020, 9, e15080.	0.5	8
3319	Testing the Effectiveness and Cost-Effectiveness of a Combination HIV Prevention Intervention Among Young Cisgender Men Who Have Sex With Men and Transgender Women Who Sell or Exchange Sex in Thailand: Protocol for the Combination Prevention Effectiveness Study. JMIR Research Protocols, 2020, 9, e15354.	0.5	7
3320	A Mobile Intervention to Improve Uptake of Pre-Exposure Prophylaxis for Southern Black Men Who Have Sex With Men: Protocol for Intervention Development and Pilot Randomized Controlled Trial. JMIR Research Protocols, 2020, 9, e15781.	0.5	15
3321	A Theoretically-Based Mobile App to Increase Pre-exposure Prophylaxis Uptake Among Men Who Have Sex With Men: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2020, 9, e16231.	0.5	27
3322	Feasibility and Acceptability of an Electronic Health HIV Prevention Toolkit Intervention With Concordant HIV-Negative, Same-Sex Male Couples on Sexual Agreement Outcomes: Pilot Randomized Controlled Trial. JMIR Formative Research, 2020, 4, e16807.	0.7	17
3323	A Mobile Sexual Health App on Empowerment, Education, and Prevention for Young Adult Men (MyPEEPS Mobile): Acceptability and Usability Evaluation. JMIR Formative Research, 2020, 4, e17901.	0.7	26
3324	Protocol Development for HMU! (HIV Prevention for Methamphetamine Users), a Study of Peer Navigation and Text Messaging to Promote Pre-Exposure Prophylaxis Adherence and Persistence Among People Who Use Methamphetamine: Qualitative Focus Group and Interview Study. JMIR Formative Research, 2020, 4, e18118.	0.7	5
3325	A Mobile Gaming Intervention for Persons on Pre-Exposure Prophylaxis: Protocol for Intervention Development and Randomized Controlled Trial. JMIR Research Protocols, 2020, 9, e18640.	0.5	8

#	ARTICLE	IF	CITATIONS
3326	Mobile App (UPrEPU) to Monitor Adherence to Pre-exposure Prophylaxis in Men Who Have Sex With Men: Protocol for a User-Centered Approach to Mobile App Design and Development. JMIR Research Protocols, 2020, 9, e20360.	0.5	9
3327	A Simple Pre-Exposure Prophylaxis (PrEP) Optimization Intervention for Health Care Providers Prescribing PrEP: Pilot Study. JMIR Formative Research, 2018, 2, e2.	0.7	19
3328	Australian Gay Men Describe the Details of Their HIV Infection Through a Cross-Sectional Web-Based Survey. Journal of Medical Internet Research, 2016, 18, e227.	2.1	1
3329	Preexposure Prophylaxis Modality Preferences Among Men Who Have Sex With Men and Use Social Media in the United States. Journal of Medical Internet Research, 2016, 18, e111.	2.1	27
3330	Formative Work to Develop a Tailored HIV Testing Smartphone App for Diverse, At-Risk, HIV-Negative Men Who Have Sex With Men: A Focus Group Study. JMIR MHealth and UHealth, 2016, 4, e128.	1.8	40
3331	Usability and Acceptability of a Mobile Comprehensive HIV Prevention App for Men Who Have Sex With Men: A Pilot Study. JMIR MHealth and UHealth, 2017, 5, e26.	1.8	129
3334	The Annual American Men's Internet Survey of Behaviors of Men Who Have Sex With Men in the United States: Protocol and Key Indicators Report 2013. JMIR Public Health and Surveillance, 2015, 1, e3.	1.2	100
3335	Factors Associated With Condom Breakage During Anal Intercourse: A Cross-Sectional Study of Men Who Have Sex With Men Recruited in an Online Survey. JMIR Public Health and Surveillance, 2016, 2, e7.	1.2	7
3336	Detailed Knowledge About HIV Epidemiology and Transmission Dynamics and Their Associations With Preventive and Risk Behaviors Among Gay, Bisexual, and Other Men Who Have Sex With Men in the United States. JMIR Public Health and Surveillance, 2017, 3, e11.	1.2	11
3337	Pre-Exposure Prophylaxis YouTube Videos: Content Evaluation. JMIR Public Health and Surveillance, 2018, 4, e19.	1.2	19
3338	Functional Knowledge of Pre-Exposure Prophylaxis for HIV Prevention Among Participants in a Web-Based Survey of Sexually Active Gay, Bisexual, and Other Men Who Have Sex With Men: Cross-Sectional Study. JMIR Public Health and Surveillance, 2018, 4, e13.	1.2	21
3339	Predictors of Facebook User Engagement With Health-Related Content for Gay, Bisexual, and Other Men Who Have Sex With Men: Content Analysis. JMIR Public Health and Surveillance, 2018, 4, e38.	1.2	25
3340	Awareness of Prevention Strategies and Willingness to Use Preexposure Prophylaxis in Brazilian Men Who Have Sex With Men Using Apps for Sexual Encounters: Online Cross-Sectional Study. JMIR Public Health and Surveillance, 2018, 4, e11.	1.2	43
3341	Pre-Exposure Prophylaxis (PrEP) as an Additional Tool for HIV Prevention Among Men Who Have Sex With Men in Belgium: The Be-PrEP-ared Study Protocol. JMIR Research Protocols, 2017, 6, e11.	0.5	27
3342	Rilpivirine: The Key for Long-term Success. AIDS Reviews, 2017, 19, .	0.5	7
3344	Letter to the editor: Pre-exposure prophylaxis for HIV in Europe: The need for resistance surveillance. Eurosurveillance, 2017, 22, .	3.9	6
3345	New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017. Eurosurveillance, 2019, 24, .	3.9	4
3346	Estimating the "PrEP Gap": how implementation and access to PrEP differ between countries in Europe and Central Asia in 2019. Eurosurveillance, 2019, 24, .	3.9	57

#	ARTICLE	IF	CITATIONS
3347	Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058. <i>Eurosurveillance</i> , 2019, 24, .	3.9	21
3348	Increase of new HIV diagnoses among men who have sex with men in Poland, 2000 to 2011. <i>Eurosurveillance</i> , 2013, 18, 20642.	3.9	19
3349	Sexual and prevention practices in men who have sex with men in the era of combination HIV prevention: results from the Presse Gays et lesbiennes survey, France, 2011. <i>Eurosurveillance</i> , 2015, 20, .	3.9	24
3350	A systematic review of evidence to inform HIV prevention interventions among men who have sex with men in Europe. <i>Eurosurveillance</i> , 2015, 20, .	3.9	39
3351	Pre-exposure Prophylaxis as HIV Prevention in High Risk Adolescents. <i>Journal of Pediatrics and Pediatric Medicine</i> , 2018, 2, 5-10.	0.9	5
3352	Shifting the Paradigm in HIV Prevention and Treatment Service Delivery Toward Differentiated Care for Youth. <i>NAM Perspectives</i> , 0, , .	1.3	7
3353	Factors Associated With Discussions of Human Immunodeficiency Virus Pre-Exposure Prophylaxis in Men Who Have Sex With Men. <i>Ochsner Journal</i> , 2019, 19, 188-193.	0.5	3
3354	“What if They Are Pre-conception? What Should We Do?” Knowledge, Practices, and Preferences for Safer Conception Among Women Living With HIV and Healthcare Providers in Gaborone, Botswana. <i>Frontiers in Global Women S Health</i> , 2020, 1, .	1.1	6
3355	The Effect of Tenofovir Disoproxil Fumarate on Bone Mineral Density: A Systematic Review and Meta-Analysis. <i>Antiviral Therapy</i> , 2020, 25, 21-32.	0.6	26
3356	Updates on Preventing HIV Infection. <i>Korean Journal of Medicine</i> , 2016, 90, 474-480.	0.1	4
3357	Ending LGBT invisibility in health care: The first step in ensuring equitable care. <i>Cleveland Clinic Journal of Medicine</i> , 2011, 78, 220-224.	0.6	85
3358	Guideline on safer conception in fertile HIV-infected individuals and couples. <i>Southern African Journal of HIV Medicine</i> , 2011, 12, 31-44.	0.3	70
3359	Southern African guidelines for the safe use of pre-exposure prophylaxis in men who have sex with men who are at risk for HIV infection. <i>Southern African Journal of HIV Medicine</i> , 2012, 13, .	0.3	5
3360	Providing HIV care to men who have sex with men in South African state sector clinics. <i>Southern African Journal of HIV Medicine</i> , 2014, 15, 10-11.	0.3	2
3361	Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection. <i>Southern African Journal of HIV Medicine</i> , 2016, 17, 455.	0.3	77
3362	Pre-exposure prophylaxis of HIV. <i>Indian Journal of Sexually Transmitted Diseases and AIDS</i> , 2011, 32, 1.	0.6	24
3363	Antiretroviral pre-exposure prophylaxis: A new opportunity to slow HIV spread in India. <i>Indian Journal of Medical Research</i> , 2016, 143, 125.	0.4	7
3364	The evolving Indian AIDS epidemic: Hope & challenges of the fourth decade. <i>Indian Journal of Medical Research</i> , 2011, 134, 739.	0.4	1

#	ARTICLE	IF	CITATIONS
3365	HIV serodiscordant relationships in India: Translating science to practice. Indian Journal of Medical Research, 2011, 134, 904.	0.4	16
3366	HIV in Indian MSM: Reasons for a concentrated epidemic & strategies for prevention. Indian Journal of Medical Research, 2011, 134, 920.	0.4	77
3367	Microbicides for HIV prevention. Indian Journal of Medical Research, 2011, 134, 930.	0.4	8
3368	Microbicides: A new hope for HIV prevention. Indian Journal of Medical Research, 2011, 134, 939.	0.4	14
3369	Pre- and post-sexual exposure prophylaxis of HIV: An update. Indian Journal of Sexually Transmitted Diseases and AIDS, 2017, 38, 1.	0.6	11
3370	HIV Treatment Cascades that Leak: Correlates of Drop-off from the HIV Care Continuum among Men who have Sex with Men Worldwide. Journal of AIDS & Clinical Research, 2014, 05, .	0.5	15
3371	Targeted Combination HIV Prevention Packages to Halt the Global HIV Epidemic. Journal of AIDS & Clinical Research, 2012, 01, .	0.5	1
3372	Adherence to Antiretroviral Therapy for the Success of Emerging Interventions to Prevent HIV Transmission: A Wake up Call. Journal of AIDS & Clinical Research, 2012, 01, .	0.5	7
3373	Are Low- and Middle-Income Countries Repeating Mistakes Made by High-Income Countries in the Control of HIV for Men who have Sex with Men?. Journal of AIDS & Clinical Research, 2012, 01, e001.	0.5	4
3374	Impact of Pill Sharing on Drug Resistance Due to a Wide-Scale Oral Prep Intervention in Generalized Epidemics. Journal of AIDS & Clinical Research, 2013, 01, .	0.5	16
3375	Acceptance to Use Daily Oral Pre-Exposure Prophylaxis (PrEP) as an HIV Prevention Method and Ability to Pay for PrEP among Men Who Have Sex with Men in Ho Chi Minh City, Vietnam. Health, 2017, 09, 1326-1336.	0.1	3
3376	The Role of the Pharmacist in Pre-Exposure Prophylaxis. Pharmacology & Pharmacy, 2014, 05, 225-228.	0.2	5
3377	Knowledge, Attitudes, and Experiences of HIV Pre-Exposure Prophylaxis (PrEP) Trial Participants in Botswana. World Journal of AIDS, 2015, 05, 10-20.	0.1	17
3378	A brief history of antiretroviral therapy of HIV infection: success and challenges. Annali Dell'Istituto Superiore Di Sanita, 2011, 47, 44-8.	0.2	85
3379	Web-based, mobile-device friendly, self-report survey system incorporating avatars and gaming console techniques. Online Journal of Public Health Informatics, 2014, 6, e191.	0.4	3
3380	Agent-based computational model of the prevalence of gonococcal infections after the implementation of HIV pre-exposure prophylaxis guidelines. Online Journal of Public Health Informatics, 2015, 7, e224.	0.4	5
3381	Antiviral Drugs - Aspects of Clinical Use and Recent Advances. , 2012, , .		6
3382	Biomedical HIV Prevention. , 0, , .		2

#	ARTICLE	IF	CITATIONS
3384	Double Oral Administration of Emtricitabine/Tenofovir Prior to Virus Exposure Protects against Highly Pathogenic Simian/Human Immunodeficiency Virus Infection in Macaques. <i>Japanese Journal of Infectious Diseases</i> , 2012, 65, 345-349.	0.5	2
3385	Barriers and Facilitators of Adherence in User-Dependent HIV Prevention Trials, a Systematic Review. <i>International STD Research & Reviews</i> , 2013, 1, 12-29.	0.2	9
3386	Transitions Between Preexposure Prophylaxis Eligibility States and HIV Infection in The Lisbon Cohort of HIV-Negative Men Who Have Sex with Men: a Multistate Model Analysis. <i>American Journal of Epidemiology</i> , 2021, , .	1.6	1
3387	Identifying Ethical and Culturally Responsive Research Activities to Build Trust and Improve Participation of Black Sexual Minority Men in Pre-Exposure Prophylaxis Telehealth Clinical Trials: Qualitative Study. <i>JMIR Human Factors</i> , 2022, 9, e28798.	1.0	5
3388	Long-term HIV Pre-exposure Prophylaxis Trajectories Among Racial & Ethnic Minority Patients: Short, Declining, & Sustained Adherence. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 166-171.	0.9	4
3389	HIV pre-exposure prophylaxis and sexually transmitted infections: intersection and opportunity. <i>Nature Reviews Urology</i> , 2022, 19, 7-15.	1.9	6
3390	HIV Serostatus Disclosure Among Men Who Have Sex with Men in China in the Era of U=U and PrEP. <i>AIDS and Behavior</i> , 2021, , 1.	1.4	5
3391	Metrics of HIV Pre-exposure Prophylaxis (PrEP) Implementation Before and After a Multidisciplinary Task Force at an Academic Institution. <i>Quality Management in Health Care</i> , 2021, Publish Ahead of Print, .	0.4	1
3392	Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1712-1717.	15.2	43
3393	The relevance of pre-exposure prophylaxis in gay men's lives and their motivations to use it: a qualitative study. <i>BMC Public Health</i> , 2021, 21, 1829.	1.2	8
3394	Barriers to Pre-Exposure Prophylaxis Uptake Among Online Male Sex Workers in the US. <i>AIDS and Behavior</i> , 2022, 26, 1572-1586.	1.4	7
3395	Provider Comfort with Prescribing HIV Pre-Exposure Prophylaxis to Adolescents. <i>AIDS Patient Care and STDs</i> , 2021, 35, 411-417.	1.1	22
3396	Experiences and challenges in sexual health service access among men who have sex with men in Kenya. <i>Global Public Health</i> , 2022, 17, 1626-1637.	1.0	5
3397	Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort. <i>AIDS Patient Care and STDs</i> , 2021, 35, 419-427.	1.1	6
3398	Chronic Hepatitis B Infection Among Preexposure Prophylaxis Users Enrolled in a Population-Based Program in British Columbia, Canada. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab492.	0.4	1
3399	Pre-Exposure Prophylaxis (PrEP) Adherence Questionnaire: Psychometric Validation among Sexually Transmitted Infection Patients in China. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10980.	1.2	2
3400	PrEP Use and Adherence Among Transgender Patients. <i>AIDS and Behavior</i> , 2022, 26, 1251-1259.	1.4	7
3401	Pre-exposure prophylaxis failure with a multiple drug-resistant HIV-1 clade C virus in Brazil. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, .	0.9	0

#	ARTICLE	IF	CITATIONS
3402	Association between HIV PrEP indications and use in a national sexual network study of US men who have sex with men. <i>Journal of the International AIDS Society</i> , 2021, 24, e25826.	1.2	7
3403	Pre-exposure Prophylaxis Uptake, Adherence, and Persistence: A Narrative Review of Interventions in the U.S.. <i>American Journal of Preventive Medicine</i> , 2021, 61, S73-S86.	1.6	31
3404	Academic Detailing to Increase Prescribing of HIV Pre-exposure Prophylaxis. <i>American Journal of Preventive Medicine</i> , 2021, 61, S87-S97.	1.6	4
3405	Toward Greater Pre-exposure Prophylaxis Equity: Increasing Provision and Uptake for Black and Hispanic/Latino Individuals in the U.S.. <i>American Journal of Preventive Medicine</i> , 2021, 61, S60-S72.	1.6	42
3406	Knowledge of HIV and HIV pre-exposure prophylaxis among medical and pharmacy students: A national, multi-site, cross-sectional study. <i>Preventive Medicine Reports</i> , 2021, 24, 101590.	0.8	6
3408	Drugs to treat HIV found to prevent infection. <i>Nature</i> , 0, , .	13.7	0
3410	Randomized Controlled Trials for HIV/AIDS Prevention Among Men and Women in Africa: Untraced Infections, Unasked Questions, and Unreported Data. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
3411	Treatment as prevention: will it work?. <i>Eurosurveillance</i> , 2011, 16, .	3.9	3
3414	HIV Pre-exposure Prophylaxis: Clinical Implications and Real-World Effectiveness. <i>Journal of AIDS & Clinical Research</i> , 2012, 03, .	0.5	0
3415	HIV/AIDS Global Epidemic human immunodeficiency virus (HIV) global epidemic human immunodeficiency virus (HIV) <i>Global Epidemic</i> . , 2012, , 4996-5020.		0
3416	Recent Advances in Anogenital Antiretroviral Microbicides and Multimodal Delivery Systems. <i>Journal of AIDS & Clinical Research</i> , 2012, 03, .	0.5	0
3417	Use of Animal Models for Anti-HIV Drug Development. , 0, , .		0
3418	HIV Epidemic. , 2013, , 3-46.		1
3419	Prevention of HIV Infection in the Absence of a Vaccine. , 2013, , 1-10.		0
3421	HIV/AIDS Global Epidemic. , 2013, , 27-62.		0
3422	Modeling the Impact of New HIV Prevention Technologies in Sub-Saharan Africa. <i>Profiles in Operations Research</i> , 2013, , 179-199.	0.3	0
3423	Randomized Controlled Trials for HIV/AIDS Prevention Among Men in Africa: Untraced Infections, Unasked Questions, and Unreported Data. , 2013, , 243-270.		2
3425	Unprotected receptive anal sex among men who have sex with men, Belo Horizonte, MG. <i>Revista MÃ©dica De Minas Gerais</i> , 2013, 23, .	0.0	0

#	ARTICLE	IF	CITATIONS
3426	HIV infection and acquired immunodeficiency syndrome. , 2013, , 465-479.		0
3427	RT Inhibitors as Microbicides. , 2013, , 329-347.		0
3429	Investigating Recent Testing among MSM: Results from Community-Based HIV Rapid Testing Attendees in France. Journal of Sexually Transmitted Diseases, 2013, 2013, 1-8.	1.0	3
3430	Implementing Biomedical HIV Prevention Advances in Thailand. , 2014, , 235-250.		0
3431	Risk Compensation in Response to HIV Prevention. , 2014, , 109-137.		0
3434	Targeting Risky Behaviors Using Nonprice Interventions: Legislation, Information, and Education. , 2013, , 117-151.		0
3438	HIV Infection among Transgender Women: Challenges and Opportunities. Journal of AIDS & Clinical Research, 2014, 05, .	0.5	0
3440	Vaginal and Rectal HIV Transmission in Humanized Mice. , 2014, , 235-245.		0
3441	Long-acting shot prevents infection with HIV analogue. Nature, 0, , .	13.7	0
3442	Using DHS to Identify Sites for HIV Prevention Trials. Etude De La Population Africaine, 2014, 28, 904.	0.2	0
3443	HIV Transmission Models: Lessons Learned for Microbicide Formulation Design. , 2014, , 55-89.		0
3444	Microbicides for the Prevention of HIV. , 2014, , 1-54.		0
3445	Antiretroviral Drug Penetration into Lymphoid Tissue. , 2015, , 1-9.		1
3446	11. "We Are Greater Than AIDS!" New Approaches and Partnerships Toward Solutions in African-American Communities. , 2015, , .		0
3447	Epidemiology and Prevention of Acquired Immunodeficiency Syndrome and Human Immunodeficiency Virus Infection. , 2015, , 1483-1502.e8.		5
3448	HIV prevention & treatment - Reasons to rejoice & remain vigilant. Indian Journal of Medical Research, 2015, 142, 633.	0.4	1
3449	Transgender Identity and Sexually Transmitted Diseases Including HIV. , 2015, , 337-344.		0
3450	HIV Risk Interventions. , 2015, , 138-144.		0

#	ARTICLE	IF	CITATIONS
3451	Food Is Medicine. , 2015, , 213-242.		2
3452	The development of resistance to antiretroviral therapy for HIV infected individuals: a systematic review. International Archive of Medicine, 0, ,	1.2	0
3453	Preexposure Prophylaxis (PrEP). , 2015, , 1-10.		0
3454	Immune Response Enhancement Strategy via Hybrid Control Perspective. Lecture Notes in Computer Science, 2015, , 1-26.	1.0	0
3455	Human Immunodeficiency Virus Infection in Women. , 2015, , 1590-1615.e8.		0
3456	Mechanisms of Action of Antiviral Agents. , 2015, , 197-210.		0
3457	Contemporary HIV Vaccines: Tissue Resident T-Cells and Strategies to Prevent Mucosal Infection. Current Topics in Medicinal Chemistry, 2015, 16, 1107-1117.	1.0	3
3458	Gay men and other Men who have sex with men (MSM), Epidemiology of HIV/AIDS Introduction. , 2016, , 1-12.		0
3459	Evaluating Published CER Evidence. , 2016, , 37-51.		0
3460	Frihet i Åen pille?. Tidsskrift for Den Norske Laegeforening, 2016, 136, 7-7.	0.2	1
3462	Fitting HIV Prevalence 1981 Onwards for Three Indian States Using the Goals Model and the Estimation and Projection Package. PLoS ONE, 2016, 11, e0164001.	1.1	2
3465	Sex, piller og moral. , 2016, 32, 285-295.	0.1	0
3466	Adherence to Antiretroviral Therapy among Patients Attending an Inner-City HIV Primary Care Clinic: Non-obvious Factors are Most Important. Journal of Human Virology & Retrovirology, 2016, 4, .	0.1	0
3467	ACQUIRED IMMUNE DEFICIENCY SYNDROME. Russian Journal of Allergy, 2016, 13, 3-19.	0.1	0
3468	Sexually Transmitted Infections in Men Who Have Sex with Men. , 2017, , 193-219.		0
3469	HIV-Infected Gay Men and Adherence to HIV Antiretroviral Therapies. , 2017, , 151-192.		0
3470	HIV Epidemiology in Latin America. , 2017, , 375-388.		2
3471	Antiretroviral Medications, Adult Care, and Treatment. , 2017, , 1-16.		0

#	ARTICLE	IF	CITATIONS
3473	From Pathology to Resiliency: Understanding the Mental Health of HIV Positive Gay Men. , 2017, , 51-74.		0
3474	Intersecting HIV Prevention Practice and Truth Among Black MSM. , 2017, , 123-140.		0
3475	Female Condoms. , 2017, , 1-7.		0
3476	HIV Prevention: Treatment as Prevention (TasP), Occupational Postexposure Prophylaxis (oPEP), Nonoccupational Postexposure Prophylaxis (nPEP), and Pre-exposure Prophylaxis (PrEP). , 2017, , 59-71.		4
3477	Prevention Clinical Trials: Highlights of Evidence and Research. , 2017, , 1-11.		0
3478	Efficacy Trials and Progress of HIV Vaccines. Journal of Cell Science & Therapy, 2017, 08, .	0.3	0
3480	Comprehensive Prevention with HIV Positive Gay Men. , 2017, , 121-149.		0
3482	HIV-1 Drug Resistance in Pre-exposure Prophylaxis Trials. , 2017, , 479-498.		0
3485	Community acceptance and HIV sexual risk among gay and bisexual men in a "atypical" Canadian city. Canadian Journal of Human Sexuality, 2017, 26, 7-16.	0.6	4
3487	Nanoparticle Encapsulation for Antiretroviral Pre-Exposure Prophylaxis. Journal of Nanotechnology and Materials Science, 2017, 4, 53-61.	0.1	2
3489	Gay men and other Men who have sex with men (MSM), Epidemiology of HIV/AIDS Introduction. , 2018, , 579-590.		0
3490	Knowledge, Normative Beliefs and Attitudes Related to Recent HIV Infection among People who Inject Drugs in Athens, Greece. Current HIV Research, 2018, 15, 386-395.	0.2	0
3491	Antiretroviral Medications, Adult Care, and Treatment. , 2018, , 72-87.		0
3492	Preexposure Prophylaxis (PrEP). , 2018, , 1659-1667.		2
3493	The Evolution of HIV Prevention Interventions and Chronic Disease Management. , 2018, , 907-939.		0
3494	Antiretroviral Drug Penetration into Lymphoid Tissue. , 2018, , 58-66.		1
3495	Female Condoms. , 2018, , 551-557.		0
3496	Prevention Clinical Trials: Highlights of Evidence and Research. , 2018, , 1713-1723.		0

#	ARTICLE	IF	CITATIONS
3497	HIV-1 Preexposure Prophylaxis. , 2018, , 886-892.		0
3510	â€œA prevenÃ§Ã£o nÃ£o sobe a Augustaâ€: homossexualidade, HIV, â€œriscoâ€ e produÃ§Ã£o de fronteiras na regiÃ£o central da cidade de SÃ£o Paulo. Sexualidad, Salud Y Sociedad: Revista Latinoamericana, 2018, , 340-372.	0.1	1
3511	Trends in Care and Treatment for Persons Aged â‰¥13 Years with HIV Infection 17 U.S. Jurisdictions, 2012-2015. Open AIDS Journal, 2018, 12, 90-105.	0.1	1
3514	Na contramÃ§Ã£o da informaÃ§Ã£o preventiva: desinformaÃ§Ã£o sobre prevenÃ§Ã£o de HIV/AIDS.. Biblionline, 2018, 14, 3-13.	0.0	1
3516	Disease Presentation, Recognition and Prevention. , 2019, , 3-63.		0
3517	Knowledge, Attitude and Practice of Healthcare Workers Towards Availability of Antiretroviral Pre-Exposure Prophylaxis in Nigeria. Journal of Clinical Research in HIV AIDS and Prevention, 2018, 3, 46-59.	0.1	3
3518	HIV-Infektion â€“ PrÃ¤valenz, Bedeutung und Implikationen fÃ¼r die PrÃvention und GesundheitsfÃrderung. The Springer Reference Pfliegerapie, Gesundheit, 2019, , 1-6.	0.2	0
3519	Development of a targeted educational intervention to increase pre-exposure prophylaxis uptake among cisgender men and transgender individuals who have sex with men and use methamphetamine in Seattle (WA, USA). Sexual Health, 2019, 16, 139-147.	0.4	14
3520	Lessons from Research Innovations in Depression and HIV in Low- and Middle-Income Countries. , 2019, , 1-22.		0
3521	Perceptions of people who inject drugs towards HIV pre-exposure prophylaxis in Australia. Sexual Health, 2019, 16, 383.	0.4	0
3523	Four Decades of Epidemiologic Science on HIV Infection and Disease, and Its Impact on Public Health Practice and Policy for Sexual and Gender Minority Persons. Delaware Journal of Public Health, 2019, 5, 64-71.	0.2	1
3524	Measuring the impact of an HIV rotation on traineesâ€™ knowledge and confidence level: The importance of inviting recent graduates. Jammi, 2019, 4, 83-89.	0.3	0
3526	Efficacy, Adherence and Side Effects of PrEP for HIV-1 Prevention. International Journal of Biology, 2019, 11, 80.	0.1	4
3527	Screening is not associated with reduced incidence of gonorrhoea or chlamydia in men who have sex with men (MSM); an ecological study of 23 European countries. F1000Research, 2019, 8, 160.	0.8	4
3530	The return of syphilis in Canada: A failed plan to eliminate this infection. Jammi, 2019, 4, 215-217.	0.3	0
3531	Evaluation of an Evidence-based and Community-responsive Fatherhood Training Program: Providersâ€™ Perspective. International Journal of MCH and AIDS, 2019, 9, 64-72.	0.3	1
3532	A Pilot Program of Pre-Exposure and Post-Exposure Prophylaxis Promotion among Men Who Have Sex with Men â€” 7 Study Sites, China, 2018â€”2019. China CDC Weekly, 2020, 2, 917-919.	1.0	5
3533	Risk, pleasure, intimacy, and seroadaptation: Examining correlates of barebacker identity in the age of biomedical HIV treatment and prevention. Canadian Journal of Human Sexuality, 2020, 29, 94-105.	0.6	1

#	ARTICLE	IF	CITATIONS
3534	Community Members' Pre-exposure Prophylaxis Awareness, Attitudes, and Trusted Sources for PrEP Information and Provision, Context Matters Survey, 2015–2016. <i>AIDS Education and Prevention</i> , 2020, 32, 102-S6.	0.6	3
3536	La profilaxis pre-exposición en el VIH: una potente herramienta preventiva todavía infrutilizada. <i>Medicina Clínica</i> , 2020, 154, 348-350.	0.3	0
3537	Network Analysis of Organizations Providing HIV Services in Chicago. <i>Journal of Public Health Management and Practice</i> , 2020, Publish Ahead of Print, .	0.7	1
3538	Knowledge and Clinical Uptake of HIV Pre-exposure Prophylaxis by Internal Medicine Residents at a Teaching Hospital in the Southern United States. <i>American Journal of Therapeutics</i> , 2020, Publish Ahead of Print, e806-e807.	0.5	0
3539	Understanding of Perceived Infectiousness and Its Influence on Sexual Behavior Among Individuals With Acute HIV Infection in Lilongwe, Malawi (HPTN 062). <i>AIDS Education and Prevention</i> , 2020, 32, 260-270.	0.6	2
3540	PrEPping for a healthier future – a concise update of current pharmacological HIV-prophylaxis practices. <i>South African General Practitioner</i> , 2020, , 77-78.	0.0	0
3541	PrEP in India's HIV Prevention Policy in the Era of Social Media and Sex Positivity. <i>Central Asian Journal of Global Health</i> , 2020, 9, .	0.6	2
3542	Editorial: Pharmacokinetics and Pharmacodynamics of Pre-Exposure Prophylaxis Against HIV. <i>Frontiers in Pharmacology</i> , 2020, 11, 1288.	1.6	0
3543	Adaptation of a Theory-Based Social Networking and Gamified App-Based Intervention to Improve Pre-Exposure Prophylaxis Adherence Among Young Men Who Have Sex With Men in Bangkok, Thailand: Qualitative Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e23852.	2.1	6
3544	Characteristics of Sexual Partnerships Among Men With Diagnosed HIV Who Have Sex With Men, United States and Puerto Rico—2015–2019. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 443-452.	0.9	3
3545	Women Are Less Likely to Be Tested for HIV or Offered Preexposure Prophylaxis at the Time of Sexually Transmitted Infection Diagnosis. <i>Sexually Transmitted Diseases</i> , 2021, 48, 32-36.	0.8	14
3547	Structural, Dosing, and Risk Change Factors Affecting Discontinuation of Pre-exposure Prophylaxis (PrEP) in a Large Urban Clinic. <i>AIDS Education and Prevention</i> , 2020, 32, 271-S13.	0.6	1
3548	Multi-level Interventions to Promote Oral Pre-exposure Prophylaxis Use Among Adolescent Girls and Young Women: a Review of Recent Research. <i>Current HIV/AIDS Reports</i> , 2021, 18, 490-499.	1.1	13
3549	Ultra-long-acting (XLA) antivirals for chronic viral hepatitis. <i>International Journal of Infectious Diseases</i> , 2022, 114, 45-50.	1.5	11
3550	Using Participatory Methods to Assess PrEP Interest and Uptake Among Young People Living in the Southeastern US: A Mixed Methods Assessment. <i>AIDS and Behavior</i> , 2022, 26, 1672-1683.	1.4	3
3551	Sexually Transmitted Infections and Sexual Healthcare of Homeless and Street-Involved Youth. , 2020, , 243-270.		1
3552	– I did not know about all these – Perceptions regarding safer conception methods by women living with HIV in Gaborone, Botswana. <i>PLoS ONE</i> , 2020, 15, e0242992.	1.1	1
3554	Determinants of Pre-Exposure Prophylaxis (Prep) Persistence in a High-Risk Population in Central Florida. <i>Journal of Investigative Medicine</i> , 2021, 69, 397-401.	0.7	3

#	ARTICLE	IF	CITATIONS
3555	Barriers and Facilitators to PrEP Initiation and Adherence Among Transgender and Gender Non-Binary Individuals in Southern California. <i>AIDS Education and Prevention</i> , 2020, 32, 472-485.	0.6	13
3556	Southern African guidelines on the safe, easy and effective use of pre-exposure prophylaxis: 2020. <i>Southern African Journal of HIV Medicine</i> , 2020, 21, 1152.	0.3	21
3557	Development of a 2-step algorithm to identify emergency department patients for HIV pre-exposure prophylaxis. <i>American Journal of Emergency Medicine</i> , 2022, 51, 6-12.	0.7	5
3558	Lessons from Research Innovations in Depression and HIV in Low- and Middle-Income Countries. , 2020, , 1-22.		0
3559	Social determinants of self-reported pre-exposure prophylaxis use among a national sample of US men who have sex with men. <i>Sexually Transmitted Infections</i> , 2020, 96, 368-374.	0.8	6
3561	HIV and Other Sexually Transmitted Infections. , 2020, , 127-139.		0
3562	HIV Prevention. , 2020, , 85-125.		0
3563	Hierarchical Modeling of the Effect of Pre-exposure Prophylaxis on HIV in the US. <i>Emerging Topics in Statistics and Biostatistics</i> , 2020, , 339-354.	0.1	0
3564	Behavioural Prevention Strategies for STI Control. , 2020, , 49-85.		0
3565	Prevention of HIV Infection. , 2020, , 1-29.		0
3566	Research Progress on Sexual Transmission of Viruses and Precautionary Principles. <i>Advances in Microbiology</i> , 2020, 09, 95-102.	0.0	0
3567	Australian interdisciplinary healthcare providers' perspectives on the effects of broader pre-exposure prophylaxis (PrEP) access on uptake and service delivery: a qualitative study. <i>Sexual Health</i> , 2020, 17, 485.	0.4	7
3570	The dynamics of a simple, risk-structured HIV model. <i>Mathematical Biosciences and Engineering</i> , 2020, 17, 4184-4209.	1.0	1
3573	Condom use philosophy and behaviors among young men who have sex with men: Variations among HIV pre-exposure prophylaxis users and nonusers. <i>Journal of the American Association of Nurse Practitioners</i> , 2021, 33, 521-528.	0.5	3
3574	A Comprehensive Review of The Impact of Health Care Expenditure and Health Outcomes on Economic Growth. <i>International Journal of Scientific Research in Science, Engineering and Technology</i> , 2020, , 585-597.	0.1	1
3575	An Experimental Study of the Effects of Patient Race, Sexual Orientation, and Injection Drug Use on Providers' PrEP-Related Clinical Judgments. <i>AIDS and Behavior</i> , 2022, 26, 1393-1421.	1.4	13
3576	A SWOT Analysis of the Guidelines on Prevention of HIV/AIDS in Japan in the Context of COVID-19. <i>Infectious Disease Reports</i> , 2021, 13, 949-956.	1.5	1
3578	Different guidelines for pre-exposure prophylaxis (PrEP) eligibility estimate HIV risk differently: an incidence study in a cohort of HIV-negative men who have sex with men, Portugal, 2014-2018. <i>Eurosurveillance</i> , 2020, 25, .	3.9	3

#	ARTICLE	IF	CITATIONS
3581	Pre-exposure prophylaxis uptake for HIV infection prevention among young men who have sex with men and transgender women in Bangkok, Thailand. <i>Journal of Health Research</i> , 2021, 35, 434-443.	0.4	1
3582	Contextualizing Evidence-Based Approaches for Treating Traumatic Life Experiences and Posttraumatic Stress Responses Among Sexual Minority Men. , 2021, , 149-161.		0
3584	New Success With Microbicides and Pre-Exposure Prophylaxis for Human Immunodeficiency Virus (HIV): Is Female-Controlled Prevention the Answer to the HIV Epidemic?. <i>Reviews in Obstetrics and Gynecology</i> , 2012, 5, 50-5.	0.7	6
3585	'Getting to Zero': are there grounds for optimism in the global fight against HIV?. <i>Indian Journal of Medical Research</i> , 2012, 136, 895-8.	0.4	1
3586	Humanized mouse models of HIV infection. <i>AIDS Reviews</i> , 2011, 13, 135-48.	0.5	135
3589	Same-sex sexual behavior of men in Kenya: Implications for HIV prevention, programs, and policy. <i>Facts, Views & Vision in ObGyn</i> , 2012, 4, 285-94.	0.5	5
3591	From trials to the public health: pre-exposure prophylaxis for HIV prevention. <i>Colombia Medica</i> , 2013, 44, 64-5.	0.7	0
3598	Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users. <i>Morbidity and Mortality Weekly Report</i> , 2013, 62, 463-5.	9.0	67
3599	HIV and syphilis infection among men who have sex with men--Bangkok, Thailand, 2005-2011. <i>Morbidity and Mortality Weekly Report</i> , 2013, 62, 518-20.	9.0	36
3600	New prospects for a preventive HIV-1 vaccine. <i>Journal of Virus Eradication</i> , 2015, 1, 78-88.	0.3	1
3601	Evidence-based HIV/STD prevention intervention for black men who have sex with men. <i>MMWR Supplements</i> , 2014, 63, 21-7.	15.3	10
3602	Is the HIV vaccine our best shot? - Why the answer to HIV prevention will be found in South Africa. , 2015, 2015, .		0
3603	Oral PrEP for HIV prevention.â€¢It works. <i>Journal of Virus Eradication</i> , 2015, 1, 168-72.	0.3	0
3604	What's new for antiretroviral treatment in women with HIV. <i>Journal of Virus Eradication</i> , 2016, 2, 67-77.	0.3	2
3605	HIV pre-exposure prophylaxis for women. <i>Journal of Virus Eradication</i> , 2016, 2, 149-55.	0.3	33
3606	Addressing the increasing burden of sexually transmitted infections in Rhode Island. <i>Rhode Island Medical Journal</i> (2013), 2014, 98, 31-4.	0.2	1
3607	PURLs: On-demand pill protocol protects against HIV. <i>Journal of Family Practice</i> , 2016, 65, 556-8.	0.2	0
3608	Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. <i>Journal of Virus Eradication</i> , 2017, 3, 168-184.	0.3	24

#	ARTICLE	IF	CITATIONS
3609	The Price of Prevention: Cost Effectiveness of Biomedical HIV Prevention Strategies in South Africa. <i>Clinical Research in HIV/AIDS</i> , 2016, 3, .	0.0	1
3610	InterPrEP. Internet-based pre-exposure prophylaxis with generic tenofovir DF/emtricitabine in London: an analysis of outcomes in 641 patients. <i>Journal of Virus Eradication</i> , 2017, 3, 218-222.	0.3	10
3611	HIV Prevention: Opportunities and Challenges. <i>Topics in Antiviral Medicine</i> , 2017, 24, 123-126.	0.1	7
3612	Assessing HIV acquisition risks among men who have sex with men in the United States of America. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2016, 40, 474-478.	0.6	1
3613	Insights in Public Health: In What Ways are Hawaii's HIV Prevention Services Engaging Gay Male Couples and Using Technology?. <i>Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health</i> , 2018, 77, 38-45.	0.4	0
3614	Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recommendations and Reports</i> , 2015, 64, 1-137.	26.7	1,132
3615	Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018. <i>Journal of Virus Eradication</i> , 2018, 4, 143-159.	0.3	2
3616	Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018. <i>Journal of Virus Eradication</i> , 2018, 4, 143-159.	0.3	15
3617	Pre-exposure Prophylaxis as HIV Prevention in High Risk Adolescents. , 2018, 2, 5-10.		3
3618	HIV preexposure prophylaxis in the real world. <i>Topics in Antiviral Medicine</i> , 2014, 22, 670-5.	0.1	0
3619	CROI 2013: New tools to understand transmission dynamics and prevent HIV infections. <i>Topics in Antiviral Medicine</i> , 2013, 21, 47-61.	0.1	1
3620	Safer conception interventions for HIV-affected couples: implications for resource-constrained settings. <i>Topics in Antiviral Medicine</i> , 2011, 19, 148-55.	0.1	36
3621	HIV prevention: integrating biomedical and behavioral interventions. <i>Topics in Antiviral Medicine</i> , 2014, 22, 702-6.	0.1	4
3622	Update of the past year: a review from IDSA 2011. <i>Topics in Antiviral Medicine</i> , 2011, 19, 187-92.	0.1	1
3623	HIV preexposure prophylaxis: new data and potential use. <i>Topics in Antiviral Medicine</i> , 2011, 19, 181-5.	0.1	13
3625	What Can We Learn From Measles? No New HIV Infections. <i>Topics in Antiviral Medicine</i> , 2015, 23, 108-10.	0.1	0
3626	Preexposure Prophylaxis For HIV Prevention: What We Know and What We Still Need to Know for Implementation. <i>Topics in Antiviral Medicine</i> , 2015, 23, 85-90.	0.1	13
3629	Implementing a Pre-Exposure Prophylaxis Intervention for Safer Conception among HIV Serodiscordant Couples: Recommendations for Health Care Providers. <i>Journal of Health Disparities Research and Practice</i> , 2018, 11, 19-33.	1.1	3

#	ARTICLE	IF	CITATIONS
3630	How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP. <i>Journal of Virus Eradication</i> , 2018, 4, 215-224.	0.3	34
3631	Pre-exposure Prophylaxis in Primary Care--A New Era in HIV Prevention. <i>Wisconsin Medical Journal</i> , 2016, 115, 6-8.	0.3	2
3632	The Relationship Between Polysubstance Injection Drug Use, HIV Risk Behaviors, and Interest in Pre-Exposure Prophylaxis (PrEP) Among People Who Inject Drugs in Rural West Virginia. <i>Journal of Studies on Alcohol and Drugs</i> , 2020, 81, 740-749.	0.6	5
3633	Management and Prevention of HIV Among Transgender Adults. <i>Topics in Antiviral Medicine</i> , 2020, 28, 474-478.	0.1	1
3634	Incident Cases of Sexually Transmitted Infections among Users of Pre-Exposure Prophylaxis for HIV Prevention in Honolulu, Hawai'i. <i>Hawai'i Journal of Health & Social Welfare</i> , 2021, 80, 148-154.	0.2	0
3635	FOREST protocol: a qualitative study exploring health and sexuality of transmasculine individuals in France. <i>BMJ Open</i> , 2021, 11, e052748.	0.8	0
3636	Approved HIV reverse transcriptase inhibitors in the past decade. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1567-1590.	5.7	31
3637	Factors Influencing the Intention of MSM to Use the PrEP Intelligent Reminder System. <i>Risk Management and Healthcare Policy</i> , 2021, Volume 14, 4739-4748.	1.2	4
3638	Preferences regarding emerging HIV prevention technologies among Toronto men who have sex with men: a discrete choice experiment. <i>Scientific Reports</i> , 2021, 11, 22252.	1.6	3
3639	Factors that motivate men who have sex with men in Berlin, Germany, to use or consider using HIV pre-exposure prophylaxis--A multi-methods analysis of data from a multicentre survey. <i>PLoS ONE</i> , 2021, 16, e0260168.	1.1	1
3640	A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 22-31.	1.5	30
3642	HIV in Specific Populations. , 2022, , 349-390.		0
3643	Sexually Transmitted Infections of the Colon and Rectum. , 2022, , 323-342.		0
3644	HIV Pre-Exposure Prophylaxis (PrEP) purchase patterns and STI occurrence among Israeli men: A cohort analysis. <i>PLoS ONE</i> , 2021, 16, e0259168.	1.1	10
3645	Changes in the profile of newly HIV-diagnosed men who have sex with men, Madrid, 2014 to 2019. <i>Eurosurveillance</i> , 2021, 26, .	3.9	4
3646	HIV PrEP access and affordability: a multidisciplinary specialty pharmacy model. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2022, 62, 853-858.	0.7	3
3647	Uptake, Retention, and Adherence to Pre-exposure Prophylaxis (PrEP) in TRIUMPH: A Peer-Led PrEP Demonstration Project for Transgender Communities in Oakland and Sacramento, California. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, S27-S38.	0.9	24
3648	We are Family: A Feasibility and Acceptability Study of an HIV Prevention Intervention With the House Ball and Gay Family Communities. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, S6-S11.	0.9	6

#	ARTICLE	IF	CITATIONS
3649	“Why You Putting This Drug in Your Body to Fight off Something that You Don’t Have?” Perceptions About PrEP Use Among Black and Latino Men Who Have Sex with Men in the U.S. South. <i>Journal of Homosexuality</i> , 2023, 70, 900-916.	1.3	4
3650	Pre-Exposure Prophylaxis Perspectives, Sociodemographic Characteristics, and HIV Risk Profiles of Cisgender Women Seeking and Initiating PrEP in a US Demonstration Project. <i>AIDS Patient Care and STDs</i> , 2021, 35, 481-487.	1.1	5
3651	Is tenofovir disoproxil fumarate associated with weight loss?. <i>Aids</i> , 2021, 35, S189-S195.	1.0	25
3652	Cost-Effectiveness of Oral Pre-Exposure Prophylaxis and Expanded Antiretroviral Therapy for Preventing HIV Infections in the Presence of Drug Resistance: A Mathematical Modelling Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3653	Lessons from Research Innovations in Depression and HIV in Low- and Middle-Income Countries. , 2021, , 169-190.		0
3654	Sample size calculation for active-arm trial with counterfactual incidence based on recency assay. <i>Statistical Communications in Infectious Diseases</i> , 2021, 13, .	0.2	3
3655	Sexual and Gender Minority People’s Physical Health and Health Risk Behaviors. , 2021, , 81-102.		3
3656	Characterizing Awareness of Pre-Exposure Prophylaxis for HIV Prevention in Manila and Cebu, Philippines: Web-Based Survey of Filipino Cisgender Men Who Have Sex With Men. <i>Journal of Medical Internet Research</i> , 2022, 24, e24126.	2.1	2
3657	A Primary Care Intervention to Increase HIV Pre-Exposure Prophylaxis (PrEP) Uptake in Patients with Syphilis. <i>Journal of the International Association of Providers of AIDS Care</i> , 2022, 21, 232595822110733.	0.6	5
3658	Association between the geographic accessibility of PrEP and PrEP use among MSM in nonurban areas. <i>Journal of Rural Health</i> , 2022, , .	1.6	9
3659	Pre-exposure prophylaxis use, HIV knowledge, and internalized homonegativity among men who have sex with men in Brazil: A cross-sectional study. <i>The Lancet Regional Health Americas</i> , 2022, 6, 100152.	1.5	17
3660	Effects Of HIV Oral Pre-Exposure Prophylaxis On Incidence Of STIS Among Female Sex Workers In Selected Drop-In Centers In Nairobi County.. <i>International Journal of Scientific and Research Publications</i> , 2020, 10, 325-333.	0.0	0
3661	Recommendations for Intervention Content to Enhance HIV Pre-Exposure Prophylaxis Uptake among Men Who have Sex with Men Receiving Care at Sexually Transmitted Disease Clinics. <i>Journal of Men’s Health</i> , 2020, 16, e47-e59.	0.1	1
3662	A REVIEW OF ANALYTICAL TECHNIQUES FOR DETERMINATION OF ANTI-HIV DRUGS. <i>International Journal of Applied Pharmaceutics</i> , 0, , 41-50.	0.3	2
3663	The Relationship Between Polysubstance Injection Drug Use, HIV Risk Behaviors, and Interest in Pre-Exposure Prophylaxis (PrEP) Among People Who Inject Drugs in Rural West Virginia. <i>Journal of Studies on Alcohol and Drugs</i> , 2020, 81, 740-749.	0.6	16
3664	Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. <i>Journal of Infectious Diseases</i> , 2022, 225, 1741-1749.	1.9	35
3665	Long-acting capsid inhibitor protects macaques from repeat SHIV challenges. <i>Nature</i> , 2022, 601, 612-616.	13.7	14
3666	Impact of Coronavirus Disease 2019 (COVID-19) on Human Immunodeficiency Virus (HIV) Pre-exposure Prophylaxis Prescriptions in the United States—A Time-Series Analysis. <i>Clinical Infectious Diseases</i> , 2022, 75, e1020-e1027.	2.9	28

#	ARTICLE	IF	CITATIONS
3667	Linking emergency department patients at risk for human immunodeficiency virus to pre-exposure prophylaxis. <i>American Journal of Emergency Medicine</i> , 2022, 54, 87-90.	0.7	6
3668	Acceptability of and Preferences for Long-Acting Injectable HIV PrEP and Other PrEP Modalities among Sexual Minority Men in Nigeria, Africa. <i>AIDS and Behavior</i> , 2022, 26, 2363-2375.	1.4	12
3669	Risk Behaviors Associated with Patterns of Sexualized Stimulant and Alcohol Use among Men Who Have Sex with Men: a Latent Class Analysis. <i>Journal of Urban Health</i> , 2022, 99, 293-304.	1.8	2
3670	HIV prevalence and incidence among men who have sex with men and transgender women in Bangkok, 2014-2018: Outcomes of a consensus development initiative. <i>PLoS ONE</i> , 2022, 17, e0262694.	1.1	2
3671	A Technology-Based Intervention Among Young Men Who Have Sex With Men and Nonbinary People (The Conectad@s Project): Protocol for A Vanguard Mixed Methods Study. <i>JMIR Research Protocols</i> , 2022, 11, e34885.	0.5	4
3672	Combining information to estimate adherence in studies of pre-exposure prophylaxis for HIV prevention: Application to HPTN 067. <i>Statistics in Medicine</i> , 2022, , .	0.8	0
3673	HIV Pre-Exposure Prophylaxis (PrEP) in a Brazilian Clinical Setting: Adherence, Adverse Events, Sexual Behavior, and Sexually Transmitted Infections. <i>Archives of Sexual Behavior</i> , 2022, 51, 2603-2611.	1.2	3
3674	Past and future of HIV infection. A document based on expert opinion. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 131-156.	0.5	2
3675	Acceptability of HIV pre-exposure prophylaxis in China: A systematic review and meta-analysis. <i>International Journal of STD and AIDS</i> , 2022, 33, 218-231.	0.5	5
3676	Implementation of Client-Centered Care Coordination for HIV Prevention with Black Men Who Have Sex with Men: Activities, Personnel Costs, and Outcomes-HPTN 073. <i>Journal of Racial and Ethnic Health Disparities</i> , 2023, 10, 183-192.	1.8	5
3677	Feasibility and Acceptability of Home-Collected Samples for Human Immunodeficiency Virus Preexposure Prophylaxis and Severe Acute Respiratory Syndrome Coronavirus 2 Laboratory Tests in San Francisco Primary Care Clinics. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab657.	0.4	5
3678	Attitudes and beliefs related to HIV risk and pre-exposure prophylaxis among transgender women in the Southeastern United States. <i>PLoS ONE</i> , 2022, 17, e0262205.	1.1	3
3679	Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention. <i>Journal of Infectious Diseases</i> , 2022, 226, 510-520.	1.9	13
3680	Divergent effects of HIV reverse transcriptase inhibitors on pancreatic beta-cell function and survival: Potential role of oxidative stress and mitochondrial dysfunction. <i>Life Sciences</i> , 2022, 294, 120329.	2.0	4
3681	Examining stigmatizing beliefs about PrEP use among Black sexual minority men: A test of explanatory mechanisms. <i>Psychology of Men and Masculinity</i> , 2022, 23, 26-34.	1.0	1
3682	What makes an optimal delivery for PrEP against HIV: A qualitative study in MSM. <i>International Journal of STD and AIDS</i> , 2022, 33, 322-329.	0.5	4
3683	CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women. <i>BMJ Open</i> , 2022, 12, e052880.	0.8	18
3684	Exploring barriers and facilitators to PrEP use among transgender women in two urban areas: implications for messaging and communication. <i>BMC Public Health</i> , 2022, 22, 17.	1.2	12

#	ARTICLE	IF	CITATIONS
3685	Recent insights suggest the need for the STI field to embrace a more eco-social conceptual framework: A viewpoint. <i>International Journal of STD and AIDS</i> , 2022, 33, 404-415.	0.5	7
3686	Results of a phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel. <i>PLoS ONE</i> , 2022, 17, e0261775.	1.1	19
3687	Gay, bisexual, and other men who have sex with men accessing STI clinics: Optimizing HIV PrEP implementation. <i>PLoS ONE</i> , 2022, 17, e0261705.	1.1	0
3688	HIV prevention: better choice for better coverage. <i>Journal of the International AIDS Society</i> , 2022, 25, e25872.	1.2	18
3689	Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States. <i>Annals of Internal Medicine</i> , 2022, 175, 479-489.	2.0	37
3690	Acceptability of a Community Health Worker Program to Link High-Risk People in Jail to HIV Pre-Exposure Prophylaxis. <i>Journal of Health Care for the Poor and Underserved</i> , 2022, 33, 149-166.	0.4	0
3691	Incidence and risk factors for recurrent sexually transmitted infections among MSM on HIV pre-exposure prophylaxis. <i>Aids</i> , 2022, 36, 1129-1134.	1.0	18
3692	Factors associated with stigma related to HIV pre-exposure prophylaxis (PrEP) use among men who have sex with men (MSM). <i>Sexually Transmitted Infections</i> , 2022, , sextrans-2021-055296.	0.8	1
3693	High-content analysis and Kinetic Image Cytometry identify toxicity and epigenetic effects of HIV antiretrovirals on human iPSC-neurons and primary neural precursor cells. <i>Journal of Pharmacological and Toxicological Methods</i> , 2022, 114, 107157.	0.3	8
3694	A Network Approach to Determine Optimization of PrEP Uptake in Athens, Greece. <i>AIDS and Behavior</i> , 2022, , 1.	1.4	0
3695	The impact of condom use on the HIV epidemic. <i>Gates Open Research</i> , 0, 5, 91.	2.0	5
3696	High Rates of Sexualized Drug Use or Chemsex among Brazilian Transgender Women and Young Sexual and Gender Minorities. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1704.	1.2	19
3697	In PrEP: Long-acting antivirals for HIV prevention. <i>Cell Host and Microbe</i> , 2022, 30, 148-150.	5.1	0
3698	Understanding PrEP Acceptability Among Priority Populations: Results from a Qualitative Study of Potential Users in Central Uganda. <i>AIDS and Behavior</i> , 2022, 26, 2676-2685.	1.4	9
3699	Challenges and Opportunities for Preexposure Prophylaxis. <i>Topics in Antiviral Medicine</i> , 2021, 29, 399-406.	0.1	2
3700	Ethics and pre-exposure prophylaxis (PrEP) in adolescents: an integrative review. <i>Jornal Brasileiro De DoenÇas Sexualmente TransmissÃveis</i> , 0, 33, .	0.1	0
3701	PrEP Use, Sexual Behaviour, and PrEP Adherence Among Men who have Sex with Men Living in Wales Prior to and During the COVID-19 Pandemic. <i>AIDS and Behavior</i> , 2022, 26, 2746-2757.	1.4	12
3702	Perceptions, motivations, and beliefs about HIV risk and pre-exposure prophylaxis (PrEP) among participants in a nurse-led PrEP service (PrEP-RN). <i>BMC Infectious Diseases</i> , 2022, 22, 196.	1.3	2

#	ARTICLE	IF	CITATIONS
3703	â€˜The High Five Clubâ€™™: Social Relations and Perspectives on HIV-Related Stigma During an HIV Outbreak in West Virginia. <i>Culture, Medicine and Psychiatry</i> , 2023, 47, 329-349.	0.7	2
3704	UK guideline for the use of HIV postâ€“exposure prophylaxisÂ2021. <i>HIV Medicine</i> , 2022, 23, 494-545.	1.0	10
3705	Association of HIV Preexposure Prophylaxis Use With HIV Incidence Among Men Who Have Sex With Men in China. <i>JAMA Network Open</i> , 2022, 5, e2148782.	2.8	11
3706	Perceptions and Practicalities Influencing Pre-exposure Prophylaxis Adherence Among Men Who Have Sex with Men in England. <i>AIDS and Behavior</i> , 2022, 26, 2768-2782.	1.4	8
3707	Increased condom use among key populations using oral PrEP in Kenya: results from large scale programmatic surveillance. <i>BMC Public Health</i> , 2022, 22, 304.	1.2	8
3708	Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis. <i>Antiviral Therapy</i> , 2022, 27, 135965352110675.	0.6	1
3709	Adherence, Sexual Behavior and Sexually Transmitted Infections in a New Zealand Prospective PrEP Cohort: 12 Months Follow-up and Ethnic Disparities. <i>AIDS and Behavior</i> , 2022, 26, 2723-2737.	1.4	4
3710	Understanding Influences on Intention to Use Pre-exposure Prophylaxis (PrEP) Among African American Young Adults. <i>Journal of Racial and Ethnic Health Disparities</i> , 2023, 10, 899-910.	1.8	4
3711	What are we learning about HIV testing in informal settlements in KwaZulu-Natal, South Africa? Results from a randomized controlled trial. <i>PLoS ONE</i> , 2022, 17, e0257033.	1.1	1
3712	High Rates of Pre-exposure Prophylaxis Eligibility and Associated HIV Incidence in a Population With a Generalized HIV Epidemic in Rakai, Uganda. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, 291-299.	0.9	3
3713	Prevalence and incidence of hepatitis C infection amongst men who have sex with men in a <scp>populationâ€“based </scp> preâ€“exposure prophylaxis program in British Columbia, Canada. <i>Liver International</i> , 2022, 42, 1528-1535.	1.9	3
3714	Long-acting preexposure prophylaxis in low- and middle-income countries: key considerations for implementation. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 135-144.	1.5	2
3715	Crossâ€“sectional trends in HIV prevalence among pregnant women in Botswana: an opportunity for PrEP?. <i>Journal of the International AIDS Society</i> , 2022, 25, e25892.	1.2	5
3716	Low PrEP adherence despite high retention among transgender women in Brazil: the PrEPParadas study. <i>Journal of the International AIDS Society</i> , 2022, 25, e25896.	1.2	18
3717	Increasing awareness of HIV preâ€“exposure prophylaxis (PrEP) and willingness to use HIV PrEP among men who have sex with men: a systematic review and metaâ€“analysis of global data. <i>Journal of the International AIDS Society</i> , 2022, 25, e25883.	1.2	39
3718	In-Situ Implant Formulation of Laurate and Myristate Prodrugs of Dolutegravir for Ultra-Long Delivery. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 2312-2321.	1.6	4
3719	A four-year observation of HIV and sexually transmitted infections among men who have sex with men before and during pre-exposure prophylaxis in Tokyo. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 762-766.	0.8	8
3720	Persistence on oral pre-exposure prophylaxis (PrEP) among female sex workers in eThekweni, South Africa, 2016â€“2020. <i>PLoS ONE</i> , 2022, 17, e0265434.	1.1	11

#	ARTICLE	IF	CITATIONS
3721	Impact of daily, oral pre-exposure prophylaxis on the risk of bacterial sexually transmitted infections among cisgender women: a systematic review and narrative synthesis. Wellcome Open Research, 0, 7, 108.	0.9	0
3722	A Pilot Study of a Patient Navigation Intervention to Improve HIV Pre-exposure Prophylaxis Persistence Among Black/African American Men Who Have Sex With Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 90, 276-282.	0.9	7
3723	The "Viennese epidemic" of acute HCV in the era of direct-acting antivirals. Journal of Viral Hepatitis, 2022, 29, 385-394.	1.0	10
3724	Low Incidence and Prevalence of Hepatitis C in Two Cohorts of HIV Pre-Exposure Prophylaxis Adherence Interventions in Men Who Have Sex with Men in Southern California. Journal of Viral Hepatitis, 2022, , .	1.0	3
3725	Optimizing an mHealth Intervention to Improve Uptake and Adherence to HIV Pre-exposure Prophylaxis in Young Transgender Women: Protocol for a Multi-Phase Trial. JMIR Research Protocols, 2022, 11, e37659.	0.5	8
3726	Technology-Based Interventions to Promote the HIV Preexposure Prophylaxis (PrEP) Care Continuum: Protocol for a Systematic Review. JMIR Research Protocols, 2022, 11, e33045.	0.5	1
3727	Sexually transmitted infections among participants in an HIV PrEP adherence trial. International Journal of STD and AIDS, 2022, 33, 397-403.	0.5	2
3728	Mass Spectroscopy Imaging of Hair Strands Captures Short-Term and Long-Term Changes in Emtricitabine Adherence. Antimicrobial Agents and Chemotherapy, 2022, 66, e0217621.	1.4	7
3729	A cohort analysis of sexually transmitted infections among different groups of men who have sex with men in the early era of HIV pre-exposure prophylaxis in France. Journal of Virus Eradication, 2022, 8, 100065.	0.3	3
3730	Preferences for Long-Acting and Alternative Modalities for PrEP among Military Men Who Have Sex with Men: Segmentation Results of an Adaptive Choice-Based Conjoint Analysis Study. Journal of Urban Health, 2022, 99, 277-292.	1.8	2
3731	Barriers and Facilitators to HIV Pre-Exposure Prophylaxis Uptake Among Men Who have Sex with Men Who Use Stimulants: A Qualitative Study. AIDS and Behavior, 2022, , 1.	1.4	4
3732	Transmission Clusters, Predominantly Associated With Men Who Have Sex With Men, Play a Main Role in the Propagation of HIV-1 in Northern Spain (2013-2018). Frontiers in Microbiology, 2022, 13, 782609.	1.5	5
3733	Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women. British Journal of Clinical Pharmacology, 2022, 88, 3674-3682.	1.1	10
3734	HIV Pre-exposure Prophylaxis Implant Stated Preferences and Priorities: Results of a Discrete Choice Experiment Among Women and Adolescent Girls in Gauteng Province, South Africa. AIDS and Behavior, 2022, 26, 3099-3109.	1.4	7
3735	HIV, STI and renal function testing frequency and STI history among current users of self-funded HIV pre-exposure prophylaxis, a cross-sectional study, Germany, 2018 and 2019. Eurosurveillance, 2022, 27, .	3.9	3
3736	Association between having a regular healthcare provider and pre-exposure prophylaxis use among men who have sex with men: a cross-sectional survey. Journal of Behavioral Medicine, 2022, , 1.	1.1	1
3737	Genital Inflammation Is Not Associated With Decreased Vaginal Tenofovir Concentrations in Women Taking Oral PrEP. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 390-395.	0.9	1
3738	Real-world safety of pre-exposure prophylaxis for HIV. Lancet HIV, the, 2022, 9, e225-e226.	2.1	0

#	ARTICLE	IF	CITATIONS
3740	Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data. <i>Lancet HIV</i> , 2022, 9, e242-e253.	2.1	13
3741	Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. <i>Lancet HIV</i> , 2022, 9, e254-e268.	2.1	66
3742	Optimizing HIV Prevention Efforts to Achieve EHE Incidence Targets. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 374-380.	0.9	5
3743	Understanding Retention in Pre-Exposure Prophylaxis Care in the South: Insights from an Academic HIV Prevention Clinic. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 306-312.	0.5	3
3744	Transactional sex, HIV and health among young cisgender men and transgender women who have sex with men in Thailand. <i>Annals of Epidemiology</i> , 2022, 72, 1-8.	0.9	1
3746	Attitudes towards, knowledge about, and confidence to prescribe antiretroviral pre-exposure prophylaxis among healthcare providers in Thailand. <i>Medicine (United States)</i> , 2021, 100, e28120.	0.4	8
3747	Same-sex behavior disclosure to health care providers associated with greater awareness of pre-exposure prophylaxis. <i>BMC Public Health</i> , 2021, 21, 2243.	1.2	2
3748	Roll-out of HIV pre-exposure prophylaxis: a gateway to mental health promotion. <i>BMJ Global Health</i> , 2021, 6, e007212.	2.0	6
3749	Integrating PrEP delivery in public health family planning clinics: a protocol for a pragmatic stepped wedge cluster randomized trial in Kenya. <i>Implementation Science Communications</i> , 2021, 2, 135.	0.8	5
3751	Knowledge of and willingness to take pre-exposure prophylaxis among men who have sex with men in Israel. <i>Israel Journal of Health Policy Research</i> , 2021, 10, 71.	1.4	5
3752	Numerical approaches for the rapid analysis of prophylactic efficacy against HIV with arbitrary drug-dosing schemes. <i>PLoS Computational Biology</i> , 2021, 17, e1009295.	1.5	3
3753	Privacy and Confidentiality Concerns Related to the Use of mHealth Apps for HIV Prevention Efforts Among Malaysian Men Who Have Sex With Men: Cross-sectional Survey Study. <i>JMIR Formative Research</i> , 2021, 5, e28311.	0.7	8
3754	Implementing pre-exposure prophylaxis for HIV prevention in women: the role of the obstetrician-gynecologist. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 764-772.	0.7	2
3755	Oral conditions and salivary analysis in HIV-uninfected subjects using preexposure prophylaxis. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2020, , 0-0.	0.7	2
3756	Feasibility, Acceptability, and Preliminary Efficacy of a Gamified Mobile Health Contingency Management Intervention for PrEP Adherence Among Black MSM. <i>AIDS and Behavior</i> , 2022, 26, 3311-3324.	1.4	3
3757	Who is using PrEP on-demand? Factors associated with PrEP use modality among Black and Hispanic/Latino emerging adults. <i>AIDS and Behavior</i> , 2022, 26, 3411-3421.	1.4	6
3758	Lost2PrEP: Understanding Reasons for Pre-Exposure Prophylaxis and Sexual Health Care Disengagement Among Men Who Have Sex with Men Attending a Sexual Health Clinic at a Large Urban Academic Medical Center in New York City. <i>AIDS Patient Care and STDs</i> , 2022, 36, 153-158.	1.1	6
3759	Why Do HIV Pre-Exposure Prophylaxis Users Discontinue Pre-Exposure Prophylaxis Care? A Mixed Methods Survey in a Pre-Exposure Prophylaxis Clinic in Belgium. <i>AIDS Patient Care and STDs</i> , 2022, 36, 159-167.	1.1	4

#	ARTICLE	IF	CITATIONS
3760	Experiences of men who have sex with men when initiating, implementing and persisting with HIV pre-exposure prophylaxis. <i>Health Expectations</i> , 2022, 25, 1332-1341.	1.1	5
3761	Individual and structural-level Correlates of Pre-exposure Prophylaxis (PrEP) lifetime and current use in a nationwide sample of young sexual and gender minorities. <i>AIDS and Behavior</i> , 2022, 26, 3365-3377.	1.4	5
3762	Next Generation Pre-Exposure Prophylaxis for Young Men who have Sex with Men: Lessons from System and Provider-level barriers to oral PrEP. <i>AIDS and Behavior</i> , 2022, 26, 3422-3435.	1.4	7
3763	Human immunodeficiency virus infection. , 0, , 360-370.		0
3782	Rate and Predictors of Ineffective HIV Protection in African Men Who Have Sex with Men Taking Pre-Exposure Prophylaxis. <i>AIDS and Behavior</i> , 2022, 26, 3524-3537.	1.4	4
3783	Utilisation of pre-exposure prophylaxis (PrEP) for HIV prevention in the Australian general practice setting: a longitudinal observational study. <i>Sexual Health</i> , 2022, , .	0.4	2
3784	Impact of pre-exposure and post-exposure prophylaxes prevention programme on HIV burden and services in a low-resource setting: a simulation modelling approach. <i>Pan African Medical Journal</i> , 2021, 40, 163.	0.3	3
3785	Awareness, knowledge, and attitudes related to HIV pre-exposure prophylaxis and other prevention strategies among physicians from Brazil and Mexico: cross-sectional web-based survey. <i>BMC Health Services Research</i> , 2022, 22, 532.	0.9	7
3787	A Mobile Phone App to Support Adherence to Daily HIV Pre-exposure Prophylaxis Engagement Among Young Men Who Have Sex With Men and Transgender Women Aged 15 to 19 Years in Thailand: Pilot Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2022, 10, e25561.	1.8	9
3788	Toward Using Twitter for PrEP-Related Interventions: An Automated Natural Language Processing Pipeline for Identifying Gay or Bisexual Men in the United States. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e32405.	1.2	1
3789	Providing HIV preexposure prophylaxis. <i>Canadian Family Physician</i> , 2022, 68, 197-201.	0.1	0
3791	Engagement with HIV and COVID-19 prevention: a national cross-sectional analysis of users on a geosocial networking app (Preprint). <i>Journal of Medical Internet Research</i> , 0, , .	2.1	0
3792	The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir. <i>Antiviral Therapy</i> , 2022, 27, 135965352110675.	0.6	4
3793	HIV pre-exposure prophylaxis: assessment of acceptability among members of HIV serodiscordant/serostatus unknown couples. <i>International Journal of STD and AIDS</i> , 2022, , 095646242210977.	0.5	0
3795	Characterizing HIV-Preventive, Plasma Tenofovir Concentrationsâ€”A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials. <i>Clinical Infectious Diseases</i> , 2022, 75, 1873-1882.	2.9	10
3796	Closing Sexual Health Service Gaps With a New Service Model in Germany: Performance of an on-Site Integrated, Cross-Sectoral, Low Threshold Sexually Transmitted Infections/HIV Counseling and Treatment Service. <i>Frontiers in Public Health</i> , 2022, 10, 793609.	1.3	1
3797	Perceptions on HIV Pre-Exposure Prophylaxis Among Urgent Care Clinicians in the Southern United States. <i>Current HIV Research</i> , 2022, 20, 204-212.	0.2	1
3798	Economic Abuse and Care-seeking Practices for HIV and Financial Support Services in Women Employed by Sex Work: A Cross-Sectional Baseline Assessment of a Clinical Trial Cohort in Uganda. <i>Journal of Interpersonal Violence</i> , 2023, 38, 1920-1949.	1.3	0

#	ARTICLE	IF	CITATIONS
3799	Community perspectives on addressing and responding to HIV-testing, pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) among African, Caribbean and Black (ACB) people in Ontario, Canada. <i>BMC Public Health</i> , 2022, 22, 913.	1.2	6
3800	Individual, Interpersonal, and Structural Factors That Influence Intentions to Use Pre-exposure Prophylaxis Among Sexual Minority Men in Miami. <i>Archives of Sexual Behavior</i> , 2022, , 1.	1.2	1
3801	Cost-effectiveness of oral pre-exposure prophylaxis and expanded antiretroviral therapy for preventing HIV infections in the presence of drug resistance among men who have sex with men in China: A mathematical modelling study. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 23, 100462.	1.3	8
3802	Elimination of HIV transmission in Japanese MSM with combination interventions. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 23, 100467.	1.3	5
3804	LGBQ-affirmative cognitive-behavioral therapy for young gay and bisexual men's mental and sexual health: A three-arm randomized controlled trial.. <i>Journal of Consulting and Clinical Psychology</i> , 2022, 90, 459-477.	1.6	31
3805	It's a win for the clinic, it's a win for the frontline, but, most importantly, it's a win for the client: Task Shifting HIV Prevention Services from Clinicians to Community Health Workers in Ontario, Canada. <i>Sexuality Research and Social Policy</i> , 2023, 20, 780-792.	1.4	3
3806	HIV Pre-Exposure Prophylaxis: What Do Pediatricians Need to Know?. <i>Pediatric Annals</i> , 2022, 51, e191-e195.	0.3	1
3808	Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. <i>BMJ Open</i> , 2022, 12, e048478.	0.8	44
3809	Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis. <i>Scientific Reports</i> , 2022, 12, 8224.	1.6	5
3810	Understanding the Association between PrEP Stigma and PrEP Cascade Moderated by the Intensity of HIV Testing. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 74.	0.9	2
3812	Precarious manhood and intentions to initiate preexposure prophylaxis among Black sexual minority men.. <i>Health Psychology</i> , 2022, 41, 474-483.	1.3	2
3813	Contribution of Sex Differences to HIV Immunology, Pathogenesis, and Cure Approaches. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
3814	Pharmacokinetics and Efficacy of Topical Inserts Containing Tenofovir Alafenamide Fumarate and Elvitegravir Administered Rectally in Macaques. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3815	A Case of a Highly Drug-Resistant HIV Detected after Irregular Use of a Self-Prescribed Antiretroviral Drug. <i>Journal of the Japanese Association for Infectious Diseases</i> , 2022, 96, 96-100.	0.0	0
3817	Non-selective distribution of infectious disease prevention may outperform risk-based targeting. <i>Nature Communications</i> , 2022, 13, .	5.8	2
3818	Towards achieving the end of the HIV epidemic: Advances, challenges and scaling-up strategies. <i>Clinical Biochemistry</i> , 2023, 117, 53-59.	0.8	1
3819	The Potential of Telecommunication Technology to Address Racial/Ethnic Disparities in HIV PrEP Awareness, Uptake, Adherence, and Persistence in Care: A Review. <i>AIDS and Behavior</i> , 2022, 26, 3878-3888.	1.4	3
3820	What Predicts a Clinical Discussion About PrEP? Results From Analysis of a U.S. National Cohort of HIV-Vulnerable Sexual and Gender Minorities. <i>AIDS Education and Prevention</i> , 2022, 34, 195-208.	0.6	1

#	ARTICLE	IF	CITATIONS
3821	Destination-Specific and Home Environment Condom Norms Influence Sexual Behavior During Travel. <i>AIDS Education and Prevention</i> , 2022, 34, 245-255.	0.6	0
3822	Real-world effectiveness of pre-exposure prophylaxis in men at high risk of HIV infection in France: a nested case-control study. <i>Lancet Public Health</i> , The, 2022, 7, e529-e536.	4.7	25
3823	URCHOICE: Preferences for Pre-Exposure Prophylaxis (PrEP) Options for HIV Prevention Among Kenyan men who have sex with men and Transgender Women in Nairobi, Kisumu and the Coast. <i>AIDS and Behavior</i> , 2023, 27, 25-36.	1.4	2
3824	Bridging the age gap: intergenerational communication of HIV risk and prevention among younger and older men who have sex with men. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2023, 35, 538-544.	0.6	4
3825	Non-use of combination HIV prevention tools and its determinants among men who have sex with men living in France. <i>Infectious Diseases Now</i> , 2022, 52, 341-348.	0.7	2
3826	Treatment of hepatitis delta and <scp>HIV</scp> infection. <i>Liver International</i> , 2023, 43, 108-115.	1.9	4
3827	Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305). <i>AIDS and Behavior</i> , 0, , .	1.4	1
3828	Uptake of Human Papillomavirus Vaccination by HIV Status and HIV Pre-exposure Prophylaxis (PrEP) Care Engagement Among Young Sexual Minority Men 17-24 Years Old in the USA. <i>Sexuality Research and Social Policy</i> , 2022, 19, 1944-1953.	1.4	2
3829	Ultra-long-acting antivirals as chemical vaccines to prevent viral diseases. <i>Future Microbiology</i> , 2022, 17, 887-897.	1.0	6
3830	The perspectives of street-involved youth who use drugs regarding the acceptability and feasibility of HIV pre-exposure prophylaxis: a qualitative study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 0, , 1-8.	0.6	0
3831	Doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections among Kenyan women using HIV pre-exposure prophylaxis: study protocol for an open-label randomized trial. <i>Trials</i> , 2022, 23, .	0.7	13
3832	Pre-exposure Prophylaxis Discontinuation During the COVID-19 Pandemic Among Men Who Have Sex With Men in a Multisite Clinical Cohort in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 91, 151-156.	0.9	5
3833	Chemsex Practices in PrEP: Beyond Addiction and Risk Toward a Healthy Sex Life- Baseline Experiences from a Hospital-Based PrEP Program in Barcelona, Spain. <i>AIDS and Behavior</i> , 2022, 26, 4055-4062.	1.4	6
3834	Prevention and Initial Management of HIV Infection. <i>Annals of Internal Medicine</i> , 2022, 175, ITC81-ITC96.	2.0	4
3835	Implementing PrEP Services in Diverse Health Care Settings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, S114-S128.	0.9	2
3836	Identification of Determinants and Implementation Strategies to Increase PrEP Uptake Among Black Same Gender Loving Men in Mecklenburg County, North Carolina: The PrEP-MECK Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, S149-S160.	0.9	6
3837	Acceptability and Appropriateness of Digital PrEP Interventions for Black and Latina Cisgender Women: Perspectives From Service Providers in Los Angeles County. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, S134-S140.	0.9	1
3838	Feasibility and Acceptability of HIV Self-Test Kit Distribution Through PrEP Clients' Social and Sexual Networks to Increase HIV Testing and PrEP Information. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, S105-S113.	0.9	7

#	ARTICLE	IF	CITATIONS
3841	Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS) Tj ETQq0 0 0,rgBT /Overlock 10 Tf	2.3	48
3842	The evolution of DREAMS: using data for continuous program improvement. <i>Aids</i> , 2022, 36, S5-S14.	1.0	7
3843	Evidence and implication of interventions across various socioecological levels to address pre-exposure prophylaxis uptake and adherence among men who have sex with men in the United States: a systematic review. <i>AIDS Research and Therapy</i> , 2022, 19, .	0.7	11
3844	From policy to practice: uptake of pre-exposure prophylaxis among adolescent girls and young women in United States President's Emergency Plan for AIDS Relief-supported countries, 2017â€“2020. <i>Aids</i> , 2022, 36, S15-S26.	1.0	7
3845	HIV at 40: kidney disease in HIV treatment, prevention, and cure. <i>Kidney International</i> , 2022, 102, 740-749.	2.6	1
3846	Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B. <i>Lancet HIV</i> , 2022, 9, e585-e594.	2.1	5
3847	The predictive value of macaque models of preexposure prophylaxis for HIV prevention. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 179-185.	1.5	4
3849	Cellâ€“toâ€“cell transmission of HIVâ€“1 from provirusâ€“activated cells to resting naÃ“ve and memory human primary CD4 T cells is highly efficient and requires CD4 and Fâ€“actin but not chemokine receptors. <i>Journal of Medical Virology</i> , 0, , .	2.5	2
3851	Associations of gender identity with sexual behaviours, social stigma and sexually transmitted infections among adults who have sex with men in Abuja and Lagos, Nigeria. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	3
3852	Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 939-943.	0.5	4
3853	Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis. <i>Annals of Pharmacotherapy</i> , 2023, 57, 306-316.	0.9	5
3854	Associations between self-test and pre- or post-exposure prophylaxis of HIV among men who have sex with men in China. <i>International Journal of STD and AIDS</i> , 2022, 33, 837-846.	0.5	1
3855	Exploring Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) Knowledge in Incarcerated Men. <i>American Journal of Men's Health</i> , 2022, 16, 155798832211071.	0.7	2
3856	Prospective study of oral preâ€“exposure prophylaxis initiation and adherence among young women in KwaZuluâ€“Natal, South Africa. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	7
3857	Uptake and Acceptability of MyChoices: Results of a Pilot RCT of a Mobile App Designed to Increase HIV Testing and PrEP Uptake Among Young American MSM. <i>AIDS and Behavior</i> , 0, , .	1.4	2
3858	Exploring the Role of Providerâ€“Patient Communication in Womenâ€“TM's Sexual Health and Pre-Exposure Prophylaxis Care in the Primary Care Settings in New York State of the United States. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8084.	1.2	0
3859	PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	29
3860	A novel â€œHIV salience and Perceptionâ€“scale is associated with PrEP dispensing and adherence among adolescent girls and young women in Kampala, Uganda. <i>AIDS and Behavior</i> , 2023, 27, 279-289.	1.4	1

#	ARTICLE	IF	CITATIONS
3861	Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults. Current Opinion in HIV and AIDS, 2022, 17, 199-204.	1.5	1
3862	Awareness, Willingness and Use of HIV Pre-Exposure Prophylaxis Among Female Sex Workers Living in Dar-es-Salaam, Tanzania. AIDS and Behavior, 2023, 27, 335-343.	1.4	3
3863	HIV drug resistance: past and current trends. Voprosy Virusologii, 2022, 67, 193-205.	0.1	2
3864	Pharmacists and the Next Generation of HIV Pre-Exposure Prophylaxis. Journal of the American Pharmacists Association: JAPhA, 2022, , .	0.7	2
3865	Texting Lost-to-follow-up PrEP Patients from a San Francisco Sexual Health Clinic. Prevention Science, 2022, 23, 1448-1456.	1.5	1
3866	PrEP program experience in a hospital HIV unit. Description of baseline user profile and identification of opportunities for improvement. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2022, , .	0.2	1
3867	Sexually transmitted diseases in people living with <sc>HIV</sc> after implementation of cost coverage of <sc>HIV</sc> pre-exposure prophylaxis by statutory health insurance in Germany. HIV Medicine, 0, , .	1.0	0
3868	Acceptability and feasibility of leveraging community-based HIV counselling and testing platforms for same-day oral PrEP initiation among adolescent girls and young women in Eastern Cape, South Africa. Journal of the International AIDS Society, 2022, 25, .	1.2	12
3869	HIV Transmission Prevention. , 2021, , 30-50.		0
3870	Ending the HIV Epidemic. , 2021, , 1-4.		0
3871	Sexual Mixing by HIV Status and Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men: Addressing Information Bias. Epidemiology, 2022, 33, 808-816.	1.2	0
3872	Determinants of PrEP Uptake, Intention and Awareness in the Netherlands: A Socio-Spatial Analysis. International Journal of Environmental Research and Public Health, 2022, 19, 8829.	1.2	7
3873	Study Evaluating Self-Collected Specimen Return for HIV, Bacterial STI, and Potential Pre-Exposure Prophylaxis Adherence Testing Among Sexual Minority Men in the United States. American Journal of Men's Health, 2022, 16, 155798832211155.	0.7	5
3874	Mobilization of systemic CCL4 following HIV pre-exposure prophylaxis in young men in Africa. Frontiers in Immunology, 0, 13, .	2.2	3
3875	Impact of daily, oral pre-exposure prophylaxis on the risk of bacterial sexually transmitted infections among cisgender women: a systematic review and narrative synthesis. Wellcome Open Research, 0, 7, 108.	0.9	0
3876	Risk Factors Associated with Loss to Follow-up Among Transgender Women Receiving HIV Pre-exposure Prophylaxis in Chiang Mai province, Thailand. AIDS and Behavior, 2023, 27, 473-483.	1.4	3
3877	Facilitators for retaining men who have sex with men in pre-exposure prophylaxis care in real world clinic settings within the United States. BMC Infectious Diseases, 2022, 22, .	1.3	4
3878	Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection. Journal of Antimicrobial Chemotherapy, 2022, 77, 2706-2712.	1.3	4

#	ARTICLE	IF	CITATIONS
3879	More than just oral PrEP: exploring interest in rectal douche, dissolvable implant, removable implant and injection HIV prevention approaches among racially diverse men who have sex with men in the Northeast Corridor. <i>BMJ Open</i> , 2022, 12, e063474.	0.8	2
3880	Characteristics of HIV seroconversions in a large prospective implementation cohort study of oral HIV pre-exposure prophylaxis in men who have sex with men (EPIC-NSW). <i>Clinical Infectious Diseases</i> , 0, , .	2.9	1
3881	Freedom as Prevention: Mechanisms of Autonomy Support for Promoting HIV Pre-Exposure Prophylaxis Use and Condom Use among Black MSM in 3 US Citiesâ€”HPTN 073. <i>Journal of Urban Health</i> , 0, , .	1.8	1
3882	Stochastic Simulation Algorithm For Effective Spreading Dynamics On Time-Evolving Adaptive Network (SSATAN-X). <i>Mathematical Modelling of Natural Phenomena</i> , 2022, 17, 35.	0.9	1
3883	Multi-level Factors Driving Pre-exposure Prophylaxis Non-initiation Among Young Women at High Risk for HIV in Kenya. <i>AIDS and Behavior</i> , 2023, 27, 106-118.	1.4	3
3884	Substance Use and Healthcare Utilization Across the Pre-Exposure Prophylaxis (PrEP) Care Cascade among Black and Latino Men Who Have Sex with Men. <i>Substance Use and Misuse</i> , 2022, 57, 1698-1707.	0.7	3
3885	Transcriptome-wide association study of HIV-1 acquisition identifies HERC1 as a susceptibility gene. <i>IScience</i> , 2022, 25, 104854.	1.9	2
3886	A Qualitative Exploration of Various Stigmas Impacting HIV Pre-Exposure Prophylaxis (PrEP) Uptake Among African American Young Adults. <i>Family and Community Health</i> , 2022, 45, 218-227.	0.5	4
3887	Roll-out of HIV pre-exposure prophylaxis use in France: A nationwide observational study from 2016 to 2021. <i>Lancet Regional Health - Europe</i> , The, 2022, 22, 100486.	3.0	8
3888	The differential impacts of early detection and accelerated antiretroviral therapy on the epidemiologic trend of sexually acquired HIV infection in Hong Kong. <i>PLoS ONE</i> , 2022, 17, e0274498.	1.1	1
3889	INTRODUCTION Disrupting the Status Quo: Building Equitable Access to HIV PrEP in the US through Innovative Financing. <i>Journal of Law, Medicine and Ethics</i> , 2022, 50, 5-7.	0.4	0
3890	Pre-Exposure Prophylaxis for HIV Infection as a Public Health Tool. <i>Journal of Law, Medicine and Ethics</i> , 2022, 50, 24-28.	0.4	5
3891	Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis. <i>Pharmaceutics</i> , 2022, 14, 1801.	2.0	1
3892	Clinical Considerations in the Selection of Preexposure Prophylaxis for HIV Prevention in Canada. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-14.	0.7	0
3893	A public health approach to monitoring HIV with resistance to HIV pre-exposure prophylaxis. <i>PLoS ONE</i> , 2022, 17, e0272958.	1.1	1
3894	Increased Risk of Sexually Transmitted Infections in Men Who Have Sex With Men Taking Preexposure Prophylaxis: A Meta-analysis. <i>Sexually Transmitted Diseases</i> , 2022, 49, 733-739.	0.8	0
3895	Determinants of Willingness to Use PrEP Among Gay and Bisexual Men in China Before Implementation: A Structural Equation Modeling Assessment. <i>AIDS and Behavior</i> , 0, , .	1.4	2
3896	Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?. <i>Current HIV/AIDS Reports</i> , 2022, 19, 384-393.	1.1	11

#	ARTICLE	IF	CITATIONS
3897	HIV prevention for the next decade: Appropriate, person-centred, prioritised, effective, combination prevention. <i>PLoS Medicine</i> , 2022, 19, e1004102.	3.9	13
3898	Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
3899	Perceived Risk of HIV Infection and Acceptability of PrEP among Men Who Have Sex with Men in Brazil. <i>Archives of Sexual Behavior</i> , 2023, 52, 773-782.	1.2	5
3900	Development of a Human Immunodeficiency Virus Risk Prediction Model Using Electronic Health Record Data From an Academic Health System in the Southern United States. <i>Clinical Infectious Diseases</i> , 2023, 76, 299-306.	2.9	7
3902	Understanding PrEP decision making among pregnant women in Lilongwe, Malawi: A mixed-methods study. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	5
3903	Low incidence of HIV infection and decreasing incidence of sexually transmitted infections among PrEP users in 2020 in Germany. <i>Infection</i> , 2023, 51, 665-678.	2.3	6
3904	Zero knowledge and high interest in the use of long-acting injectable pre-exposure prophylaxis (PrEP) among adolescent men who have sex with men and transgender women in two capital cities in Brazil. <i>BMC Public Health</i> , 2022, 22, .	1.2	6
3905	Pre-exposure prophylaxis for HIV: effective and underused. <i>Cmaj</i> , 2022, 194, E1164-E1170.	0.9	0
3906	Translational Models to Predict Target Concentrations for Pre-Exposure Prophylaxis in Women. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 909-923.	0.5	1
3908	Provider-client rapport in pre-exposure prophylaxis delivery: a qualitative analysis of provider and client experiences of an implementation science project in Kenya. <i>Sexual and Reproductive Health Matters</i> , 2022, 30, .	0.7	1
3909	Evaluating group-sequential non-inferiority clinical trials following interim stopping: The HIV Prevention Trials Network 083 trial. <i>Clinical Trials</i> , 0, , 174077452211183.	0.7	0
3910	Narrative review of studies on HIV pre-exposure prophylaxis in Brazil and its implementation in the public health network. <i>Global Public Health</i> , 0, , 1-14.	1.0	1
3911	Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study. <i>PLoS Medicine</i> , 2022, 19, e1004097.	3.9	9
3912	Socio-behavioral correlates of pre-exposure prophylaxis use and correct adherence in men who have sex with men in West Africa. <i>BMC Public Health</i> , 2022, 22, .	1.2	8
3914	Modeling the potential impact of pre-exposure prophylaxis for HIV among men who have sex with men in Cameroon. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	1
3915	A Profilaxia pré-exposiçŁo ao HIV em um serviçŁo no oeste do Paran. <i>Brazilian Journal of Health Review</i> , 2022, 5, 18033-18044.	0.0	0
3916	Changes in high-risk sexual behavior, HIV and other STI testing, and PrEP use during the COVID-19 pandemic in a longitudinal cohort of adolescent men who have sex with men 13 to 18 years old in the United States. <i>AIDS and Behavior</i> , 2023, 27, 1133-1139.	1.4	3
3917	Impact of a clinical pharmacist within an HIV PrEP program for patients experiencing homelessness. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2023, 63, 324-329.	0.7	1

#	ARTICLE	IF	CITATIONS
3918	Sexual behaviour changes and HIV infection among men who have sex with men: evidence from an open cohort in China. <i>BMJ Open</i> , 2022, 12, e055046.	0.8	1
3919	Vaginal microbial shifts are unaffected by oral pre-exposure prophylaxis in South African women. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
3921	Randomized Trial of Individualized Texting for Adherence Building (iTAB) Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals: The iM-PrEPT Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 91, 453-459.	0.9	3
3922	Recommendations for Improving Oral Pre-exposure Prophylaxis Implementation and Social Marketing in Ugandan Fisherfolk Communities: A Qualitative Exploration. , 0, , 0272684X2211136.		2
3924	Health system opportunities and challenges for PrEP implementation in Kenya: A qualitative framework analysis. <i>PLoS ONE</i> , 2022, 17, e0259738.	1.1	3
3925	The <sc>ATEAM</sc> study: Advances in technology to enhance <sc>PrEP</sc> adherence monitoring (<sc>ATEAM</sc>) among young men who have sex with men. <i>Clinical and Translational Science</i> , 2022, 15, 2947-2957.	1.5	2
3926	Providers' Attitudes and Experiences with Pre-Exposure Prophylaxis Implementation in a Population-Based Study in Kenya and Uganda. <i>AIDS Patient Care and STDs</i> , 0, .	1.1	4
3927	Perceived Barriers to and Facilitators of Long-Acting Injectable HIV PrEP Use Among Black, Hispanic/Latino, and White Gay, Bisexual, and Other Men Who Have Sex With Men. <i>AIDS Education and Prevention</i> , 2022, 34, 365-378.	0.6	5
3928	PrEP Demographics and Disparity: The Race, Ethnicity, Gender Identity, Sex Assigned at Birth, Sexual Orientation and Age of Current PrEP Use. <i>Journal of Community Health Nursing</i> , 2022, 39, 213-226.	0.1	3
3929	Perceived influence of alcohol consumption, substance use, and mental health on PrEP adherence and condom use among PrEP-prescribed gay, bisexual, and other men-who-have-sex-with-men: a qualitative investigation. <i>BMC Public Health</i> , 2022, 22, .	1.2	1
3930	Improving HIV preexposure prophylaxis implementation within healthcare settings. <i>Aids</i> , 2022, 36, 1883-1885.	1.0	0
3931	The Use of HIV Pre- and Postexposure Prophylaxis Among a Web-Based Sample of HIV-Negative and Unknown Status Cisgender and Transgender Sexual Minority Men: Cross-sectional Study. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e31237.	1.2	4
3932	Identifying HIV sequences that escape antibody neutralization using random forests and collaborative targeted learning. <i>Journal of Causal Inference</i> , 2022, 10, 280-295.	0.5	0
3933	Management and treatment of human immunodeficiency virus. , 2022, , 1585-1610.		0
3934	Integrating enhanced HIV pre-exposure prophylaxis into a sexually transmitted infection clinic in Lilongwe (ePrEP STI): A prospective cohort study (Preprint). <i>JMIR Research Protocols</i> , 0, , .	0.5	0
3935	Factors associated with long-term HIV pre-exposure prophylaxis engagement and adherence among transgender women in Brazil, Mexico and Peru: results from the ImPrEP study. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	16
3936	PrEP-related stigma and PrEP use among gay, bisexual and other men who have sex with men in Ontario and British Columbia, Canada. <i>AIDS Research and Therapy</i> , 2022, 19, .	0.7	3
3937	The Relationship Between HIV Pre-exposure Prophylaxis Stigma and Treatment Adherence Among Current HIV Pre-exposure Prophylaxis Users in the Southeastern U.S.. <i>AIDS and Behavior</i> , 2023, 27, 1478-1485.	1.4	3

#	ARTICLE	IF	CITATIONS
3938	Intimate Partner Violence and Willingness to Use Pre-Exposure Prophylaxis Among Men Who Have Sex With Men in Chengdu, China. <i>Journal of Interpersonal Violence</i> , 0, , 088626052211271.	1.3	1
3940	Development and Evaluation of Dissolving Microarray Patches for Co-administered and Repeated Intradermal Delivery of Long-acting Rilpivirine and Cabotegravir Nanosuspensions for Paediatric HIV Antiretroviral Therapy. <i>Pharmaceutical Research</i> , 2023, 40, 1673-1696.	1.7	11
3941	Current Perspectives on the Determinants of Acceptability of Pre-Exposure Prophylaxis and Nonoccupational Post-Exposure Prophylaxis among People at Risk for HIV: A Scoping Review. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 12605.	1.2	0
3942	Understanding the factors that impact effective uptake and maintenance of HIV care programs in South African primary health care clinics. <i>Archives of Public Health</i> , 2022, 80, .	1.0	1
3943	Medicaid Spending on Antiretrovirals from 2007-2019. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	0
3944	Effectiveness of interventions aimed at reducing HIV acquisition and transmission among gay and bisexual men who have sex with men (GBMSM) in high income settings: A systematic review. <i>PLoS ONE</i> , 2022, 17, e0276209.	1.1	6
3945	MTN-033: a Phase 1 Study Comparing Applicator versus "œas Lubricant"•Delivery of Rectal Dapivirine Gel. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	1.4	0
3947	HIV awareness and prevention strategies among transgender women in the Eastern and Southern United States: findings from the LITE Study. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	4
3948	Challenges with PrEP Uptake and Adherence Among Gay, Bisexual, and Other Men Who Have Sex with Men in Kisumu, Kenya. <i>AIDS and Behavior</i> , 2023, 27, 1234-1247.	1.4	7
3949	Examining the Awareness, Acceptability, and Adoption of Conventional and non-conventional Forms of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention Among jail-involved Black Sexual Minority men (BSMM) and Black Transgender Women (BTW) in Two Diverse US Cities. <i>AIDS and Behavior</i> , 2023, 27, 1304-1313.	1.4	1
3950	Out-of-pocket Expenses and Time Spent on Clinic Visits Among HIV Pre-exposure Prophylaxis Users and Other Clinic Attendees in Eswatini. <i>AIDS and Behavior</i> , 0, , .	1.4	4
3952	Retrospective audit of a convenience cohort of individuals on HIV pre-exposure prophylaxis in Alberta, Canada. <i>Jammi</i> , 0, , .	0.3	0
3953	Between- and Within-Individual Sociodemographic and Psychological Determinants of PrEP Adherence Among Men Who have Sex with Men Prescribed a Daily PrEP Regimen in Wales. <i>AIDS and Behavior</i> , 0, , .	1.4	1
3954	Qualitative inquiry into perceptions of HIV pre-exposure prophylaxis among people who inject drugs living with hepatitis C in Seattle, WA, USA. <i>Harm Reduction Journal</i> , 2022, 19, .	1.3	1
3955	Human Immunodeficiency Virus Treatment and Prevention for Pregnant and Postpartum Women in Global Settings. <i>Obstetrics and Gynecology Clinics of North America</i> , 2022, 49, 693-712.	0.7	1
3957	Clinic-Integrated Mobile Health Intervention ("œJomPrEP"•App) to Improve Uptake of HIV Testing and Pre-exposure Prophylaxis Among Men Who Have Sex With Men in Malaysia: Protocol for an Intervention Development and Multiphase Trial. <i>JMIR Research Protocols</i> , 2022, 11, e43318.	0.5	6
3958	Same-Sex Marriage Laws, Provider-Patient Communication, and PrEP Awareness and Use Among Gay, Bisexual, and Other Men Who have Sex with Men in the United States. <i>AIDS and Behavior</i> , 2023, 27, 1897-1905.	1.4	2
3959	Costs of Providing Preexposure Prophylaxis for HIV Prevention at Community Health Centers in the United States. <i>Public Health Reports</i> , 0, , 003335492211330.	1.3	0

#	ARTICLE	IF	CITATIONS
3960	Examining pharmacies'™ ability to increase pre-exposure prophylaxis access for black men who have sex with men in the United States. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2023, 63, 547-554.	0.7	4
3961	Human Immunodeficiency Virus Preexposure Prophylaxis: The Next Wave in Emergency Department-Based Human Immunodeficiency Virus Prevention. <i>Annals of Emergency Medicine</i> , 2022, , .	0.3	0
3962	MPrEP+ study protocol: a prospective cohort study assessing the feasibility and acceptability of an HIV pre-exposure prophylaxis (PrEP) strategy for male clients of female sex workers in Kisumu, Kenya. <i>BMJ Open</i> , 2022, 12, e064037.	0.8	0
3963	Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaques. <i>EBioMedicine</i> , 2022, 86, 104338.	2.7	5
3964	A focused multi-state model to estimate the pediatric and adolescent HIV epidemic in Thailand, 2005â€“2025. <i>PLoS ONE</i> , 2022, 17, e0276330.	1.1	0
3965	Nucleoside Triphosphate Diphosphohydrolase 1 Exhibits Enzymatic Activity toward Tenofovir Diphosphate. <i>Drug Metabolism and Disposition</i> , 2023, 51, 385-391.	1.7	4
3966	Chemsex in HIV preâ€“exposure prophylaxis users: Assessment of mood disorders and addictive behavior. <i>Fundamental and Clinical Pharmacology</i> , 2023, 37, 639-649.	1.0	2
3967	Social Determinants of Health During the COVID-19 Pandemic in the US: Precision Through Context. , 2022, , 397-425.		1
3968	A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial of Radiopaque Islatravir-Eluting Subdermal Implants for Pre-exposure Prophylaxis Against HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2023, 92, 310-316.	0.9	8
3969	Interrogating the promise of long-acting HIV pre-exposure prophylaxis. <i>Trends in Molecular Medicine</i> , 2022, , .	3.5	2
3970	Advancing considerations of context in the evaluation and implementation of evidence-based biomedical HIV prevention interventions: a review of recent research. <i>Current Opinion in HIV and AIDS</i> , 2023, 18, 1-11.	1.5	3
3971	PrEP use and stigma among a sample of older adults in Columbus, Ohio. <i>International Journal of STD and AIDS</i> , 2023, 34, 122-129.	0.5	1
3972	Cell and Tissue Specific Metabolism of Nucleoside and Nucleotide Drugs: Case Studies and Implications for Precision Medicine. <i>Drug Metabolism and Disposition</i> , 2023, 51, 360-368.	1.7	3
3973	Pharmacokinetics, the immunological impact and the effect on HIV ex-vivo infectivity of maraviroc, raltegravir and lopinavir in MSM using Post-exposure Prophylaxis.. <i>AIDS Research and Human Retroviruses</i> , 0, , .	0.5	0
3974	Willingness to Recommend Pre-Exposure Prophylaxis for HIV Prevention Among Mexican Non-Physician Health Providers: A Cross-Sectional Study. <i>Current HIV Research</i> , 2023, 21, 7-17.	0.2	0
3975	Interventions to increase the uptake and continuation of pre-exposure prophylaxis (PrEP) by adolescent girls and young women at high risk of HIV in low-income and middle-income countries: a scoping review. <i>BMJ Global Health</i> , 2022, 7, e009474.	2.0	5
3976	Persistently elevated risk of syphilis among HIV-positive men receiving care in a status-neutral setting: A retrospective analysis. <i>Sexually Transmitted Diseases</i> , 0, Publish Ahead of Print, .	0.8	1
3977	Longâ€“acting injectable cabotegravir for<scp>PrEP</scp>: A gameâ€“changer in<scp>HIV</scp>prevention?. <i>HIV Medicine</i> , 2023, 24, 653-663.	1.0	5

#	ARTICLE	IF	CITATIONS
3978	Characterizing the Impact of the COVID-19 Pandemic on HIV PrEP care: A Review and Synthesis of the Literature. <i>AIDS and Behavior</i> , 2023, 27, 2089-2102.	1.4	6
3979	Pre-exposure prophylaxis in the era of emerging methods for men who have sex with men in the USA: the HIV Prevention Cycle of Care model. <i>Lancet HIV</i> , 2023, 10, e134-e142.	2.1	2
3980	Pharmacology of boosted and unboosted integrase strand transfer inhibitors for two-dose event-driven HIV prevention regimens among men. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, 497-503.	1.3	3
3981	Pre-exposure prophylaxis in France: How many MSM are eligible and how much will it cost?. <i>PLoS ONE</i> , 2022, 17, e0278016.	1.1	0
3982	Engaging Latino sexual minority men in PrEP and behavioral health care: multilevel barriers, facilitators, and potential implementation strategies. <i>Journal of Behavioral Medicine</i> , 2023, 46, 655-667.	1.1	8
3983	Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model. <i>Aids</i> , 2023, 37, 561-570.	1.0	3
3984	Implementation of PrEP in Latin America. <i>Lancet HIV</i> , 2023, 10, e70-e71.	2.1	2
3985	Substance Use and Adherence to HIV Pre-Exposure Prophylaxis in Studies Enrolling Men Who Have Sex with Men and Transgender Women: A Systematic Review. <i>AIDS and Behavior</i> , 2023, 27, 2131-2162.	1.4	6
3988	Black Sexual Minority Men's Stigma-Based Experiences Surrounding Pre-exposure Prophylaxis in the Southern United States. <i>LGBT Health</i> , 2023, 10, 245-251.	1.8	4
3989	PrEP stigma among current and non-current PrEP users in Thailand: A comparison between hospital and key population-led health service settings. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
3990	Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
3991	Evolution of Risk Behaviors, Sexually Transmitted Infections and PrEP Care Continuum in a Hospital-Based PrEP Program in Barcelona, Spain: A Descriptive Study of the First 2 Years' Experience. <i>Infectious Diseases and Therapy</i> , 2023, 12, 425-442.	1.8	2
3993	Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 114, 29-40.	2.3	4
3994	Prevalence of renal and bone risk factors among individuals prescribed oral pre-exposure prophylaxis for HIV. <i>IJID Regions</i> , 2023, 6, 68-75.	0.5	1
3995	Sexual behaviors, cannabis, alcohol and monkeypox infection. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	1
3996	Psychometric Properties of an Adapted Stigma Scale and Experiences of Stigma Associated with HIV Pre-exposure Prophylaxis Use Among Men Who have Sex with Men: A Mixed Methods Study. <i>AIDS and Behavior</i> , 2023, 27, 2397-2410.	1.4	1
3997	Intervention treatment distributions that depend on the observed treatment process and model double robustness in causal survival analysis. <i>Statistical Methods in Medical Research</i> , 2023, 32, 509-523.	0.7	1
3998	Examining the Role of Autonomy Support, Goal Setting, and Care Coordination Quality on HIV PrEP Adherence in Black Men Who Have Sex with Men: HPTN 073. <i>AIDS Patient Care and STDs</i> , 2023, 37, 22-30.	1.1	1

#	ARTICLE	IF	CITATIONS
3999	Awareness and use of HIV pre-exposure prophylaxis and factors associated with awareness among MSM in Beijing, China. <i>Scientific Reports</i> , 2023, 13, .	1.6	4
4000	Structure-Based Stabilization of SOSIP Env Enhances Recombinant Ectodomain Durability and Yield. <i>Journal of Virology</i> , 2023, 97, .	1.5	10
4001	Web-Based Harm Reduction Intervention for Chemsex in Men Who Have Sex With Men: Randomized Controlled Trial. <i>JMIR Public Health and Surveillance</i> , 0, 9, e42902.	1.2	0
4002	HIV Pre-exposure Prophylaxis Persistence and Adherence Among Men Who Have Sex With Men in Four US Cities. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2023, 93, 34-41.	0.9	4
4003	Estimating benefits of using on-demand oral prep by MSM: a comparative modeling study of the US and Thailand. <i>EClinicalMedicine</i> , 2023, 56, 101776.	3.2	2
4004	Prophylaxie pré-exposition au VIH : efficace et sous-utilisée. <i>Cmaj</i> , 2022, 194, E1544-E1550.	0.9	0
4005	Insights into HIV-1 Transmission Dynamics Using Routinely Collected Data in the Mid-Atlantic United States. <i>Viruses</i> , 2023, 15, 68.	1.5	0
4007	Economic Burden of HIV in a Commercially Insured Population in the United States. <i>Journal of Health Economics and Outcomes Research</i> , 0, , 10-19.	0.6	0
4008	Discontinuation of government subsidized HIV pre-exposure prophylaxis in Australia: a whole-of-population analysis of dispensing records. <i>Journal of the International AIDS Society</i> , 2023, 26, .	1.2	3
4009	Travestis, transgender women and young MSM are at high risk for PrEP early loss to follow-up in Rio de Janeiro, Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2023, 27, 102733.	0.3	3
4010	“I don’t know why I am taking this pill”: Young women navigation of disclosure and support for PrEP uptake and adherence in Eastern Cape Province, South Africa. <i>PLOS Global Public Health</i> , 2023, 3, e0000636.	0.5	2
4011	Client Responses to Video-Based Communication Skills Training Involving PrEP for HIV: Tailoring an Individual Sexual Health Intervention for Sexual Minority Men in Relationships. <i>AIDS and Behavior</i> , 2023, 27, 2463-2477.	1.4	3
4012	Economic Burden of HIV in a Commercially Insured Population in the United States. <i>Journal of Health Economics and Outcomes Research</i> , 2023, 10, .	0.6	0
4013	HIV pre-exposure prophylaxis (PrEP) knowledge among general practitioners in 2020: A French survey. <i>Infectious Diseases Now</i> , 2023, 53, 104649.	0.7	1
4014	Attitudes towards participating in research involving digital pill systems to measure oral HIV pre-exposure chemoprophylaxis: a cross-sectional study among men who have sex with men with substance use in the USA. <i>BMJ Open</i> , 2023, 13, e067549.	0.8	1
4015	MSM with HIV: Improving prevalence and risk estimates by a Bayesian small area estimation modelling approach for public health service areas in the Netherlands. <i>Spatial and Spatio-temporal Epidemiology</i> , 2023, 45, 100577.	0.9	4
4016	Predictors of Human Immunodeficiency Virus Pre-Exposure Prophylaxis (PrEP) Uptake in a Sexual Health Clinic With Rapid PrEP Initiation. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	1
4017	Human Immunodeficiency Virus Infection. , 2013, , 1475-1482.e1.		0

#	ARTICLE	IF	CITATIONS
4018	Health Literacy as a Mediator of the Relationship Between Socioeconomic Position and Pre-Exposure Prophylaxis Uptake Among Men Who Have Sex with Men Living in France. <i>Health Literacy Research and Practice</i> , 2023, 7, .	0.5	1
4019	Perception of <sc>PrEP</sc>â€related stigma in <sc>PrEP</sc> users: Results from the <sc>ANRSâ€PREVENIR</sc> cohort. <i>HIV Medicine</i> , 2023, 24, 938-945.	1.0	1
4020	Personalizing prevention: Advances in pharmacotherapy for <sc>HIV</sc> prevention. <i>Pharmacotherapy</i> , 2023, 43, 305-320.	1.2	1
4021	Low rate of pre-exposure prophylaxis and post-exposure prophylaxis uptake and high prevalence of transmitted drug resistance among newly diagnosed primary HIV infections in Shenzhen, China: a real-world retrospective study. <i>Chinese Medical Journal</i> , 2022, 135, 2730-2737.	0.9	1
4022	Longitudinal patterns of initiation, persistence, and cycling on preexposure prophylaxis among female sex workers and adolescent girls and young women in South Africa. <i>Aids</i> , 2023, 37, 977-986.	1.0	4
4023	Providing HIV pre-exposure prophylaxis to men who have sex with men and transgender women in hospitals and community-led clinics in Thailand: acceptance, patterns of use, trends in risk behaviors, and HIV incidence. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2023, 35, 524-537.	0.6	0
4025	HIV/AIDS Global Epidemic. , 2023, , 221-250.		1
4026	Scholarly literature in HIV-related lesbian, gay, bisexual, and transgender studies: A bibliometric analysis. <i>Frontiers in Psychology</i> , 0, 14, .	1.1	0
4027	Multi-dimensional mismatch and barriers for promoting PrEP among men who have sex with men in China: a cross sectional survey from the Demand-side. <i>AIDS Research and Therapy</i> , 2023, 20, .	0.7	1
4028	Predicting and influencing PrEP use: the role of motivational and attitudinal factors. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2023, 35, 1354-1364.	0.6	0
4029	Injectable long acting antiretroviral for HIV treatment and prevention: perspectives of potential users. <i>BMC Infectious Diseases</i> , 2023, 23, .	1.3	2
4030	Roll-out and effectiveness of HIV pre-exposure prophylaxis in France: An overview. <i>Therapie</i> , 2023, , .	0.6	0
4031	High Prevalence of Asymptomatic Sexually Transmitted Infections in Austrian Pre-Exposure Prophylaxis Users: A Prospective Observational Study. <i>AIDS Patient Care and STDs</i> , 2023, 37, 115-118.	1.1	1
4032	Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study. <i>PLoS ONE</i> , 2023, 18, e0280339.	1.1	0
4033	Development of a tool to assess HIV prevention readiness of adolescent girls and young women in HPTN 082 study. <i>PLoS ONE</i> , 2023, 18, e0281728.	1.1	0
4034	Sexual mixing patterns in men who have sex with men: network approaches for smart resource allocation. <i>Sexual Health</i> , 2023, 20, 126-133.	0.4	0
4036	What motivated men to start PrEP? A cross-section of men starting PrEP in Buffalo city municipality, South Africa. <i>BMC Public Health</i> , 2023, 23, .	1.2	5
4037	Post-exposure and pre-exposure prophylaxis as HIV preventive measures. <i>Zdravstvena Zastita</i> , 2022, 51, 32-45.	0.0	0

#	ARTICLE	IF	CITATIONS
4038	Development of an acceptance based PrEP intervention (ACTPrEP) to engage young black MSM in the South utilizing the Adaptome Model of intervention adaptation. <i>Journal of Contextual Behavioral Science</i> , 2023, 28, 60-70.	1.3	0
4039	Health Economics Research on Non-surgical Biomedical HIV Prevention: Identifying Gaps and Proposing a Way Forward. <i>Pharmacoeconomics</i> , 2023, 41, 787-802.	1.7	1
4040	Uptake and continuation of HIV pre-exposure prophylaxis among women of reproductive age in two health facilities in Kisumu County, Kenya. <i>Journal of the International AIDS Society</i> , 2023, 26, .	1.2	2
4041	Agreements, Behaviour, and Change: Sex Outside the Relationship in Male HIV-negative Partners in HIV Serodiscordant Relationships in Australia, Brazil, and Thailand. <i>AIDS and Behavior</i> , 0, , .	1.4	0
4042	Process description of developing HIV prevention monitoring indicators for a province-wide pre-exposure prophylaxis (PrEP) program in British Columbia, Canada. <i>PLoS ONE</i> , 2023, 18, e0283025.	1.1	0
4043	Increased HIV Transmissions With Reduced Insurance Coverage for HIV Preexposure Prophylaxis: Potential Consequences of Braidwood Management v. Becerra. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	1
4044	Correlates of self-reported and biomarker based adherence to daily oral HIV pre-exposure prophylaxis among a cohort of predominantly men who have sex with men in Nigeria. <i>PLoS ONE</i> , 2023, 18, e0282999.	1.1	1
4045	Knowledge domain and emerging trends in HIV pre-exposure prophylaxis: A visualization analysis via CiteSpace. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	0
4046	Exploring the causes of preexposure prophylaxis of HIV failure—future developments for overcoming the same—a mini review. <i>Journal of Human Virology & Retrovirology</i> , 2019, 7, 1-5.	0.1	1
4047	Utilizing Community Based Participatory Research Methods in Black/African American and Hispanic/Latinx Communities in the US: The CDC Minority HIV Research Initiative (MARI-Round 4). <i>Journal of Community Health</i> , 2023, 48, 698-710.	1.9	3
4048	Adolescent and young adult research across the HIV prevention and care continua: an international programme analysis and targeted review. <i>Journal of the International AIDS Society</i> , 2023, 26, .	1.2	0
4049	Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men. <i>Hepatology</i> , 2023, 77, 2084-2092.	3.6	8
4050	Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 387-409.	21.5	35
4051	PrEP perception and experiences of adolescent and young gay and bisexual men: an intersectional analysis. <i>Cadernos De Saude Publica</i> , 2023, 39, .	0.4	3
4052	Between risk and pleasure: reflections on HIV prevention and care in the current context of PrEP use by men who have sex with men. <i>Cadernos De Saude Publica</i> , 2023, 39, .	0.4	0
4053	Interdisciplinarity in HIV prevention research: the experience of the PrEP1519 study protocol among adolescent MSM and TGW in Brazil. <i>Cadernos De Saude Publica</i> , 2023, 39, .	0.4	15
4054	PrEPare for Work: A Pilot Randomized Controlled Trial of an Intervention to Optimize HIV PrEP Outcomes Among Male Sex Workers. <i>AIDS and Behavior</i> , 2023, 27, 3294-3305.	1.4	2
4055	Exploring preferences and decision-making about long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young sexual minority men 17–24 years old. <i>Scientific Reports</i> , 2023, 13, .	1.6	4

#	ARTICLE	IF	CITATIONS
4056	Prediction of Sex and the Potential Use of On-Demand PrEP Among Young Men Who Have Sex With Men in the U.S.. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2023, Publish Ahead of Print, .	0.9	0
4057	Important steps for PrEP uptake among adolescent men who have sex with men and transgender women in Brazil. <i>PLoS ONE</i> , 2023, 18, e0281654.	1.1	1
4058	Prevalence and Correlates of HIV-Associated Health Behaviors in a Population-Based Sample of Puerto Rican Adults, 2019. <i>Ethnicity and Disease</i> , 2023, 33, 17-25.	1.0	0
4059	More than prevention: early adoption of HIV pre-exposure prophylaxis (PrEP) by gay and bisexual men in New Zealand. <i>Culture, Health and Sexuality</i> , 2024, 26, 222-235.	1.0	0
4060	A Comparison of COVID-19 Vaccine and PrEP Hesitancy Among Individuals Living in Mississippi: A Qualitative Study. <i>AIDS and Behavior</i> , 0, , .	1.4	0
4061	PrEP policy implementation gaps and opportunities in Latin America and the Caribbean: a scoping review. <i>Therapeutic Advances in Infectious Disease</i> , 2023, 10, 204993612311640.	1.1	0
4062	Causal Effects of Stochastic PrEP Interventions on HIV Incidence Among Men Who Have Sex With Men. <i>American Journal of Epidemiology</i> , 2024, 193, 6-16.	1.6	0
4063	Geosexual Archetype, Preventive Behaviours, and Sexually Transmitted Infections among High Risk Men who Have Sex with Men. <i>Sexually Transmitted Diseases</i> , 0, Publish Ahead of Print, .	0.8	0
4064	A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	1.8	3
4065	The Fidelity of a Pharmacy-Based Oral HIV Pre-Exposure Prophylaxis Delivery Model in Kenya. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2023, 93, 379-386.	0.9	2
4066	Barriers and facilitators to <scp>HIV Pre-Exposure</scp> Prophylaxis (<scp>PrEP</scp>) in Specialist Sexual Health Services in the United Kingdom: A systematic review using the <scp>PrEP</scp> Care Continuum. <i>HIV Medicine</i> , 2023, 24, 893-913.	1.0	7
4067	Exploring Current Practice, Knowledge, and Challenges of Sexually Transmitted Infection/HIV Management and Pre-Exposure Prophylaxis Among Japanese Health Care Professionals: A Cross-Sectional Web Survey. <i>AIDS Patient Care and STDs</i> , 0, , .	1.1	0
4092	Prevention, treatment and cure of HIV infection. <i>Nature Reviews Microbiology</i> , 2023, 21, 657-670.	13.6	21
4124	HIV/AIDS Prevention. , 2024, , 139-151.		0
4150	Sex Differences in HIV Infection. <i>Current Topics in Microbiology and Immunology</i> , 2023, , 61-73.	0.7	0
4165	Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence. <i>Nature Medicine</i> , 2023, 29, 2748-2752.	15.2	3
4219	Preliminary feasibility of a wrist-worn receiver to measure medication adherence via an ingestible radiofrequency sensor. , 2023, , .		0
4239	HIV/AIDS Among Sexual and Gender Minority Communities Globally. , 2024, , 183-220.		0

#	ARTICLE	IF	CITATIONS
4242	Interventions, Barriers, and Facilitators to Address the Sexual Problems of Gay, Bisexual and Other Men Who Have Sex with Men Living with HIV: A Rapid Scoping Review. AIDS and Behavior, 2024, 28, 450-472.	1.4	0